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INTRODUCTION 
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INTRODUCTION 
In 1977 Andreas Gruntzig introduced a catheter-based therapy for the percutaneous man-
agement of patients with coronary artery disease. This became known as percutaneous 
transluminal coronary angioplasty (PTCA). Initially there were many skeptics and pessimists. 
The technology, however, evolved rapidly. With the advent of specialized catheters, guidewires, 
stents, and adjuvant pharmacotherapy, the indications for PTCA have expanded to include 
more urgent, comorbid cases and complex coronary disease. Furthermore, these innovations 
have largely solved earlier problems related to elastic recoil, dissection and restenosis of the 
treated segment. In particular, the introduction of stents with the capacity to elute drugs to the 
injured arterial wall has been shown to be an effective and overall safe approach to suppress 
intimal hyperplasia. The excellent results of DES in clinical trials and everyday clinical practice, 
in synergy with important improvements in adjuvant drug therapy, have expanded the indica-
tions of percutaneous coronary interventions even further. Within 10 years of its introduction, 
the number of PTCA procedures has surpassed the number of revascularizations accomplished 
by coronary artery bypass graft surgery. 
Nowadays, treatment of unprotected left main coronary artery disease, chronic total occlu-
sions, multi-vessel disease and the treatment of high-risk patients alike are considered the"new 
frontiers" of PCI. Part of this thesis relates to clinical results from registries and trials conducted 
in this subset of patients with complex coronary disease. The results demonstrate that PCl can 
be performed with encouraging outcomes both at short and long-term follow-up. However, 
there's still room for improvement- particular attention to techniques of intervention, materi-
als and devices is warranted. 
The progress made in PCI has also stimulated the development of techniques for the treatment 
of structural heart disease. New percutaneous techniques such as alcohol septal ablation and 
septal coil embolization to treat patients with hypertrophic cardiomyopathy are progressively 
entering clinical practice as safe and effective alternatives to surgery. Our results show that 
the introduction of a limited "therapeutic" infarction as a result of ethanol injection or the 
deployment of coils within the hypertrophied septal myocardium leads to localized thinning 
and regional contractile dysfunction, which expands the left ventricular outflow tract and thus 
reduces LVOT gradient and the resulting symptom. 
Congestive heart failure treatment has today a "new frontier": cell transplantation therapy. The 
possibility of repairing and growing new myocardium within the necrotic tissue as a result of 
cell transplantation has been widely studied in both experimental and clinical conditions, using 
different types of cells with different delivery approaches. The characteristics of the ideal cell 
still remain to be defined, but it appears clear that, among the cells efficient in the treatment 
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of heart disease, cells that are autologous, non embryonic, do not require culturing to obtain 
a therapeutic dose. These can be administered during the same procedure and may be logisti-
cally easier to use. In this thesis we report our preliminary experience with transplantation of 
autologous myoblast and adipose-derived stem cell in patients with ischemic heart disease 
and heart failure. 
Similar to the materials and techniques used for interventions, there have been important ad-
vances in adjuvant pharmacotherapy. In particular, with PCI emerging as the new gold standard 
ofcarefor ACS reperfusion therapy, new questions are arising about the best pharmaco-invasive 
strategy to limit the amount of myocardial damage occurring during the ischemia and early 
reperfusion periods. In this view, we tested a new type of hemoglobin-based oxygen carrier 
(HBOC) that, because of its ability to deliver oxygen directly to endothelium and tissues, may 
help to restore tissue oxygenation in post-stenotic areas during PCI.In this thesis we report the 
primary results of the proof-of-concept trial whereby HBOC was used in stable patients with 
coronary artery disease to assess its safety. 
OUTLINE OF THE THESIS 
Thesis- Part 1 
The first part of the thesis examines the safety and efficacy of drug eluting stent implantation 
in patients with unprotected left main coronary artery disease. In chapter 2, we report the 
results of the DELFT Registry, an international multicenter registry that enrolled 358 consecu-
tive patients with a minimum follow-up period of 3 years. Chapter 3 and 4 are sub-studies of 
the DELFT Registry and focus on the impact of stent selection on clinical outcomes (SP-DELFT) 
and on long-term clinical outcomes of diabetic patients with ULMCA disease treated with DES 
{D-DELFT). The comparison between percutaneous and surgical treatment of patients with left 
main disease is explored in chapter 5 white chapter 6 and 7 report findings on a limited and ret-
rospectively selected group of patients who underwent PCI with sirolimus-eluting stent {SES) 
implantation and the comparison, in terms of clinical outcomes, between SES and bare metal 
stents (BMS). Chapter 8 is a large multicenter registry that explores the long-term safety of drug 
eluting stents and evaluates the occurrence of late and very late stent thrombosis following 
elective DES implantation in ULMCA stenosis. Finally, by a meta-analysis on 1278 patients, 
the risk-benefit balance of percutaneous DES implantation for ULMCA disease, in itself and in 
comparison with BMS-based PCI and CABG has been analyzed in chapter 9. 
Thesis- Part 2 
This section of the thesis examines percutaneous treatment of chronic total occlusions {CTO) 
in the drug-eluting stent era. Chapter 10 reports the long term follow up results of saphenous 
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vein graft recanalization compared to native vessel recanalization in a small population of 
post-CABG patients. Chapter 11 focuses on percutaneous retrograde approach, a novel and 
interesting technique that appears to be promising. So far however only limited data are avail-
able on this strategy. Finally the role of CTCA in the treatment of patients with CTOs is explored 
in chapter 12, a single center retrospective registry designed to identify potential predictors 
of success and to measure the risk-benefit ratio of this imaging technique performed in this 
particular subset of patients. 
Thesis- Part 3 
The safety and efficacy of DES in patients with high risk features has been evaluated in this 
thesis section. In chapter 13 the immediate and long-term results (12 months follow-up) of 
paclitaxel-eluting stent implanted in a high cardiovascular risk population with complex 
coronary lesions are reported while chapter 14 focuses on the short and long-term results 
of mutivessel PCI performed in patients with severe systolic dysfunction. The safety of an 
unrestricted use of DES has been questioned in several trials and independent meta-analysis, 
leading however to unclear or conflicting results. Chapter 15 provides a critical appraisal of 
recently published meta-analysis focusing on this issue. Finally, in chapter 16, the role of the 
Tandemheart (a percutaneous trans-septal ventricular assist device) in the context of high-risk 
percutaneous coronary interventions has been tested in a small population of emergent and 
elective patients. 
Thesis- part 4 
This section of the thesis focuses on the acute and chronic effects on left ventricular haemody-
namics of percutaneous septal ablation for obstructive hypertrophic cardiomyopathy (HCM). 
The changes of leftventricularfuncion were assessed by pressure-volume loops, dynamic data 
acquired by online pressure-volume signals obtained by a combined pressure-conductance 
catheter introduced into the left ventricle. Chapter 17 reports the acute changes in systolic and 
diastolic left ventricular function after alcohol induced septal myocardial ablation {PTSMA) 
and shed a light on the complex series of events that follow the procedure and that result 
in a new haemodynamic status. The chonic effects that PTSMA determines on systolic and 
diastolic left ventricular function are assessed and reported in chapter 18, while chapter 19 
reports the acute results obtained in a patient with HCM treated with the novel method of 
septal coil embolization. 
Thesis- part 5 
This section describes cell characteristics, traditional and experimental delivery techniques and 
first clinical outcomes of cell transplantation performed in patients with cardiac heart failure 
secondary to ischemic heart disease. Chapters 20 and 21 describe characteristics, capabilities 
and the results derived from in-vitro and in-vivo studies of adipose-derived stem cells (ADSCs), 
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a new promising source of multi-potent stem cells. The APOLLO study, first in man trial con-
ducted with ADSCs in patients with acute myocardial infarction is also described. Early clinical 
results of autologous skeletal myoblast used in the treatment of post-infarction injuries are 
reported in chapters 22 and 23 and 24 while chapter 25 focus on the early experience of cell 
transplantation procedures using a magnetic navigation supported delivery system. 
Thesis- part 6 
This last section of the thesis describes the early results obtained from the clinical use of 
Hemopure, an haemoglobin-based oxygen carrier that because of its ability to restore tissue 
oxygenation might play an important role in the setting of acute coronary syndromes. Chap-
ter 25 describes the result of the COR-001 trial, a phase II, single center trial designed to test 
haemodynamic effects, safety and tolerability of intra-venous administration of Hemopure in 
patients scheduled for PCI. The encouraging results obtained in COR-001 trial led to the design 
of the COR-002 pilot trial, a single center, placebo-controlled, single blind trial conceived to test 
capabilities of Hemopure to restore and maintain myocardial oxigenation when injected in an 
ischemic territory. 
SUMMARY AND CONCLUSIONS 
Taking into consideration the published literature to date, the use of drug-eluting stents {DES) 
in patients with unprotected left main (ULM) coronary artery disease appears overall beneficial 
in comparison with bare metal stents (BMS).In particular, the use of DES is associated with sig-
nificant reductions in target lesion revascularization, target vessel revascularization and MACE 
(major adverse cardiac events).ln unspecified lesions, in-stent restenosis has been linked to the 
occurrence of acute coronary syndromes; but in the setting of left main restenosis, the risk of 
sudden cardiac death becomes a concern. Thus, the anti proliferative action of DES is of para-
mount importance in ULM lesions, and to date, DES should likely be recommended whenever 
percutaneous coronary interventions (PC I) for ULM is envisioned. Pooled analyses of registry 
data confirmed the early and mid-term safety and efficacy of DES implantation over BMS, under 
the premise that PCI is performed by experienced operators. Also, very-long-term follow-up of 
patients with ULM coronary artery disease treated with DES demonstrated a satisfactory rate in 
both single and composite outcomes. The progressive reduction of adverse events over time 
suggests 
that DES are persistently effective. When PCI is performed electively, the event-free survival 
over a period of3 years is excellent. This is independent of lesion location, stenting technique or 
type of drug-eluting stent used. When PCI is performed emergently, the favourable long-term 
clinical outcomes are hampered by lower event-free survival at shorter term follow-up. 
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It is interesting to note that in the in diabetic population with unprotected left main coronary 
artery disease the efficacy of DES is significantly influenced by the use ofinsulin.lnfact,adverse 
outcomes comprising cardiac death, myocardial infarction, need of re-intervention and MACE 
was significantly increased in patients with insulin-dependent diabetes mellitus. The safety 
profile of drug-eluting stents appeared overall consistent with what has been reported in 
recent trials and registries focusing on selected patient/lesion subsets. The incidence of definite 
acute, sub-acute, late and very late stent thrombosis was low and not significantly related to 
cardiac death. 
Notwithstanding the encouraging results obtained with DES for the treatment of ULM 
coronary artery disease, current guidelines still recommend surgical revascularization as the 
primary procedure. In all major institutions, current standard approach to patients presenting 
with significant ULM coronary artery disease is to have them evaluated by both interventional 
cardiologists and cardiac surgeons and to reach the decision to opt for PCI or surgery by con-
sensus, on the basis of hemodynamic conditions, vessel I lesion characteristics, the presence of 
comorbidities and patient and/or referring physician preferences. 
The results of the recently published SYNTAX trial represent a milestone and certainly will be 
taken into consideration in the upcoming guidelines. Guidelines are dynamic and in constant 
flux and have to be updated according to new evidences coming from clinical experience. 
New-generation DES approved for clinical use, new technical strategies, new adjuvant thera-
pies performed in the cath-lab, and prolonged dual antiplatelet treatment have significantly 
decreased the risk of adverse events (including late in-stentthrombosis), making PCI a safe and 
effective alternative to surgery in several high-risk subsets of patients. 
In the context of chronic total occlusions both sirolimus-eluting stents and paclitaxel elut-
ing stents have now been reported to be correlated with improved long-term clinical and 
angiographic outcomes compared with their BMS counterparts. Several studies reported high 
procedural success rates {particularly evident using the retrograde approach), single digit rest-
enosis rates and no increase in stentthrombosis or late occlusion after DES implantation. Good 
clinical results were observed also in chronically occluded saphenous vein grafts. Though the 
benefit of DES in this lesion subset has not been formally evaluated {SVG lesions have been 
excluded from randomized trials), the available data coming from observational studies are 
encouraging. Remaining issues are the long-term safety and efficacy of DES in SVG lesions, 
considering that long-term events frequently result from the progression of other lesions in 
the vein. Regardless of the future progress in this field, we think that DES treatment currently 
is the best approach for SVG lesions. Despite extensive real-life use of DES in patients with 
multivessel disease, we cannot deny that sufficient data are still lacking. Rather than looking at 
the incidence of new revascularizations, which may be considered an acceptable"side effect" of 
any PCI strategy compared with CABG, we need to demonstrate equivalency or superiority in 
terms of Ml and death evaluated no earlier than 5 years. 
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Coronary artery disease aside, advances in cardiovascular interventional techniques have 
allowed percutaneous treatment of conditions that either previously required open operations 
or have not been amenable to treatment. 
Hypertrophic obstructive cardiomyopathy is a relatively common condition (prevalence of 
around 1 in 2000 persons) . The traditional method for the management of these patients has 
been the use of beta-blockers or calcium channel blockers, dual chamber pacing or surgical 
ventricular septal myectomy. Over the last decade, percutaneous approach to treatment of out-
flow tract gradient by ablating or creating a controlled infarction of the ventricular septum, has 
also been shown to be safe and effective. Percutaneous transluminal septal myocardial abla-
tion (PTSMA) as well as septal coil embolization acutely reduce systolic function and improve 
diastolic function, maintaining cardiac output and stroke work. At long~term follow-up, the 
effects on general haemodynamics improve; in fact, while the LV-aortic gradient remaines low 
and active and passive LV diastolic properties are stable, myocardial contractility and systolic 
funcion improve. The indications for performing PTSMA are still being defined. Up to date, this 
novel technique may be a particularly attractive alternative in the elderly or those who because 
of significant co-morbidities cannot undergo /are refused by surgeons. 
The enormous improvements in PCis led to excellent rates of survival after an acute 
myocardial infarction. This increase has lead to a concomitant increase in the prevalence of 
post-infarction heart failure (HF) with at least a third of patients manifesting HF symptoms 
within a year. Currently, this increase is attributed both to limited efficacy of pharmacological 
agents at reducing left ventricle remodelling and HF exacerbations, and to underutilization of 
these drugs in general practice. Finally, post-infarction HF patients are surviving longer, in part 
because of a wider use of implantable cardioverter defibrillators. With the awareness that both 
tissues and bone marrow (BM) contain undifferentiated immature 'stem' cells normally used to 
replenish body tissues throughout life, and that these cells can be harvested and delivered to 
sites of injury, a new therapeutic option has emerged: the transplantation of stem or progenitor 
cells for functional repair or even regeneration of vasculature, acutely injured and/or failing 
myocardium or previously irreversibly damaged heart- giving hope for cell-mediated preven-
tion, treatment and possibly even cure of CVD. Trials performed to date have focused on the use 
of BM-MNCs, EPCs, MSCs and other cells throughout the continuum of cardiovascular disease, 
from advanced coronary atherosclerosis to end-stage HF, with the most patients treated follow-
ing AMI. Three recent meta-analyses suggest that BM-MNCs provide statistically significant yet 
small (in clinical terms} benefit when administered post-AMI. However, on dose examination 
of individual studies, the outcomes are discrepant. Whether the discrepancies represent differ-
ences in disease context, patient population, cell type and dose or some other factors remains 
to be resolved. In other words, 7 years after the initiation of the first study we still have as many 
(or more) questions as answers. 
Among the variety of cells studied, autologous skeletal myoblasts are one of the most 
encouraging cell sources for cardiac repair. They are of their autologous origin, the ability to 
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be amplified in vitro, and have high proliferative potential resistance to ischaemia and pre-
clinical efficacy. These characteristics have led clinical investigators to evaluate the effect of 
transplanted autologous myoblasts in patients with post-infarction heart failure. Myoblasts 
differentiate into myotubeS and maintain muscle properties when transplanted into an infarct 
area. The direct contribution 
of these eng rafted cells in improving systolic function was noticed in several studies that 
indicated a 
positive effect of skeletal myoblasts on myocardial contractility lasting over time and cor-
relating with the number of implanted cells. 
Recently it has been shown that adipose tissue, in addition to committed adipogenic, 
endothelial progenitor cells and pluripotent vascular porgenitor cells, contains multipotent 
cells, similar to MSCs. ADSC have extensive proliferative capacity, are able to undergo differ-
entiation along both mesenchymal lineages and non-mesenchymal lineages, are known to 
secrete a large number of angiogenesis-related cytochines and display and immunoprivileged 
behavior. 
This finding has generated major interest because, in contrast to bone marrow, large quanti-
ties of adipose tissue can be easily harvested with minimal morbidity, making it an appealing 
source for cell therapy. The APOLLO trial will provide important data about the safety and 
efficacy of these cells in humans, providing an essential insight on what could be their role in 
the treatment of cardiovascular disease. 
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Objectives The purpose of this study was to Investigate the long-term safety and efficacy of percutaneous coronary Interven-
tion (PC!) with drug-eluting stent (DES) Implantation for unprotected left main coronary artery (ULMCA) disease. 
Background 
Methods 
Long-term clinical outcomes after DES Implantation for ULMCA disease have not yet been ascertained. 
From April 2002 to April2004, 358 consecutive patients who underwent PCI with DES Implantation for de novo 
lesions on ULMCA were retrospectively selected and analyzed In 7 European and US. tertiary care centers. No 
patients were excluded from the analysis, and <:all patients had a minimum follow-up of 3 years. 
Results Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovas-
cular events (MACE}-free survival Jn the whole population was 73,5%. According to the Academic Research Con-
sortium definitions, cardiac death occurred In 9.2% of p;rtlents, and relnfarcUon, target lesion revascularlzatlon 
(TLR), and target vessel revascularizatlon (TVR) occurred In 8.6%, 5.8%, and 14.2% of patients, respectively. Def-
Inite stent thrombosis occurred !n 2 patients (specifically at 0 and 439 days). In elective p;rtlents, the 3-year 
MACE-free su!VIval was 74.2%, with mortality, relnfarctlon, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, 
respectively. In the emergent group the 3-year MACE-free su!VIval was 68,2%, with mortality, relnfarct!on, TLR, 
and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively. 
Concluslons Routine DES Implantation In ULMCA disease seems encouraging, with favorable long-term clinical 
results. (JAm Coli Cardloi2008;51:2212-9) © 2008 by the American College of Cardiology Foundation 
Preliminary trial results confirmed that implantation of drug-
eluting stents (DES) to treat unprotected left main coronary 
artery (UL.\1CA) lesions is a feas1ble and relatively safe 
approach in appropriately selected patients (1-5). However, 
coronmy "'"'Y bypass grafting (CABG) still remains the 
treatment of choice in this cohort (6,7). Lack of long-term 
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follow-up (>2 years) data and increasing awareness of the 
potentially fatal consequences of stent thrombosis (ST) or 
in-stent restenosis in this patient subset is proving a significant 
deterrent to off'er percutaneous coronary intervention (PCD 
with DES implantation in patients amenable to CABG 
(8-12). 
The main goal of this study was to generate the longest 
availitble follow-up data and identi.o/ associated predictors for 
adverse outcomes in patients undergoing intervention with 
DES for UllvlCA lesions in a ~real-world" setting with an 
international, multicenter, retrospective regi.stry design. 
Methods 
Population. Between April2002 and April2004, consec-
utive patients who underwent PCI with a sirolimus-eluting 
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stent (SES) or paclitaxel-eluting stent (PES) for de novo 
lesions in the ostium, shaft, or distal ULMCA were iden-
tified retrospectively and analyzed in 7 European and U.S. 
tertiary health care centers. All patients had confirmed 
myocardial ischemia related to ULMCA disease. 
Patients were stratified into risk classes with the European 
Sporn fo, Cru-diac Opcrativo lfuk Ev.lluation (EuroSCORE) 
(13) (fru,lc 1). Subjects with ' EumSCORE >6 wcrc 
defined as high risk, and those with a EuroSCORE >9 as 
very high risk. Additional information about the risk of 
mortality and morbidity was generated with the Society of 
Thoracic Surgeons (STS) score. Data analysis was per-
formed with the approval of the institutional ethics com-
mittees of the hospitals and/or universities involved. 
Procedures and medications. All intenrentions were per-
formed according to concurrent guidelines . .Angioplasty 
strategy, use of periprocedural glycoprotein ITb!TIIa inhib-
itors, route of arterial access, pre-dilation devices, intravas-
cular ultrasound guidance, and prophylactic intra-aortic 
balloon pump use was at the discretion of the operator. 
All elective patients were pre-treated with aspirin, clopi-
dogrel (75 mg/day 3 days before the procedure or 300-mg 
loading dose), and low-molecular-weight or unfractionated 
heparin (administered in the cath lab, before guidewire 
insertion). Heparin was titrated to maintain an activated 
clotting time > 250 s. In general, patients who underwent 
emergent PCI received oxygen adjusted according to 
blood saturation before cardiac catheterization, aspirin 
100 to 160 mg chewed, a 300-mg loading dose of clopi-
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dogrel, and intravenous heparin 
to maintain the activated clotting 
time >250 s. 
Complete revascularization 
was attempted in all patients at 
the time of the index PCI. Sig-
nificant lesions that were not 
treated during the index proce-
dure were staged and treated 
generally within 1 month. 
After the procedure, all pa-
tients were prescribed lifelong as-
pllin (75 to 100 mgiday), o.nd 
prolonged (at least 6 months) 
dual antiplatelet therapy of aspi-
rin + clopidogrel or aspirin + 
ticlopidine was recommended. 
Repeated revascularization was 
only perfonned if there was ei-
ther symptom recurrence or in-
ducible ischemia related to the 
ULMCA disease. 
.Angiographic follow~up was 
performed according to institu-
tional guidelines, usually be-
tween 6 and 9 months after the 
procedure. 
Definitions. Technical success 
was defined as the successful de-
ployment of the stent(s) in the 
target lesion. 
Procedural success was defined 
as left main revascularizati.on with 
a ::S300Al residual diameter stenosis 
by quantitative coronary angiogra-
lnlllrctlon 
BMS"' baro-metul stent(s) 
CO= cardlaelllnrth 
EF"' ojoctlon froctlon 
EuroSCORE = E~rop!lan 
SY$Wm fol' Cardiac 
Opomtlvo Risk EValuation 
Kl = bomodynamlc 
Instability 
IDOM = lnsuii!Hiopondont 
MACE "' mujor oll\tlmlll 
cardiae cvont(s) 
Ml = myowdlnllnfarctloll 
PCI = porcutancous 
coronary Intervention 
PES = poclltnxoJ.ollltlng: 
.tont(s) 
ULMCA = IIIIProtocbld left 
main coronory artory 
phy, without major procedural or post-procedural adverse 
events (death, myocardial infarction [lviTJ, emergency t1rget 
vessel revascularization, or acute ST). 
Hemodynamic instability (HI) was defined as the pres-
ence of hypotension (systolic blood ·pressure <90 mm Hg) 
associated with signs of global or regional hypoperfusion, 
without meeting all of the criteria for cardiogenic shock. 
Emergency PCI was defined as a PCI in patients 
treated before the beginning of the ne.'\.1: working day with 
cardiogenic shock, ST -segment elevation myocardial infarc-
tion, or unstable angina associated with signs of progressive Hl 
unresponsive to standard medical treatment 
Death was classiiied as either cardiac death (CD) or 
noncardiac, according to the Academic Research Consor-
tium (ARC) de£nitions (14). Deaths that could not be 
classi£ed were considered cardiac. 
Target lesion revascularization (TLR) was defined as any 
repeat percutaneous intervention of the target lesion or 
other complication of the target lesion. The target lesion 
was defined as the treated segment from 5 mm proximal to 
the stent and to 5 mm distal to the stent. 
Target vessel revascularization (TVR) was defined as any 
repeat PCI of any segment of the target vessel, defined as 
the entire major coronary vessel proximal and distal to the 
target lesion, including upstream and downstream branches 
and the target lesion itself 
A major adverse cardiac event (MACE) was defined as 
the occurrence of CD, nonfatal :MI, or TVR during the 
follow-up period. 
Definite, probable, and possible stent thromboses were 
determined according to the ARC definitions (14). Stent 
thrombosis was defined as acute, subacute, late, and very late 
if the event occurred within 24 h, 30 days, <1 year, or > 1 
year, respectively, after the procedure. 
Myocardial infarction was defined as a creatine kinase-:M:B 
mass increase > 3 times the upper limit of normal, associated 
with chest pain lasting > 30 min or with new evident electro-
=liographic chan!;". 
Data collection and follow-up. All data relating to hospital 
admissions, procedures, and in-hospital outcomes were col-
lected in each center with the hospital recording network. 
lnfonnation regarding clinicll status was collected at clinic 
visits and by telephone interview. When the patient was not 
reachable, the information was sought from the referring 
physician, hospital electronic database, or Municipal Civil 
Registries. The data collection was carried out with a dedicated 
electronic case report form ( CRF). All of the explored variables 
in the CRF were defined and number-coded before the CRF 
was sent to each participating center. At 3 years the clinical 
follow-up was 10QO,.U. This protocol was approved by the 
hospital ethics committees and is in accordance with the 
Declaration of Helsinki. Written informed consent was ob-
tained from every patient 
Statistical analysis. Continuous variables are expressed as 
mean :::: SD, and categorical variables are o..-pressed as 
counts and percentages. 
The :MACEs are reported hierarchically. Survival curves 
were generated by the Kaplan-Meier method, and survival 
among groups was compared with the log-rank test. 
Bivariate and multivariate analyses were performed to 
identify independent predictors of adverse events. Specifi-
cally, all variables significantly associated with the clinical 
event of interest on bivariate analysis (p < 0.10) were 
entered into subsequent models. After appropriate checks 
for underlying assumptions, multiple variable Cox propor-
tional hazard analyses were then performed, with the enter 
method for all pertinent covariates. Results of multiple 
variable Cox analyses are reported as hazard ratios with 95% 
confidence intervals and p values . .All analyses were per-
formed with SPSS version 12 statistical software (SPSS 
Inc., Chicago, Dlinois). A 2-tailed p value < 0.05 was 
considered significant for hypothesis testing. 
Results 
Baseline characteristics. Baseline clinical characteristics 
are shown in Table 2. 
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~~~~ Baseline Clinical Characteristics 
""'""' Moo 
BMI(I<Um') 
Artorlol h)'l)llrton~lon 
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"'ollltus; NIDDM ~ oonlnoulln-dopoMOl1t dllll>o!os mollltuo; PCI ~ porcutMOO"' corono'l' Into~ 
wmtlon; otllor obbrtrllo~ono osln Toblo l.. 
Patients (n = 358) of mean age 66.1 ± 112 years and 
mean body mass inda 26.7 ::!:. 4.7 kg1m2 were treated for 
ULMCA stenosis with DES. During the same period, a 
total of 680 patients with significant ULMCA disease 
undenvent C.A.BG in the 7 participating centers. Men 
comprised 73./'0Al of the cohort. One hundred eight patients 
(30.2%) were diabetic. Of these, 58 (162%) had insulin-
d'Pendent diabetes mcllitu; (IDDM) and 50 (14%) had 
non-IDDM. Almost one-half of the patients (162, 45.3%) 
had a prior history of acute myocardial infarction (AMI), 
!OS (302%) hod hod a prmous PC!, ond 68 (18.9%) hod 
previously undergone CABG. The most common admis-
sion diagnosis was stable angina (158, 44.1%), followed by 
WlStablc mgina (!50, 41.9%), AMI (30, 8.4%), cardiogenic 
shock (10, 2.8%), and silent ischemia (10, 2.8%). The mean 
ejection fraction (EF) was 48.6 ± 12.8%, and the mean 
EuroSCORE was 6.4 :::: 4.1. 
In the emergent subgroup, mean EuroSCORE was 9.9 :::: 
3.5, and the most common diagnosis on admission was 
AMI (n = 31, 44.3%), followed by unstable angina with HI 
(n = 29, 41.4%) ond cardiogenic ;hock (n = 10, 14.3%). 
The risk of mortality and morbidity or mortality calcu-
lated by Society ofThoracic Surgeons (STS) score were 1.6 :±:: 
0.7% and 13.5 ± 4.1% in the elective group and 22.3 ± 
6.4% and 46 ± 11.3% in the emergent group, respectively. 
Procedural and angiographic characteristics. Procedural 
and angiographic characteristics are shown in Table 3. In 
~~~~ Anglogrnphic and PrOC1.!ldural Charaeterlstics reference vessel diameter was 3.71 ± 0.54 mm, and mean minimal lumen diameter was 3.32 ± 0.57 nun. Multivessel 
Emcrt:ont PC! 70(l..9.6) treatment was performed in approximately one-half of the 
UAwrthHI 29(41.4) population (50.8%). 
"'' 
31(44.3) Procedurnl and in-hospital outcomes. Procedural and 
cs 10{14.3) in-hospital outcomes are summarized in Table 4. Technical 
LcsJon IOCildon 
success was achieved in 100% of cases and procedural 
Ostium/shaft 94(26.3) 
Distal 2&4{73.7) success in 89.6%. Overall, the in-hospital death rate was 3%, 
OES and the post-procedural111 rate was 7.3%. Urgent TLR 
Cyphur 195 (54.5) was required in 0.3% and urgent TVR in 0.8%, and the 
'~~ 163{45.5) incidence of MACE was 11.1%. In-hospital death and 
Appi'Qneh MACE were significantly more likely after emergent rather 
Single stol'lt 203 (56.7) than elective procedures (12.8% vs. 0.7%, p < 0.001, and 
Multiple stunt 155 (43.3) 22.8% vs. 8.3%, p < 0.001, respectively). 
S\Qntlng to<:hnlquo 
PrQv~lonol 203 (56.7) 
V-stentlng 30 (8.3) 
lncldence of Adverse Events in the Whole Population, 
Hton~nr:: 14 (3.9) In Eleetlve Patients, and in Emergent Patients 
Cn.lshlng 95 (26,S) 
CUlotta 16 (4.4) 
_, 
"'''" 
Emortont 
Muld~ossoltroatmont 182 (50.$) (n = 358) (n c: 288) (n = 70) pValuo 
Stcnts/pll~ont 1.47 (S29(3S8) In-hospital 
Stentdlametor, mm 3.23 :!: 0.31 co um 2(0.7) 
"""' 
<0.001 
Stcnt Hmgth, mm 17.3:!: 6,7 ., 26(7.2) 20(6.9) 6(8.6} ,, 
P11H:!Itn~on 169(47.2) nR 1(0.3) 0(0) 1(1.4} 
,., 
Thrombeetomy 5(1.4) 1VR 3(0.8) 2(0.7) 1{1.4} '·" 
Cutting 28{7.8) MACE 
""'" 
24 (8.3) 16 (22.8) <0.001 
Rotabllllor 8{2.2) 
"''"" N co 12 (3.3) 2(0.7) 10 (14.3) <0.001 Atherectomy 5{1.4) ~ Post-dlla~on 188(52.5) ., 26(7.2) 20(6.9) 6 (8.6) 039 
~ MWdmallnfla~on pressure, atm 16.$:!: 2.8 nR 2(0.6) 1(0.3) 1(1.4) 025 v 
Flll(llklsslng 133 (37.2) 1VR 3(0.8) 2(0.7) 1(1.4) .... 
28 BIUOr balloon sllll, mm 3.53:!: 0.55 
"''' 
41(11.4) 24(8.3) 17 (24.3) <0.001 
"" 
50(:13.9) 6months 
Post-procodurol RVO, mm 3.71:!: 0.54 CD 17(4.7) 5 (1.7) 12(17.1) <0.001 
Post..procoduml MLD, mm 3,32:!: 0.57 
., 26{7.2) 20(6.9) 6(8.6) 
'"' 
TIMI flow at bascll~ nR 9{2.5) $(2.7) 1(1.4) OM 
,., 61(17) 
"' 
21(5.8) 1$(6.2) 3(4.3) 
'"" 
24(6.7) 
"'" 
64{17.8) 43(14.9) 21(30) 0.003 
273 [76.3) 
'" 
Anl:logrophlc follow-up 255 [71.2) co 24(6,7) 1i(3.8) :13(18.6) <0.001 
., 27(7.5) 21(7.3) 6(8.6) ,.., 
Volu .. Ci'l<lnll!>n{%). 
"' 
14{3.9) 13(4,5) 1{1.4) 
" AMI - IICUI<I m)IOCMdlol lnfo~011; CS ~ <:nrdk>g,.,le oltook; DES ~ drug.,ILI!Ing ston~ ~I ~ 
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roforo""o , .... , dil>m<>tor, l'lMI : Thrombolysis In M)IOCMdlollnlorttlon: UA - unstllblo on;!lno, 
"'" 
87 (24.3) 
""'-'' """'' 
0.046 
'"' brief, elective PCis comprised 80.4%, and emergent PCis co 33(9.2} 18(6.2) 15(21.4) <0.001 
comprised 19.6% of procedures. Sirolimus-eluting stents ., 31(8.6) 24(8.3) 7(10) M 
were deployed in 54.5% of patients, and paclitaxel-eluting nR 21(5.8) 19(6.6} 2(2.8) 
'"" 
stents were deployed in 45.5%. Baseline Thrombolysis In 1VR 51(14.2) 46(16) 5[7.1) 0.037 
Myocardial Infarction (TIMI) flow assessment in the MACE U5(32.1) 88 {30.5) 27 {38.5) 0.126 
ULMCA was 0 to 1 in 17% of patients, 2 in 6.JOAI, and 3 in >3"' 
76.3%. Lesions were more frequently distal (73.7%) than co 3S (1o.6) 20(6.9) 18 (25.7) <0.001 
ostiaJ/shaft (26.3%). The ULMCA was treated with mul- " 32 (8.9) 24(8.3) 8 (11.4) 0.27 
tiple stents in 43.3% of cases, and crush stenting (26.5%) nR 22 (6.1) 19 (6,6) 3(4.3) 0.3< 1VR 55(15.3) 47 (16.3) 8 (11.4) 02 
was favored over V-stenting (8.3%), Culotte (4.4%), and MACE 125(34.9) 91{31.6) 34 (48.5) 0.006 
T -stenting (3.9%) techniques. Mean stent diameter was 
323 ::!: 0.31 mm, mean stent length was 17.3 ::!:: 6.7 mm, Vnluos !:)Yon as n I%). CD ~ car<Jioc d<>OtO: MAC£ - 1'1111)« od110roo <:nr<Jioc OI'Cnls; Ml ~ myocar<J~IInfnrctlon:TLR ~ 
and the stents/patient ratio was 1.47. Mean post-procedural tOUtlloolon ~osculllrtmt!on: TVR ~ tOUtl """"'' ""'oocu~rtmt!on. 
Follow-up clinical outcomes. Follow-up clinical out-
comes at 30 days, 1 year, and 3 years are shown in Table 4 
and in Figure 1. Patients were followed up for at least 36 
months (range 36 to 60.2 months). Angiographic follow-up 
was available in 71.2% of patients. 
At 30 days, the incidence of CD was 3.3% and was 
significantly higher in emergent procedures when compared 
with elective (14.3% vs. 0.7%; p < 0.001). The incidence of 
A CD and Ml 
""::o-.:: I 
-:Tl.r<. I, -~. 
I 
I 
I 
I 
' I 
•m• 
""' 
B MACE 
C TVR 
Kaplan-Meier CUrves 
from mojor ndllorso car~Jiac events (MAC€]. (C) Froedom from target vessel fCI'l!S' 
culartmtlon (TVR). Solid U11011 ~ eloctlll:l potlcnts (Elc.:); solid boklllno$ ~ whOle 
popui::ltlon ['Nholo): dashed lines~ cmorgont po~cnts (Emorg). Tho p vnluo repre-
sents tl1o dlfforencc bctwoon the cloctlll:l ond tho emcrgont groups. 
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111, TLR, and TVR was 7 .2%, 0.6%, and 0.8%, respec-
tively. A MACE occurred in 11.4% and significantly more 
frequently with emergent procedures compared with elec-
tive (24.3% vs. 8.3%; p < 0.001). 
At 1 year, the incidence of CD was 6.7% and the incidence 
of MI, TLR, and TVR wcre 7 S%, 3.9%, and 10%, ""1""-
tively. A MACE occurred in 24.3% of patients. The associa-
tion with CD and MACE remained significant for emergent 
cases when compared with elective procedures (18.6% vs. 3.8%, 
p < 0.001, ond 32.9% vs. 222%, p = 0.046). 
The 3-year incidence of CD was 9.2%, and the incidence 
of MI, TLR, and TVR wcre 8.6%, 5.8%, and 142%, 
respectively. A MACE occurred in 32.1% of cases. Occur-
rence of CD (21.4% vs. 6.2%; p < 0.001) but not MACE 
(38.5% vs. 30.5%; p = 0.126) remained significantly higher 
in emergent cases relative to elective cases. 
Data derived from the Kaplan-Meier survival curves are 
reported in Figure 1. Of note, the great majority of events 
occurred within 1 year in both groups of patients (72.7% 
and 85.4% in the elective and in the emergent group, 
respectively), whereas the cumulative event rate tended to 
stabilize over time. 
Stent thrombosis. The ST events are described in Table 5. 
De£nite ST occurred in 2 (0.6%) patients at 0 and 439 
days. Probable ST occurred in 4 (1.1 %) patients, and 
possible ST occurred in 16 (4.4%) patients. Concerning the 
de£nite ST, acuteST occurred in 1 patient (0.3%) and very 
late in 1 (0.3%). No subacute and lateST occurred. 
Acute ST occurred in a patient with acute coronary 
syndromes who underwent emergent PCI and received a 
single DES for a significant ostial lesion. Very late ST 
occurred in a patient with stable angina who underwent an 
elective PCI and received 3 DES for a significant lesion 
located in the distal left main. One-year dual antiplatelet 
therapy was recommended and thus, at the time of the ST 
event, was not ongoing. Both -events occurred in patients 
who were classified as very-high-risk patients (Euro-
SCORE 9 and 11). No case of definite ST resulted in CD. 
Multivariable analyses. Results of multivariable analyses 
are presented in Table 6 and Online Tables 1 and 2. Of 
note, the following were identified as independent predic-
tors of cardiac death (CD): age, shock, EuroSCORE, and 
impaired EF (<50%). The IDDM and EuroSCORE were 
significant predictors of :MACE and IDDM; impaired EF 
and multiple stenting predicted the need for TVR 
Discussion 
The main findings of this report are the following: there was 
a high clinical and procedural success rate associated with 
DES insertion to treat ULMCA stenosis. Follow-up at 30 
days, 6 months, and 3 years demonstrated a satisfactory rate 
of :MACE. Of note, the great majority of adverse events 
occurred within the first year, whereas thereafter, the event 
rate tended to stabilize over time, suggesting a prolonged 
efficacyofDES over time. When elective and emergent PCI 
30 
- ST According to ARC Definitions 
""' """"' ""' '"""" (<24h) (<3Gda)'ll) (<:lyr) (>1yr) 
"'"' DcflnltcST 1(0.3) 0(0} 0(0) 1(0.3) 2(0.&) 
P!QbDbl~ ST 1(0.3) 2(0.&) 0(0) 1(0.3) 4(1.1) 
Possible ST 0(0) 0(0) 8(2.2) 8(2.2) 16(4.4) 
Totll 2(0.6) 2(0.6) 8(2.2) 10 22(6.1) 
Volu .. glvenll!.n{%), 
ARC = Aclldomlc R~Jo<!oreh Conoertlum;ST c stont thromtmb, 
were compared, the former was associated with excellent 
3-year event-free survival. whereas emergent PCI was asso-
ciated with a lower but satisfactory clinical success rate. In 
terms of safety, there were only 2 cases of definite throm-
bosis that occurred in a very-high-risk patient. Overall, the 
ST rates were lower than in other lesion subsets (15). 
General population and elective patients. Very-long-
term safety and efficacy data for DES used to treat ULMCA 
disease in unselected consecutive patients are lacking. Thus, 
it is difficult to put into perspective the results of our report. 
In the bare-metal stent (BMS) era, patients with UL\'ICA 
disease treated percutaneously were carefully selected. Lee 
et al. (16) reported on 5-year follow-up patients (n = 187) 
with ULMCA disease that was treated percutaneously with 
BMS. All were elective and had nonnal EF and a low rate 
of distal left main involvement (37%). Moreover, when 
compared with our population, patients were signi£cantly 
younger (56 :±: 11 years vs. 66 :!: 11 years) and had a lower 
incidence of hypertension (27% vs. 66%), hypercholesterol-
emia (30% vs. 64%), and diabetes (20% vs. 30%), and 
signi£cantly higher post-procedural minimal lumen diame-
ter (4.1:!: 0.7 mm vs. 3.3:!: 0.57 mm). A crude comparison 
of the 2 populations after 3-year follow-up shows a higher 
cumulative incidence of CD (9.2% vs. 2.3%) and lower 
MACE-free suMval (73.5% vs. 77.5%) in our series relative 
to that ofLee et a1. (16). After exclusion of emergent patients 
(n = 70) and elective patients with an EF <50% (n = SO), 
a repeat comparison of our cohort with that of Lee et al. (16) 
demonstrates a similar cumulative incidence of CD (1.2% 
vs. 23%) and rate of MACE-free survival (77.7% vs. 
77.5%). Thus, treatment ofULMCA in higher-risk popu-
lations with DES achieves results similar to that of lower-
risk populations treated with BMS. 
Lee et al. (16) reported a cumulative incidence of TLR 
after 1 and 3 years (TVR rate not reported) of 18.8% and 
20.7%, respectively, whereas the incidence in our compara-
ble subpopulation was 2.9% and 6.7%, respectively. These 
data are consistent with published results from DES versus 
BMS nmdomized trillis (17-20). 
Recent reports (1,5) of DES use to treat ULMCA in 
selected populations showed considerable variability in the 
incidence of CD (range 0% to 11%), TVR (range 6% to 
15%), and MACE (nmge 2% to 26%) at l·y= follow-up. 
This variability most likely represents relative differences in 
the inclusion and exclusion criteria applied and a lack of 
long-term follow-up results and makes comparison difficult. 
A study conducted by Shciban et a1. (3) reported excellent 
results in terms of death, TVR. and MACE at 12 and 24 
months in a population of 85 consecutive unselected pa-
tients who underwent ULMCA revascularization with 
DES. Although from a small population derived from a 
single center, these results are in line with ours and suggest that 
DES implantarion in "real-world~ patients with UL\1CA 
disease is both feasible and safe and effective over time. 
The survival curve showed that the main occurrence of 
adverse events-in terms of CD, l\.11, and TVR-was 
within the first 12 months, whereas thereafter, the curves 
showed a progressive tendency to flatten. In the overall 
popularion and in the elective subgroup, the 79.7% and 
76.5% of all CDs and Mls, respectively, occurred within 
the first ye'JI of follow-up. Consistently, 70.90/o (69.3% in the 
elective subgroup) of all TI'Rs and 75.7o/o (72.7% in the 
elective group) of all MACEs occurred within the first year, 
suggesting that the enhanced antiproliferative dfect ofDES 
is persistent and that, in this specific popularion, the 
so-called "catch-up" phenomenon seems not to occur at this 
point in time in this popularion. This is in line with the 
2-year reports available so far (3). 
In addition, our results suggest that treatment of elective 
patients with ULMCA disease with DES does not difer 
significantly from treatment of those with mulrivessel disease 
in terms of MACE. In fact, our findings are in line with those 
reported by Morice et al. (21) in the REALITY (Sirolimus 
versus Paclitaxel-eluting Stents ln De Novo Coronary Artery 
Lesions) trial in 2006. The noncwnulative incidence of 
MACE (matched for our de£nirion of MACE) at 1 ~ye'JI 
follow-up in the REALITY trial was 14.75% (14.6% in the 
IJII Multlvarlable Prcdlctors of Freedom From Adverse CtlnlC<JI Events 
VarlDblo 00 MACE 
"" 
"'' 
:1.06 (1.01·:1.11). ~- 0.010 
IDDM 2.85 {1.29-6,j.7), p ~ 0,009 2.92 (:1.60·5.30), ~ < 0.001 
Sho<k 11.0 (1,88.63.9), p ~ 0.008 
B.lroSCORE .us (1.01·1.31}. p ~ 0.046 1.10 (1.02~1.19), p n O,Q14 
LVEF(<SO%) 1.03 (1.01~1.0$), p ~ 0.050 
Mul~pl~ st<:ntlnl! 4.51 (1.07·19.0}, p ~ 0.040 
Only olgnlflCil!\t (p < 0.05) pr001cto,. or<> roponod,'"' hamrO mtlo!l (95% COT'II'klol1«>1nloNalo}, p \IIIIUOO. 
[uroSCOR£ a Eur<>pOM S)'!ilom lor C.rdlac 0$>01'11~"" Rlol< Ewtluotkln; lOOM ~ lnoulln-dopOndont dlob<ltos n'IIIMI!Uo; LVD' ~ loft V<mti10ulor ojoctl011 trottlon; oiiiM abbn>Y~OI"''"' In TabOr 4. 
SES group; 14.9% in the PES group) compared with 222% in 
our cohort. Furthennore, the incidence of CD, :MI, and TVR 
(matched with our definition ofTVR) was 125%, 5.55%, and 
7.95%, ~ely, in the REALITY trial (average of theSES 
and PES groups) versus 3.5%, 73%, and 11.1% in our report. 
Diabetes mellitus, multiple stenting, and impaired EF 
were found to be independent predictors of TVR in our 
population, which is consistent with a similar published 
analysis in other coronary lesion subsets (22). 
Emergency PCI. Percutaneous treatment ofULMCA dis-
ease in an emergent setting is not supported by current and 
prior American College of Cardiology/ American Heart 
Association (ACC/ AHA) guidelines for percutaneous cor-
onary interVention (7) and reflects the lack of available data 
for the acute and long-term safety and efficacy of PCI in this 
particular subset of patients. 
In the present study, at 30 days the incidence ofMA.CE was 
significandy higher than in the elective group (243% vs. 83o/o, 
p < 0.001). At 3-year follow-up, however, the dllference in 
MACE-free survival between the elective and the emergent 
group was only 6% (742% vs. 682'1, respectively, p = 033). 
It is noteWorthy that although TVR was over-represented 
among adverse events at 3-year follow-up in the elective group 
(52.3% of all adverse events), CD represented the major 
component in the emergent group (55.5% of all adverse 
events). Thereby, the 3-year incidence ofTVR was shown to 
be signifieancly lower in the emergent group (p = 0.04), 
whereas conversely the incidence of CD and MI at 3 years was 
found to be significantly higher in these patients when com-
pared with the elective group (p = 0.005). 
& in the elective population, the survival curve showed that 
the v:JSt majority of adverse events occurred within the first year 
of follow-up. In these patients, 86.6% of all CDs and :Mrs, 
802% of all nrRs, and 85.4% of all MACEs occurred in the 
first 12 months. The incidence 'of CD and MI at 12 months 
was significantly lower in the elective PCI population com-
pared with the emergent PCI population (risk ratio 2.11, 95% 
confidence intem.l137 to 32). However, this early diference 
was no longer present after this point in time. This suggests 
that the increased risk is limited to the early post-treatment 
period and that patients who had an event-free survivnl at 1 
year have comparable clinical outcomes at 3 years. 
Christiansen et al. (23) recently reported clinical out-
comes among patients undergoing emergency PCI for A..\11 
in patients with ULMCA (n = 27). Compared with our 
series, the population had similar baseline characteristics 
and a similar surgical risk score but did not receive DES 
routinely, and in 1 patient plain old baJloon angioplasty 
alone was performed. The MACE rate at 6-month 
follow-up in Christiansen's report and in our group was 41% 
and 30%, respectively. Interestingly, CD was the most 
prominent component of MACE, consistent with our 
findings. In our series, the very-high-risk profile of patients in 
whom CD occurred (EuroSCORE 13 ::!:: 3, mean EF 38 ::!:: 
11%, CS as diagnosis at admission in 8 of15 patients) and 
absence of procedure-related or ST -related CDs suggest 
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that CD occurred owing to the clinical presentation and 
comorbidities rather than the procedure or "performance" of 
the device implanted. 
Comparison with CABG. Current A CCI AHA guidelines 
for PCI recommend surgical revascularization as the pri-
mary procedure for patients with ULMCA disease (6). The 
main reason for this recommendation is that long-tenn 
outcomes of surgical revascul.arization, including in the 
rubpopulation with UL\ICA diseas~ are a"llilible (24,25,26), 
whereas few data exist to allow evaluation of long-tenn 
safety and efficacy of PCI with DES for ULMCA 
disease, and no randomi7..ed trial has been published that 
compares the 2 treatments. Results of the ongoing 
SYNTAX (SYNergy Between PCI VVith TAXUS and 
Cardiac Surgery) and COlviBAT (Comparison of Bypass 
Surgery and Angioplasty Using Sirolimus-Eluting Stents 
in Patients With Unprotected Left Main Coronary 
Artery Disease) studies are awaited. 
'Three-year cumulative survival of elective patients with 
ULMCA disease enrolled in the CASS (Collaborative 
Study in Coronary Artery Surgery) study was 91% for the 
surgical group (24), which is in line with the cumulative 
survival rate in our elective group (93.4%). 
Recent retrospective studies (27,28) reported 1-year 
follow-up outcomes of patients undergoing CABG for 
UL.\1CA disease. The range of incidence of death, MI, 
TVR, and MACE was 52% ro 8.5%, 15% to 32.4%, 5.5% 
to 5.7%, and 24.8% to 46.6%, respectively. Compared with 
our population, this represents a similar incidence of death 
and lower incidence of TVR but an apparently higher 
incidence of11l and 11ACE. In these studies, the average 
risk score and the proportion of patients stratified as at low-
or high-risk scores are similar to the population in our study. 
However, because the assessment was performed with 
different risk score systems, caution should be taken while 
interpreting and comparing the outcomes of the aforemen-
tioned studies. The 3-year follow-up outcomes ofCABG in 
elective patients with isolated ULMCA disease were re-
cencly described by d'Allonnes et a!. (25). At 3 J"'"S, 
cumulative survival and freedom from MACE were 92% 
and 87%, respectively. Compared with our series, survival 
was comparable but our incidence of MACE was higher, 
mainly ov.ring to the higher rate ofTVR. 
Stent thrombosis. In thls regisny, the defullte ST occurred 
only in 2 cases. The patient in whom definite acute ST 
occurred was taking dual antiplatelet therapy, whereas the 
patient with very late ST was only taking aspirin at the time 
of the adverse event. Index PCI was performed in the 
context of acute coronary syndromes (unstable angina, 
emergent PCI) in the acute ST case, whereas in the other 
case the procedure was elective, performed in a patient with 
stable angina. 
In our study, definite ST was not associated with CD, 
and the overall incidence was as low as in other high-risk 
DES populations. Real-world DES registries with long-
term follow-up (15) have reported an overall incidence of 
N 
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mortality related to ST of <10%, and most recently, in the 
ERACI (Argentine Randomlzed Study: Coronary .Angi.o-
plasty With Stenting Versus Coronary Bypass Surgery in 
Multi.vessel Disease) ill ST analysis (29), death rdated to 
"confirmed ST" occurred only in 1 of5 patients (subacute ST 
in a patient who stopped.clopidogrel3 days before the event). 
Conclusions 
V ery-long-tenn follow-up of patients with ULMCA dis-
ease treated with DES demonstrated a satisfactory rate in 
both single and composite outcomes. The progressive re-
duction of incidence of adverse events over time suggests 
that DES are persistently eff'ective. Elective PC! patients 
had an excellent event-free survival over the 3-year period. 
The PCis in emergent patients, although hampered by an 
early lower event-free survival, also had a favorable long-
term clinical success rate. In tenus of safety, the definite ST 
rate was lower than in other high-risk lesion subsets. 
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OUTCOMES IN PATIENTS TREATED FOR 
UNPROTECTED lEFT MAIN CORONARY 
ARTERY DISEASE: THE SIROUMUS VS 
PACliTAXEl DRUG-ElUTING STENT FOR 
lEFT MAIN REGISTRY (SP-DELFT) 
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Impact of drug-eluting stent selection on long-tenn clinical outcomes in 
patients treated for unprotected left main coronary 
artery disease: The sirolimus vs paclitaxel drug-eluting 
stent for left main registry (SP-DELFT) 
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Aim: To compare the long-term relative efficacy and s:llety ofSES and PES in patients undcrgoingpcrcut:meous coronary intervention (PCI) for 
unprotected left main coronary artery (ULMCA) disease and to evnluate the role oflesion location and stenting technique in determining outcomes. 
Methods and results: FromApril2002 to April2004, 288 consecutive p!ltien$ who underwent elective PCI with DES impl:mtJ.tion for de novo 
lesions on tiLMCA have been retrospectively selected and :m:tlyzed in seven European and US tertiary care centers. All patients had a minimum 
follow-up of3 years. SES was used in 152 patients while 136 received PES. Isolated o~iial-shnft disease was present in 27% of patien$, Dh"tll LM 
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and 67.1% vs. 66.2% in the distal-<louble stcnt group. Definite stent thrombosis occurred only in 1(0.3%) patient at 439 days. 
Conclusions: In elective p.ltients wbo undcrwcntPCI for de novo lesions in the ostium, sba.ft or distal ULMCA, long-term clinical outcomes with 
SES and PES use were similar independently of lesion location and stenting technique. 
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1. Introduction 
Percutaneous coronary interVention (PCI) using drug-elu-
ting stents (DES) has become the preferred revascularization 
strategy for unprotected left main coronary artery (LLMCA) 
cliscasc in patients at high risk for surgery. Recent studies 
report encouraging long-term clinical outcome [1-4]. How-
ever. lesion location and stcnting technique can influence the 
incidence of adverse events. Presence of ostial and shaft 
lesions is a.<;Sociatcd with favorable outcome and a low res-
tcnosis rate [5,6]. In contrast. rcvascularization of clistal 
LMCA lesions is associated with less favorable outcome, 
particularly when a double stent approach is preferred [7]. 
The 2 most widely used and stuclied drug-eluting stcnts nrc 
the sirolimus-eluting stent (SES; Cypher, Johnson & Johnson 
Cordis.. Miami, Florida) and paclitaxcl-cluting stent (PES; 
Ta'CUS.. Boston Scientific, Natick. Massachusetts). Recent stu-
dies evaluating the relative safety and efficacy ofboth DESs in 
a variety of patient subsets have shov.rn inconsistent results 
[8.9]. Importantly, there is little data comparing clinical out-
come associated with use of SES and PES to treat ULMCA 
disease, and stuclies reporting very long-term data arc notably 
lacking. Thus, the aim of this study was to compare the relative 
efficacy and safety ofPCI with SES and PES in patients with 
U'LMCA disease. In adclition, the role oflesion location and 
stenting technique in dcternUning outcome was evaluated. 
2. Methods 
2.1. Population 
Consecutive patients who underwent elective PCI with SES 
or PES for de novo lesions in the ostium. shaft or illstal 
ULMCA between April 2002 and April 2004 in seven 
European and US tertiary health care centers.. were identified 
retrospectively and analyzed. Patients with acute myocardial 
infarctions or carcliogcnic shock were excluded from the ana-
lysis. All patients had confirmed myocardial ischenria related 
to 1.-LMCA clisease. Factors that determined choice of a 
percutaneous approach over surgcry included coronary ana-
tomy and lesion characteristics, patient preference, referring 
physician preference and surgical risk. lligh surgical risk 
was defined as a EuroSCORE (European system for carcliac 
operative risk evaluation) >6. All patients provided written 
informed consent prior to the procedure. Data analysis was 
performed with the approval of the institutional ethics com-
mittees of the hospitals and/or universities involved. 
2.2. Procedures and medications 
All PCis were performed according to concurrent guide~ 
lines. Type of stcnt, stenting strategy, usc of periprocedural 
glycoprotein IIb/ITia inhibitors, route of arterial access, pre-
dilation devices, intravascular ultrasound guidance and pro. 
phylactic intra-aortic balloon pump usc was at the discretion of 
the operator. The choice to use a single or double stentstratcgy 
was driven by the anatomical location and extent of coronary 
artery disease. In gencrol. a single stent strategy was used 
in isolated distal ULMCA stenosis (DISTAL-Single) and a 
double stent strategy in cases of distal ULMCA stenosis in~ 
volving both left anterior descending (LAD) and left cir-
cumflex (LCX) coron:uy artery ostia (DISTAL-Double) or in 
cases where plaque shift occurred. All patients were pre~ 
treated with aspirin. clopidogrel (75 mglday 3 days prior to the 
procedure or 300-mg loading dose) and low~molecular-weight 
orunfractioncd heparin (administered in the cath~lab, before 
guidc~wirc insertion). Heparin was titrated to maintain an 
activated clotting time> 250 s. After the procedure, all patients 
were prescribed lifelong aspirin (75-1 00 mg/day) and pro-
longed (at least six months) dual antiplatclet therapy (DAT) of 
aspirin 100 mglday and 75 mg/day clopidogrel or 250 mg 
ticlopidine twice daily. Repeated rcvascularization was only 
performed if there was either symptom recurrence or inducible 
ischenria related to the 'ULMCA disease. 
2.3. Defmitions 
Technical success was defined as successful deployment of 
a stent(s) in the target lesion. Procedural success was defined 
as ULMCA rcvascularization with ::::;;30% residual cliamctcr 
stenosis by quantitative coronary angiography, without major 
procedural or post-procedural adverse events (death, myocar-
dial infarction, emergency target vessel rcvascu1arization or 
acute stent thrombosis). Death was cla..<;Si:ficd as either cardiac 
(CD) or non-earcliac, according to the Academic Research 
Consortium (ARC) definition. Deaths that could not be clas-
sified were considered cardiac. Target lesion revasculari=ation 
(TLR) was defined as any repeat percutaneous intervention of 
the target lesion or other complication of the target lesion. The 
target lesion was defined as the treated segment from 5 :mm 
proximal to the stent to 5 nun distal to the stent Target vessel 
rev·asculari=ation (TVR) was defined as any repeat PCI of any 
segment of the target vesseL defined as the entire major cora. 
nary vessel proximal and distal to the target lesion, including 
upstream and downstream branches and the target lesion itscl£ 
Major adverse cardiac event (MACE) was defined as the 
occurrence of cardiac death (CD), nonfatal myocardial infarc~ 
tion (Ml) or TVR during the follow-up period. 
Defmite. probable and possible stent thromboses (ST) 
were determined according to the ARC definitions. Stcnt 
thrombosis was defined as acute, sub-acute, late and very late 
if the event occurred within 24 h, 30 days,< 1 year or> 1 year 
respectively, after the procedure. Myocardial infarction was 
defined as creatine kinase-:ME mass increase > 3 times the 
upper limit of normal. associated with chest pain lasting 
> 30 mill or with new evident electrocardiographic changes. 
2.4. Data collection, and follow~up 
All data relating to hospital admissions. procedures and in-
hospital outcomes were collected in each center using the 
hospital recording network. Clinical follow-up was scheduled 
P!easecitethislllticleas: Me!igu. E. ctlil, lmpactofdrug-eludngstcntseleCtiQn onlong-tcnricliciculouteorru:s iri patients.t;rcn~OO.foruriprot<Xt«lleftmain ~onm:y 
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for all patients every 6 months up to 48 months by office visit 
or telephone interview. \Vhen the patient wus not reachable, 
the information was sought from the referring physician.. 
hospital electronic database or Municipal Civil Registries. At 
3 years the clinic::U follow~up was 100%. This protocol was 
approved by the hospital ethics committees and is in accor~ 
dance with the Declaration of Helsinki 
2.5. Statistical analysis 
Normally distributed variables were analyzed using 
parametric tests and non~normally distributed data using 
non-parametric tests. Continuous variables arc expressed as 
mcan±SD or mcdian±SD and differences were compared 
using Student t test or Mann Whitney test Categorical 
variables arc expressed as counts and percentages. Differ-
ences between sub-groups were assessed by Fisher exact test 
or chi~squarc test, as appropriate. Differences between the 
SES and PES groups were also tested according to lesion 
location. MACEs were reported hierarchically. A propensity 
score was constructed using logistic regression to control for 
potential confounders. The propensity score addressed the 
probability that a patient would receive either a SES or a 
PES and was computed using a logistic regression model, 
into whlch all the baseline clinical and angiographic vari~ 
abies contained in Tables 1 and 2 were entered. To adjust for 
possible confounders between the two groups. the resulting 
score as well as clinical. angiographic and procedural vari-
ables with a p value <0.1, were included as covariates in a 
Cox proportional hazards regression model. Survival curves 
were generated at mean of covariates and differences bet~ 
ween groups were evaluated and reported using hazard 
ratios (HRs) with 95% CI and p values. Landmark analysis 
Table 1 
&scline clinical chamctcristic~. n (%) 
SES (11m I 52) PES (n=136) P m!uc 
Ago 65,7±113 65.6±11.1 0.94 
Mro llO (72.3) 103 (75.7) 0.59 
B>JJ 27.4±4.1 26.5±5.4 0.34 
Arterial hypertension 107 (70.3) 85 (62.5) 0.16 
Hypcrcbol~ierolcmin 100 (65.7) 88 (64.7) 0.8 
Current h'lllO!cing 52 (34.2) 46 (33.8) 0.99 
Diabetics 55 (36.1) 39 (28.6) 0.16 
IDDM 24 (15.8) 28 (20.5) 0.35 
Fruniliar risk fuctor 35 (23) 38 (27.9) 034 
Previous AMI 72 (47.3) 6<i (48.5) 0.9 
Previous PC! 53 (34.8) 44 (323) 0.7 
Previous CABG 41 (27) 35 (25.7) 0.89 
Diagnosis at admis~ion 
Stable :mgina 72 (47.3) 86 (63.2) 0.006 
Unstable angina 75 (49.3) 46 (33.8) 0.007 
Silent ischemia 5 (3.2) 4 (2.9) 0.86 
LVEF 49.4:::12.3 50±11.7 0.7 
EuroSCORE 6.1±4 5.3±3.5 O.o7 
BMI. body ma.'<.'> index; IDDM, in.w!in dependent diabetes mc!li~ AMI. 
acute myocardial in:furctlon; PCI. percutaneous coron:uy intervention; CABG. 
comn:uy artery by-pa<;s gr:rl't:. L VEF, left ventricular ejection frnction. 
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Table 2 
Angiographic :md procedural ehw.teterihtics, n (%) 
SES (n"'152) PES {n=136) Pvaluc 
Osti.umlslmft lesions 37 (24.3) 41 (30.1) 0.26 
Dhltullcsions 115 (75.6) 95 (69.8) 0.29 
Single hient approach 48 (31.5) 37 (27.2) 0.41 
~ultiplc >tent approach 67 (44) 58 (42.6) 0.9 
v >tenting 13 {8.5) 9 {6.6) 0.53 
Thienting 19 (12.5) 2 (1.4) <0.001 
Crushing 35 (23) 24 (!7.6) 025 
Culotte 0 (0) 23 (16.9) <0.001 
Stent.~ per jXIticnt 1.5 1.4!; 059 
Stcnt di:unetcr 3.18±032 3.31±0.29 <0.001 
Stent length 17±7.5 18.6±6.9 0.07 
Pre-ciiilltion 72 (47.3) 51 (37.5) 0.19 
Thrombectomy 2 (1.3) 0 (0) OS 
Cutting 13 (8.5) 14 (10.2) 0.68 
Rombl:!tcr 3 (1.9) 4 (2.9) 0.71 
Athmctomy 2(1.3) 3 (2.2) 0.67 
PM -dilution 89 (58.5) 59 (43.3) 0.005 
PO>.i protedu.ral RVD 3.71±0.64 3.74±0.46 0.79 
PO>.i procedural MLD 3.33±0.65 331±0.52 0.86 
Other vessels tre:lted 75 (49.3) 67 (49.2) 0.99 
DES. drug-eluting sterll~ RVD, refcrence vessel dirunctl!l'; MLD, minimal 
lumen diameter: F1J, follow-up. 
wns performed with the landmark set at 12 months to 
provide separate descriptions of the early and late relative 
risk of :MACE in the SES and PES sub~groups. Outcomes 
between the two sub-groups were compared using risk ratios 
with 95% Cis. All analyses were performed using SPSS 
version 12 statistical software (SPSS Inc .• Chicago. lllinois). 
A two~tailed p value <0.05 was considered significant for 
hypothesis testing. 
Tablc3 
Adjm;tcd freedom from CD. ML TLR. TVR and MACE{%) at 3-yc:un; Ft: in 
the 05tiu!/shaft, di:>tal-sing1e >tent and distul-multi stent groups 
SES (11~152) PES (11"'!36) HR.' 95%Cl Pvalue 
OstiaUshaft (n ~ 78) 
CD 98.7 99.3 1.27 0.56-2.8 0.62 
'" 
93.8 96.7 3.57 0.36-8.9 02.7 
1U 96.1 96.3 1.03 0.06-1.41 0.86 
TVR 94.1 85.3 0.4 0.63-2.58 0.33 
MACE 76.3 83.1 1.78 0.53-5.94 0.34 
Distal·sing!t: (11 ~85) 
CD 96.7 92.6 0.51 0.09-2.67 0.42 
Ml 99.3 96.3 0.2 O.o2-l.S2 0.15 
TLR 98.7 98.5 0.72 0.15-4.8 0.81 
TVR 93.4 84.6 0.45 O.ll-1.7 0.24 
MACE 80.3 72.8 0.5 0.2-12.7 0.14 
D~,·tal-doubli: (n ~ 125) 
CD 97.4 95.6 0.4!; 0.1-2.2 0.34 
MI 9D.I 86.8 0.76 0.25-2.3 0.63 
TLR 89.5 85.3 0.56 0.15-2.1 0.39 
TVR 86.2 83.8 0.54 0.17-1.67 0.28 
MACE 67.1 66.2 0.61 0.3-1.21 0.15 
CD. cardiac dl:lllh; MI. myocardial infarction: TLR. tlrgct lesion rcvasculariza-
tion; TVR. tlrgct v~el revu:>culurization; MACE. major adverse cardiovns-
culur events. 
Please c!tcthi.~-tll'iictel!S'. MeligaE, ctal, lmp&cfo:!' dtug-elutlngstenisdcctlon onlong-tinn clinico.J outcomes In patict1tstte1rted forllnpr¢tected Jeftmaln¢rODlllY 
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3. Results 
3.1. Baseline clinical, angiographic and procedural 
characteristics 
Baseline clinical, angiographic and procedural character~ 
isticsofall patients (n=288) stratified by DES type are shown 
in Tables I and2. Duringthcsamcperiod. a total of680 patients 
with significant ULMCA disease underwent CABG in the 7 
participating centers. The SES group (n = 152 patients) and PES 
group (n= 13 6 patients) were comparable in all baseline charac~ 
tcristics with the exception of clinical presentation, the usc ofT 
and culotte stenting techniques, mean stent diameter and usc 
of post~dilatation. In both groups. approximately 75% of 
all lesions were distal and 600/n of these were treated with a 
double stent approach. The favored stcnting technique wus 
crush stenting. Differences depending on lesion location were 
tested and were not significant 
3.2. Follow-up clinical outcomes 
Clinical outcome at 3 years is stratified by DES type, 
lesion location and stenting approach and shown in Table 3. 
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All patients were followed-up for at least 36 months (range: 
from 36 to 60.2). Rates of survival free from any of the 
events investigated were independent from lesion location 
and stenting approach and did not differ significantly bet-
ween SES and PES groups. In the DISTAL-double sub~ 
group, usc of T~stcnting technique was associated Mth a 
significantly lower incidence of MACE (HR 0.21, 95% 
CI: 0.05-0.97.p=0.046). Adjusted curves derived from Cox 
survival analysis arc displayed in Fig. I. Freedom from MACE 
(SES vs. PES) was 76.3% and 83.1% in the ostial/shaft group. 
80.3% and 72.8% in the DISTAL-single group and 67.1% vs. 
66.2% in the DISTAL-double group. 
After pooling the DISTAL-single and DISTAL-double 
sub--groups. 3~ycar:frccdom from MACE in theSES and PES 
groups was 75.4% and 67.3% respectively (HR 0.65, 95% CI 
0.37-Ll5,p=O.l5). 
Definite ST occurred in 1 (0.3%) patients at439 days (very 
lateST). Probable ST occurred in I (0.3%)patientand possible 
ST in 12 (4.2%) patients. No acute, sub-acute and late ST 
occurred. Very lateST occurred in a patient with stable angina 
who underwent an elective PCI and received 3 PES for a 
significant lesion located in the distal left main (LM). One~ year 
DAT was recommended and. thus, at the time of the ST event 
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Fig. I. Adj~1cd MACE-free ~'Ul"Vivnl curves :md landmark :mnly~'i.~ of the o~1ia!hhaft (p:md A). DISTAWingle (panel B), DISTAL-double (p:mcl C) and wbolc 
DISTAL (p:mcl D) groups. Solid lines, SES group; dotted lines, PES group: RR. PES-SES ri>krntio with 95%confidence intervnl (in bmckct>). Dn~OM. Days 
free from MACE.l.m1dm:uk wus po~itioned ut 1 y= (ly). 
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was not ongoing. The event occurred in a patient who was 
classified as very bigh~risk patient ( euroSCORE"" 11 ). The ST 
event did not result in CD. 
4. Discussion 
The main findings of this study are the following: 1) at 
3 years. patients treated with SES and PES had similar inci-
dence of CD. Ml TLR. TVR and MACE-free survival; 
2) SES and PES performed comparably in bifurcation lesions. 
independent of whether a single and double stent approach 
was employed: 3) the majority of events in either group 
occurred within the first year, suggesting that the safety and 
efficacy profile of the two stents remain unchanged at long-
term follow-up; 4) when compared to SES. PES was asso-
ciated with a higher incidence ofMACE only within the first 
year offollow-up. 
Since their introduction into clinical practice, a number of 
trials and meta-analyses have compared efficacy and safety 
of SES and PES. In some cases. the results indicated that 
SES usc was associated with a lower risk of MACE [I 0], re-
intcrvention and stent thrombosis [9] while other studies 
demonstrated no differences in outcome [8,11]. In addition, 
others indicate that SES use may be associated with a lower 
incidence of TLR when deployed in challenging/high-risk 
lesions such as bifurcation lesions [12], small vessel size 
lesions [13] and long lesions [14]. 
Data comparing the relative safety and efficacy ofSES and 
PES in patients with VLMCA disease are lacking and when 
available only provide short-mid term follow-up. A previous 
study [15] reported no significant difference in angiograpbic and 
clinical outcomes associated with SES and PES usc for LMCA 
PCI at a median follow-up of22 months. However, long-term 
data are not available and it is still unclear whether lesion 
location or complexity may have a differential affect on device 
pcrfonnance and result in a significant difference in clinical 
outcomes. This bas been shown in non-lJLMCA populations. 
In our overall study cohort, adjusted freedom from adverse 
events at 3-year follow-up did not differ significantly between 
the SES and PES groups. The presumed advantage ofSES in 
terms ofTLR and MACE was not confirmed in this series of 
patients. Our findings indicate that performance of the two 
stents varies over time but that 3 year outcome does not differ 
significantly. 
In patients with ostialishaft lesions of an L'LMCA. both 
SES and PES were associated with excellent long-term clinical 
outcome. Our rc:,"Ults were in line with those recently reported 
by Chieffo ct al. in a similar population [ 5]. Interestingly, in our 
study freedom from CD (98.7% SES vs. 99.3%PES.p=0.62), 
TLR (96.1% SES vs. 96.3% PES p=0.86) and MACE (76.3% 
SES vs. 83.1% PES.p=0.34) was comparable to that reported 
in studies of highly selected populations with single de novo 
lesions that excluded patients with U'LMCA disease [16.17] 
Thus percutaneous treatment for this type oflesion may have 
the safety and efficacy requirements to be considered primary 
therapy. 
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In most non-left main randomized controlled trials. the 
lower incidence of TLR for SES was mainly related to a 
significantly lower in-stent late loss compared to PES. The 
impact oflate lumen loss on vessel hacmodyo.amics in ostial 
left main lesions may be less significant due to the relatively 
short stcnt length and bigger stcnt diameter. Thus, clinical 
outcome may depend less on differences between the two 
devices. Landmark analysis of the ostiallshaft sub-group sho-
wed that the two stents behaved similarly over time. Most 
adverse events in either both groups occurred within the first 
year (75% SES vs 82% PES). Thereafter the survival curves 
flattened progressively, suggesting a persistent anti~prolifcra­
tivc effect ofDES through time. 
Analysis oflesions involving the cfu;tal portion ofU'LMCA 
revealed no significant difference between SES and PES in the 
incidence of CD, !v11, TLR. TVR and MACE at 3-ycars. The 
stents performed equally whether the lesion was treated with a 
single or double stent approach. A previous study [12] with 
shorter follow-up reported that the deformed stent structure 
and overlapped struts may alter drug distnbution and reduce 
the efficacy of PES under these conditions. however this 
finding was not replicated in our study. In fact in both the 
DISTAL-single and DISTAL-double sub-groups, the land-
mark analysis showed a significantly higher risk ratio in terms 
of MACE associated with usc of PES within the first year that 
was not confirmed at the end of the follow-up period. 
Effects of sample size on these results and the po&."i.bility of 
introducing a type II error were tested by pooling the two 
DISTAL sub-groups. In this setting the landmark analysis 
again showed a significantly higher incidence of MACE 
associated with usc of PES only within the first year. In line 
with these results. long~tcrm follow-up NUS studies con-
ducted in patients treated with SES [18] and PES [19] show 
that, after the 1st year, the increase of neointimal volume was 
still significant in theSES (84% increase between 1st and 2nd 
year and an additional37% increase between the 2nd and the 
4th) while ithcldalmoststcady in the PES (<5% increase after 
the 1st year), suggesting a possible "eatch~up" phenomenon 
over time with SES. It is interesting to note that, in the 
DISTAL-double sub-group. the usc of T-stcoting technique 
was significantly associated with a lower incidence of MACE 
(HR 0.21, 95% CI: 0.04-0.97.p=0.04), suggesting that a less 
"aggressive" approach.. when feasible. lead to better clinical 
outcomes independent of DES type implanted. 
In this registry, definite ST occurred only in 1 case. The 
patient in whom definite ST occurred received 3 PES and 
was only taking a::.1Jirin at the time of the adverse event In 
our study, definite ST was not associated with cardiac death 
and the overall incidence was as low as in other high-risk 
DES populations. 
4.1. Limitations 
The present study was designed as a retrospective multi-
center registry and therefore lacks randomization and inten-
tion-to-treat data. Significant differences between the two sub-
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groups in tcnns of stent diameter, stenting technique and use of 
post-dilation. though included in the Cox model, may have 
influenced the results. Moreover, since no sample size calcu-
lations were performed, we acknowledge that our results may 
be affected by a type II error. 
5. Conclusions 
In elective patients who underwent PCI for de novo lesions 
in the ostium. shaft or distal ULMCA. long-term clinical 
outcomes with SES and PES use were similar and this finding 
was independent oflesion location and stentingtccbnlquc. The 
proposed advantage of SES, reported in some non-left main 
trials, was not confirmed in the present study. Our long-term 
clinical data suggest that in ULMCA lesions, SES and PES 
perform differently over time but ultimately arc associated 
with similar clinical outcome. 
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Abstract 
Aims: Diabetes mellitus (OM) plays an important role in the developme11t of coro11ary artery disease. 
Although previous studies have associated drug-elutil1g ste11t (DES) impla11tatio11 i11 diabetic patients with 
favourable cli11ical a11d at1giographic outcomes, the very lo11g-term efficacy of these devices i11 diabetic 
patients u11dergo"mg PCI for significant unprotected left mai11 coronary artery (ULMCA) disease has not 
been established yet 
Methods and results: Co11secutive diabetic patients (n::=lOO). who undetwel1t elective PCI with DES for 
de novo lesions i11 an ULMCA betwee11 April 2002 and Aprii 2004 i11 seven tertiary health care ce11tres, were 
identified retrospectively a11d a11alysed. Consecutive non-diabetic patients (n:=l93). who underwent elective 
DES implantation for ur1protected ULMCA disease, were selected as a control group. All patients were 
fOllowed for at least 36 months. At 3-years follow-up, freedom from cardiac death & myocardial il1farction 
(CDMI), target lesion revascularisatiorJ ITLRJ and target vessel revascularisation {TVRJ did not differ 
significa11tiy between groups. The adjusted freedom from major adverse cardiac eve11ts {MACE, defined as 
the occurre11ce of CD, Ml or TVRJ was 63.4% ir1 the OM group and 77.6% in the controls {P<l).OOll. When 
divided into lOOM a11d NIDDM sub-groups, il1sulin-dependent OM {lOOM) but not nor1 IDDM {NIDDMJ 
patie11ts had significantly :ower freedom from CDMI, TLR, TVR and MACE compared to controls. 
Conclusions: These results suggest that major improvements in DES technology and pharmacotherapy are 
still required to improve cli11ical outcome and that the decision to perform percutaneous revascularisatiot1 
in this subset of patients should be taken cautiously and on a case by case basis. 
*Corresponding author: Thoraxcenter, Ba-583, S Gravendijkwa/240, 3015 CE, Rotterdam, The Netherlands 
E-mail: p. w.j.c.serruys@erasmusmc.nf 
(f) Europ;J Ed11ian 2008. All ngh/5 rcs.::rved. 
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Introduction 
Diabetes mellitus negatively impacts clinical outcome in patients 
undergoing surgical or percutaneous arterial revascularisation1-3. 
Proposed explanations for this increased vulnerability include 
greater atherosclerotic plaque burden, longer lesion length and 
aberrant neointimal proliferation after stenting in diabetics. Several 
tria!s conducted in diabetic patients determined that percutaneous 
coronary intervention (PCI) with drug-eluting stents (DES) 
significantly reduced restenosis, resulting in superior long-term 
clinical and angiographic results, when compared with bare metal 
stents (BMS)4•5• However, whether PCI with DES is a safe and 
effective alternative to CABG remains a matter of debate&-9• 
Importantly, there is little data that addresses clinical outcome 
associated with DES use to treat unprotected lett main coronary 
artery (ULMCA) disease in diabetic patients, and studies reporting 
very-long term data are notably lacking. 
Thus, the aim of this study was to report for the first time, very-long 
term clinical outcome data for diabetic patients undergoing PCI to 
ULMCA lesions with DES, and to identify potential predictors of 
adverse events using an international, multicentre, retrospective 
registry design. 
Methods 
Population 
Consec1..'1ive diabetic patients who underwent elective PCI with SES 
or PES for de novo lesions in an ULMCA between April 2002 and 
April 2004 in seven European and US tertiary health care centres, 
were identified retrospectively and analysed. Patients were eligible 
for inclusion if they were undergoing pharmacological treatment 
with either hypoglycaemic agents or insulin at the time of the index 
procedure. Patients with acute myocardial infarction or cardiogenic 
shock at the time of admission were excluded from the analysis. 
Consecutive non-diabetic patients, who underwent elective DES 
implantation for unprotected ULMCA disease at the same centres 
over the same time period, were selected as a control group. All 
patients had confirmed myocardial ischaemia related to ULMCA 
disease. Factors that determined choice of a percutaneous 
approach over surgery included coronary anatomy and lesion 
characteristics, patient preference, referring physician preference 
and surgical risk. Patients were stratified by risk class using the 
European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) {Table 1). Subjects with a EuroSCORE >6 were 
defined as high-risk and those with a EuroSCORE >9 as very high-
risk. Data analysis was performed with the approval of the 
institutional ethics committees of the hospitals and/or universities 
involved. 
Procedures and medications 
All PCis were performed according to current guidelines. Route of 
arterial access, type of stent, stenting strategy, use of peri procedural 
glycoprotein lib/Ilia inhibitors, intravascular ultrasound guidance 
and prophylactic intra-aortic balloon pump use was at the discretion 
of the operator. 
Table 1. Baseline clinical characteristiCS-
OM., i:iOiiDM'" , P'v.lWf' 
(n•100) ~n·193) , 
Age (ye~rs) 55.5±9.6 65.4:!:11.8 0.44 
Moo 72(72) 141{73.1) 0.79 
BMI (Kg/m2) 27.7-±4.7 25.4±5 0.18 
Arterial hypertension 71(71) 124(64.2) 0.29 
Hypercholesterolaemia 65(55) 127(65.8) 0.98 
Current smoking 40(40) 59(30.6) 0.12 
IDDM 55{55) O(O) NA 
NIDDM 44(44) 0{0) NA 
Familiar risk factor 30(30) 44(22.8) 0.18 
Previous AMI 53(53) 85(44.6) 0.18 
Previous PO 36(36) 62{32.1) 0.52 
Previous CABG 19(19) 31(16) 0.52 
Diagnosis at admission 
Stable angina 50{50) 107(55.4) 0.37 
Unstable angina 49(49) 77(39.9) 0.13 
Silent ischaemia 1(1) 9(4,7) 0.09 
LVEF {"'o) 51.3±11.6 48.7;1:12.2 0.1 
EuroScore 6.2±3.74 5.65±3.96 0.25 
OM: diabetic pJticnts; non OM: non diabetic patients (control group); BMI: 
body mass index; IODM: insulin-liependent diabetes mellitltS; NIDOM: non 
insulin-dependent diabetes mellitus; AMI: acute myocardial infarction; PO: 
percutaneous coronary intervention; CABG: coronJry artery bypass gr.rft; 
LVEF: left ventricular ejection fulction 
All patients received 325mg of aspirin, clopidogrel (75 mg/daythree 
days prior to the procedure or 300-mg loading dose) and low-
molecular-weight or unfractioned heparin titrated to maintain an 
activated clotting time >250 s. Complete revascularisation was 
attempted in all patients at the time of the index PCI. Significant 
lesions that were not treated during the index procedure were 
staged and treated generally within one month. After the procedure, 
all patients were prescribed lifelong aspirin (75-100 mg/day) and 
prolonged {at least six months) dual antiplatelet therapy (OAT) of 
aspirin 100-325 mg/d and 75 mg/d c!opidogrel or 250 mg 
ticlopidine twice daily. Repeat revascularisation was only performed 
if there was either symptom recurrence or inducible ischemia 
related to the ULMCA disease. 
Definitions 
Technical success was defined as successfui deployment of a 
stent(s) in the target lesion. 
Procedural success was defined as ULMCA revascularisation with 
::::; 30% residual diameter stenosis by quantitative coronary 
angiography, without major procedural or post-procedural adverse 
events (death, myocardial infarction, emergency target vessel 
revascularisation or acute stent thrombosis). 
Death was classified as either cardiac (CD) or non-cardiac, 
according to the Academic Research Consortium (ARC) definition:0• 
Deaths that could not be classified were considered cardiac. 
Target lesion revascularisation {TLR) was defined as any repeat 
percutaneous intervention of the target lesion performed for 
restenosis or other complication of the target lesion. The target lesion 
was defined as the treated segment from 5 mm proximal to the stent 
to 5 mm distal to the stent 
Target vessel revascularisation ITVRl was defined as any repeat PCl 
of any segment of the target vessel, defined as the entire major 
coronary vessel proxima: and distal to the target lesion, including 
upstream and downstream branches and the target lesion itself. In 
the context of LMCA disease, the TVR definitior. comprises the 
whd.e lett coronary system. 
Major adverse cardiac event (MACE) was defined as the occurrer.ce 
of cardiac death (CD), nonfatal myocardial infarction (Mil or TVR 
during the follow-up period. 
Definite, probable and possible stentthromboses were determir.ed 
according to the ARC definitions. Stent thrombosis was defirted as 
acute, sutNcute, late and very late if the event occurred within 
24 hr, 30 days, <1 year or >1 year respectively, after the procedure. 
Myocardial infarction was defined as creatine kirtase-MB mass 
irtcrease >3 times the upper limit of rtormal, associated with chest pain 
lasting >30 min or with new evident electrocardiographic changes. 
Data co!!ection, ami fonow-up 
Information regarding clinical status was collected at clinic visits 
ar.d by telephone interview scheduled 30 days after the procedure 
artd then every six months. When the patient was not reachable, 
information were gathered from the referring physician, hospital 
electrortic database or Municipal Civil Registries. The data collection 
was carried out using a dedicated electronic case report form 
{CRF). Ail the explored variables in the CRF were defined and 
11umber-coded before the CRF was sent to each particip<~ting 
centre. At three years the clinical follow-up was 100%. This protocol 
was approved by the hospital ethics committees and is in 
accordance with the Declaratio11 of Helsinki. Written informed 
conse11t was obtained from every patient 
Statistical analysis 
Normally distributed variables were analysed using parametric tests 
and rton-normally distributed data using no11-parametric tests. 
Continuous var'1abies are expressed as mea11 ±SD and differences 
were compared using Student t test. categorical variables are 
expressed as cou11ts and percentages. Differe11ces beU.Veert sub-
groups were assessed by Fisher exact test or chi-square test, as 
appropriate. Bivariate a11d multiple variable analyses were 
performed to iderttify independe11t predictors of adverse events. 
Specifically, ail variables significantly associated with the clinical 
event of interest on bivariate analysis {jX(l.lO) were entered into 
subseque11t models. After appropriate checks for u11deriying 
assumptions, multivariate Cox proportional hazard analysis was 
then performed, with the enter method for ail pertinent covariates. 
Results of multivariate Cox analyses are reported as hazard ratios 
{HRl with 95% confidence intervals ar:d p values. MACEs were 
reported hierarchically. Survival curves were ge11erated at mean of 
covariates and differences between groups were evaluated and 
reported using hazard ratios (HRsl with 95% Cl and p values. 
1..'3ndmarkanalysis was performed with the la11dmarksetat 12 months 
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to provide separate descriptions of the early and late relative risk of 
MACE in theSES and PES sub-groups. Outcomes in the Wo sub-
groups were compared using risk ratios with 95% Cis. All analyses 
were performed using SPSS versiort 12 statistiC<ll sofuvare {SPSS 
Inc., Chicago, IL, USA). A two-tailed p value< 0.05 was considered 
significant for hypothesis testing. 
Results 
Baseline clinical, pmcedurai and angiographic 
characteristics 
Baseline characteristics are showrt in Table 1 and 2. Baseline 
characteristics were comparable in the study populatio11 (n,lOOJ 
and control group (n,193). The majority of patients were male, 
siightly overweight, with hypertension and/or hypercholesterolemia. 
Nearly half of the population had had a previous Ml and were 
admitted to the hospital with the diagnosis of stable angina. Among 
OM patiertts, 56% had IDDM and mean EuroSCOREwas6.2±3.74. 
Table 2. Angiographic and procedural characteristics, n(%). 
DM -- nonDM p \laltle 
. _ .(n•100) _ (n•193). 
Lesion location 
Ostium/shaft 21(21) 51(31.6) 0.55 
Distal 79(79) 132(58.4) O.Q7 
DES 
Cypher 51(51) 95(49.2) 0.09 
Taxus 39(39) 98(50.8) 0.09 
Approach 
Single sl:ent 56(56) 114(59.1) 0.61 
Multiple stent 44(44) 79(40.9) 0.51 
Stenting technique 
Provisional 55(56) 114(59.1) 0.61 
V stenting 8(8) 15(7.8) 0.94 
T stenting 5(5) 7(3.6) 0.57 
Crushing 26(26) 49(25.4) D.9 
Culotte 5(5) 8(4.1) 0.73 
Multivessel treatment 50(50) 94(48.7) 0.86 
Stents per patient 1.51:1:0.61 1.45±0.57 0.43 
Stent diameter {mm) 3.22±0.3 3.25±0.32 (),49 
Stent length (mm) 18.4±7.1 17.3±7.3 D.2 
Pre-dilation 68(68) 112{58) 0.19 
Thrombectomy 2(2) 1(0.5) ().59 
Cutting 9(9) 18(9.3) 0.91 
Rotablator 3(3) 4{2.1) 0.62 
Atherectomy 1(1) 4{2.1) D.S 
Post-dilation 79(79) 144(74.6) 0.45 
Maximal inflation pressure {atm) 16.7±3.1 16.9±2.6 0.68 
Final kissing 44(44) 74(38.3) ().68 
Bigger balloon size (mm) 3.5±0.46 3.5±0.59 0.61 
Post procedural RVD (mm) 3.78±0.54 3.69±0.56 0.43 
Post procedural MLD (mm) 3.41±0.53 3.27±0.6 0.23 
Angiographic FU 73(73) 131(67.9) 0.36 
OM: diabetic patients; nonOM: non diabetic patients (control group); DES: 
drug-eluting stent; RVO: reference vessel diameter; MLO: minimum lumen 
diameter; FU: follow-up. 
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In both groups, approximately 75% of all lesio11s were distal and 
4D% of these were treated with a double stent approach. The 
favoured ste11ti11g tech11ique was crush ste11ti11g. Duri11g the same 
period, a total of 680 patients with sig11ificant ULMCA disease 
underwent CABG in the seven partlcipatil1g centres. 
ronow-up clinical outcomes 
Short a11d long-term clinical outcomes are summarised in Table 3. 
All patients were followed for at least 36 months (range: from 36 to 
57). No major differences in clinical outcome were found betwee11 
the two groups at 30 days FU. Conversely, at 1-year, the incidence 
of CD, TLR, TVR and MACE was significantly higher i11 the OM 
group, compared to the controls. At 3--years FU, the incidence of 
overall death was 13% in the OM group and 7.2% in the non OM 
group (p=0.04). The i11cidence of TLR, TVR and MACE remained 
significantly higher in the study group but CD failed to reach 
statistical significance (p=0.058). 
Adjusted curves derived from Cox survival analysis are displayed in 
Figure 1 (panels A-D). Freedom from MACE was 63.4% in the DM 
group and 77.6% in the controls (P<(l.OOll but freedom from 
CD&MI, TLR and TVR did 11ot differ significantly between groups. 
When divided into IDDM and NIDDM sub-groups, lOOM but not 
NIDDM patients had sigl1ificantly lower freedom from COM I, TLR, 
TVR and MACE compared to controls. 
Table 3. Incidence of adverse events. 
In-hospital CD 
M1 
TLR 
lVR 
MACE 
30 days co 
MI 
TLR 
lVR 
MACE 
5 months CD 
Ml 
TLR 
lVR 
MACE 
1 year CD 
MI 
TLR 
lVR 
MACE 
3 years CD 
M1 
TLR 
lVR 
MACE 
DM 
~ .(n•lOO) 
1(1) 
3(3) 
0(0) 
0(0) 
3(3) 
2(2) 
3(3) 
1(1) 
O(O) 
5(5) 
4{4) 
3(3) 
4(4) 
7(7) 
15{15) 
8{8) 
3{3) 
7(7) 
12(12) 
24{24) 
10(10) 
3(3) 
10(10) 
15(15) 
31(31) 
· "" ·no·noM·" "j)"VilU'ii' 
(n•193) 
1(0.5) 0.45 
3(1.6) 0.22 
0(0) NA 
1(0.5) 0.65 
4(2.1) 0.26 
2(1) 0.3 
3(1.5) 0.22 
0(0) 0.34 
1(0.5) 0.65 
6{3.1) 0.17 
3(1.5) 0.13 
3(1.6) 0.22 
4(2.1) 0.18 
5(2.6) 0.05 
12(5.2) 0.009 
5(2.6) 0.03 
4{2.1) 0.26 
6{3.1) 0.07 
10(5.2) 0.02 
22(11.4) 0.003 
10{5.2) 0.058 
7(3.5) 0.26 
9(4,7) 0.04 
17{8.8) 0.04 
35(18.1) 0.005 
DM: diabetic patients; nonDM: non diabetic patients (control group); CD: cardiac 
death; MI: myocardial infarction; TLR: taf9& lesion rw.~SCUiarisation; TVR: target 
vessel revascutarisation; MACE major adverse cardiac events (MACE are reported 
hierarchie<~Uy). 
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Figure 1 (panels A·D). Freedom from CDMI, TLR, TVR and MACE. at 
means of covariates. The nonDM subgroup was taken as reference 
group. P values, derived from the comparison between each subgroup 
with nonDM, are shown only when statistical significance was reached. 
Multiple variable analyses 
Results of multiple variable analyses are presented irt Table 4. Of 
note, IDDM was identified as an independe11t predictorfor CD, TVR. 
TLR and MACE. EuroSCORE predicted CD and MACE, and 
hypercholesterolaemia, current smoking and stent diameter 
predicted Ml, TVR and TLR, respectively. 
Discussion 
The main findings of the present study are the following: 1) long· 
term freedom from CD and Ml of diabetic patients undergoing PCI 
for ULMCA disease are for the first time reported; 2) diabetic 
patierrts had a significantly higher incidence of MACE, comP<Jred to 
non-OM patients and this primarily reflects a higher TVR rate; 3) the 
majority of adverse events occurred within the first year and 
thereafter the event rate tertded to stabilise over time; 4) IDDM 
patients had significantly worse clinical outcome compared to 
NIDDM and non-DM patients. 
Diabetes mellitus plays a major role in the development and 
progression of corona!)' artery disease. Proposed mechanisms to 
explain the increased severity of CAD and poorer outcomes after 
PCis in diabetic patients include a heightened inflammatory 
response, endothelial dysfunction, increased plaque burden and 
altered coagulation processes1:·14• Introduction of DES has 
dramatically reduced t.'le rate of stent restenosis and broadened the 
indications for PCI. This advance has shifted many subSets of 
patients with complex angiographic disease into the realm of 
percutaneous revascularisation and away from CABG. Previous 
large studies of diabetiC patients have assodated DES Implantation 
with favourable mid-term ciinical and angiographic resu1ts2.1:...:7. 
However, the impact of DES on vety long-term clinical outcome is 
still largely unknown. Furthermore, the efficacy of these devices in 
diabetic patients undergoing PCI for significant ULMCA disease has 
not been established. 
For the first time, the present results indicate that DES implantation 
in diabetic patients with ULMCA disease is feasible and effective 
over time. Notwithstanding the higher risk profile of our cohort 
(mean EuroSCORE 6.2±3.74), freedom from CD and Ml was 
Table 4. Independent predictors of adverse events. 
IDDM 
Current smoking 
HR-4.597 
(1.159-18.237) 
p-0.03 
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comparable with that of a previously reported study in diabetics with 
other subsets of lesions:a19. Consistent with these results, freedom 
from TLR in the DM patients was not significantly different from the 
control group, confirming the results of previous IVUS studies in 
which DES led to similar results both in DM and non-OM patients20.21. 
The presertce of left main coronary artety disease, especially whert 
it is rtot associated with other vessel disease, does not appear to 
increase the risk of adverse events. We speculate that large vessel 
s'1ze together w'1tl1 prolonged dual arttiplatelet therapy that is usually 
prescribed to these patients may partially mitigate adverse 
responses previously determined in these patients after PC I. 
Diabetic patients had significantly higher 1-year MACE rates 
compared with non diabetic patients. This was mostly driven by a 
higher rate of TVR. These results are in line with the ARTS II 
diabetic sub-study findings22 and confirm the tendency in this 
subset of patiertts to develop rtew lesions and to have faster 
progression and more complex patterns of disease2324• 
Previous studies have associated paclitaxel-eluting stents with a 
s'1gnificant reduction in MACE 'm diabetic patients when compared 
to siroiimus. This advantage was hypothesised to be related to the 
different pathways targeted by the two compounds, which, in the 
case of paclitaxel was not affected by insulin-resistanceZS. Although 
in our study the sample size for this comparison is small, when 
tested in the multivariable model, SES and PES did not differ in 
efficacy. Although the "aggressiveness" of CAD in diabetic patients 
is indisputable, the relatively high incidence of MACE in this 
population could be also a matter of definitions. in fact, it is worth 
noting that in the context of LMCA disease, the TVR definition 
compr'1ses the whole left coronary system and therefore the 
likelihood of a re-intervention due to a new lesion is much higher In 
this subset when compared to populations with multivessel disease. 
The survival curves showed that adverse events mainly occurred 
within the first 12 months, while thereafter the curves progressively 
flattened. This tendency was particularly evident in the DM group, 
irt which 77.4% of all MACEs occurred within thefirstyearoffollow-up. 
Moreover, the landmark analysis showed a significantly increased 
risk ratio for incidence of MACE in the DM patients relative to the 
rton-DM group at one year. Our results, though underpowered to 
HR-3.678 
(1.123-12.044) 
p-o0.031 
HR-2.873 
(1.039-7.943) 
p-0.042 
HR~11.454 
(2.053-63.914) 
[J"''.005 
HR-2.590 
{1.581-4.244) 
!)<0.001 
Hypercholesterolaemia 
HR=4.487 
(1.365-14.749) 
poo0.013 
EuroSCORE 
Stent diameter 
HR~1.336 
(1.22-1.46) 
P<{l.001 
HR,.1.524 
(1.326-2.687) 
p--0.002 
HR~l.063 
(1.001-1.128) 
[J"''.047 
CD: cardiac death; MI: myocardial infurction: TLR: target lesion revascu!arisation; 1VR: target vessel revascularisation; MACE major adverse cardiac events; 
IDDM: insulin-dependent diahctes mellitus 
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detect these differences, are consistent with findings in previous 
studies that identify diabetes as a strong Independent predictor of 
progression of atheroma burden23.24 . Based on our findings, 
diabetic patients with ULMCA disease undergoing PCI with DES 
im:?lantation should be followed closely, and especially during the 
first year after the procedure. 
In the present study, adverse outcorr.e comprising CDMI, TLR, TVR 
as well as MACE W<Js significantly increased in diabetics treated with 
insulin. In contrast NIDDM patients had clinical outcomes that were 
not significantly different from the control group. This finding, which is 
consistent with prior reports19.26-28, has several potential explanations. 
These include direct effects of exogenous insulin on neointirnal 
prol"tferaf1on and express"1on on IL-6 and TNP.30. Furthermore, type 
II diabetic patients may have more severe cardiovascular disease at 
the time when insulin treatment is instituted3'.32. 
At 3-year follow up, SO% of IDDM patients experienced an adverse 
event In IDDM patients that underwent surgical revascularisation, 
the 5-year incidence of death was 12.2%33 while the incidence of 
MACE W<Js 25%34• Though limited, these results suggest that major 
improvements in DES technology and pharmacotherapy are still 
required to improve clinical outcome and that the decision to 
perform percutaneous revascularisation in this subset of patients 
should be decided cautiously and on a case by case basis. 
limitations 
The present study was designed as a retrospective multicentre 
registry and therefore lacks randomisation and intention-to-treat 
data. Since no sample size calculations were performed, we 
acknowledge that our results may be affected by a type II error. 
Moreover, information on HbAlc is missing and its potential impact 
on clinical outcomes could not be evaluated. 
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CHAPTER 5 
PERCUTANEOUS CORONARY INTERVENTION 
OR CORONARY ARTERY BYPASS GRAFT 
FOR UNPROTECTED LEFT MAIN CORONARY 
ARTERY DISEASE: THE ENDLESS DEBATE 

with r=cuhrization up to 24 months, and in the TOSCA-2 
(Total Occlusion Study of Canad:t) trial (24), a substudy of the 
OAT study, there was a trend toward more favorable remodeling. 
The re~:ults of the OAT study do not prove or disprove the 
benefits of !ate revn.sculari.zation in patients similar to the patients 
in the OAT study and certainly do not apply to the entirety of 
po~1:-Alvii patients. Unfortunately, de>-pite the efforts of investi-
gators like the OAT Investigators, only 3,560 patients have been 
randomized to d:tte, and they may not be enough to draw 
meaningful conclusions mdlor identifY subgroups of patients with 
greatest benefit or risk from late revn.sculariz:ttion. 
We thank Dr. Dl::tvik and colleagues for this opportunity to 
c1ariJY that our analysis was not designed to prove or disprove the 
findings of the OAT study, which likely applies to a minority of 
patients after .A..\11. Instead, we set out to analyze :ill available 
evidence and demonstrated the benefit of late rcvascularization of 
the IRA late after AJI.fl. 
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Percutaneous Coronary 
Intervention or Coronary Artery 
Bypass Graft for Unprotected 
Left Main Coronary Artery 
Disease: The Endless Debate 
Th-e ~state-of~ the art paper written by Taggart et al.. (1) calls into 
qu-estion the current evidence in support of percutaneous coronary 
intervention (PCI) for the treatment of unprotected left main stem 
disease. In view of the :fuct that current guidelines still indic:tte 
coronary artery bypass grafting (CABG) as the "standard of care,~ 
the authors conclude that the use of drug-eluting stents (DES) in 
"off-label~ cases should be discouraged and that good surgic:tl 
54 
candidates with unprotected left mn.i.n coron:uy artery (ULMCA) 
dise:lSe should undergo surgical revnscul.arization. These conclu~ 
sions, although absolutely reasonable, r.tise 2 questions: 1) Is 
CAJ3G really proven to perform better thm PCI in this subset of 
patients? 2) Is CABG to be recommended in :ill good surgical 
candidates? 
In m attempt to justif}r their conclusion, the authors presented 
6 studies conducted in patients with ULMCA disease who had 
undergone CABG. Of note, none of these studies had clinical 
follow-up periods of longer tbnn 2 years, md only 2 out of 6 had 
a clinical follow-up longer than 1 year (Lu et al. [2] and Yeatman 
ct al. [3]). The mortality rate of 5% to 6% reported by these studies 
is truly encouraging. However, the authors did not mention the 
impressive occurrence of post-procedural morbidity in these pa-
tients. In the study conducted by Lu et al. {2) on 1,197 patients 
who underwent CABG for L"LMCA, the rntcs of in-hospital 
adverse events were the following: mortality 2.8%, renal failure 
3.9%, g:tstrointestin:ll complications 3.6%, stroke 2.2%, post~ 
procedurnl myocardi:ll infarction 7.1%, reoperation for bleeding 
2.8%, stcm:ll wound infection 42%, chest infection 5.3%, venti~ 
htion >48 h 6%, stay after oper:1tion >14 d:tys 9.3%. The 
incidence of death in patients undergoing CABG for Ul.l\1CA 
clisease was reported to be 11.3% at 1 year in the Cleveland Clini.c 
Foundation Data (4), 12.8% at 3 yeas in the New York Byp:ass 
Surgery Registry (5), 13.2% at 5 years in the study conducted by 
d'.AJlonnes et al. (6), and 22.6% at 5 years in the Duke Carcliology 
Datlbase (7). These results are far worse tha.n those reported by 
the authors and do not appear to be superior to those reported in 
5ever::U PCI studies. 
In discussing the experience with bare~met:ll stents (EMS), the 
authors presented the results from earlier PCI studies that enrolled 
almost exclusively high~risk patients. The upoot late outcomes 
after ULMCA stentingwith EMS are compared with the excellent 
results obtained in the SoS (Stentor Surgery) trial. This compar-
ison of u:tpples versus pears,~ i.e,, left main dlsease in high-risk 
patients versus 2~ to 3~vessel clisease in stable patients, is not a 
proper scientific argument, In that speci£c study, the comparison 
betWeen CABG and PCI resulted in no sutistic:illy significant 
differences in terms of death, myocardial infarction, or stroke :tt 
1-year follow~up (8). With regard to DES implantation, the 
authors describe a selection of studles that presents an important 
nonhomogeneity in terms of trial design: consecutive (e.g., Valgi~ 
migli et al. [9], Lee et al. [10]) vs. selective (de Lczo et al. [11]) 
patient enrollment a.nd, in some studies, the usc of DES was not 
exclusi.ve (e.g., approximately 40% of patients from the Bologna 
Registry received EMS). Moreover, the authors clid not take into 
account the importance and influential outcomes of the various 
~1:enting techniques used for distal left main dlsease. 
It therefore seems difficult to draw any conclusions from the 
pooling of these results :tnd, furthermore, compare them with the 
outcomes obtained in the surgical literature. In the DELFT 
(Drug Eluting stent for LeiT main) registry (12), the 3~year 
incidence of e:trdiac death, target vessel revascularization, and 
major adverse c:ll'diovn.scular events (MACE) in the elective 
subgroup was 6.2%, 16%, :tnd 30.5%, respectively. Recent 
studles conducted on patients with ULMCA who underwent 
surgical revascularization reported a similar incidence of death, 
a lower incidence ofTVR, but an apparently greater incidence 
of MACE (9,13). 
Additionally, it was noted by the authors that distal left main 
disease is a major and independent predlctor of MACE at 
mid~term follow~up (9) and argued that: uthc precise anatomical 
location and complexity of left main stenosis , , . have negligible 
influence on the success of CABG.~ Two issues deserve further 
cbrification with respect to this statement: 1) In patients under~ 
going PCI, distal left main disease is associated with a higher risk 
for reintervention but not necessWy death or myocardial infarc~ 
tion. which :1te predominantly affected by surgical risk status. 2) To 
the best of our knowledge, there are no data supporting the notion 
that outcomes after surgery arc not affected by the location of the 
lesion within the left main stem. Distal left main disease may 
simply be a marker of severe, dllfuse coronary disease and, as such, 
C:ll'I'Jwith it a worse prognosis irrespective of the final revascular~ 
iz:ttion strategy. 
In all major institutions, current standard approach to patients 
presenting with significant ULMCA disease is to have them 
evaluated by both interventional cardiologists and cardiac surgeons 
and to reach the decision to opt for PCI or surgery by consensus, 
on the basis of. 1) hemodynamic conditions; 2) lesion chmcter~ 
istics; 3) vessel size; 4) the presence of comorbidities; 5) quality of 
:ll'terial mdlor venous conduits for grafting; and 6) patient :tndlor 
referring physician preferences. Patients are :llways fully informed 
about the potcnti.al risks and outcomes ofboth the surgical :tnd the 
percutaneous approaches. Stating that ~patients n.re influenced into 
making a pre-ordained choice~ and that cardiologists ~instigm:e~ 
patients in making these choices is speculative. 
Should all good candidates for surgery go to surgery and poor 
candidates to PCI? So far, there is no strong evidence that one 
approach i.~ better than the other in terms both of clinical outcomes 
and quality of life (QslL). A recent meta~analysis by Bravata et :ti. 
(14) of 23 randomized controlled tri:lls showed no difference 
betWeen PCI and CABG in terms of mortnlity :tt 10 years' 
follow~up. Health-related Q>L is of particular value in coronary 
artery disease, because the objective of intervention is not only to 
avoid clinical adverse outcomes but also to relieve symptoms md 
improve function and ability to participate in daily activities. 
Long~term stuclies comparing Q>L related to these 2 therapeutic 
strategies arc not available but the results coming from the 
available literature reported so far no major dift'erences (15-18). 
Current guidelines still recommend surgical revascularization as 
the primary procedure in ULMCA patients, but considering them 
as ~the body of criminal hw~ is not :llways appropriate. Guidelines 
are dynamic and in const:tnt flux and have to be updated according 
to new evidences coming from clinical experience, and not vice-
versa. It is important to realize that new~generation DES approved 
for clinical use, new technical stratcgles, and prolonged dual-
antiphtelet treatment have slgnificantly decreased the risk of 
adverse events (including late in~stent thrombosis) after PCI. 
fundornized clinical trials arc necessary to shine a light on this 
endless debate, The LE..\1ANS trial (19) ill the only reported 
randomized trial comparing PCI versus CABG for ULMCA 
disease. The increased short~term complication rate in the CABG 
group appeared to be minimized by stressing similar 1~year 
:MACE results in the 2 groups. Moreover, no late in-stent 
thrombosis occurred both in the BMS and in the DES groups, 
demonstrating that percutaneous treatment of UL\1CA is safe. 
Results of the complete SYNTIIX (TAXUS Drug-Eluting Stent 
Versus Coro=y Artery Bypass Surgery for the Treatment ofNar~ 
rowed Arteries) study, which enrolled 700 randomized patients with 
UL\1CA disease, will be presented at the 2008 European Society of 
Cardiology congress. Until then, judicious individual assessment of 
each patient should prev:lll, that ill to say, we should keep trying to 
treat p:ttients-tlut do not fit in the current recommendatioru.~ 
according our current clinical experience and judgment. 
~On the mt:!:mlaim of truth you can m:ver dimb in win: titherJfm 
will read; a point higher up today, r:;r Jfm will be training yrmr 
po"Jxr-s so that you will be able to dimb higher tfnntn'rlr.;;.~ 
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Reply 
We are grateful to Dr. Mcligu and colleagues for their interest in 
our :J.rti.cle (1). They mise sevecl imponant issues that we will 
address in a slmilar order. 
The first issue deals with mortality and morbidity after coronary 
artery bypass grafting (CABG), As referenced in our article (1), the 
mortality for ill 5,003 patients with left main stem stenosis 
undergoing CABG in the United Kingdom in 2003 was 3% (and 
<2% in 17,000without left main stem [LMS] stenosis and 1% in 
3,102 patients in the ART [Arterial Revascularisation] trial). 
Because enough is known about post~CABG complications, risk 
models have been developed to reliably predict their occurrence, 
whereas si.m.ilar data are quite lacking in the percutaneous coronary 
intervention (PCI) domain. 
In addition, although :ill postoperative morbidity is unsatisfuc-
tory, the reality is that, with the exception of stroke (1% to 2%), 
most of it is self-limiting and of little consequence to the patient 
over the long term. To eqtmte early postoperative morbidity to the 
reduced survival and marked increase in the need for reintervention 
with PCI over the long term is arguably a :fulse economy. 
Furthermore, long~tcrm mortality from CABG (as well as PCI) 
may also reflect other co-existing morbidities, rather than being 
attributable to ischemic heart disease. 
VVith regard to b:rrc-met:U stents, we stated explicitly that 
superior results were obtained in lower-risk patients and that, as 
for CABG, the results of PCI would also be disadvantaged by 
greater~risk patients. Although Dr. Me!i.ga and colleagues state 
that there was no significant difference in mortality betvreen 
CABG and PCI in the SoS (Stent or Surgery) trial at 1 year, it 
should be noted that, at 5~year follow-up in this srudy (2), there 
was a significant reduction in the risk of mortality with CABG 
(6.6%) versus PCI (10.9%), reinforcing the well-known observ:t-
tion that the bendit ofCABG often accrues with time. We agree 
with Dr. Meli.ga and colleagues that substantial heterogeneity 
among drug-eluting stent trials precludes pooling them together. 
Accordingly, we did not perform a meta-analysis. Our aim was 
simply to present ill the published studies in the literature. 
The complexity and precise anatomical location of distal left 
main stem disease, along with its frequently associated multivessel 
coronary disease, is not relevant during CABG because bypass 
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Long-Term Clinical and Angiographic Outcomes of Treatment of 
Unprotected Left Main Coronary Artery Stenosis With 
Sirolimus-Eiuting Stents 
Imad Sheiban, MD:l.,*. Emanuele Meliga, MD'\ Claudio Moretti, MD'\ 
Giuseppe G.L. Biondi-Zoccai, MD', Giuseppe Rosano. MD, PhDb, Filippo Sciuto, MD'. 
Walter Grosso Marra, MD'\ Pierluigi Omede, MDa. Argyrios Gerasimou, MDa, and 
Gian Paolo Trevi. MDa 
Favorable early results of percutaneous drug-.eluting stents in unprotected left main (LM) 
disease are available, but outcome data beyond 6 to 10 months are lacking. We evaluated 
the long-term results of sirolimus-eluting stents (SESs) in patients with LM disease. From 
November 2002 to December 2004, consecutive patients with LM disease, without contra-
indications to double antiplatelet therapy and undergoing SES implantation, were enrolled 
prospectively. The primary end point of the study was occurrence of major adverse 
cardiovascular events. In tota185 patients were treated with 118 SES and followed for 595 
± 230 days. Event-free survival rates at 1 year and 2 years were 85.5% and 78.6%, 
respectively. Only 2 deaths occurred overall (2.4% ), the first in-hospital in a very high-risk 
patient according to the European System for Cardiac Operative Risk Evaluation and the 
second in a patient with severe systolic dysfunction already at the index procedure). 
Myocardial infarction was adjudicated in 3 patients (3.6%), 2 occurring periprocedurally 
and 1 during follow-up for a de novo nontarget lesion. There were 7 (10.8%) target lesion 
revascularizations at 24 months, with all but 1 percutaneous and in a subject with bifur-
cation LM disease at baseline. At 9-month angiography, late loss was 0.15 ± 0.81 mm and 
restenosis rate was 8.2%. An increased incidence of adverse events was noted in patients 
undergoing SES after dilation with extremely oversized balloons. No case of stent throm-
bosis was reported. In conclusion, this single-center experience suggests that percutaneous 
use of SESs to treat LM disease in unselected high-risk patients is safe and effective even 
1 year after implantation. © 2007 Elsevier Inc. All rights reserved. (Am J Cardiol2007; 
100:431-435) 
Use of drug-eluting stents in real-life patients with unprotected 
left main (LM) disease is becoming more common. at least in 
selected centers.1.:: de~;pite the uncertainty on their long-term 
outlook.3 It is thus pivotal to accurately appraise the outcome 
of sirolimus-eluting stent (SES) implantation after the conven-
tional threshold for midterm follow-up (i.e .• 6 to 12 months). 
Toward this aim. we conducted a prospective single-center 
observational study to assess the long-tenn safety and efficacy 
of SES implantation in patien~ with LM disease. 
pected coronary artery disease. we prospectively enrolled 85 
consecutive patients (4.0%) with significant LM stenosis 
(C!:50% diameter stenosis by visual estimate). coronary 
anatomy suitable for percutaneous revascularization. and 
undergoing SES implantation. SESs (the default drug-elut-
ing stent in our center) were used without restrictions. i.e., 
in patient$ with chronic stable angina pectoris with docu-
mented myocardial ischemia and those with acute coronary 
syndromes (unstable angina pectoris, ST -elevation myocar-
dial infarction. non-$T -elevation myocardial infarction). 
Only patient$ with contraindications for antiplatelet or an-
ticoagulation therapy or allergy to sirolimus were excluded. 
Methods 
From a total population of 2.126 consecutive patients re-
ferred for coronary angiography to our institution (a tertiary 
academic care center with an annual caseload of > 1,000 
percutaneous coronary interventions) between November 
2002 and December 2004 because of established or sus-
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Patients were stratified into risk classes using the Parson-
net~ and European System for Cardiac Operative Risk Evalu-
ati.Qn (EurOSCORE)S systems. High-risk subjects were defined 
as those with a Parsonnet score 2::15 or EuroSCORE 2::6. and 
very high-risk patients as those with a Parsonnet score 2::20 or 
EuroSCORE C!:13. Notably. none of the included patients had 
absolute contraindications to bypass surgery. All patients were 
fully informed about the possible early and late risks of the 
procedure and of alternative management strategies. and writ-
ten infonned consent was obtained from all patients. All pa-
tients received pretreannent with low-molecular-weight hepa-
rin or unf:ractionated heparin, aspirin. and clopidogrel (!5 mg/ 
www.NConline.org 
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day begun 2:3 days before the procedure or 300-mg loading 
dose). Periprocedural use of glycoprotein llb/illa inlnbitors 
was at the discretion of the operator. After the procedure, 
patien~ received clopidogrel 75 mg/day for 6 months for 
patients with stable coronary disease at admission and 12 
months for those with unstable coronary disease. and aspirin 
<::.75 mg indefinitely for all. The study complied with the 
Declaration of Helsinki. and formal ethics committee approval 
was waived because of the observational design. 
Intravascular ultrasound was perfonned for lesions with 
inadequate visualization by angiography only (e.g., prepro-
cedurally for highly eccentric but noncritical stenoses and 
periprocedurally to clarify the nature of luminal haziness). 
Predilation of the LM coronary artery was pctfonned only 
in case of very tight or calcified lesions by using undersized 
conventional balloons. Stent deployment was achieved by 
inflating the delivery balloon at nominal pressure. Addi-
tional de bulking devices (rotablator or cutting balloon) were 
used only in patients with fibrous/calcified lesions in which 
predilation 'Nith standard balloons failed. Stent overexpan~ 
sion 'Nith high~pressure inflations with short noncompliant 
balloons was performed in those selected cases 'Nith subop-
timal stent expansion by visual assessment taking care not 
to determine geographic miss or edge dissection.6 Regard-
less of lesion location, the LM artery was fully stented in all 
patients. Lesions involving the ostium or shaft without in-
volvement of bifurcation (n = 33) were treated 'Nith a single 
stent whereas lesions involving bifurcation (n = 52) were 
treated with 1 of the follo'Ning procedures according to 
operator choice: stenting across the left circumflex coronary 
artery (n = 6), stenting across the left anterior descending 
ostium (n = 7), kissing stenting (i.e., V stenting: n = 8). or 
provisional T stenting (n == 31). In no cases were "crushing" 
and "culottes" techniques performed.7.t~ Final kissing bal-
loon dilation was petformed in all 52 patients with distal 
LM bifurcation lesion. Procedural success was defined as 
LM revascularization 'Nith a residual stenosis <30% at 
online quantitative coronary angiogram. without major pro-
cedural or postprocedural adverse events (death. myocardial 
infarction. or emergency target vessel revascularization). To 
ensure the safety and efficacy of revascularization proce-
dures. all were performed by 2 experienced interventionists 
(IS and CM) with a personal caseload of > 1.000 percuta-
neous coronary interventions and extensive experience in 
ancillary techniques (e.g .. intravascular ultrasound and use 
of the Rotablator). 
Quantitative coronary angiography was performed using 
dedicated software with an automated edge-detection sys-
tem (Inturis Viewer 1.2. Philips Medical Image Packing 
System. Eindhoven. The Netherlands). For the purpose of 
this study, baseline, postprocedural. and follow-up quanti-
tative coronary angiographies were performed offline. Min-
imal lumen diameter, percent diameter stenosis. reference 
vessel diameter. lesion length. acute gain, and late loss were 
evaluated.Q Binary rcstenosis was defined as lumen decrease 
>50% at the segment site on quantitative angiogrmn. and 
the specific pattern of restenosis was adjudicated. 10 After 
discharge. patients were evaluated in the outpatient clinic 
from 30 to 40 days. Angiographic follow-up was scheduled 
after 6 to 9 months or sooner if driven by clinical symptoms 
or documented myocardial ischemia. Patients were then 
Table 1 
Ba.'>C!ine clinical cbar:~cteristics (n "' 85) 
Age~) 
Arterial hypertension 
Blood hypercholesterolemia 
Current smoking 
Noninsulin-dcpendcnt diabetes mellitus 
Insulin-dependent diabetes mellitus 
Chronic renal failure 
PcripherJ.I artery di~c 
Previous myocardial inf:~rction 
Previous percut:mcous coronary intervention 
Prcviou.~ coronary artery bypru;s grafting 
Diagnosis at :~dm.ission 
Stable angina pectoris 
Silent myocardial i'>Chem.ia 
Acute pulmonary edema 
Unst:!blc angina pectoris 
Non-ST-clcv:~tion myocardial infarction 
ST-elevation myocardial infarction 
Left ventricul:lr ejection frnction (%) 
EuroSCORE 
P:m:onnct score 
Table 2 
Angiogruphic and procedurnl charnctcristics (n "' 85) 
Lesion 1oc:!tion 
Ostium 
Shaft 
Bifurcation 
Multivesscl coronary disease 
Multives._'>Cl coronary stenting 
Glycoprotein IIb!IIIa inhibitor u.~e 
lntr:wa.'\Ctll:lf ultru.wund 
Intra-aortic balloon pump 
Rotational athercctomy 
Stent~ per patient 
Stent di:uneter (mm) 
Stcnt length (mm) 
After dilat:!tion (%) 
Maximal intl:ltion pressure (atm) 
Treatment for bifurcationallcsions 
1 stent 
2 stents 
Final kissing balloon 
68:!: 10 
70 (82%) 
72(85%) 
49 (58%) 
20 (24%) 
9(11%) 
9 (11%) 
3(4%) 
20(24%) 
25 (29%) 
24{2&%) 
16(19%) 
11 (13%) 
11 (13%) 
1(1%) 
40 (47%) 
6 (7%) 
11 (13%) 
55:!: 10 
13:!: 5 
12:!: 7 
14(17%} 
20 (24%) 
52(61%) 
75 (88%) 
69(81%) 
30 (35%) 
9(11%) 
7(8%) 
1(1%) 
1.38 (118/85) 
3.21:!: 0.29 
14.1 :!:5.4 
55 (65) 
18.8:!: 2.8 
24(46%) 
2S (54%) 
52(100%) 
followed by outpatient visits or monthly telephone inter-
views. A final telephone interview or office visit was per-
formed at the end of the follow~up period in every patient 
Occurrence of adverse events was documented by hospital 
records or coroner report. with deaths categorized as due to 
cardiac and noncardiac causes. In particular. those deaths 
that were not classifiable but had no other underlying pos-
sible cause were considered cardiac. 
The primary end point of the study W'J.S occurrence of major 
adverse cardiovascular events (MACE) at follow-up. defined 
a.~ occurrence of death. nonfatal myocardial infarction. or tar-
get vessel revascularization (including target and nontarget 
lesion revascularizations). Myocardial infurcti.on was defined 
as a creatine kinase-MB mass increase >3 times the upper 
limit of normal. Acute or subacute stent thrombosis was de-
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Table 3 
Major ;~dverse cardiovascular event~ daring follow-up 
Cumul:rtive Rate of Adverse Events rn Hospital 3-mo Follow-up 
(n "'85) (n"' 85) 
Domh 1 {1.2%) 1 (1.2%) 
Myocardial infarction 2(2.4%) 2(2.4%) 
Target lesion reva."tuluri7ztion 0 0 
Target ve~sel re~culurizution 
Stent thrombo~is 
Stroke 0 
Total MACES~ 3{3.5%) 3(3.5%) 
~Defined a_~ de~th. rnyoe:rrdial infarction, or target vessel reva_'ICuluriza.tion. 
fined as angiographic evidence of stent occlusion or cardiac 
death or myocardial infarction within 24 hours or 30 days, 
respectively, after the procedure.11 Late stent thrombosis was 
defined as angiographic evidence of stent thrombosis. cardiac 
death, or myocardial infarction in the target territory (Le., left 
anterior descending or left circumflex coronary artery) occur-
ring 30 days to 6 months after the procedure, Very late stent 
thrombosis was defined as angiographic evidence of stent 
thrombosis or cardiac death or myocardial infarction in the 
target territory or myocardial infarction in the target territory 
occurring >6 months after the procedure. 
Data are expressed as mean ±. SD for continuous variabl~ 
and as frequencies for categorical variables. Differences be-
tween groups were assessed using chi-square and Student's t 
tests. A 2-tailed p value <0.05 was considered statistically 
significant Overall survival and survival free from MACEs 
were assessed according to the Kaplan-Meier method. Multi-
variable analysis was performed to detect clinical and angie-
graphic variables related to acute and long-term events. 
Results 
Baseline clinical and angiographic characteristics are listed 
in Tables 1 and2. Patients' mean age was 68 ± 10 years: 24 
patients (28%) patients had previous percutaneous coronary 
intervention on other coronary vessels, 20 (24%) had pe-
ripheml artery disease. and 4 (5%) chronic renal failure; and 
ejection fraction was 52 ±. 10%. The principal clinical 
indication for referral was unstable angina in 40 (47%) 
followed by acute myocardial infarction in 17 (20%), with 
ST~elevation myocardial infarction in 11 (13%) and non-
ST~elevation myocardial infarction in 6 (7%). 
On baseline angiogram multivessel coronary artery dis-
ease was found in 75 patients (88%) and multi vessel treat~ 
ment was performed in 69 (92%). LM coronary lesions were 
located mainly at the bifurcation in 52 (61%). and a minor-
ity involved only the ostium (14, 16%) or the shaft (20, 
23%). According to the EuroSCORE and Parsonnet scoring 
systems 29 patients (34%) were considered at high risk and 
15 (17%) at very high risk. Lesions not involving bifurca~ 
tion were treated with a single stent; distal lesions were 
treated with a single stent in 24 patients (43%) by a provi-
sional T~stenting technique and with 2 stents in 28 patients 
(57%) using a modified T~stenting technique or V stenting. 
Baseline reference vessel diameter was 3.84 ±. 0.46 mm. 
minimum lumen diameter was 1.41 ±. 0.46 mm. and mean 
percent stenosis was 62.1 :± 12.3%. rn totalll8 SESs were 
6-mo Follow-up 12.-rno Follow-up 
(n "'85} (n = 85) 
1{1.2%) 2 (2.4%) 
3 (3.6%) 3 (3.6%) 
2{2.4%) 5(6.0%) 
2{2.4%) 5(6.0%) 
0 0 
0 0 
6{7.1%) 10{12%) 
Table 4 
Q=titative coronary angiogrupby 
Baseline angiography (n ~ 85) 
Reference vessel diameter (mm) 
:M:inimum lumen diameter (mm) 
Diameter stenosis(%) 
Po~tproccdural angiography (n = 85) 
:M.inimu.rn lumen diameter (mm) 
Diameter stenosis(%) 
Acute gain (nun) 
Follow-up angiography (n "' 71) 
Minimum lumen diameter (mm} 
Diameter stenosis(%) 
Lmc lumen lo:;s (mm) 
Binary angiogmphic restenosis 
Om'll 
Focol 
Diffu."t 
Ostium or shaft lesion.~ 
Bifurcation lesions 
24-mo Follow-up 
(n "'65) 
2(3.1%) 
3(4.6%) 
7 (11%) 
7 (11%) 
0 
12(19%) 
3.S4:!: 0,4() 
1.41 :!: 0.4() 
62.1:!: 12.3 
3.53 :!: 0.35 
9.4:!: 4.2 
2.12:!: 0.49 
3,03:!: 0.83 
18.9:!: 7.2 
0.15:!: 0.81 
7(10%) 
6(86%) 
1 (14%) 
1 (14%) 
6(86%} 
implanted. with a stent diameter of 3.21 ::: 0.29 mm and a 
stent length of 14.1 ±. 5.4 mm. 
Procedural details are listed in Table 2. and in~ho:>"Pital 
events are presented in Table 3. Procedural success was ob-
trtined in 82 patients (97%), with intraprocedural death occur-
ring in 1 patient (1%) and postprocedural non-Q-wave myo-
cardial infarction in 2 patients (2%). No patient had acute 
in-stent thrombosis. emergence coronary artery bypass grafting, 
stroke.. or cardiac arrest Overall complico.tions rate was 3.4% 
(3 patients). Minimum lumen diameter changed from 1.41 ± 
0.46mm to 3.53 ± 0.35 mm with an acutegainof2.12::!:: 0.49 
mm. Mean residual stenosis was 9.4 ±. 4.2% (Table 4). 
Clinical follow-up was complete and all patients were 
followed for 2::12 months after the percutaneous procedure. 
Mean follow-up duration was 596 ±. 230 days (range 365 to 
826). No events occurred after discharge in the first 3 
months of follow-up: at 6 months 1 patient developed an 
acute myocardial infurction (1.2%). In this patient angio-
gram documented that the infarct-related artery was the first 
obtuse marginal branch of the left circumflex artery with a 
de novo thrombotic occlusion. Target lesion revasculariza· 
tion ms needed in 2 patients (2.4% ). with in~segment re-
stenosis localized at the ostium of the left circumftex artery 
in these patients. :'>l'o death due to late angiogrnphically 
adjudicated stent thrombosis occurred. At 12 months of 
follow-up, l cardiac death related to congestive heart failure 
62 
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Figure 1. Event-free survival mtc (88% and 82.3% nt 1 und 2 y=, 
re:;pectively). 
occurred. This patient had severe left ventricular dysfunc-
tion at the index procedure Oeft ventricular ejection fraction 
32%). but postmortem autopsy was not performed. 
During follow-up 3 other patients underwent target lesion 
revascularization within 12 months. and target lesion revascu-
larization was needed in additional2 patients 2:12 months after 
the index procedure. No late or very late thrombosis or myo-
cardial infarction occurred in the rem:lining 65 patients. Event-
free survival rates at 1 year and 2 years offollow-up were 88% 
and 82.3%, respectively (Figure 1). 
Nine-month angiograpbic follow-up was performed in 71 
patients (83%), whereas 13 patients declined angiographic 
control: these patients were without symptoms and events. 
Late lumen loss was 0.15 ±. 0.81 mm. and overall binary 
angiographic restenosis rate was 9.8% (7 patients). with reste-
nosis occurring in the mid LM artery in 1 patient and in the 
bifurcation lesions in the remaining 6. Four restenoses oc-
curred in stents with a diameter <3.5 rnm (all overexpanded 
with a 4.0-mm balloon during the index procedure). Moreover. 
occurrence of events during follow-up suggested an inverse 
association between risk and duration of follow-up. with 12 
adverse events occurring in the first year of follow-up (66.7%), 
5 occurring in the second year (27.8%), and only 1 occuning 
after the second year of follow-up (5.5%). 
Incidence of angiographic and clinical outcomes in high-risk 
patients. diabetics. ejection fraction :S35%, age >80 y~ mul-
tivessel stcnting. multivessel di..<;ease.. previous myocardial infarc-
tion. previous percutaneou.~ coronary intervention. bifurcmion in-
volvement stent <35 mm, or postdilation with > 3Smm 
balloons was similar to that: of the over.ill population. Specifically. 
none of the subgroups was significantly a..<;S()Ciated with an in-
crease in clinical or angiographic MACE.«. However, patients 
treated "extremely" after dilation (thus achieving a final stent 
diameter 1 mm greater than the nominal stent size) showed a 
marginally significant increase (p = 0.049) in risk of clinical 
MACEs. likely due to a lack of l:Jrgc-dimneter SESs in the be-
gjnning of our experience. which had to be oven:lilated to achieve 
adequate stent expansion and apposition. 
Discussion 
The present study suggests that use of drug-eluting stents to 
treat LM disease in unselected patients without major contra-
indications to cardiac surgery may be feasible. safe, and a..-;so-
ciated with a high procedural success rate. These findings are 
based on the lack. in our population. of episodes of stent 
thrombosis and on the very low incidence of procedure-related 
complications and in-hospital adverse events rate although 
many procedures were primary angioplasties forST -elevation 
myocardial infarction. In addition. the safety of SES implan-
tation in LM lesions is confirmed by the extremely low fatility 
observed. Early death occurred in only 1 patient classified as 
very high risk according to the EuroSCORE and the Parsonnet 
score who had a complex bifurcation lesion and died of cru-· 
diogenic shock during hospitalization. 
Unprotected LM disease occurs in up to 5% of patients 
undergoing coronary angiography. with as many as 50% 
also having associated 3-vessel coronary disease and/or 
co-morbidities that pose a hlgh risk for any type of invasive 
procedure. Although coronary artery bypass grafting has 
been the treatment of choice of LM disease for decades,1z 
percutaneous revasculari7..ation had been attempted for LM 
disease in the balloon-only and bare metal stent eras. with 
suboptimal results.13•14 Percutaneous revascularb..ation for 
LM disease may carry a potential risk of early and late 
failures. and these findings led to evidence-based recom~ 
mendations restricting percutaneous revasculari7..ation for 
LM disease only to patients with prohibitive surgical risk.15 
Since market approval of SESs, several interventionists 
have employed these devices not only in patients with LM 
disease at very high surgical risk (e.g .. acute ST-elevation 
myocardial infarction) but also in those with more favorable 
anatomy and/or clinical characteristics.1 Although prelimi-
nary data from high-volume centers. including comparisons 
between drug-eluting stents and surgery, 16-18 have provided 
promising results for early and midterm rates of MACEs in 
patients with unprotected LM disease treated with drug-
eluting stent implantation (with midterm MACEs and target 
vessel revascularization as low as 5.8% and 1.9%, respec-
tively),19 all reports published to date were relatively small 
and lacked long~term follow-up.16.2o.z1 The latter fea~ is 
a major limitation of the available evidence base. espeCially 
because of recent data suggesting a potential long-term 
hazard with drug-eluting stents. 3·:::?. 
Late follow-up confirms that the risk of events after LM 
stenting with drug-eluting stent.~ progressively decreases 
over time. even if some attrition persists.n Further. the rate 
of binary angiographic restenosis was relatively low ru:d all 
but 1 restenotic lesion was focal and treatable with remter-
vention. Although such a restenosis rate appears lower than 
those with bare met:l.l stents. a rate of 10% with SES could 
still be clinically dis-satisfying compared with the patency 
of bypass grafts (especially in the left internal mammary 
artery). IS Moreover, our data based on selective use of a 
2-stent approach indicate that it is feasible, safe. and likely 
less associated with thrombosis than a systematic 2-stent 
strategy. 7 •8 
In our study some patients received 3.0-m.m SESs be-
cause the 3.5-m.m SESs were not available at the beginning 
of enrollment In these patients stents were overexpanded 
with oversized noncompliant balloons (2:3.5 m.m diameter). 
Such a stem after dilation with an oversized balloon (bal-
loonfstent ratio > 1.2) was the predictor of MACEs at fol-
low·up. Although previous studies seemed to support such 
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a practice,.u this risk was particularly magnified for stents 
expanded to a final diameter > 1 m.m than their nominal 
size. suggesting that extreme stent overexpansion may lead 
to strut fracture. polymer damage, irregular drug elution. 
and/or suboptimal plaque scaffolding. 
Drawbacks of this work are those typical of single-center 
observational studies with a relatively small sample.25 
Given the lack of large studies on SES implantation for LM 
disease and especially of any study reporting on long-term 
outcomes. this study. despite its inherent limitations in in-
ternal and external validities, adds important information 
about the use of SESs in this patient subset. 
Despite our promising results. the importance of pa-
tient selection and multidisciplinary approach (involving 
a noninvasive cardiologist and a cardiac surgeon) seems 
pivotal to identifying those patients with LM disease 
more likely to benefit from drug-eluting stents and less 
likely to be harmed by it.2<> 
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Abstract 
Aim: This study compares the clinical and angiographic outcomes of sirolimus eluting stent {SESl and bare 
metal stent (BMS) implantation for unprotected left main coronary artery (ULMCAl stenosis. 
Methods and results: We analysed 141 unselected patients with unprotected LMCA stenosis: 72 were treat-
ed with SES and 69 with BMS. SES patients were younger, with a higher ejection fraction, had more often 
hypertension, family history and were more often smokers. The procedural success rate was 94.2% in SES 
group and 87% in BMS group. In SES group there were 2 periprocedural myocardial infarction (3%). 
1 intra-procedural death {1.4%) and 1 in-hospital death (1.4%) and respectively 2 (3%),4 (6%) and 
3 (4%) in BMS group. No incidents of stent thrombosis, stroke and emergent CABG occurred during hos-
pitalisation in either group. SES patients showed a lower late lumen loss (0.5±0.8 mm vs 1.1±1.0 mm; 
P<0.05) and a lower nine-month angiogr:aphic restenosis rate {13.6% vs 24.3%; p=NS). The MACE free 
survival rate at 2 years was 83% in the SES group vs 55% in the BMS group (P<0.001). 
Conclusions: SES implantation for unprotected LMCA stenosis in "real world" population appears safe with 
a low restenosis and MACE rate at follow~up. 
• Corresponding author: Jnterventional Gardio/ogy; Division ofGardiology; University of Torino, San Giovanni Hospi!EI, Corso Bramante 88-90, 10126 
Torino, !!Ely 
£·mail: ishefban@yahoo.com 
© EuropJ Edition 2006. All nehts reserved. 
68 
Introduction 
Lesions in the LM are still considered a standard indication for sur-
gical revascu!arisation1-3, unless several studies have demonstrated 
the safety and feasibility of unprotected LMCA intervention using 
BMS.:-22. In effect the main limit of this approach is the in-stent 
restenosls (ISRJ, often associated with an increase of long-term mor-
tality19. Recently, several studies and reports suggest that use of DES 
has been associated with a lower restenosis rate and with favourable 
clinical oLrtcomes even though these studies included small number 
of patients and low rates of angiographic follow up23-:.'!l. The aim of the 
present study is to provide a further contribution in this controversial 
field reporting the clinical and angiographic outcomes of the use of 
SES in the treatment of unprotected LMCA stenosis and comparing 
the results with those of BMS in the same patients subset 
Methods 
Study population 
From July 2002 to December 2004, 72 consecutive patients who 
were admitted to the lnterventional cardiology Laboratory under-
went percutaneous coronary intervention (PCIJ procedures with 
SES 'rmplantafronfor cr'ifrcal unprotected LMCA d'rsease. The control 
group consisted of 69 consecutive patients selected from 
December 2000 to December 2004 with similar angiographic find-
ings and treated with BMS implantation. 
PCI procedure was performed when a suitable anatomy for stenting 
was present, associated with symptomatic LMCA disease or docu-
mented myocardial ischaemia. Patients with contr<~indication for 
double anti-aggregation or anticoagulation therapy were excluded. 
The informed consent was obtained in accordar:ce with the 
Declaration of Helsinki. 
For every pafrent, we evaluated the following basenne parameters: 
cardiovascular risk factors (age, sex, hypertension, diabetes, hyp-er-
l'lpidaemia. family history for coronary artery disease !CAD] and cig-
arette smoking), presence of prior myocardial infarction, previoL:s 
coronary artery bypass graft (CABGJ or PTCA, presence of specific 
comorbidity (such as chronic renal failure and peripheral vascu-
iopathy), clinical presentation (ST Elevation Myocardial Infarction, 
or STEMI; Non ST Elevation Myocardial Infarction, or NSTEMI; 
unstable angina, or UA; stable angina; ventricular arrhythmias; 
ac1.rte pulmonary oedema, or APE; or instrument signs of ischaemia), 
ang'rographic pattern (extension of CAD, lesion location and quanti-
tative coronary angiography, or QCA, evaluation). 
The patients were also stratified in risk classes using both Parson net 
score system and EuroSCORE (European system for cardiac opera-
tive evaluation). 
Procedural characteristics included the foiiD'Ning parameters: treat-
ment of distal LMCA bifurcation with single or double stent: the util-
isation of final kissing balloon for bifurcation lesions, debulking pro-
cedure (directional or rotational atherectomy}, pressure wire or 
intra-vascular ultrasound (IVUSl guided revascularisations and use 
of intra-aortic balloon pump (lAB Pl. Creatine kinase (CK) measure-
ments were systematically performed on admission and every 3 hr. 
for the subsequent 24 hr., and then every 12 hr. for 2 days. The 
peak value of CK-MB and Ttroponin were estimated for each 
patient Aspirin was administered to all patients before the proce-
dure and indefinitely thereafter. A loading dose of clopidogrel was 
performed at least 4 hours before the catheterisation and the dou-
ble anti-aggregation therapy (aspirin+ clopidogrel or aspirin+ ticlo-
pidine) continued for at least 6 months. Glycoprotein lib/lila 
inhibitor use was at the discretion of the operator. 
Stenting procedure 
In gener<~l, predilation was performed or:ly in very tight lesions using 
undersized conventional balloons. In calcified lesions, a matched 
balloon to vessel size (1:1) was used. The stent deployment was 
achieved by inflating the delivery balloon at nominal pressure. In 
selected cases, the stented segment was then further dilated with 
high pressure balloon inflations, to achieve the optimal diameter. All 
the lesions has been fully covered: lesions involving ostium or shaft 
without involvement of bifurcation were treated with a single stent. 
Lesions involving bifurcation were treated as follows: stenting across 
left circumflex artery (LCXJ-ostium. stenting across left anterior 
descending-LAD-ostium, kissingstenting and provisional T-stenting. 
No lesion was treated with crushing or culotte technique. Final kiss-
ing balloon dilation was performed In almost all patients. IVUS guid-
ance was used in those :esions with a not completely convincing 
final angiographic aspect. 
Quan-Jtitative coronary ang~ography {Q.CA) ana~ysis 
Using a semi-automated dedicated softvare (lnturis viewer package 
softvare 1.2 version, Philips), ail the angiograms were analysed at 
baseline, after procedure and at follow-up, measuring minimal 
lumen diameter (MLD), percent diameter stenosis. reference vessel 
diameter (RVD), lesion length, acute gain and late lumen loss. The 
reference diameter has been obtained as average diameter of .prox-
imal and distal normal segments or in contiguous normal segments 
in case of ostial and bifurcation lesions. 
foilow-up 
The fo!low-up ended for all patients on the 30th April 2005; 
the mean follow-up period for the whole population was 
23.6±12 months 08±8 months in SES group; 29±10 months in 
BMS group). Periodical phone inteNiews and office visits were 
scheduled at 1, 3, 6 and 12 months and at the end of the fellow-up 
period (April 2005). A coronary angiography was routrnely per-
formed after 9 months, or earlier if driven by clinical symptoms or 
documented myocardial ischaemia. 
Definition 
Procedural success was defined as revascularisation with a residual 
stenosis <30% at the QCA, without major intra procedural or in-hos-
pital adverse events (acute myocardia: infarction, or AMI: death or 
emergent CABG). 
Deaths were divided into cardiac and non cardiac: those that were 
not surely classifiable were considered as cardiac. 
Major adverse cardiac events (MACEs) were defined as the occur-
rence of death, non-fatal Ml, stroke and TLR!TVR. 
Use of S£$ vs SMS in thfJ treatment of unprotected LMCA $Mnosis 
Target lesiol1 revascularisatiol1 (TLR) was defined as a11y revascular-
isatiOI1 011 the treated segment. 
Target vessel revascularisation (TVR) was defined as any revascu-
larisation on the treated vesseL 
STEM I was defined as increase of Ck-MB 3 times over the upper 
limit of normal together with typical ST elevatiol1 at the ECG controL 
NSTEMI was defi11ed as increase of Ck-MB 3 times over the upper 
limit of normal without ST elevation at the ECG control. 
Restenosis was defmed as lumen reduction at the segment site (i.e. 
stent length plus 5 mm proximally and distally) >50% at the QCA. 
High risk patients had Parsonnet >15 and EuroSCORE > 6. Very 
high risk patients had Parsonnet >20 and EuroSCORE > 13. 
Statistical analysis 
Univariate analysis was performed to evaluate baseline clinical and 
angiographic differences in the t.No groups: multivariate analysis 
was performed to evaluate correlations bet.Neen baseline clinical 
and procedural parameters and the recurrence of intra-hospital 
adverse events or MACEs during the follow-up. Data are expressed 
as mean:t:SD for continuous variables and as frequencies for cate-
gor'lcal variables. 
Difference betweel1 group were evaluated using chi-square and 
Student-Ttest MACE-free survival distributions were assessed accord-
ing to the Kaplan Meier method. To comp.:lre MACE-free survival 
between the two groups we used the Log-Rank test All the analysis 
were performed using dedicated software (SAS and Statistical. 
Results 
Patients and fesion characteristics 
The baseline clinical and angiographic characteristics are sum-
marised in Tab!es 1 and 2. At the univariate analysis patients tre<Jt-
ed with SES compared to EMS group were younger (68% vs 73.6%; 
P< 0.05), had a higher ejection fraction, or EF (55.2% vs 46%; 
P<(l.OS). had more hypertension (85% vs 57%: P< 0.05), family 
history (24% vs 10%: P< 0.05), were more otte11 current smokers 
(24% vs 6%: p<0.05), were more ofte11 tre<Jted with strJti11s (44% vs 
19%: !)<0.05): patients tre<Jted with BMS more often ;Jresented 
with NSTEMI (25% BMS, 7% SES: ;xO.OSl and distal lesion loca-
tion was significantly higher in EMS group (58% in SES group 
vs.70% in BMS group; P<0.05l comp.:lred to SES group, 
Procedural results 
Procedural character'ISfiCS are shown i11 TableS. Compared to the 
group tre<Jted with EMS, theSES group needed less IABP (8% vs 
20%; !)<0.05) and received more often post-dilatation (65% vs 
30%: !)<0.05). Final kissing balloon dilation was performed in almost 
al'• paf,ents with no d'lfference '1n two groups (90"/o DES group, 88% 
BMS). IVUS guidance was used in both groups with no significant 
difference (DES group n"" 8-11 %; BMS group n=3- 4%). The proce-
dural success rate was 94.2% in SES group and 87% in BMS group. 
Table4 shows intra-procedural and in-hosp'tlal adverse events. 
Periprocedural Ml occurred in 2 patients (3%) in SES group a11d 
2 patients (3%) in EMS group (p=:NS); intra-procedural de<Jth 
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Table 1. Baseline dinical characteristics 
. ~:_)ES(ll'•l2).·. ~. ::_BMS(n~69L,.- . .P _Vawe 
- TiitaC M9o TOtal--- M~ii .. 
' (%1 . ~D) .. (%) •• . ~D) 
"' 
68(10) 73.5(11.8) «)" 
Men 56(77) 48(69) NS 
Hypertension 61(85) 39(57) <0,05 
Diabeti!S (NIODM and IDDM) 16(22) 14(20) NS 
IDDM 8(11) 6(9) NS 
Current smokers 17(24) 4(6) <0.05 
Family history 17(24) 7(10) <0.05 
Hypercholestero!aemia 42(SS) 31(45) NS 
Use of statins 32(44) 13(19) <0,05 
Chronic renal fuilure 3{4) 8(~1 NS 
P<!ripheral vasculopathy 17(24) 17(25) NS 
Known coronal)' 
ArttiY Disease (CAD) 34{47) 38(55) NS 
Previous AMI 21(29) 29(42) NS 
Previous CABG 14{19) 10(14) NS 
Previous Per 20{28) 15(22) NS 
Mean Ejection Fraction 55.2(10.3) 46.0(12.9) <0.05 
Awte pulmonary oe!lema 1(1) 1(1) NS 
srEMI 9(13) 4(6) NS 
NSTEMI 59) 17(25) «)" 
Unstable angina 34(47) 32(46") N5 
Stable angina 9(8) 2(3) NS 
Documented ischaemia 9(13) 12(17) NS 
Qth., 59) 1(1) NS 
SE$. Siro!imus Eluting Stent group; BMS-- Bare MetalStent group; SO.. stand;m! devi~tion; 
~notsignifimr:t 
occurred in 1 patient (1.4%) in SES group and ir. 4 patients {6%) 
in EMS group (Table 5). In-hospital death occurred in 1 patient 
(1.4%) in SESgroupand in 3 patie11ts {4%) in BMSgroup {Table 5). 
No il1cidents of subacute stent t\lrombos\s, stroke and emergent 
CAEG occurred. Total in-hospital adverse events rate was 5.8% in 
SES group versus 13% in BMS group. 
follow-up resulls 
Nine months angiographic foilow-up was performed on 44 p.:ltients 
(61 %) of SES group and 01137 patients {54%) of BMS group. Event 
driven angiography was performed on 12 SES patients (28%) and 
on 7 BMS patients (19%). The QCA results are summarised i11 
Table 2. Late lumen loss was significantly lower i11 theSES group 
{0.5±0.8 mm vs. 1.1±1 mm; !)<0.05) than BMS group; the angie-
graphic restenosis rate was lower as well, even though p value was 
not stat'1sticaily significant {13.6% vs 24.3%; p=:NS). 
In theSES group restenosis occurred in 7 patiel1ts; 71% of resteno-
sis {n=o5) occurred in patients with bifurcation LMCA lesions: all the 
re-stenosis, except one, were found out at the nine-month angie-
graphic control in asymptomatic patients; restenosis were ali focal, 
except one, and all were successfully tre<Jted with a new SES 
implantrJtion (Table 6). 
Clinical research 
Table 2. Baseline angiographic characteristics. Table 3. Baseline procedural characteristics. 
·::sES(ii-;.n)"" )MS(i1.;,_6g): ~\·iilJJt ~:--"sES{n;nr:· ···- "" BMS(U;6g):':"" 't:Yalil't 
·rotat -·Mean· -TOtiC Mean·- - 'TotiC"-'MW!' ···-"TOtiiC' '"Mean·· 
(%) .... (SO) (%) ~D) i•l . ~'I (%) ~D) 
I~DEX PROCEDURE Doublestent 24(33) 25(36} NS 
Ba~Une QCA 72(100} 69(100) Single stent 18(25) 23(33) NS 
FinalQCA 72(100) 69(100} Stents per patient 138{0.6) 1.59(0.78} NS 
Baseline minimal lumen U~ of additional high-pressure 
Diameter,mm 1,4(0.5) 1.6(0.4) NS balloon 47(65) 21(30) <0.05 
final minimal lumen Maximal balloon size,mm 3.8(0.2) 4(0.4) 
diameter, mm 3.5(0.3) 3.8(0.3} NS Maximal inflation pressure, atm 18.9(2.9) 17.8(3.4) 
Baseline diameter stenosis,'lo 62(12.3) 59.8(9.5) NS Multivessel involvement 63(88) 66(96) N$ 
final diameter stenosis,% 9.5(4.2) 7.2(4.6) NS Primary Pcr 5(ry ·~2) NS 
Baseline reference Rescue Pcr 
0(0) 0(0) NS 
diameter, mm 3.7(0.4) 4.0(0.3) NS Multives:sel treatment ~I~ I 63{91) N$ 
Final reference 2vesse\s 
35(49) 40{58) 
diameter, mm 3.9{0.3) 4.1(0.4) NS 3 ves~l5 23(32) ~(33) 
Lesion length, mm 20{19) 22.1(16.2) NS Use of glycoprotein 2b/3a inhibitors 25(35) 21(30) NS 
Stent diameter, mm 3.2(0.28) 3.5(0.3) NS Directional coronary 
Ostium 25(35) 21(30) NS atherectomy (DCA) 2(3) 2(3) NS 
Shaft 19(26) 17(25) NS Rotablator 1(1) 0(0) NS 
Bifurt<ltion 4-2(58) 4800) <0.05 Kissing balloon predilatation 21(29) 16(23) NS 
9 MONTHS ANGID-CONTROL Guidance of intravascular 
~ Baseline QCA 44{61) 37(54) ultrasound (IVUS) 8(11} 3(4) NS 
0 FinalQCA (restenosis) 6(8) 9(13) Support of intra-oortic c. balloon pump (IABP) 6(8) 14{20) <0.05 
" Baseline minima\ lumen ~ 55- Sirolimus Eluting Stem: group; BMS- Bare Metal Stem: group; SO.. stmdard deviJtion; u diameter,mm 3(0.8) 2.9(1.1) NS NS..notsignificant 
70 Final minimal lumen 
diameter, mm 3.3{0.6) 3.5(0.6) NS Table 4. Irrba-procedural and in-hospital adverse events. 
Ba~line diameter stenosis, 'k 18.9(22.4) 25(24.8) NS 
. " ........... ·-- .-.. ·:=SES{ii,;;72)~--·BMS'(ii;;69) '""""p"\.iiliiii'-. 
final diameter stenosis, 'lo 14.2(9.8) 113(10,8) NS 
" ••. c ••.• Total!%) T"'t(%) . 
Baseline reference Periproe€l!uralMI (non Q) 2(3) 2(3} NS 
diameter, mm 3.8(0.6) 4(0.8} NS Intraprocedurnl death 1(1.4) 4(6) NS 
final reference 
diameter, mm 3.8(0.5) 3.9(0.3) NS Intrahospital death 1(1.4) 3(4) NS 
Lesion length, mm 4-.4(13) 4.1(1.4) NS Acute stent thromllosis 0(0) 0(0) NS 
l.Jtelumen loss 0.5(0.8) 1.1(1) <0.05 Emergent CABG 0(0) 0(0) NS 
Acute gain 2.1(0.5) t2{0.5) NS Stro< 0(0} 0(0) NS 
SES- Sirolimus Eluting Stent group; BMS- Sare MetalStent group; SD- stmdard deviation; 
'""' 
4(5.8) 9(13) NS 
NSc notsignlllcant Sf.S.. Sirolimus Eluting Stcnt group; BMS- Bare Metal Stent group; NS.. not significant 
Table 5. Intra procedural arxl in-hospital deaths in SES and BMS group. 
"Agi'~:·--· ""··:·E(" ::·Miilti~GiiW!Yeiiii!iif" ""tliliiQ(riiiriif~Oi(": "·:-Flirsonner :fUiOSCOJtt:::~ ·::"~"-'ta~:ot~eatfl~:::·-
SB 
liP 64 45 Yo Cardiac arrest 20 15.12 Cardiogenic shock 
2tH 43 54 Yo Cardi09enic shock 18 16.13 MOF 
BMS 
liP 73 35 Yo Cardi09enic shock 15 10.44 Cardi09enic shock 
2TP so 60 No Stemi 20 9.28 Cardiogenic shock 
3 IP 83 55 Yo Unstable ~ngina 25 14.11 P£A 
4tP 64 35 Yo Nstemi 70 50.72 P£A 
5 IH 66 45 Yo _, 45 2C7 Cardiogenic shock 
6tH 00 40 Yo Nstemi 72 35.97 Sudden death 
7tH 73 25 Yo Unstable angina 12 10.64 MOF 
IP ~ intraprocedur.~l event: IH ~ intr<lhospital event EF- ejection fraction; MOF- multi organ fuilure; PEA- pu15e\ess electric:at activity 
Use()( S£$ vs BMS in the tre&tment-0~ unProtected ~MCA stonosis 
Table 6. Patients of theSES group with angiographic restenosis. 
Agt::Geiidiii': -Le$i0ii:I.Otatf01i: -:_~ResteiiOSiS:pattem:·:~-·ei'Dctdiiiii.:: 
76,M ostium focal repeat SES stenting 
73,M bifurcation focal repeat SES stenting 
69,F bifurcation fuol repeat SES stenting 
77,M bifurcation focal POBA 
68,M bifurcation fuol repeat SES stenting 
53,M bifurcation fuol repeat SES stenting 
69,M ostium diffuse repeat SES stenting 
In the BMS group restenosis occurred in 13 patients and all were in 
patients with bifurcation LMCA lesions; 5 patients underwer.tangio-
graphic cor.trol for recurrence of angir.a and 8 were scheduled 
ar.giographic controls; restenosis were focal in 4 patier.ts while in 9 
were diffuse. All except or.e (sent to CABGJ were successfully treat-
ed with SES imp!antation. 
Clinical follow-up information was collected in 100% of the patients in 
theSES group and 99% in the BMS group. The mean clinical follow-
up duration was 18±8 months in SES group; 29±10 months in BMS 
group. Target lesion revascularisation at one year was petiormed in 6 
SES patients and in 9 BMS patients (13.6% vs 24.3%, P:NSJ. No 
deaths or acute Mls occurred in either group. The MACE free survival 
rate at 2 years was 83% in theSES group vs 55% in the BMS group 
(P<(l.OOl); see Figure 1 (Kaplan-Meier curves for two-years MACE-
free survival in patier.ts treated with SES and BMS. A statisticaliy sig-
nificar.t difference was observed between the two groups - log 
ral"lk=0.00131. MACE = major adverse cardiac events including 
death, no11-fatai myocardial infarction, stroke and TLR/TVRJ. 
At the multivariate analysis the only variable related with a signifi-
callt reduction of MACE was the use of SES (p_-0.0024); on the 
other side, variable significantly related with an increased MACE 
incidence was the presence of bifurcation iesion Cp=0.025). 
Patients over 75 years, diabetics, with a poor EF (<35%) and High 
risk patients (EuroSCORE>6 and Parsonnet >15) had a slightly 
higher MACE incidence, though p value was 11ot statisticaily sigllifi-
cant in both groups {p=0.16 and p=0.09). 
u 
1,0 
MACE·FREE SURVIVAL 
o CompiQtc +Consornd 
:[~~~~ 
yc~rs 
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SES vs BMS for ULMCA stenosis 171 
Discussion 
The findings of the present study show that in patients with coronary 
artery disease, SES implantation for the treatment of unprotected 
LMCA lesions is feasible and safe. 111 fact, it is associated with a low 
procedure-related complication rate and without subacute or late 
stent thrombosis. Compared to SES, BMS implantation is associated 
with a higher intra-procedural complication rate. This might be due 
to the fact that patients treated with BMS were elder and with lower 
ejection fraction. Long-term dinical outcome was also better in 
patients treated with SES likeiy due to the reduction of in-stent 
restenosis with the use of SES (13.6% vs 24.3%; p=NS). 
In co11trast with prior studies24.28 that included a large number of 
elective patients, this one can be co11sidered a "real world" study: 
the population of the study were consecutive "ail comers" patients 
including those with poor EF, with "very high risk" profile 
(EuroSCORE>13 and Parsonnet> 20), diabetics and patients who 
underwent primary percutaneous coronary intervention (PCl) for 
actJte coronary syndromes (AMI or UAJ. This might explail"l the 
slightly lower procedural success rates of this study compared to 
previous sbJdies and for this reason the results obtained in this 
study might be considered excellent, despite the high risk profile of 
our populatio11. High-risk sub-groups indeed don't move away sig-
niflcantiy from the whole population i11 terms of incidence of MACE. 
The only negative predictor of MACE seems to be the presence of 
distal LMCA bifurcation lesion, though the rate of lesions involving 
bifurcation is significantly different in the two groups (58% in SES 
group vs. 70% in BMS group; p<0.05J. 
LMCA bifurcatioll lesions are still considered infeasible for percuta-
neo~>s intervention both tor the technical d'1fficulties of stenting and 
the higher incidence of in-stent reste11osis il"lvolving the iarge side 
branches (especially left circumflex artery). Several studies compar-
ing the use of SES with historical controlsJ2-34 for the treatment 
of LMCA bifurcation lesions, showed a very low restenosis rate in the 
main vessel and no benefit ir. terms of reduction of restenosis 
of side branch with the use of SES for both bifurcation branches 
(tNo stents) over single stent and balloon angioplasty for the second 
branch (provisional T stenting). Moreover, no superiority of single 
technique IT Stenting vs Coulotte vs Crush) has ever bee11 demon-
strated. 
Thus, even in the era of the drug eluting stent the higher overall 
restenosis rate in bifurca~ion lesions remains a chalienge. However 
the compelling results of this study and othersJ2-34 showing very low 
rates of restenosis and TLR indicate that the treatment of LMCA 
bifurcation may become an achievable goal for PCI with SES. 
Clinical follow-up demonstrated that the use of SES significantly 
reduces the incidence of MACE; the event-free survival at 2 year 
was83% in SESgroup vs 55% in BMS group (log rank= 0.00131), 
corresponcii11g to a 62.3% relative reduction of risk; moreover, the 
use of SES was related with a 93.7% relative reduction in all cause 
death (survival at 2 years: 98% SES vs 68% BMS; log-rank = 
0.00009) and with a 91% relative reduction in cardiovascular death 
(survival at 2 years: 98% SES vs 78% BMS; log rank= 0.00119). 
These results suggest that the use of SES is associated both with 
a better quality of life due to a reduction in event driven hospitalisa-
tions and with a lower incidence of cardiovascular death. 
72 
It is indeed well known that in-stent restenosis leads more often to 
repeat interventions (PCI or surgery) and also might influence long 
term survival because might cause sudden death. SES has been 
shown to be very effective in suppressing intimal growth even in 
complex LMCA lesions (as documented also in the present study) 
reducing long term in-stent restenosis which is consequently trans-
lated by better long-term clinical outcomes. 
While prior studies have demonstrated safety and efficacy of DES 
implantation on a relatively short-term period30.3:, this study has 
prolonged the mean observational period up to 2 years, providing 
important confirmation of sustained safety and effectiveness of SES 
Implantation for unprotected LMCA stenosis. 
The major limitation of the present study is represented by the fact 
that some diTferences can be found in the baseline clinical and 
lesion characteristics betvveen the t.No groups; patients belonging to 
BMS group are older, with a lower LVEF, more often presented with 
NSTEMI and more frequently were affected by distal LM stenosis. 
This means that the poorer outcome of BMS group might have been 
Influenced by the higher risk profile of BMS patients and therefore 
that the superiority of DES shown in this paper could be less evident 
if the two groups were right balanced. Moreover these findings are 
based on a single centre observational study and that the number 
of patients is relatively small to generalise our results to all patients 
with LMCA lesions. Data deriving from long term and muH:icentre 
randomised study comparing SES implantation and bypass surgery 
are needed and will help us to clarify better the potentiality and the 
role of this approach. 
Conclusions 
The use of BMS for the treatment of ULMCA lesions is associated 
with a high events rate both in hospital and during FU period. On 
the other hand, SES implantation for the treatment of the same 
lesion subset in a "real world" population is safe and effective, with 
a very low procedure-related complication rate and with an 
extremely encouraging 2 years MACE free survival (83%) both for 
low risk patients and for high risk sub-groups. 
Based on these findings and those already reported in literature, 
PCI for ULMCA with SES implantation should be suggested. 
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CHAPTER 8 
LATE AND VERY LATE STENT THROMBOSIS 
FOLLOWING DRUG-ELUTING STENT 
IMPLANTATION IN UNPROTECTED LEFT 
MAIN CORONARY ARTERY: A MULTICENTRE 
REGISTRY 
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Aims 
Methods 
and results 
Conclusion 
Keywords 
To evaluate the occutTel'lce of late and very late stent thrombosis (ST) following elective drug-eluting stent (DES) 
implantation in unprotected left main coronary artery (LMCA) stenosis il'l a large multicentre registry. 
All 731 consecutive patients who had sirolimus- or paclitaxel-eluting stent electively implal'lted in de novo lesiOI'IS on 
unprotected LMCA in five centres were included. ST was defined according to Academic Research Consortium defi. 
l'litions. Four (0.5%) patients had a definite ST: three early (two acute and Ol'le subacute) and one lateST, no cases of 
very late definite ST were recorded. AU patients survived from the event Three patiel'lts had a probable ST. There-
fore, 71731 (0.95%) patients had a definite or a probable STand all were on dual antiplatelet therapy at the time of 
the event Possible (eight late and 12 very late) ST occurred in 20 (17%) patients.At 29.5 ± 13.7 months fot!ow-up, a 
total of45 (62%) patients had died: 31 (42%) of cardiac death, Ninety five (119%) patients had a target-vessel and 76 
(10A%) a target-lesion revascularization. Angiographic follow-up was performed in 548 patients (75%): restenosis 
occurred In 77 (14.1%) patients, 
Elective treatment of LMCA stenosis with DES appears safe with a 0.9% incidence of definite and probable ST at 
29.5 ± 13.7 months. 
Stent • Left main coronary artery • Drug-eluting stents • Stent thrombosis 
Introduction follow-up, this is a feasible and safe approach.11 - 19 To date, no 
study has specifically addressed the prevalence ar1d predictors of 
late and vel)' late ST following elective DES implantation in unpro.. 
tected LMCA lesions. The aim of the present study is therefore to 
evaluate the occurrence of late and very late ST following elective 
DES implantation in unprotected LMCA stenosis in a large multi· 
centre registry. 
Some concerns have recer;tly been roUsed regarding the risk of late 
and very late stent thrombosis (ST) following drug-eluting stent 
(DES) implantatior\.1- 10 Registry data of percutaneous coronal)' 
inter.rentions (PCI) with DES use in unprotected left main core.. 
r~ary artery (LMCA) lesions showed that at mid-term clinical 
~Corresponding author: Td: +~ 02 2643 7331, hx: +39 02 2643 7339, Emal~ co\omb<:>.:mtonlo@h>r.lt 
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Methods 
This study included all consecutive patients with a stenosis in an unpro-. 
tected LMCA electively treated with PCI and sirolimus- (SES, Cypher, 
Cordis, johnson & johnson Company, Warren, NJ, USA) or 
paditaxel..eluting stcnt {PES, Taxus. Boston Scientific. Natick. MA 
USA) imp!antrLtion in frve centres (Sat! R:!ffuclc Hospitll and EMO 
Centro Cuorc Columbus in Milan: San Giovanni Battista Hospital 
in Turin, ftaly: E~mus Medical Center - Thoraxcenter, The 
Ncther!ands: the Asan Medical Center, Korea and University of 
Cllifornia, Los Angeles Medical CcntC!r) between March 2002 and 
March 2006. The dat:t were prospectively collecte<J in the single 
centres and rctrospectivcly entered into a common dambase. P:tticnts 
with ST or 11011-ST elev:ttion myocardial infurctions {Mis) were 
excluded from the analysis. The decision to perform PCI instead of 
surgery wrJS considered when one of these tNO conditions WJS 
present: suitable anatomy for stenting and preference by patient for 
a percutaneous approach or suitable anatomy for stenting and dis'm-
centive for surgery defined as a Euroscore ?,:6 and/or prior coronary 
artery bypass grafting (CABG) with failure of all conduits. 
Coronary angioplasty and DES implantation were performed 
according to the practice of fully covering the disCJSed segment 20.21 
At the start of the procedure, a bolus of unfractionated heparin was 
administered at 100 IU/kg to achieve an activated dotting time of 
> 250 s. Glycoprotein lib/lila inhibitors were admi:listered at the dis-
cretion of the operator. Clinical follow-up was scheduled and obtained 
for all patients at 1, 6, 12, :md 24 months by office visit or direct tele-
phone call to the patients. Patients eligible for longer clinical follow-up 
were contacted at 36, 48, and 60 months. 
Dual antiplatelet therapy (OAT) 0.e. aspirin 100 mg daliy and dopi-
dogrel75 mg daily ortidopidine 250 mg twice daily) was administmted 
according to local proctice (for at least 6 months after the procedure in 
Rotterdam :md Turin and 12 months in Milan, SeouL :md los Angeles). 
All patients were advised to remain on aspirin (100 mg die) lifelong. 
In addition, cilostJZol was also given to some patients for 1 mon-th 
(in Seoul). 
Dct1iled information on adherence :15 well :15 rezons and date for 
discontinuation of OAT was obtalned in all patients. 
Angiographic follow-up was scheduled between 4 :md 9 months or 
earlier if non-invasive evaluation or clinical presentation suggested the 
presence of ischaemia. 
Definitions 
ST was defined on the basis of the Academic Research Consortium 
definitions according to the timing of presentation z early (0-30 
days), late (31-360 days), or very late (> 360 days) and to the follow-
ing trilevel of certainty: 
Definite ST in the presence of an acute coronary syndrome a.'ld 
either ;mgiographic or pathological (autopsy) conflrrn:ttion of ST: 
Probable ST in case of :m acute Ml involving the tlrget-vessel 
territory without angiographic confirmation of thrombosis or other 
identified culprit lesion and/or any unexplained death within 30 days: 
Possjb/e ST in the case of any unexplained death after 30 days. 
The following major adverse cardiac events (MACE), during hospital 
Stly and at follow-up, were also analysed: death, CABG, Ml, tlrget 
lesion rcvascularization (TLR), :md tlrget vessel revascularlzation 
(1VR). 
Deaths were classified :15 either cardiac or non-cardiac. Cardiac 
death was defined :lS :my death due to a cardiac cause (e.g. MI. low-
output failure. fatal arrhythmia), procedure-related deaths, and death 
of unknown cause. 
Non-Q-wave Ml was defined :15 an eleV<ttion of serum creatine 
kinase (CK) MB isoenzyme that was three times the upper limit of 
normal (ULN) in the absence of pathological Q-wavcs. 
Rcstenosis was defined :15 >SO% luminal narrowing at t,e segment 
site (stent and 5 mm proximal and distll) demonstrated at the 
follow-up :mgiography. regardless of clinical symptoms. 
TLR was defined zany rcvascularization performed on the treated 
segment: TYR w:lS defined as any re-intervcntion performed on the 
treated vessel considering also treatment of any segment in the left 
anterior descending and circumflex arteries. 
The European system for cardiac operative risk evaluation (Euro-
score) was used to stratify the risk of death at 30 days. 21 The patients 
were stratified as high risk in the presence of a Euroscore ;::6. 
Unstlble angina was defined according to the presence of: (i) rest: 
angina (usually> 20 min); (ii) new onset ( <2 months) severe exertion 
angina of at least Canadian Cardiovascular Society Classification 
(CCSC) class Ill in severity: (iii) re<:ent ( <2 months) accelerntion of 
angina :15 reflected by an increase of at least one CCSC class to at 
least CCSC class Ill. 
Event adjudication 
All the events in patients included in this registry were first evaluated 
by at least two co-authors from the participating centres and then by 
two co-authors of the coordinating centre on the bzis of detailed 
reports from each of the participating centres. 
Statistical analysis 
Continuous datl were reported as mean ± Stlndard deviation (SD) or 
median Dnterquartile range (lQR)J :15 appropriate. In general, differ-
ences in proportions were tested with l test or Fisher's exact test. 
while differences in continuous variables with Student's t-tcst or 
Wilcoxon rank sum test. 
At unfvariate logistic regression analysis the following covariates 
were assessed: age, gender, diabetes. left ventricular ejection fraction 
(LYEF), unstable angina. Euroscore, DAT, duration of OAT (<6 
months, 6-12 months, >12 months), dlstallMCA. intravascular ultra-
sound (IVUS) guidance, baseline reference vessel diameter, bzeline 
minimal luminal diameter, stent type, both brnnch stenting, crush tech-
nique, stent length, final kissing balloon inflation, and m;rximum 
inflation pressures. Among continuous variable, no pre-specified 
cut-offwas employed. Because of the small number of events observed 
in a datlSct of 731 patients. exact odds ratios (OR) with associated 
95% confidence intervals (CI) and two-tailed P-values were computed 
using permutltion resampling. 
In order to obtain parameter estimates adjusted for potential col!i-
nearity among covariates, exact conditional analyses were carried out 
re-n.mning the exact logistic regressions with one covariate at a time :lS 
a fixed factor and treating the remaining as nuisance parameters. 23 The 
Stltistica\ Analys'1s System program ver.;ion 9.1 (SAS Institute, Cary, 
NC. USA) was used for data analysis. 
All authors have read and agreed to the ma.'luscript :lS written. 
Results 
Baseline clinicaL lesion, and procedural characteristics arc sum-
marized, respectively, in Tob!es 1 ar>d 2. A total of731 patients with 
unprotected LMCA were electively treated in our centres with 
DES implantation. Oroe hundred and seventy six (24.0%) patients 
were diabetic and 333 (45.5%) had unstable angina. Mean age 
was 63.1 ± 11.8 years and LVEF 54.8 ± 10.9%. Median and IQR 
of Euroscorc was 3.0 (2.0-6.0): a Euroscore !::6 was present in 
Table I Clinical characteristics of the study population 
n = 731 p:!tients 
Age (years) 63.1 ±11.8 
Fermle gender, n (";0 189 (25.8) 
Hypertension, n (%) 427 (58.4) 
Hypcrc:holcstcro!aemla, n (%) 368 (50.3) 
Smoking, n (%) 247 (33.8) 
Diabctes mellitus, n (%) 176 (24.0) 
UnSClblc angina, n (%} 333 (45.5) 
LVEF (%) 54.8 ± 10.9 
Chronic rem! f.lllure, n {%) 40 (5.5) 
Euroscore, me<Jian (IQR) 3.0 (20-6.0) 
Euroscorc <:; 6, n (%} 262 (35.8) 
LVEF.Ieft wmtrleular ejcetl¢n f!':letJon (%). 
Con~nuoos dlt.l were repol't~d iiS mean± SO or median and lnterquartlle rnnge 
(IQR.) 1l$ approprl:!te. 
Table 2 Lesion and procedural characteristics 
n = 731 patients 
Oirol n (",i) 559 (76.5) 
Numbl:!r of vessels treate<J 12 ± 0.8 
Numbl:!r of lesions tre.1te<J 13 ±: 1.5 
IABP, n (%) 96 (13.1) 
GP lib/lila inhibitors usage, n (%) 102 {13.9) 
IVUS zuidancc, n (".;;) 337 {46,1) 
DCA or rotablator, n (%) 24 (33) 
Cypher stent implantation, n (%) 536 (733) 
Taxus stent Implantation, n (%) 196 (26.8) 
Both br.mches ::tented/distal n (%) 276 (49.4} 
Stent length (mm) 25.0 = 15.1 
Maximum batloon diameter (mm} 3.7±0.6 
Maximum pressure Inflation (atm) 17.5±3.7 
IABP. lntra«~rtle balloon pump lmplant.l~on; GP llbnlla inhibitor:: ~c. usc of 
glycoprotein llb/Jila lnhlbJtor:; during the proeo:dure: IVUS, lntrnVOI5eutar 
ultrn.sound; DCA, dircalonal coron~r; athereaOf!'l)'. 
Oatl :ml presented liS pcrcent.lges and n'IC:In ±SO. 
36% of the patients. The number of treated vessels was 2.2 ± 0.8 
and the number of lesio11s 23 ± 1.5; 27% of the patients also had 
right coronary artery disease. An intra-aortic balloon pump was 
used i11 96 (13.1%) patients.ln 337 (46.1%) patients IVUS guidance 
was performed. Refere11ce vessel diameter of the LMCA was 3.7 ± 
0.6 mm. At least one SES was implanted '1n 536 (73.3%) and PES i11 
196 (26.8%) patients: in one patient both PES and SES were used. 
In 559 (765%) patients the stenosis was located at the distal 
segment of the LMCA. When the distal left main was treated, 
the stenting strategy adopted was provisional (cross-over) 
approach i11 283 (50.6%) patients. 'crush' in 120 (21.5%), 'V stent-
ing i11 80 (14.3%), 'modified T i11 52 (9.3%) and 'culotte' in 24 
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(4.3%). Final kissi11g balloon i11flation was performed in 64% of 
the cases. 
The median duratiol1 of OAT was 8.8 months QQR. 6.0-20.7). 
Stent thrombosis 
Definite stent thrombosis 
Four (054%) patients had a definite ST. Three patie11ts had an early 
(tw'o acute and o11e subacute) a11d only one a late definite ST. 
Early definite stent thrombosis 
Among the three patients with early defi11ite ST; one had an intra-
procedural ST successfully treated with intravenous adm1nistratiol1 
of abdximab, i11tracoro11ary administration of recombinant tissue 
plasminogen activator (r-TPA) and additional stent implantation 
(the patie11t was found to be a poor responder to dopidogrel): 
the second occurred some hours after the PCI and was success-
fully treated with emergency CABG: and the last occurTed 
12 days after the index procedure. All the three patiems had the 
thrombotic event while 011 OAT a11d aU of them are alive at the 
time of this report 
Late and very late definite stent thromOOsis 
Only one patient had a definite late ST at 3.9 months while on 
DAT. The patient had an acute anterior Ml and angiographically 
proven ST in the proximal left anterior descending artery success-
fully treated with repeat PCI. This patient died of lung cancer 10 
months after the thrombotic event. No cases of very late definite 
ST were recorded, 
Probable stent thrombosis 
Probable ST occurTed in three patients. In aU the three, the event 
occurTed early and was adjudicated because of the occurre11ce of 
sudden death within 30 days from the procedure, in the absence of 
an autopsy or control angiography. 
Therefore, a total of 7!731 (0.95%) patients had a definite or 
probable ST. Characteristics of patients with defi11ite or probable 
STare illustrated in Table 3; baseline, lesion, procedural character-
istics of patients with definite or probable ST vs. patients without 
definite or probable STare illustrated in Tab{e 4. 
At univariate exact logistic (unconditional) analysis. age 
(OR= 1.07, Cl 95% 1.00-1.16: P = 0.03), LVEF (OR= 0.94, 
Cl 95% 0.90-0.98; P= 0.007) and Euroscore (OR= 1.19, 
Cl 95% 1.07-1.34; P = 0.003) were correlated to definite or prob-
able ST. At condttionalunivariate analysis, only LVEF (OR= 0.94, 
Cl 95% 0,89-0.99: P = 0.03) and Euroscore (OR= 1.22, Cl 95% 
1.06-1.41: P = 0.008) were associated with definite or probable 
ST (Table 5 and Figure 1A). 
Possible stent thrombosis 
Possible stent thrombosis was adjudicated in 20 patiems in whom 
the cause of death was unexplained (no autopsy or control al1gio-
graphy was performed). 
late possible ST occurred in eight and very late possible ST in 
12 of these patients. Eight of these patients were on OAT at the 
time of the event and 12 had suspended OAT (10 because of 
the hospital protoco~ one because of gastric symptoms and 
80 
Table 3 Characteristics of the patients with definite and probable stent thrombosis 
Patient 
'"ro Ago LVEF Unstable Lesion Stent Stcnting Time of the OAT at the time 
score (years) r•l angina location type tc<hnique event (days) of the event 
··························· 
Definite ST 
55 55 No Dlrol T""' Cn.~sh ye; 
n 30 y, Dlrol Cypher Cross-over Ye; 
10 71 45 y, Dlrol Tx-:us v 12 y" 
4 11 71 35 No Dlrol Tx-:u~ Crush 116 y, 
......................... . .................. 
Probable ST 
12 76 40 y, Dlrol Cypher Cn.~sh 12 y" 
15 78 39 y, Ostium Tx-:us Cross-over y" 
10 85 30 y, Dlst:LI Cypher Cross-over y" 
lYEf. lcit ventrlc!Jar~j~ctlo~ fr<ldlon: DAT.dual M~~tclet therapy; ST, ~ent thrombos\;. 
Table 4 Baseline, lesion. procedural characteristics of 
patients with definite or probable stent thrombosis vs. 
patients without definite or probable stent thrombosis 
Patients with Patients without 
definite or definite or 
probable stent probable :rtent 
thrombosi$ thrombosis 
(n=7) (n= n4) 
Age (ye.:.rs) 725 ± 9.2 63.1 ± 11.8 
LVEF (%) 39.1 ± 8.8 54.9 ± 10.8 
M.:.lc gender 5 rt5%) 537 (74.1%) 
Unst:Lble angln.:. 5 (71.5%) 328 (45.3%) 
Dl.:.betes 2 (28.5%) 174 (24."1%) 
Euroscorc 9.6 ± 4.6 4.0±3.0 
Dl>tallocation 6 (85.7"/o) 554 (76.5%) 
Both br.111ch stentlng' 4 (66.6%) 272 (49.1%) 
Stent length (mm) 25.8±14.0 25.0 ± 15.8 
Referencev!!SSel (mm) 3.32± 1.0 3.4 = 0.5 
IVUS done 3(421%) 334 (46.8%) 
DAT 7 (100%) 117(16.1%) 
Myocardi.:.l intlrctionb 4 (57.1%) 9 (1.24%) 
Target lesion 4 (57.1%) 74 (10.2%) 
r=culari;:;:rtion 
Cardiac de.:.th 3 (428%) 28 (3.86%) 
OAT, dualantlplatdct thernpy atthetlme of the thrombotic e'lent Dn pJtient;:;wlth 
dcflnOtc or probable :rtent thrombosis (ST)] or at the time ofl<~St clinical follow-up 
(In p:rtient;:; without dcflnlte or prob~ble ST), 
'Both branch stentlng: the percentages are c:Jitulatcd eonsidenng only patients 
with dlstalle::lon loc:atlon. 
0in myocardial infarctions arc o:d~dc<l perl-pro<:e<lurat myot::lrdiallnfaralons 
unless occurred following ST. 
o11e because of abdominal surgery). Clinical characteristics were 
u11favourable in most of these patients: 8/20 (40%) were > 75 
years old, 13/20 (65%) patle11t had a LVEF <40% and a Euroscore 
:::_6 (Table 6). 
In-hospital and long-term major adverse 
cardiac events 
In-hospital a11d lo11g·term clinical outcomes are illustrated in 
Table 7. 
During hospitalizatiol"l, five (0.68%) patle11ts died: all of them 
were > 75 years and had a Euroscore >6. None of these patients 
had a11 :mgiographically or pathologically proven ST. Sudden death 
occurred i11 215, and probable ST cannot be excluded. Non·Q· 
W<Ne Ml occurred i11 69 (9.4%) of the patients. 
At 29.5 ± 13.7 months, cumulatively 45 (6.2%) patients died: 31 
(4.2%) of cardiac death. During the follow-up period, 11 patie11ts 
experie11ced a Ml and nine of them were 110t il"l the target vessel 
(t;No were due to angiographically proven ST i11 a ste11t not i11 the 
target vessel). Seventy six (10.5%) patients underwent TLR and 95 
(13.0%) a 1YR (83 re--PCis :md 12 CABG). Angiographic follow-up 
was performed in 548 patients {75%); restenosis occurred i11 77 
(14.1%) of these patients. Notably, the mnge a11d exte11t of cli11ical 
follow-up did not differ among the different centres. 
At univariate exact logistic {unconditional) analysis, age 
(OR= 1.06, Cl 95% 1.03-1.09: P = 0.0001). LVEF (OR= 0.94, 
Cl 95% 0.92-0.96: P < 0.0001), Euroscore (OR= 1.21. Cl 95% 
1.13-1.30; P< 0.0001), unstable angina (OR= 3.73. Cl 95% 
1.54-11.6: P = 0.002) and IVUS guidance (OR= 0.93. 
Cl95% 0.16-0.93: P= 0.03) were correlated to cardiac death. At 
conditional analysis. only unstable angina (OR= 3.25, C1 95% 
133-9.05; P=0.007), LVEF (OR=0.79. C1 95% 0.87-0.97; 
P= < 0.0001) and Euroscore (OR= 1.18, Cl 95% 1.04-1.23; 
P = 0.003) were correlated to cardiac death (Figure 1B). 
Discussion 
The main findings of this study are: (i) the incidence of definite ST 
is relatlvely low (0.5%): 75% of the cases occurred within 30 days 
and none after 1 year: all the patients were successfully treated a11d 
survived from the event 0i) the cumulative occurrence of definite 
ar1d probable ST is 0.95% and at conditional analysis exact logistic 
analysis was correlated with the Euroscore ar~d LVEF, but not with 
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Table S Unconditional and conditional analysis of the predictors of definite and probable stent thrombosis 
Uncontfrtional analr.;i$ Conditional analysis 
OR 95% exact Cl p OR 95% exact Cl p 
.......................... 
·························· 
DES type 0.5174 0.1950-1.2693 0.1728 0.5531 0.2081-13732 0.2420 
Gender 0.8708 0.1409-9.2236 1.0000 o.6m 0.1044-7.4699 0.9417 
Age (yew;) 1.0783 1.0052-1.1620 0.0343 1.0649 0.9860-1.1595 0.1154 
Diabetes 1.2503 0.1182-7.7574 1.0000 0.8982 0.0814-5.8378 1.0000 
Unmble JJlgin~ 3.0184 0.4903-31.9183 03171 17247 0.4283-29.6316 0.4045 
LVEF (%) 0.9436 0.9027-0.9829 0.0072 0.9417 O.SB94-0.9934 0.0280 
Reference vessel (mm) 1.1958 0.5949-19384 0.7899 1.2420 0.5879-3.4065 0.74B2 
MLO (mm) 0.9489 0.2923-3.0104 0.9327 1.2245 o.m5-l9770 0.7357 
M.:tXimum pressure (~tm) 1.1592 0,9807-13545 0.0798 1.1639 0.9775-1.3656 0.0862 
Stcnt length (mm) 1.0055 0.9552-1.0474 0,7544 1.0152 0.9573-1.0656 0.5395 
Olmllocatlon 1.8425 0.2208-85.4474 0.9695 0.7260 o.~0-55.154~ 1.0000 
Kissing bnUoon infutlon 1.9497 0-4.9615 1.0000 22424 0-6.0158 1.0000 
Type of stentlng technique 1.9465 0.3910-9.6902 0.6171 1.5316 0.2979-7.8749 1.0000 
Both br.mch stcnting 3.1327 0.4454-34.8600 0.3339 22919 0.3134-26.3552 0.5863 
Eurosco~ 1.1996 1.0758-1.3422 0.0026 1.2193 1.0577-1.4124 0,0076 
wus 0.8758 0.1273-5.2108 1.0000 1.4492 0.2006-9.1331 0.9194 
OAT dlscorttinuation 0.1464 0.0219-0.8813 0.0347 0.1524 0.0196-0.9889 0,0485 
OAT duration, 12 months 0.6076 0.1193-22452 0.8555 0.4343 0.0836-1.6713 0.3823 
OAT duration, 6 months 1.2958 0.2753-4.4804 1.0000 1.3891 0.2899-4.9297 1.0000 
DES, drug-eluting stent; MLD, minimal lumen dl~mew, !VUS, lntr.~voscular ultrasound; OAT. dual antlpbtelct ther.~py, 
the duration of OAT (at the time of the thrombotic event all 
patients were on OAT): (iii) there ms a 4.2% cumulative cardiac 
mortal'rty and 61% cumulative total mortality rate at 295 ± 13.7 
months follow-up. 
According to current European Society of Cardiology and 
American Heart Association/American College of Cardiology 
guidelines the presence of a stenosis in the LMCA 0f a patient is 
not eligible for CABG) is considered a Class lib or lla ir~dication 
for PCI, respectively.2425 According to these guidelines, when a 
patient is eligible for CABG, PCI has a class Ill indication, irrespec· 
tive of the lesion location. Some retrospective studies evaluating 
surgical treatment forth is disease reported an in-hospital mortality 
varying from 1.7 to 7.0% and a 1-year mortality of 6-14%?6- 30 
Recently, encouraging results have been reported with elective 
DES implantation in LMCA with a 1-year mortality of 
0-5%,11·13·17•31 The need for TLR in these registries varied from 
0 to 14%.11·13•17•19.31 lr~deed, the presence of ostial and mid-shaft 
lesions in the LMCA was associated with a more favourable 
outcome and an extremely low restenosis rate.12•31 
Recently some concems have been raised about the long-term 
safety of DES implantation.1- 10 A multicentre registry analysing 
> 3000 patients electively treated with DES (in 67% for an off-label 
indication) reported a ST ir~cidence, at 18 months. of 1.9% (which 
included definite and possible ST).1 Half of the events occurred 
within 30 days, Similarly, another registry reported that most 
(60%) ST occurs within 30 days? In this study, which included 
patients w'1th acute coronary syndromes, a 2.9% cumulative '1nci· 
der~ce of definite ST was reported in 8146 patients at 3 years. 
The presence of an act~te coromry syndrome was ar1 independent 
predictor of ST. 
No study has thus far addressed the issue of ST following DES 
implantation in the subset of unprotected LMCA lesions. Our 
study represents the largest (n = 731) series of patients with 
unprotected LMCA lesions electively treated with DES. According 
to clinical and lesion characteristics, our study population was at 
moderately low surgical risk (Euroscore ::: 6 in almost 36% of 
the patients), but at intermediate risk for angioplasty (distal left 
main in 76% of the patients). The occurrence of in-hospital 
MACE. which included non-Q-wave Ml (defined as an elevation 
of serum CK MB isoenzyme that was three times ULN), was in 
accordance with previous reports. Only four (O.S%) patients had 
a definite STand all of them were on DAT at the time of the 
event This finding may point out the importance of evaluating indi· 
vidual responsiveness to antiplatelet therapy.33 Interestingly one 
patient who developed intra-procedural ST and in whom we 
measured platelet inhibition, was found to be a non-responder 
to dopidogrel ln three (75%) patients. definite ST occurred 
within 30 days and only in one at 3.9 mor'lths, All the four patients 
who had definite ST survived from the event after having been suc· 
cessfu!lytreatcd: three w'ith repeat PCI and one V¥ith CABG. Three 
of the patients are still alive at the time of this report and one died 
because of lung cancer. 
Even if we consider definite and probable ST together (which 
included three deaths within 30 days in the absence of angiographic 
or pathological confirmation of ST) the low incidence of 0.95% is 
still quite reassuring. Again, all patients had the event while on 
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100 i 
LVEF r-HI OR~ 0.94, 95%0 0.89....0.99; P- 0.03 
Euroscorc OR- 1.22, 95%CI 1.06-1.41;P- 0.008 
0.01 0.1 10 
(B) 
0.01 0.1 10 
100 
LVEF OR- 0.79, 95% CI 0.87-0.97; P$.0.0001 
t:nstllble angina OR- 3.25, 95% CI 1.33-9.05: P ~ 0.007 
Euroscore OR -1.18, 95%Cll.D4-L23;P- 0.003 
0.01 0.1 10 
Figure I Predictors at condition~\ ~natysis of definite or prob<1ble stent thrombosis (A) and ardiac death (B). 
DAT. At conditiollal exact logistic analysis, the occurrence of defi-
nite and probable ST was correlated with Euroscore and LYEF. 
This finding is consistent with predictors identified in general PCI 
populations. 1.3 Therefore, no unique ST predictor among LMCA 
lesions was identified in our analysis. 
Regarding the 20 (2.7%) patients with possible ST (unexplained 
deaths after 30 days) we need to take into account that many of 
these patie11ts had high risk ci'laracteristics for cardiac death unre-
lated to ST (Table 6): at conditioml exact logistic analysis, cardiac 
death was corTe\ated to Euroscore and LVEF. Moreover, at least 
nine of the patients with probable ST would mect the inclusion cri~ 
teria for MAD IT II (multkentre automatic defibrillator implantation 
trial), which reported an expected overall mortality of19.8% and a 
sudden cardiac death rate of 9.8% at 2 years in the control 
group.3435 Eight patients were still on OAT at the time of death 
and 12 were not (10 suspended OAT according to the hospital 
protocol and only t:No prematurely). 
Furthermore. the cumulative occurrence of death (cardiac ar1d 
non~cardiac) at 29.5 ± 13.7 months follow-up was 4.2 and 6.2%, 
respectively. These rates arc encouraging if compared with mortality 
rates following CABG at a similar clinical follow-up time period. 
The low rates of cardiac death in our study could also be justi-
fied by the exclusion of patients presenting with a MI. In addition. 
we cannot exclude that the low rate of cardiac events reported in 
our study were due to the fact that LM stenting was performed in 
highly experienced centres. 
Additionally, only 11 (1.5%) patients experienced a Ml during 
follow~up, nine of which were not in the target vesseL Interestingly, 
t:No were due to angiographically proven ST not in the target 
vesseL 
In our registry the long-term efficacy of DES in this subset of 
lesions is confirmed by a TLR and TVR rate (83 re-PCis and 12 
CABG) of 10 and 13%, respectively, and a restenosis rate of 14% 
even with 76% of lesions involving the distal LMCA So far, no ran~ 
domized data comparing PCI with DES implantation vs. CABG are 
avai\able.11.15·16 The 'Synergy bet:Neen Percutaneous Intervention 
with TAXUS® and Cardiac Surgery' (SYNTAX) trial was recently 
conducted and included 710 patients with left main disease ran-
domized to receive either a PES or CABG. Interestingly. the 
study was not powered to detect any difference between CABG 
and PCI with DES in the subset of unprotected LMCA lesions 
but only in triple-vessel disease. 
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Table 6 Characteristics of the patients with possible stentthrombosis 
Patient Eom ... LVEF u..-~ Lesion Stent Stenting Time of the OAT at the time 
~·~ (yC:lr$) (%) angina location trl"' technique event (days) of the event 
................. ..................... 
1 72 26 No Dim! 
2 65 55 No Dlsml 
48 57 Y5 Distal 
4 53 61 y~ Distal 
13 82 28 y~ Distal 
7 
" 
35 y" Distal 
11 71 20 y" Distal 
4 6l 65 No Distal 
5 54 35 No Distal 
10 72 30 No Distal 
11 77 30 y" Distal 
12 11 so 30 y" Distal 
13 56 40 y~ Distal 
14 75 45 y~ Ostium 
15 10 72 40 y" Distal 
16 80 30 y~ Distal 
17 4 78 60 y, Distal 
18 11 82 30 No Dim\ 
19 10 51 25 y, Distal 
20 25 S1 50 y"' Ostium 
LVEF, left w:ntrl~ubr t)octlon frar:Jon; DAT, du~l ~ntlplatclet ther:~py: N/A. not ~ppii<:Jble. 
Table 7 Major adverse cardiac event at hospitalization 
and at long-term cUnical follow-up 
In-hospital. n - 731 Follow-up, n - n6 
Cardiac death, n {%) 5 (0.~ 26 (3.6) 
T otll death. n (%) 5 (0.~ 40 (55) 
MI. n (%) 69 (9.4) 11 (15%) 
TLR. n (%) 2 (03) 76 (105) 
1VR n (%) 2 (03) 95 {13.0) 
MACE,n (%) 73 (9.9%) 138 (19.0) 
Ml, myoeardlollnfamlon: TLR, tli'gct lesion ~ubriz.\~on: TVR. t:~rget Ye$lel 
rev.seulariz:atlon: MACE. rNjor adverse e:mll•c eve11ts.. 
D~t:l :i'j) presented :LS perccnt3ge-;. 
Study !imitations 
This is a retrospective multicentre registry. No ·o prion" sample 
size has been calculated. Artother limitation is the length of 
clinical follow-up. Moreover we cannot exclude that some of 
the unexplained deaths that occurred at follow-up could have 
been a ST because of the absence of an angiographic andfor 
pathological examination. Differer~t durations of DAT were pre-
scribed amortg the centres due to different institutio11al 
practices. 
Cypher Cross-over 1162 No 
Cypher v 175 No 
Cypher Cross-over 790 No 
Cypher Crush 546 No 
Cypher Crush 154 No 
Cypher Cross-over 1390 y~ 
T~us Crush 443 y, 
T~us Crush 955 No 
Cypher v 
'" 
y" 
Cypher Cross-over 623 y~ 
Taxus Cross-over 270 No 
Taxus Culotte 156 No 
Tnxus Cross 
"' 
No 
Cypher N/A 1j49 No 
T;rxus Culotte 352 No 
T;rxus Cross-over 243 No 
T:lXUs Cross-over 482 y" 
T;rxus Cross-over 180 y" 
Cypher Cross-over 757 y" 
T:lXUS N/A 99 y~ 
Conclusions 
In this multicentre registry. the elective use of DES ir'l unprotected 
LMCA ster10sis appears to be safe and effective at 29.5 ± 13.7 
clinical follow-up. Definite and probable ST occurred in 0.9% of 
the patients. Further studies with longer durations of fot!ow-up 
as well as uniform ar1d prespedfied durations of OAT are 
needed in order to better clarify the issue of safety following 
DES implar'ltation in unprotected LMCA lesions. 
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admlnl::tr.t~on on drug-eluting stent thrombo51::.. j Am C!JII Cardlol 2007;49: 
2312-2317, 
34. M= AJ, :Z.rcba W, Hall WJ, Klein H, V\lilber DJ, Dnnom DS, Daubert JP, 
Higgins SL Brown MW, Andrew,; ML. Prophyllctlc impt;mCition of a dcllbril:ator 
In pa~ent with myO<:Ordla1 infarction and reduced ejection fr.~ctlon. N Eng!) !~e<i 
2002:346:Bn -883. 
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The above article uses a new reference style being piloted by the 
EHJ that shall soon be used for all articles. 
CHAPTER 9 
A COLLABORATIVE SYSTEMATIC REVIEW 
AND META-ANALYSIS ON 1278 PATIENTS 
UNDERGOING PERCUTANEOUS DRUG-
ELUTING STENTING FOR UNPROTECTED LEFT 
MAIN CORONARY ARTERY DISEASE 
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A collaborative systematic review and meta-analysis 
on 1278 patients undergoing percutaneous 
drug-eluting stenting for unprotected left 
main coronary artery disease 
Giuseppe G.L Biondi-Zoccai, MD, a,o Marzia Lotrionte, MD,b.o Claudio Moretti, MD," Emanuele Meliga, MD," 
Pierfrancesco Agostoni, MD,e Marco Valgimigli, MD, PhD,~ A:o.gcla Migliorini, MD/ David Antoniucci, MD/ 
Didier ClniC., MD, R Giuseppe Sangiorgi, MD,bJ Abide Chieffo, MD, hJ Antonio Colombo, MD, hJ 
Matthew J. Price, MD, I PaulS. Tcirstein, MD,l Evald H. Christiansen, MD, k Antonio Abbate, MD, 1 Luca Testa, MD, b 
Julian P.G. Gun:o., MD, m Francesco Burzotta, MD, b Antonio Laudito, MD, n Gian Paolo Trevi, MD," and 
I::mad Sheiban., MD" Turin, Rome, Ferrara, Gussago, Florence, and Milan, Italy; Antwerp, Belgium; Toulouse. 
France; La]o"Od, C4; Aarhus, Denmark; Richmond, VA; and Sheffield. United Kingdom 
Background Cardiac surgery is the standard treatment for unprotected left main disease {UlM). Drug-eluting stent (DES) 
implantation has been recently reported in patients with UlM but with unclear results. We systematically reviewed outcomes of 
percutaneous DES implantation in UlM. 
Methods Several databases were searched for clinical studies reporting on ;:::20 patients and ;:::&month follow-up. The 
primary end point was major adverse cardiovascular events (MACEs; ie, death, myocardial infarction, or target vessel 
revascularization [fVR]) at the longest follow-up. Incidence and adjusted risk estimates were pooled with generic inverse 
variance random-effect methods (95% Cis). 
Results From 823 initial citations, 16 studies were included (1278 patients, median follow-up 10 months). Eight were 
uncontrolled registries, 5 nonrandomized comparisons between DES and bare-metal stents and 3 nonrandomized 
comparisons between DES and CABG, with no properly randomized trial. Meta<~nalysis for DES-based PCI showed, at the 
longestfollow-up, rates of 16.5% (ll.l'Yo-21.3%) MACE, 5.5% (3.4'Yo-7.7%) death, and 6.5% (3.7'Yo-9.2%) TVR. Comparison 
of DES versus bare-metal stent disclosed adjusted odds ratios for MACE of 0.34 (0.16-0.71), and DES versus CABG showed 
adjusted odds ratios for MACE plus stroke of 0.46 (0.24-0.90). Meta-regression showed that disease location predicted 
MACE {P = .001) aod NR {P = .020), whereas h;gh-dskfeatures pred;cted death {P = .027). 
Conclusions Clinical studies report apparenrly favorable early and midterm results in selected patients with UlM. 
However, given their limitations in validity and the inherent risk for DES thrombosis, results from randomized trials are still 
needed to definitely establish the role of DES implantation instead of the reference treatment, surgery. (Am Heart J 
2008; 155:27 4-83.) 
Coronary artery bypass gr:lfting (CABG) has been 
considered the standard treatment for significant l.Ulpro-
tected left main coronary disease (ULM) since the late 
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1970s. Percutaneous coronary intervention (PO) for l)L'\1 
was attempted as early as 197i with balloon angiop~"ty. 
but the risk of failure was soon recognized.1 Bare-metal 
stents (BMSs) later provided important early and midterm 
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Figure t 
S23 citations retrieved from 
dalab~se mrches 
774 ~\les/3bs!racls excluded 
because non-relevant 
49 complete articles assessed 
according to the selection criteria 
32 articles excluded according to 
explicit inclusion!exclliSion criteria 
7 dupf1e;afl:! pubflcations 
4 enrolling <20 patients 
9 ongoing 
7 unpublished 
5 !&ng BMS only 
17 studies (16 cohorts) finally 
included in !he systematic review 
Reviewing process. 
clinical benefits to the overall group of patients under-
going PCI by reducing periprocedural risks (eg, the need 
for emergency CABG), restenosis, and target lesion 
failure~ however, the impact of BMS on PCI for ULM has 
been limited.:: Drug-eluting stents (DESs) have been 
introduced into clinical practice in the Iru,1: few years and 
proved able to reduce the risk of r~1:enosis.3 Thu:;, they 
hold the promise of improving the outlook ofPCI for 
LL\1. Several reports have indeed been published on the 
short- and midtenn results of DES-based PCI for LL\1, but 
most were limited by retrospective nature, small size, 
and/or single-center design. To thoroughly appraise the 
risk-benefit balance of percutaneou:; DES implantation for 
ULM, in itself and in comparison \'lith BMS.based PCI and 
CABG, we performed a sy~1ematic review and meta-
analysis of pertinent studies. 
Methods 
'This review WJS reported according to e!>tlblished method$,~ 
minimizing duplication risks.5•6 BioMedCentrnl, clinic:tltltlls. 
gov, Google Schohlr, and PubMed were searched <January 2000-
September 2006),6 without I:t.nguage restrictions. Citations were 
screened at title/ab~tr.lct levd and retrieved as full reports. 
Studies were induded if the following criteria applied: (a) PO 
with :.tent impl:t.ntation, (b) for L'LM: disea...;e, (c) m.ing DES, and 
(d) in :2:!20 patients. E."'::clusion criteri:l were as follows: (a) 
duplicate publication, (b) ongoing/unpublished ~-rudy, (c) 
publication only as an ab~1:ract or as conference proceedings, (d) 
inclusion of patients not undergoing PCI of the 11.1\1, and (e) lack 
of :2:!6.month follow-up. 
Table 1. Included studies 
Study design and 
first author/study name 
Observotionol cohorts on DES 
Cou""Y 
Patients 
treated 
with DES 
Agostoni et ol9 Netherlands 58 
de l.e%o et al15 Spain 52 
DudeketaP 6 Poland 28 
KOMATE18 Korea 54 
Lozano et oFO Spain 42 
Migliorini etaF,. Italy 156 
Price et aF3 United Stoles 50 
Woodetol2'i* UnitedStotes 100 
Nonrondomized studies of DES vc~s BMS 
Carriii et a112 " France 120 
Chieffo et oP0 t ltoly 85 
Christiansen etaP4 " Denmark 46 
HonetoP 7 China 138 
Porketal11 Koreo 102 
Sheiban et ol24 • Italy 85 
Non randomized studies of PCI vs CABG 
Chieffo et ail3 t Italy 107 
Loo et oJl9 United Stoles 50 
Palmcrini et a122 Italy 94 
KOMATE, KOroon Mulficcntar hgoplo1ly TEom. 
'Updotod oftor diroctoommunicc~on with tho original invostigctors. 
tDupliOJtc publkcfion likely or odmowledgod. 
The primary end point was major adverse cardiovascular 
events (MACEs), defined as composite of death, nonf.tttl 
myocardial infarction, or target vessel revascularization (IVR). 
The coprimary end point was major adverse cerebrocardiova...;.. 
cul:J.r events (MACCEs). Secondary end points were individual 
components of:MACE. Other details on patients, procedures, and 
:.tudy designs were ab~1:racted, 6 and internal validity of induded 
:.tudies was appr:tised.' 
All principal invetigators of included srudies were 
repeatedly contacted. 
Continuous variables :l.!'e reported as mean (SD) or median 
(range) and categorical "'al'i:lbles as n ("/o), PoolingWJS performed 
according to randomclfect models with generic inverse variance 
weighting with Rev Man 4.2 (The Nordic Cochrane Center, 
K0behvn. Derunark) for computing incidence e!>timates (95% 
Qs). For nonr.:mdomized controlled compariSons. adjm.ted risk 
e!>timates were pooled after logarithmic tr.tnsformation accord· 
ing to random-effect models with generic inverse variance 
weighting. Subgroup,6 sensitivity, and meta~ion analyse! 
were performed to appraise robm.tness and explore moder.l.tors 
(SPSS 11.0; SPSS, Chicago, IL). Stath.tical heterOgeneity was 
appr:tised with / 2 and small ~tudy bias with funnel plots and 
regression ana.ly~is. Uru:r.djm.ted Pvalues :l.!'e reported through-
out, with hypothe!>is teting set at the 2·t:illed .05 levd, 
Results 
From 823 initial dtations (Figure 1), we excluded 806 
hits, leaving 17 studies.9-::5 (fables I and II). The 17 
included studies reported on a total of 16 nonduplicate 
cohorts, enrolling 1278 subjects undergoing PO 'With 
DES for ULM disease. Eight studies were observational 
reports on 540 patients treated 'With 
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Table II. Mol or excluded studies 
Study Country Patients Design Reason for exclusion 
Arompatzis ct al {2003) Netherlands 31 Observational cohort Duplicate publication 
Arompatzis ct al {2004) Ncthe~onds 16 Observational cohort Duplicate publication 
Bcrengucr ct al (2005) Spain 7 Observational cohort Duplicate publication 
CARDIA 12006) UK 600 RCT of PCI vs CABG Ongoing 
COMBAT Worldwide 1800 RCT of PCI vs CABG On hold 
oCYPHER [2006) Worldwide 171 Observational cohort Unpublished 
Erglis ct al O,ropo 103 RCT of DES vs BMS Unpublished 
European Registry Europe 224 Observational cohort Unpublished 
French Mulficcnlcr T oxus Study France 150 Observational cohort Ongoing 
Hcrz ct al (2005) Israel 4 Non-RCT of PC! vs CASG <20 Patients induded 
Klm et al (2006) Koreo 116 Observational cohort Duplicate publication 
Korean Randomized Study Ko= 124 RCT of PCI vs CABG Ongoing 
LE MANS (2005) Poland 37 Observational cohort Unpublished 
Lefevre ct al France 146 Observational cohort Unpublished 
Leipzig Study Germany 200 RCT of PCI vs CABG Ongoing 
l.opez-Palop ct al (2004) Spain 10 Observational cohort <20 Patients included 
Munich Study Germany 340 RCT of CYPHER vs T oxus Ongoing 
Palmerini ct al (2005) Italy 42 Observotionol cohort Duplicate publication 
Peszck-Przybylo et ol {2006) Poland 62 Observational cohort <20 Patients included 
Pohl ct ol (2004) Germany 23 RCT of PCl vs CA8G BMS usc only 
REVASCULARIZE United States NA RCT of PCl vs CA8G Ongoing 
SECURE United States 20 Observational cOOat Unp~lished 
SYNTAX Worldwide 1500 RCT of PO vs CABG Ongoing 
Tcplitsky et al {2004) brod 11 Observational cohort <20 Patients induded 
TRUE Europe 115 Observational cohort Unpublished 
Volgimigli ct ol (2005) Netherlands so Before-afler study Duplicate publication 
Valgimigli ct al (2006) Netherlands 110 Observational cohort Duplicate publication 
Roferon~ ore avoiloblc from the ~Of!'ll:llOI'lding outhor upon roqu~t. NA, Not avoiloblo <)( opplicoblc; RCT, rondomizcd dinicoltriol. 
DES,9.15,16,Is.w.2I.23.25 6 ::.'tl.ldies were nonrandomized 
comparisons of PO "With DES (n = 576) ven.-us BMS (n = 
509), 11).12•1'1' 17·2'1 and 3 were nonrandomi7..cd comparisons 
ofPCI "With DES (n = 251) vm'US CABG (n = 419).13·22·23 
Median follow-up was 10 months (range 6-19 months). 
The overall internal validity of all included studies was 
only moderate, given the presence of several potential 
threats to ::.'tl.ldy quality. Details on included ::.'tl.ldies are 
available in Tables ill and IY. 
All studies provided enough details on the primary end 
point (ie, MACE or MACCE); however, incomplete 
reporting of other events was common (fable V). 
Overall analysis (Figures 2 and 3) showed inhospital death 
in 2.3% (1.1-3.4, / 2 = 7.4%) and inhospital myocardial 
infarction in 2.5% (1.2-3.8, / 2 = 27%). Overall midterm 
follow-up showed MACE in 16.5% (11.7-21.3, / 2 = 84%), 
death in 5.5% 0.4-7.7, / 2 = 64%), and TVR in 6.5% 
(3.7-9.2, / 2 = 80%). Comparing MACE in studies limiting 
follow-up to 6 montbs14'18'19·21 ·22 vm'US those extending 
follow-up to >6 montbs"-13·1s-17·20·23-25 showed rates of, 
respectively, 14.2% (5.4-23.0, / 2 = 85%) and 17.7% 
(11.7-23.8, p = 86%). 
Multivariable adjusted e::.Lirruttes for DES vs BMS were 
reported only by a handful of studies, 10'12·24 for a total of 
206 patients treated "With DES versus 190 "With BMS 
(Figure 4). Pooled analysis showed the superiority of DES 
both in follow-up MACE and TVR. (m>pectively, odds ratio 
[OR] = 0.34 [O.l<Xl.71], P = .004, ! 2 = 45.3%, and OR= 
034 [0.12-0.94], p = .04, I'= 0%). 
Adjusted estimates for the DES-based PCI versus 
CABG were reported only by Chieffo et al13 and Lee 
et a!, 19 for a total of 157 patients treated "With DES and 
265 "With CABG (Figure 4). Meta-analy::.is for the 
occurrence of MACCE at follow-up sugge::.ted the super-
iority of DES vm'US CABG (OR= 0.46 [0.240.90], 
P = .02, P = 0%), even if this e::.Lirrutte should be viewed 
with caution, given the small number of patients 
included, the "Width of the ICs, and the caveats on the 
internal validity of included studies. 
Subgroup analyses were petfonned for (a) DES 
implantation for nonbifurcationall'L"t\1, (b) DES 
implantation for UL"t\1 in low-risk patients, and 
(c) DES implantation for ULM in high-risk ::.11bject:s. 
Given the limited details provided by the individual 
::.'tl.ldies on these subgroups despite repeated efforts to 
contact the primary authors, computations perfonned 
on the available data are hereby reported as C..'Xploratory 
finclings only, 
Including a recent update from a multicenter registry 
and excluding duplicate sources, a total of 285 patients 
with nonbifurcational UL\1 and treated "With DES had 
detailed follow-up data?11'14'15·21•24-26 Pooled analysis 
showed inhospital death in 0.9% (Oo/.,..2,1%, 12 = 0%) and 
myocardial infarction in 3.2% (Oo/o-5.6%, / 2 = 0%), 
Table 111. Characteristics of :~eluded studies 
Surgical 
high· SES/ 
risk Angiogrc~phic O<al PES 
Ago Ma~ Diabetic ACS Non-bifurcation-a! features LVEF COPD RF follow•up antiplatelet 
""' Study (y) (%) (%) (%) uLMrlol r~ol· {%) {%) {%) (%) regiment (%) 
Agostoni 63± 13 69 33 32 AS NA 48± 12 NA NA NA A+C, NA 
claf 6m 
Carriii 66± 12 75 29 63 0 NA 59:!: 11 NA NA 100 A+C, 0/100 
ctoJ12 6m 
Chieffo 63± 12 84 21 31 19 AS 51± 11 NA NA 85 A+C, NA 
etoP 0 ><Sm 
Chieffo 64± 10 NA 19 32 19 32 52± 10 NA 6 85 NA 51/49 
etoJ1 3 
Christianson NA NA NA NA 46 43 NA NA NA NA A+C, NA 
otoJ1 4 >3m 
dol= 63 ± 11 42 35 83 58 NA 57± 13 NA NA 67 A+C, 100/0 
etoJ1 5 12m 
Dudek NA NA NA NA NA NA NA NA NA NA A+C, 46/54 
etoJ1 6 6·12m 
Hoo 62 ± 11 NA 29 AS 29 NA NA NA NA 36 A+C, NA 
etoJ1 7 :t: &9m 
KOMJ..TEra 59±9 68 Zl 65 67 NA 60± 18 NA 4 44 A+C, 65/35 
6m 
Leoetol19 72± 15 50 36 66 40 64 51± 15 NA 16 42 A+C, 84/16 
6m 
Lozano 70 ± 11 60 33 17 31 100 371 NA NA 51 A+C, 71/19 
etof!O 3-6m 
Migliorini 70± 10 80 32 69 15 61 Zl§ NA Zl 84 A+C, 26/74 
otoF1 6m 
~ Polmerini 73± 11 70 26 63 20 64 52± 14 16 20 66 NA 68/32 
~ etoF 
"" 
Pork et ol11 60± 11 75 28 60 29 NA 60•8 NA NA 84 A+C, 100/0 ~ 
u 6mll 
90 Price et oF
3 69± 13 64 26 34 6 58 241 NA 16 98 A+C, 100/0 
indefinite~ 
Sheibon24 68± 10 77 22 67 40 46 55± 10 NA 4 61 A+Cor 100/0 
A+T, 
6m 
Wood 68± 13 64 30 NA 31 NA 47± 13 NA NA NA A+C, NA 
claf" >6m 
ACS, Acuto coronary syndrome; LVEF, lcltvontriculor ejection fraction; COPD, chronic pvlmoi'IOryob:trudivo d"~so; RF, rei'IOI foill.lfl1; SES, ~irolimu:"'luting !lent I of ell DESs); PES, 
paditaxol·oluting !lent I of oil DES!). 
•Proportion with LYEF :>40%. 
t A slonds for mpirin, C for dopidogroJ, ond T for lidopidiM, followed by duration in months of duo] onliplo!clclthcropy. 
:j:Policnts with cjoction froction ILVEFJ :>45%. 
§Proportion with LVEF :;35%, 
li Gb:iozt>l wos obo odmini:tcrod for 1 month oftor !he procedure. 
!Defined o: EuroSCORE ~or PorsonMI scom;: 15. 
whereas after a median follow-up of 10 months, MACE available for 312 patients with surgical high-risk features 
occurred in 14.7% (6.2'%-23.2%, fl.= 75%). death in 4.1% (European System for Cardiac Operative Risk Evaluation 
(1.7%-6.6%, 12 = 0%), and TVRin 6.7% (0.9'%-12.4%, ~6 or Parsonnet score ~15). 1 0,H.20.21 •21 Random-effect 
fl. = 64%). Available studies reported on a total of 260 quantitative pooling yielded inhospital death in 6.6% 
patients with surgicallow·risk features (European System (3.6o/o-9.7"Ai, 12 = 0%) and myocardial infarction in 1.3% 
for Cardiac Operative Risk Evaluation <6 or Parsonnet (0"/o-3.0%, 12 = 0%), whereas after 8 months, MACE 
score <15).10'H'21 '24 Meta-analysis sho-wed inhospital occurred in 20.6% (11.9"/o-29.2%, / 2 = 75%), death in 
death in 3.0% (0%-6.1%, / 2 = 0%) and myocardial 12.0% (7.5o/o-16.6%, ! 2 = 26%), and TVR in 6.4% 
infarction in 3.0% (O.lo/o-6.0%, P = 0%), whereas after 8 (0./o/o-12.1%, p = ii%). 
months, .MACE occurred in 15.7% (7.7o/o-23.7%,J2 = 74%), Weighted least squares meta-regression disclosed a 
death in 4.8% (1.6%-8.0%,12 = 00/o), and TVRinS.S% (1.~/o- highly statistically significant interaction between the 
15.1%, ! 2 = 77"/o), Conversely, detailed event rates were rate of nonbifurcational UL\1 and the risk of MACE 
Review and meta-analysis on DES for ULMCA disease ]91 
Table IV. lntemal va!idi!y of included studies 
Prospective Multicenter Selection Perionnance Attrition Detection Multivariable adjustment 
Study design enrolment bias bias bias bias for potential confounders 
Agostoni ot of No No s D Probably adoquato 
CarriCotaP 2 y~ No B B A Probably adequate 
Chieffoetati 0 No y,. s s A Probably adequate 
ChieffoetaP 3 No No s s A B Probably adequate 
Christiansen et all.l y,. No c s D s None reported 
do leza ot aP5 No y" s s A s None reported 
Dudek et oP 6 Undoor No s s D s None reported 
Han et ar7 No No c B c s None reported 
KO/v\ATE18 Undoor y,. B s c c None reported 
lee et al19 No No s B D s Probably adequate 
l.o::ano et af20 y~ y,. s s c None reported 
Migliorini et aP1 No No B s B Probably adequate 
Polmerini et oF y"' No B c c None reported 
Park et oP 1 No No s A c None reported 
Price otaP No No B A s Probably adequate 
Sheiban et afU No No s A s Probably adequate 
WoodotaP No No B A s None reported 
Riiol bi(t$ is expr=cd (t$A (low[, B (modorotc), C {hi9h), or D Uneomploto reporting). 
Table V. Unadjusted clinicoi outcomes 
foJIOW"Up 
lnhospital In hospital Fallow-up completion MACE MACCE Death Ml Stroke TVR ST 
Study N death{%) MlrloJ (m) (%} r~oJ r~oJ (%} r~oJ {%) (%} r~oJ 
Agostoni et al 9 58 2 3 14 100 16 NA 5 3 NA 7 NA 
Corrie et aP4MS arm . 57 0 5 10 100 66 NA 7 5 NA 26 0 
Corrie et aP 2-DES arm 49 4 3 10 100 13 13 10 3 0 2 1 
Chieffo et oP 0-BMS arm 64 0 8 12 100 42 NA 1A NA NA 30 0 
Ch'dfo ot oP 0-DES arm B5 0 6 12 100 25 NA 4 NA NA 19 1 
Chieffo et oP 3-CABG arm 1A2 2 26 12 100 42 A4 8 27 2 6 NA 
Chieffo ot oP 3-DES arm 107 0 9 12 100 33 3A 3 10 1 20 1 
Christiansen et ai14-BMS arm • 39 31 3 6 100 A4 A4 31 5 0 s NA 
Christiansen et oi14-DES arm A2 2 0 6 100 7 7 5 2 0 5 2 
de leza et ol15 52 0 A 12 100 6 NA 0 A NA 2 0 
DudekotaP6 36 NA NA 9 NA 1A NA NA NA NA 0 NA 
Han et aP 7 -BMS arm 3A NA NA 12 NA 27 NA 9 3 NA 15 NA 
Han et oP 7 -DES arm 138 NA NA 12 NA 11 NA 7 1 NA 10 NA 
KO/v\ATEla 5A 2 0 6 S1 5 NA 2 0 NA 2 0 
lee et aP 9-CABG arm 123 5 2 6 NA 14 17 11 2 8 1 NA 
lee et aP 9-DES arm 50 2 0 6 NA 11 11 4 4 0 7 0 
l.ozonoetof20 A2 10 0 10 100 26 NA 20 A NA 2 1 
Migliorini et aP1 • 156 7 1 6 100 2A 2A 11 1 0 12 0 
Palmorini et oP-CABG arm 164 NA NA 6 NA 1A NA 11 13 NA NANA 
Palmerini et oP-DES arm 94 NA NA 6 NA 22 NA 9 13 NA NANA 
Park eta111-BMS arm 121 0 s 12 100 25 NA 0 s NA 17 0 
Park et oi11-DES arm 102 0 7 12 100 9 NA 0 7 NA 2 0 
PricoetaP 50 0 s s 100 5A NA 10 10 NA A4 A 
Sheibon ct ofA -BMS arm 69 10 3 10 99 36 36 20 3 0 13 0 
Sheiban ot afA-DES arm • 77 3 3 10 100 9 10 3 3 1 4 0 
WoodetaP' 100 2 3 19 100 19 NA 6 3 NA 7 1 
MI,Myocordid irlnrdion;sr, stcntthrombosis. 
'Updated after communicotion with investigators. 
(~ = -O.Dl5 [-Q.OOS to -0.022], P = .001) (Figure 5). adjusted R2 = 0.58). The prevalence of high-risk 
Intriguingly, location of UlM disease could explain as features proved to be a statistically significant predictor 
much as 58"/o of the observed variability (R2 = 0.61, of midterm follow-up case fatality (13 = 0.017 [0.003-
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0.031], P = .02i, R2 = 0.58, adjusted R2 = 0.51) but 
not of midterm MACE (P = .55). On the other hand, 
TVR was significantly associated with the rate of 
nonbifurcational ULM (~ = -0.016 [-0.003 to -0.030], 
P = .020). Angiographic follow-up rate, despite being a 
common cause of event inflation in coronary 
intervention studies,27 was not significantly associated 
with MACE or TVR. 
Sensitivity analyses conducted with fi.'i:eddect, and 
DerSimonian-Laird methods confirmed the findings of the 
original analyses. Tc'ting for small study bias showed no 
statistical significance (P = .63). 
Discussion 
The present meta·anal~is. reporting on DES implanta-
tion for ULM, has the following implications: published 
reports on DES use now include > 1200 subject5, 
confirmjng that this treatment option has been already 
adopted into clinical practice despite the lack of a sound 
Review and meta~ana!ysis on DES for ULMCA disease 193 
Figure 3 
A 
Agostoni et al (2005, 53 pts) 
... 
-c Lee et , 
iii 
0 15 30 45 60 
Rate of mid-term MACE(%) 
B 
Chieffo e: 111 
clelezoet~ 
... 
.. , Lo:onoet u; 
i i 
Palmeril'li et 
Price et 
Wocd 
0 15 30 45 60 
RaW of mid-!2rm death (%) 
Overall risk of MACEs (A), death (B), and TVR (C) at a median follow·up of 10 months (range 6·19 months} in patients treated with DESs for UIM. 
evidence base; although overall results suggest an 
apparently favorable risk of :MACE in selected patients, 
most ~>tudies are fraught with validity threats; moreover, 
clin.ical follow-up is to date still limited at the midterm 
threshold; thus, results from randomized trials comparing 
percutaneous VCThUS $llfgical revascularization are still 
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needed to establish the role of percutaneous DES 
implantation in the evidence-based medicine hierarchy in 
comparison with the reference treatment, surgery, 
especially given the recent concerns raised on late stent 
thrombosis.28 
Unprotected left main disease occurs in 5% of patients 
undergoing coronary angiograph1'"'9 and has been, for 
decades, a strict indication for CABG. Since DES 
approval,3 interventionists have begun to use them not 
only in patients with UL'\:1 at very high surgical risk but 
also in those with more favorable char:tcteristics.30 Most 
reports were, however, small single-center O..'})eriences, 
with obvious limit:Ltions in external validity. The available 
evidence on patient selection and risk stratification in 
patients Wldergoing PCI with DES for ULM has already 
established that nonbifurcationall.JL\1 is associated with a 
more favorable prognosis than !fu.la! (ie, bifurcation) 
ULM, but whether surgery should be the first-line 
treatment even for nonbifurcational ULM remains 
debated?6 Recent data have lead to an overall reappraisal 
of the long-tenn safety ofDES,31 given the likely increase 
in stent thrombosis, and this has had even greater 
implications on DES-based PCI for lJL.\1 . 
Notwithstanding the limitations of included studies, 
we aimed to provide a comprehensive ~)'Uthesis of the 
evidence on DES for UL\1. We identified several studies, 
including regb"'tries or nonrandomi7.ed comparison of 
DES versus BMS or CABG, but no randomized trials. 
Pooled analyses of registry data from the present work, 
including> 1200 patients, support the early and midterm 
safety of DES implantation, e:;'Pecially in carefully 
selected patients and under the premise that PCI is 
performed by e.xperienced operators in centers with on-
site surgical bad.-up. The beneficial impact of DES over 
BMS in these le:.ions is clearly and lUlalli.mously shown 
in the available controlled :.LUdies. Indeed, in-stent 
restenosis has been called into question as a potential 
cause of acute coronary syndromes in Uil!>"PCcified 
lesions, but in L'L\1 restenosis, it is well known as a 
potential cause of sudden cardiac death or myocardial 
infal'ction. Thus, the antiproliferative action of DES iS of 
paramolUlt importance in UL\1lesions, and to date, DES 
should likely be recommended whenever PO for U1M 
is envisioned. Nonetheless, our findings on DES in 
general, and on the comparison with CABG in 
particular, should be viewed in light of the need to w.tit 
for the long-term results of ad hoc randomized trials (eg, 
COMBAT, SYNTAX, and REVASCULARIZE studies) before 
drawing any definitive conclusion. 
Among the limitations of this work, drawbacks of 
systematic reviews of nonr.mdomized studies are well 
known, and this type of meta-analysis is obviously inferior 
to randomized controlled trials in the evidence 
hierarchy.'1 More specific limits of this work include the 
extent of statistical inconsi:,>tency, the differences in 
patients and techniques among different centers, the lack 
96 
of data on MACE for the PCI v~11S CABG comparison, 
and the frequent limitations in included studies, which 
should be strongly borne in mind and prompt the design 
and conduction of more rigorous observational as well as 
randoolli:ed studies. 
We thank original authors for their help. This study Is 
part of a training project of the Meta-analysis and 
Evidence-based Training in Cardiology Center; Turin, 
Italy (http://wwwmetcadio.org). 
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INTERVENTION FOR CHRONIC TOTAL 
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CHAPTER 10 
CHRONIC TOTAl OCClUSION TREATMENT 
IN POST-CABG PATIENTS: SAPHENOUS 
VEIN GRAFT VERSUS NATIVE VESSEl 
RECANAliZATION-lONG-TERM FOllOW-UP 
IN THE DRUG-ElUTING STENT ERA 
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Chronic Total Occlusion Treatment in Post-CABG 
Patients: Saphenous Vein Graft Versus Native 
Vessel Recanalization-Long-term Follow-up 
in the Drug-Eluting Stent Era 
Emanuele Meliga, MD, Hector M. Garcia-Garcia, MD, MSc, Neville Kukreja, MRCP, 
Joost Daemen, MD, Shuzou Tanimoto, MD, Steve Ramcharitar, MD, PhD, 
Carlos A.G. van Mieghem, MD, Georgios Sianos, MD, Martin van der Ent, MD, PhD, 
Willem J. van der Giessen, MD, PhD, Pim de Feyter, MD, PhD, 
Ron van Domburg, PhD, and Patrick W. Serruys, * MD, PhD 
Objective: To compare the postprocedural and long-term clinical outcomes of two 
groups of patients, all presenting with chronic saphenous vein graft {SVG) occlu· 
sion, who underwent either SVG or native vessel reopening. Background: Chronic 
total occlusions (CTO) treatment in patients who underweiltPrevious surgical 
revascularilation is a dilemma and the choice of performing native vessel or SVG 
recanalization is not always easy. Methods: Between July 2002 and October 2004, a 
total of 260 patients were successfully treated for a CTO. Of them, we selected all 
patients (n = 24) who had previous bypass surgery with graft occlusion. Of this final 
group, 13 patients underwent a percutaneous graft recanalization while 11 under· 
went native vessel reopening. Results: Primary end points were in-hospital and 
3-year rates of death, myocardial infarction, target lesion revascularization, and tar· 
get vessel revasculari:zation. No events occul'l'&d in either group during the in-hos· 
pital period. Cumulative 3-year event-free survival in the native vessel and SVG 
group was 81.8% and 83.9% respectively (P = NS). One death and one TVR 
occurred in each group. Conclusion: In selected cases, SVG reopening instead of 
the native vessel is feasible. In such a high-risk population, drug-eluting stent im· 
plantation in both SVG and native CTO lesions is associated with good long-term 
outcomes. oe 2007 Wlloy·Uss, Inc. 
Key words: percutaneous coronal}' intervention; total occlusions; bypass grafts; coronal}' 
INTRODUCTION 
Chronic total occlusions (CfOs) remain one of the 
most challenging problems for interventionists as the 
procedural success rate and acute outcome are still rei~ 
atively poor [1-6]. Percutaneous treatment of saphe~ 
nous vein grafts (SVGs) occlusions. notwithstanding 
the use of drug-eluting stent (DES) and new protection 
devices. remains exacting [7]: the atherosclerotic dis· 
ease in SVGs is pathologically different from the 
native vessel. showing soft and friable lesions usually 
with a poorly developed fibrous cap and large and 
bull)' thrombi that tend to occupy the entire length of 
the graft [8-12]. Which revascularization treatment 
should we then recommend to patients with chronic 
SVG occlusions? Is it worthwhile to treat the SVG 
always attempt to treat the native bypassed coronary 
arteries? 
To clarify this issue better we compared the clinical 
outcomes of two groups of patients, all presenting 
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chronic SVG occlusion. who underwent either SVG or TABLE I. Baseline Clinical Characteristics 
native vessel reopening. 
METHODS 
Population 
Demographic and procedural data regarding all 
patients undergoing PCI at our centre were prospectively 
entered into a dedicated database. Between July 2002 
and October 2004, a total of 351 patients had a CTO 
treatment attempt in our center: 260 were successfully 
treated (74.1%). Of them, we retrospectively selected 
only those patients (n = 24) who had undergone previous 
saphenous vein bypass grafting and subsequently had 
total occlusion of one or more grafts. Of this final gr-oup, 
13 patients underwent a percutaneous reopening treat· 
ment on the occluded graft while 11 underwent percuta-
neous reopening of the native vessel (Table I). 
Exclusion criteria were unsuccessful attempt and 
intolerance or contraindication to clopidogrel. No -other 
predefined clinical inclusion or exclusion criteria were 
considered. and the indication for PCI was decided on 
clinical and angiographic characteristics. 
End Points 
The primary outcome measures investigated were 
the occurrences of death, myocardial infarction (111), 
target vessel revascularization (TVR). target lesion 
revascularization (TLR), and major adverse cardiac 
events (MACE) defined as a nonhierarchical composite 
of all cause death, nonfatal :MI. or repeat revasculariza. 
tion during hospital stay and at 3 years. 
Definitions 
CTO was defined as a complete coronary obstruction 
(TIMl flow grade 0) with an estimated duration of >3 
months. Technical success was defined as the ability to 
cross and open the occluded segment with no more 
than 40% residual stenosis in all views: procedural 
success was defined as a technical success with no in-
hospital MA.CE. :Ml was defined as a threefold CK-
:rvm increase: hemodynamic instability was defined as 
the occurrence of sustained ventricular arrhythmias or 
prolonged hypotension (BP < 90/60 mm Hg). TLR 
was defined as any revascularization performed on the 
treated segmen~ TVR was defined as any reinterven· 
tion performed on the treated vessel. 
lnterventional Technique 
The operators performed the procedure according to 
standard techniques of the time via the femoral or 
brachial approach. All procedural and technical details 
and the choice of devices were left to the operator's 
judgment. In the cardiac catheterization laboratory, 
Catheterization :md Cardiovascul:tr Interventions DOI 10.1 002/ccd. 
SVG group Native group 
{N = 11) {N = 13) P value 
Age {yenrn) 67.8::!: 12.4 60.8::!: 10.9 NS 
Women,n {%) 1 {7.6) 2 {18.1) NS 
Diabetes mellitus. n {%) 5 {38.4) 3 {27.2) NS 
Hypertension, n {%) 7 {53.8) 4 {36.6) NS 
Current smoking. n {%) 2 {15.3) 2 (18.1) 
" Familiarity, n {%) 7 (53.8) 6 {54.5) i\"S 
Dislipidemiu. n {%) 10 {76.9) 9 {81.1) xs 
Prior myocardial inf=tion. n (%) 7 {53.8) 6 {54.5) ::\S 
Prior PCI, n {%) 5 {38.4) 7 (63.6) ~s 
Oinical. pr=nt:ltion (ACS), n {%) 6 {46.1) I {9) <0.05 
SVG, saphenous vein gr:Ut: PCI. percutaneous coronnry intervention: 
ACS, acute coronnry syndrome. 
patients received a bolus of 10.000 units of heparin 
followed by repeated boluses per a weight-based proto-
col to achieve an activated clotting time >250 sec. All 
the lesions were treated with DES implantation. Peri~ 
procedural abciximab was administered at the opera-
tor's discretion. After the procedure, clopidogrel (75 
mg daily) was prescribed to all patients for 6 months 
after stent implantation; aspirin was given indefinitely. 
Follow-up 
A follow-up visit or telephone interview was sched· 
uled at 30 days. 6 months, 1 year. and then yearly. 
Civil registries were queried in case of death. to deter-
mine whether it was or not a cardiac death. A health 
questionnaire was subsequently sent to all living 
patients with specific questions on rehospitalization 
and MA.CE [13.14]. All repeat interventions and reho~ 
spitalizations were prospectively collected during fol-
low~up and entered into a dedicated database. An exer~ 
cise tolerance test was recommended after 6 months in 
event-free patients; angiographic follow~up was per-
formed only in those patients with recurrence of symp-
toms or with a positive stress test. 
Statistical Analysis 
Variables with normal distribution were analyzed 
using parametric tests while variables with a non-normal 
distribution were analyzed with nonparametric tests. 
Continuous variables are expressed as mean ± SD or 
median ± SD and differences were compared using 
Student's t test or Mann-\Vhitney test. Categorical varia-
bles are expressed as counts and percenta.?es; differences 
were assessed by Fisher's exact test or x- test, as appro-
priate. All statistical tests were two-tailed. When more 
than one clinical event occurred in a patient. all the 
events occurring were considered for survival analysis. 
All analyses were performed using SPSS version 12 
statistical software (SPSS Inc .. Chicago, IL). A P value 
< 0.05 was considered significant. 
Published on behill' of The Society for Cardiovuscul:tr Angiography :md Interventions {SCAI). 
TABLE II. Angiographic and Procedural Characteristics 
SVG group Native group 
(N= 11) (N= 13) P value 
Three vessel disease, n (%) 13 (100) 7 {63.6) <0.05 
TL location, n (%) 
LAD 2 (15.3) 0 (0) NS 
LCX 4 (30.7) 7 (63,6} NS 
RCA 7 (53,8) 4 (36.6) NS 
Baseline RVD (mm) 3.04:!: 0.36 2.71 :!: 0.31 <0.05 
Postproccdure RVD (mm) 3.28:!: 0.24 2.89:!: 0.29 <0.05 
Ostial location. n (%) 11 (84.6) 2 {18.1) <0.05 
Calcified lesions. n (%) 3 (23) 5 {45.4} 
" Number of guiding 
c:ltbet~patient 1.07 :.':. 0.1 1.7 :.':. 0.9 <0.05 
Number of guide wireS/patient 2.!5 :.':. 1.34 2.17:!: 1.1 
" Number of balloons/patient 1.53:!: 0.87 1.63 :.':. 0.8 ~s
TL number of placed 
stent..;/patient 3.3 :!: 1.54 2.27 :.':. 0.46 <0.05 
TL average diameter stent (mm) 3 ± 0.3 2.62 :!: 0.24 <0.05 
11.. average length stent {mm) 22.9 ± 6.5 21.5 :!: 4.4 NS 
Total number of treated lesioDS 1.76:!: 0.92 1.72 ± 0.78 NS 
Total number of placed 
stents(patient 4 ± 1.65 3:!: 1.54 <0.05 
Total avel':l.ge diameter 
stcnt (mm) 2.97 :!: 0.35 2.6:!: 0.1 <0.05 
Total average length ~'lent (mm) 22.4 ± 4.94 21.4:!: 3.7 KS 
Use of distal protection, n (%) 5 (38.4) 0 (0) NS 
Procedural time (min) !48 ± 39 135 ± 36 NS 
Contr:tst amount (ml) 360 :!: 112 399 :!: 133 NS 
Periprocedural abciximab, n (%) 8 (61.5) 5 (45.4) NS 
RVD, reference vessel diameter. LAD. left anterior descending: LCX, 
left circumilcx: RCA, right coronary artery: TL, target lesion; SVG, sa-
phenous vein gruft. 
RESULTS 
Baseline and Procedural Variables 
Baseline clinical and angiographic characteristics are 
shown in Tables I and IT. 
In our population. the median time from bypass sur-
gery to the index: percutaneous was 10 years (range: 
10 months to 20 years). In the SVG group, distal em-
bolic protection was used in 38.4%. There were no 
significant differences in the two groups except that 
patients Mth PCI for SVG versus native artery occlu-
sion presented more often Mth acute coronary syn-
drome (46.1% vs. 9.0%: P < 0.05). three vessel dis-
ease (100% vs. 63.6%~ P < 0.05), received a slightly 
higher number of stents (4 ± 1.65 vs. 3 ± 1.54: P < 
0.05) and Mth a larger mean diameter (2.97 ± 0.35 
vs. 2.6 = 0.1 mm: p < 0.05). 
Procedural and In-Hospital Outcomes 
Procedural and In-Hospital Outcomes are summar-
ized in Table ill. 
Both technical and procedural success rates were 
100%. No death, postprocedural infarction, or urgent 
re-PCI occurred in either group. Two patients experi-
CTO treatment in post-CABG patients I 103 
TABLE Ill. Procedural and In-Hospital Outcomes 
SVG group Native group 
(N = 11) (N= 13) P value 
Procedural succe:>.~ l':lte (%) 100 100 NS 
F'mal TIMI flow grade 3, n (%) 11 (100) 13 (100) NS 
Hemodynamic instability. n (%) 2 (15J) 0 (0) NS 
IABP. n (%) I (!.6) 0 (0) NS 
Tempornry pacing. n (%) I (!.6) 0 (0) NS 
Perforation.. n (%) 0 (0) 0 (0) NS 
In-ho~pital death. n (%) 0 (0) 0 (0) NS 
Postproccdural MI, n (%) 0 {0) 0 {0) NS 
Urgent TVR, n (%) 0 (0) 0 (0} NS 
Postproccdural CK level~ (Ll) 123::!: 66 99 :!: 50 NS 
IABP. intra aortic balloon pwnp: TVR, target vessel revascularization; 
TIMl. thrombolysis in myocardial infarction: SVG, saphenOlL.~ vein gruft: 
MI, myocardial infarction: CK. creatine-kinase. 
enced hemodynamic instability, both in the SVG 
group. One patient needed an intra-aortic balloon pump 
(none in native vessel group) and one patient needed 
temporary pacing (none in native vessel group). 
Follow-up Clinical Outcomes 
Three-year follow up clinical outcomes are shown in 
Table IV. 
One patient dropped out after 9.2 months (276 
days). One patient in the native vessel group died 11 
months (335 days) after the procedure: one patient in 
the SVG group died 24 months (720 days) after the 
procedure. There was one TVR in the native vessel 
group (13 months after the index procedure) and one 
in the SVG group (5.2 months after the index proce-
dure). No MI or re-CABG occurred in the follow-up 
period. The cumulative MACE free survival rate at 36 
months was 81.8% in native vessel versus 83.9% in 
the SVG group. 
DISCUSSION 
The main findings of this study are that SVG re-
opening instead of the native vessel is a feasible and 
an interesting option in selected cases and that DES 
use in this population is safe Mth good long-tenn out-
comes. Undoubtedly this can be considered one of the 
most challenging and highest risk populations ever 
treated in the DES era: patients 'Nith previous CABG. 
treated Mth a PCI in SVGs or native vessels for a 
CTO. What today can be considered "real world clini-
cal practice." albeit still not so common. was discour-
aged a few years ago: in an editorial published by our 
group in 1993 [1] it was suggested to avoid percutane-
ous treatment of SVG lesions and to opt for revascu-
lari.zation of the native vessel if re-CABG. as a serious 
alternative, was not feasible. 
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TABLE IV. Three-Year Follow-up Clinical Outcomes 
SVG group Native group 
(N"" 11) (N"" 13) Pv:llue 
Deaths, n (%) 1 (1.6) 1 (9) M 
MI. n (%) 0 (0) 0 (0) ~s 
Re-CABG, n {%) 0 (0) 0 (0) NS 
Re-PCL n (%) 1 (7.6) 1 (9) NS 
MAC&,n(%) 2 (15.3) 2 (18.1) NS 
:N.ll, myocardinl infarction; CABG, coronary :utcry bYJXL"-~ graft; PC1, 
percutaneous coron:uy intetVention: MACE, major adverse cardiac 
events: SVG, saphenous vein graft. 
The 2005 ACC/AHA guidelines for PCI indicate 
that the average technical success rate of recanalizing 
cro is 65%; advances in technical skills and introduc-
tion of new devices have enabled in some centers to 
reach a 70% or greater technical success rate, which 
anyway is still considerably lower compared with the 
92% success rate ofPCI for overall lesions [15-18]. 
Consistent with these data, technical success rate 
between July 2002 and October 2004 in our centre 
was 74.1 %. It is well known that interventional 
maneuvers on vein grafts are difficult and often associ-
ated with a high risk of complications: lesion crossing. 
balloon inflation, and stent deployment can easily per-
forate the vein wall or dislodge friable atherosclerotic 
and thrombotic material, causing distal embolization 
and slow-flow or no-refiow phenomenon [1.19]. 
Which therefore were the elements that led the inter-
ventionist to attempt reopening a SVG instead of the 
native vessel? 
The decision was basically taken on angiographic 
features: the presence of diffuse, complex, or ostial 
blunt lesions in tortuous, calcified native vessels 
deterred their recanalization while. on the other hand, 
good graft conditions. short shaft or ostial tapered 
SVG lesions or the presence of sequential grafts en-
couraged a reopening attempt. 
DES, new protection devices, and antiplatelet drugs 
make the attempt easier. Recent studies reported that 
DES implantation (both sirolimus and paclitaxel elut-
ing stents) reduced in-stent restenosis and improved 
both short- and long-term revascularization rates after 
successful CTO recanalization in native vessels com-
pared with bare metal stents [20-22]. Moreover. distal 
protection devices (e.g. FilterWire EX) and platelet 
glycoprotein llb/IIla inhibitors have been shown to be 
effective in elective PCI in SVGs by reducing distal 
embolization and slow-flow or no-reflow phenomena 
[23--25]. 
In this study, the use of DES for CTO recanaliza-
tion. associated with the use of antiplatelet drugs led 
to excellent postprocedural and in-hospital outcomes. 
No death, :MI. urgent TVR, or distal embolization 
Catheterization nnd Cnrdi.ovnscular IntetVentions DOI 10.1002/ccd. 
occurred in either group. Additionally. only two 
patients with PCI for SVG occlusion had in~hospital 
hemodynamic instability (15.3%). one requiring an 
IABP and one requiring temporary pacing. 
Three-year follow-up outcomes are good especially 
considering the high baseline risk profile of our popula-
tion: prior CABG. advanced age. prior infarction, three-
vessel and diffuse coronary disease, and diabetes melli-
tus were common characteristics of this population. 
However, despite the encouraging outcomes of DES 
use, up to 50% of late cardiac events in patients with 
SVG lesions are due to disease progressions at different 
sites rather than the initial target [26,27]; so a high 
MACE rate should be expected in this population. 
At 3 years. two patients died (one in each group) and 
two underwent a re-PCI (one in each group). MACE~ 
free survival rate at 36 months in the native vessel and 
SVG groups were 81.8% and 83.9% respectively, with-
out statistical difference between the groups. 
This compares favorably with existing data on DES 
use for native vessel CTO treatment, with reported 
overall MACE-free survival rate at 6 and 12 months of 
90-91% and 87-84% respectively [20.28.29]. although 
still few data are available on DES use for SVGs CTO 
treatment. A recent report by Ge et al. showed an 
overall MACE-free survival at 6 months of 88.5% in 
SVG lesions [30]. in line with the results of DES use 
on native vessels. Though based on a very small, 
highly selected population with peculiar angiographic 
features and though should be interpreted with great 
caution. these results show encouraging follow-up 
results probably thanks to DES, new guide wires gen-
eration, and new specific devices introduction. In 
selected cases, SVG recanalization instead of the 
native vessel with DES can therefore be an interesting 
option with a high procedural success rate: moreover, 
DES implantation in both SVG and native CTO lesions 
is associated with an equal effect on MACE-free sur-
vival at 3-year follow-up. 
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RETROGRADE SEPTAl APPROACH FOR A 
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A sizable portion of clinically relevant coronary obstructive 
lesions is constituted by chronic total occlusions (CTOs), 
and successful revascularisation ofCTOs is thus pivotal for 
patients' prognosis and symptomatic relief. Unfortunately, 
the percutaneous approach to CTO is still fraught by a 
non~negligible risk of failure (ranging from 10% to 30%) 
[lJ. Technical and technological developments have 
brought major improvements also in this field of imerven~ 
tiona! cardiology, and the percutaneous retrograde ap~ 
proach appears among the most promising and interesting 
techniques [2]. Only limited data are, however, available 
on this strategy. We hereby present the case of a patient 
with multivesscl coronary disease who underwent sue· 
ccssful recanalisation of a challenging CTO of the right 
coronary artery (RCA) by means of a septal retrograde 
approach. 
The patient. a 78~year~old man known for chronic atrial 
fibrillation and ischaemic cardiomyopathy due to a 
remote anterior myocardial infarction, had been admitted 
to our institution for recurrent episodes of acute pulmon· 
ary oedema. He had previously (1988) undergone coron~ 
ary angiography and percutaneous transluminal coronary 
angioplasty (balloon·only) in the left circumflex artery. 
Baseline electrocardiogram showed tachycardic atrial 
fibrillation, QS complexes in the precordial leads, and 
diffuse ST~T changes, in the absence of signs of myo· 
cardia! necrosis in the inferior leads. Non·viability of 
the anterior left ventricular wall and, conversely, viability 
of the inferior wall were established by imaging 
tests. Coronary angiography during the current admission 
disclosed a CTO of the mid left anterior descending 
coronary anery (LAD), a critical stenosis of the first 
obtuse marginal branch, and a CTO of the mid RCA. 
with extensive collateral vessels connecting the LAD and 
RCA systems (Fig. 1). Mtcr expeditious treatment of the 
obtuse marginal branch by coronary angioplascy and 
stenting with two bare·metal stents (Driver, Medtronic. 
:Milan, Italy) (Fig. Za), we attempted to recanalisc ante~ 
gradely the RCA occlusion. Despite the usc of both 
hydrophilic and non~hydrophilic stiff guidcwircs and 
the successful crossing of the occlusion, we could not 
gain lumen re~cnrry (Fig. Zb). We thus completely 
changed strategy and purposefully attempted retrograde 
recanalisation of the RCA through a proximal septal 
branch of the LAD using a 0.014" Choice PT wire 
(Boston Scientific, Genoa, Italy). We managed to reach 
the distal stump of the CTO and, after delivering a 
low~profilc ovcr~the~wirc balloon (Maverick, Boston 
Scientific) for increased support (Fig. Zc), we crossed 
the CTO and achieved intra~luminal re~entry in the 
proximal RCA and ascending aorta (Fig. Zd). Mter 
extensive prcdilation by means of the balloon advanced 
retrogradely, the procedure was then completed by 
antegrade re-wiring (Choice PT) (Fig. Ze), prcdilation, 
stencing with two sirolimus·clucing devices (3.5 x 13 mm 
and 3.5 x 33 mm Cypher stcnts, Cordis, Milan, Italy) in 
the proximal and mid RCA. and balloon-only angioplasty 
of the distal tract of the RCA and its postcro~lateral 
branch (Fig. Zf). The final angiographic result appeared 
satisfactory, with the notably persistence of brisk collat~ 
eral flow from the acute marginal branch of the RCA to 
the LAD (Fig. 3). 
The post~procedural course was uneventful, except 
for a minor and transient rise in serum creatinine, and 
the patient could be safely discharged a few days later 
on a 6-month prescription for clopidogrcl, as well as 
long~tcrm aspirin and warfarin (due tO chronic atrial 
fibrillation, targeted at an international normalised ratio 
of 2.0-2.5). At 6~month clinical follow-up, the patient 
was still asymptomatic for angina, with minor dyspnoea 
during intense exertion (New York Heart Association 
class 1), in the absence of other episodes of pulmonary 
oedema. 
This clinical vignette, showing the feasibility and tech~ 
nical details pertinent to retrograde recanalisation of a 
coronary CTO, shows that this novel approach appears as 
a promising adjunct to the armamentarium of interven-
tionalists. Coronary CTOs represent a sizable portion of 
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Flg.1 
Baseline coronary angiography showing a chronic total occlusion of tho mid left anterior descending coronary artery (*), a subocclusive stenosis of 
the first obtuse marginal branch \•) of the left circumflox artery, and a chronic total occlusion of the right coronary artery (•••). Note the extensive 
collateral vessels from the left circumflex and loft anterior descending coronary arteries to tho distal right coronary artery (arrows), and from the acute 
marginal branch of the right coronary artery to the left anterior descending coronary artery (arrowheads). 
clinically significant coronary lesions, yet percutaneous 
approaches still face a non-negligible risk of failure in 
this lesion subtype [1]. Given the potential benefits 
associated w1th recanalisation of CTOs associated with 
symptoms or signs of myocardial ischaemia [3], such as 
the present one, it is pivotal to further develop devices 
and techniques in order to increase success rates. Among 
the most recent innovations, and on top of drug-eluting 
stents [41, is the retroe:rade approach, based on the 
rccanalisation of a CTO by a retrograde fashion through 
the contralateral coronary artery and its collateral supply 
[2,5-9]. Despite its potential for increasing success rates 
and its diffusion also among peripheral interventionalists 
[8], only a handful of reports focusing on this technique 
are available, the largest to date including as few as 
21 patients [8]. VVc believe that the present case provides 
further support for its very selected usc in challenging 
CTOs. 
Retrograde septal approach for a challenging CTO 1111 
(a) Percutaneous transluminal coronary angioplasty and bare-metal stenting of tho obtuse marginal branch (stents are highlighted by the dashed 
line). Percutaneous recanalisation of the right coronary artery occlusion, with initially unsuccessful antegrade approach (b), followed by 
successful retrograde wiring (c-e}. pre-dilation with an over·the·wire balloon advanced retrogradely in a septal branch, and, finally, successful 
a~tograde crossing of the occlusion (D. Arrows indicate the retrogradely advanced guidewire, and arrowheads the antegradely advanced 
WlrQS, 
Fig. 3 
Final angiographic result after drug-eluting stenting of the proximal and mid right coronary artery and balloon·only dilation of the distal right 
coronary artery and its postero·lateraJ branch (stentsare highlighted by the dash-ed lines). Notably, collateral vessels to tho left anterior descending 
coronary artery were not injured by the revascularisation procedure. 
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On the other hand, this retrograde approach should be 
mainly considered as a last option, given that severe 
complications (including collateral vessel occlusion with 
septum hacmatoma and associated infarction) have 
already been reported [10]. Such recommendation for a 
very selective adoption of this strategy is even more 
relevant for operators ~ithout extensive experience in 
CTO recanalisation and unfamiliar with emergency p-eri~ 
cardiocentesis. :-.ionctheless, the reuograde technique 
does not appear at preliminary analysis of the literature 
significantly more hazardous than other strategies for 
challenging CTOs (e.g., subintimal tracking and arterial 
re-ontry) [8,11]. 
In conclusion, further and larger clinical investigations of 
this novel approach should be pursued to fully charac-
terise its potential and limitations in the setting of the 
percutaneous management of carefully selected patients 
with challenging and clinically significant CTOs. 
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COMPUTED TOMOGRAPHY IN TOTAl 
CHRONIC OCClUSIONS (CTTO REGISTRY): 
RADIATION EXPOSURE AND PREDICTORS 
OF SUCCESSFUl PERCUTANEOUS 
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Abstract 
Aims: There is rto mention in the current "appropriateness criteria for CTCA" of the need of CTCA investi-
gation prior to an attempt at recanalisation of a CTO. To define better the role of CTCA in the treatment of 
pa~ients with CTOs, we peiTormed CTCA in a consecutive cohort of eligible patients who were scheduled 
for percutaneous recanalisatlon of aCTO. 
Methods and results: Symptomatic patients due to a CTO suitable for percutaneous treatmen~ were 
included. One hundred and thirty-nine (142 CTOs) patients were studied. Overall success rate was 62.7%. 
By CTCA, the occlusion length was 24.9±18.3 vs. 30.7±20.7mm in successful and failed cases (p;:;:Q.l), 
but the frequency of patients with an occ:usion iength >15 mm was different, i.e. 63.2% vs. 82.7%, 
respectively (p::0.02). Severe calcification, (>50% GSA) was more prevalent in failed cases (54.7% vs. 
35.9%, P=0.03). Calcification at the entry of the occlusion was present in 58.5% of the failures vs. 41.6% 
of the successful cases (p:::il.04), while calcium at the exit was not different. The length of calcification was 
8.5±8.4 vs. 5.5±6.6 mm in the failed and successful cases respectively (p=0.027). By multivariable 
analysis, the only independent predictor of procedural success was the absence of severe calcificatiort as 
defined by CTCA. 
The mean effective radiation dose of the PCI was 39.3±30.1 mSv. The mean effective radiation dose of CT 
scan was 22.4 mSv: 19.2±6.5 mSv for contrast-enhanced scan, 3.2±1.7 mSv for calcium scoring scan. 
Conclusions: More severe calcified paf..erns, as assessed by CTCA, are seen in failed cases. The radiation 
exposure during a CT scan prior to a CTO PCI is considerable, and further studies are required to 
determine whether this extra d'1agnostic study is warranted. 
• Corresponding author: Department of cardiology; Erasmus Medical Center, Thoraxcenter, Ba583a, Erasmus MC, 'S·Gravendijkwa/230, 3015 CE 
Rotterdam, The Netherlands 
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CT Coronaiy ani.iography in -Chrome tot<J( oCclusiOnS 
Abbreviations list 
CCA Conver~tiortal corortary angiography 
CTCA Computed tomography coronary angiography 
CTO Chronic total occlusion 
PCi Percularteous coronary intervention 
Introduction 
Since success rate have remained unchanged over the last few 
years, there has been a decrease in the number of attempted 
percutaneous coronary interventions (PCIJ in patients with chronic 
total occ1us'1ons (CT0)1• In the search for new therapeutk 
approaches to reopen the occluded vessel, many new CTO-
dedicated guidewires and devices have become availableZ. Until 
recently, innovative imagir1g tools to provide the operator guidance 
during the most exacting phase of the procedure, i.e. crossing the 
lesion, have been lacking. Commor~ly, in angiography these !esions 
appear as missing segments within two vessel ends. In addition, the 
angiogram does not provide reliable information with regard to the 
trajectory of the occluded segment, its length and tissue 
composition, variables that have been correlated with low 
procedural success rate-'. Computed tomography coronary 
angiography (CTCAJ has developed into a reliable noninvasive 
technique to evaluate a patient for the presence of obstructive 
coronary artery disease~. Although, preliminary data suggests that 
computed tomography coronary angiography (CTCAJ might be of 
beneficial guidance in attempting revascularisation of a CT05, there 
is no mention in the current "appropriateness criteria for CTCA" of 
the rteed of a CTCA investigation prior to an attempt at recanalisation 
ofCTO. 
To define better the role of CTCA in the treatment of patients with 
CTOs, we performed CTCA in a cortsecutive cohort of eligible 
patients who were scheduled for percutaneous recanalisation of 
a CTO. We investigated artgiographlc and computed tomographic 
predictors of success and measured the amount of corttrast 
material used during PCI artd CTCA as well as the radiation exposure 
for both techniques. 
Material and methods 
Study population 
Betweer1 April 2002 and March 2007, those eligible for this study 
included ali consecutive patients presenting with symptomatic 
coronary artery disease due to aCTO. SpeciTically, patients without 
contra-indications for CTCA, suitable for percutaneous treatment 
who had provided written informed consent, were included. CTCA 
was considered contra"indlcated in following situations: irregular 
heart rhythm, inability to sustain a sufficiently long breath hold (20 
secortds with the 16-slice CT scanner, 15 seconds with the 64-slice 
or dual·source CT scartner), renal dysfunction (creatinine clearance 
<60 m:lmin as defined with the Cockroft formula)6, hearing 
disability, artd known contrast allergy. 
ACTO was defined as either an occlusion on angiography with no 
antegrade filling of the distal vessel other than via collaterals or 
minimal antegrade flow (TIM I flow 0 or 1J7·8• Ail included patients 
had a native vessel occlusion estimated to be at least of three 
months duration based on either a history of sudden chest pain, 
a previous acute myocardial infarction in the same target vessel 
territory, or the time betlleen the diagnosis made on coronary 
angiography and PC I. The type of CTO was either de novo or due to 
in~stent restenosis. 
The protocol was approved by the local ethics committee and is ir1 
accordance with the principles of Good Clinical Practice for Trials of 
Medicinal Products in the European Community and the Declaration 
of Helsinki. All patients signed a written informed conser~t 
All the CT scans were discussed between the operator of CTO 
procedure and someone trained to interpreting CTCA prior to the 
interventional procedure. 
All interventional procedures were performed by operators who 
were highly experienced in the treatment of CTOs, with the 
inteNentlonal strategy left to the discretion of the operator. Wires 
were used in a stepwise progression, starting with a wire that had 
a relatively less traumatic tip (Graphix Intermediate, Boston 
Scientific Corporation, Miami, Fl, USA) or a hydrophilic wire (Choice 
PT Plus, Boston Scientific Corporation, or Crosswire NT, Terumo 
Corporation, Tokyo, Japan) and progressing to stiffer wires (Miracle, 
Asahi lntec, Nagoya, Japan) and specialised technologies (Safe-
Cross, Intraluminal Therapeutics, Carlsbad, NM, USA; or The 
CROSSER™ CTO Recana!isation System FlowCardia Inc, CA, USA; 
or the laser Guidewire, Spectranetics, Colorado Springs, CO, USA). 
Detailed description of these devices and explanation of our 
approach to treat CTO patients has been previously reported<. 
Procedural failure was defined as the inability to cross the occlusion 
with a guidewire. 
All patients were pretreated with 300 mg of clopidogrel, which was 
continued at a dose of 75 mg/day for 6 months. All patients were 
advised to maintain aspirin (<:80 mg/day) !lfelong. 
Definitions 
Procedural success: defined as successful opening of the chronic 
occlusion and restoration of fiow (<50% residual stenosis and TIM I 
2-3flow). 
Type of CTO: defined according to two characteristics, location 
(native vessel vs. graft) and quality (de novo or in-stent restenosis). 
Occluded length: defined as the non-contrast enhanced segment of 
the vessel from the proximal to the distal end of the occlusion in the 
least foreshortened view on angiography or the 3-dimensional 
measurement of the occlusion using a dedicated software program 
(Circulation®, Siemens, Germany) of the CT worKstation (Leonardo). 
Stump morphology: defined as the entry site of the occlusion that 
has either a tapered- {central or eccentric) or a blunt appearance. 
Side branch at the entry site: defir.ed as the presence of any side 
branch, irrespective of the size, withirt3 mm proximal to the entry of 
the occlusion. 
Bridging coflaterals: presence of multiple sma!l collaterals 
connecting the proximal and distal lumens of the vessel by spanning 
through or around the occluded segment. This characteristic can 
or~ly be measured by corwentional angiography (CA). 
Occlusion ends in bifurcation: the presence of a side branch larger 
than 1.5 mm within 3 mm distally to the distal end of the occlusion. 
Rentrop classification9: grading of collateral filling v.ras as follows: 
(}:;none, l=filling of side branches only, 2=partial filling of the 
epicardial segment, S=complete filling of the epicardial segment 
This classification only applies for conventional angiography since in 
CTCA the distal part of the vessel is almost always filled with 
contrast and thus can be regarded as Rentrop class 2 or 3. 
Calcification: was def.ned as follows; 
- By conventiollal allgiography, defined as mild, moderate or 
severe. 
- By CTCA, the number of separate calcium spots was coullted 
and their length measured. The presence of calcium at the entry 
and exit side of the occlusion was annotated. AI\ the spots were 
evaluated ill a cross-sectional view to assess whether the 
calcificatioll occupied more than SO% of the cross-sectional 
vessel area at ally location within the occluded vessel segment 
Finally, the amoullt of calcium in the occluded segment was 
quantified, using dedicated software. 
Tortuosity: was defined as the presence of bends proximal to the 
lesior~. By angiography, this feature v.ras ollly scored in a binary 
fashion (yes/no), i.e. <or> than 45 degrees, while by CT, the ar~gle 
of all the separate vessel ber~ds was measured. (Figure l} 
Angulation: was defilled as the presence of bellds w'1thin the 
occluded segment By angiography, only a binary scoring system 
was used (yesfno), while by CT. the angle was measured ill 
subsequent bends within the occlusion. (Figure 2) 
Conventional coronary angiography (CCA) 
Two experienced observers who were unaware of the results of the 
CT scalls allalysed each film; consensus was needed for each 
assessed parameter. Quarttitative anglographic analysis (CAAS II, 
Pie Medical, Maastricht, The Netherlands) v.ras periormed to 
measure the vesse: diameter prior to the occlusion side. The ler~gth 
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Figure 1. Assessment of tortuosity by computed tomography coronary 
angiography. (a) Angiographic image showing an occlusion (arrow) of 
the right coronary artery (RCA). (b) Volume-rendered CT image of the 
RCA, showing the occlusion (arrow) distal to the origin of the margo 
acutis. (c) 3-dimensional CT angiographic view of the coronary 
vasculature, illustrating the tortuosity of the vessel before the 
occlusion, with 4 consecutive bends. (d) same image as panel c but 
looking at the vessel from posterior; the final bend before the start of 
the occlusion is marked (43 degrees). 
of the occluded vessel segment was aiso quantified. The other 
variables, i.e. location of the occlusior~, morphology of the stump, 
the presence of a side brar~ch in the vicinity of the entry (<3 mm), 
col laterals and calcificatior~ were reported qualitatively, 
Figure 2. Assessment of angulation by computed tomogrophy coronary angiography. (a) Maximal intensity projection of the right coronary artery 
(RCA) showing the vessel with the entry (arrow) and exit side (a"owhead) of the occlusion in one plane. (b) 3-dimensiona/ CT angiographic view, 
illustrating the angulation within the occlusion: in this case 2 bends are visible. 
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Conventitmai comnary angiography: calculation 
of effective dose 10 
The Axiom study reports for each PCI procedure the used 
projections, the geometrical gantry settings and the generator 
settings for each digital cinematography (DCM), the used 
fluoroscopy time and the total dose-arro product (DAP). The DAP is 
mrosured by an integral device in the x.ray tube, placed after the 
filters and the collimator and takes into account the quality, quantity, 
size and duration of the used x-ray beam. 
A PC-based X-ray Monte Carlo program, from the Radiation and 
Nuclear Safety Agency, Helsinki, Finland, PCXMC, (reference 
Tap"1ovaara M, Lakkisto M, Servomaa A. A PC-8ased Monte Carlo 
Program for calculating Patient Doses in Medical X-Ray 
Examinations. STUK-A139. Radiation and Nuclear Safety Agency, 
Helsinki, 1997) was used to estimate effective doses from 
conventional angiography. We did not correct for each gantry 
setting. We assumed al! radiation was given in the Left Anterior 
Oblique 30 (LAO 30) projection, while the effective dose with careful 
simulation of all used gantry settings during OCM and fluoroscopy 
differed <2%. The focus-skin distance was 65 em and the 
estimated entrance field size was 95 cm2 with a quality of 70 kV. 
Ci patient se~ection, scan pmtocol and image 
reconstwction 
A card\ac CT scan was performed in the fortn'1ght before PC I. DL>r'mg 
the described study period 3 successive scan generations were used 
in our centre. Up to July 2004, CT data were acquired using a 15-
slice CT scanner (Sensation 16, Siemens, Germany). From August 
2004 to March 2006, CT dalcl were acquired using a 64-slice CT 
scanner (Sensation 64, Siemens, Germany) and from April 2006 on 
the latest dual-source CT scanner (Somatom Definition, Siemens, 
Germany) was used. In the period until March 2006, we 
systematically slowed down the heart rate in patients with a heart rate 
above 65 bpm, using 100 mg metoprolol or a non-dihydropyridine 
calcium-antagonist (diltiazem 60· 120 mg) orally 1 hour before the 
scan. An additionallY bolus of metoprolol (5-10 mg) was occasionally 
administered where the heart rate remained above 65 bpm. After that 
period we did not use extra medication to slow down the heart rate. 
Instead, nitrates were systematically given as a sublingual spray 
(0.4 mg) to all patients 5 mirlUtes before initiation of the scan 
provided the systolic blood pressure was above 100 mmHg. 
Scan parameters for each of the 3 scanner types were the following: 
- 15-sllce CT scanner: collimation 16x 0.75 mm, tube rotation time 
375 ms. tube voltage of 120 kV, table feed 3 mm per rotation. For 
the non-enhanced scan we used a tube current of 150 mAs and 
applied prospective x-ray tube modulation. For the angiographlc 
scan we used a tube current that ranged between 500 and 
600 mAs without the use of dose pulsing. 
- 54-slice CT scanner: collimation 64x0.6 mm, tube rotation time 
330 ms, tube voltage of 120 kV, table feed 3.8 mm per rotation. 
For the non-enhanced scan we used a tube current of 150 mAs 
and applied prospective x-ray tube modulation. For the 
angiographic scan we used a tube current that ranged between 
850 and 960 mAs without the use of dose pulsing. 
- dual-source CT scanner: collimation 64x0.6 mm, tube rotation 
time 330 ms, tube voltage of 120 kV. For the non-enhanced scan 
we used a tube current of 84 mAs per tube and full X-ray tube 
current was given during 50-70% of the RR interval. For the 
angiographic scan we usee a tube current of 412 mAs per tube 
and limited th'1s amount of tube current to 25-70% of the RR-
interval. Pitch values were adapted to heart rate (minimal pitch 
value of 0.2 for slow heart rates, up to a maximal pitch value of 
0.45 with higher heart rates). 
The contrast-enhanced scan was obtained after the intravenous 
injection of 70-100 ml of contrast material (iomeprol, 400 mg 
iodine/ml, lomeron® with the 16- and 54-slice CT scanner or 
iopromiCe, 370 mg iodine/mi. UltravisfD with the dual source CT 
scanner) through a large antecubital vein at a flow rate of 4-
5 ml/sec, followed by 40ml of saline flush at 4 mils. A bolus tracking 
technique was used to monitor the appearance of contrast material 
in the ascending aorta. Once the signal in the ascending aorta 
reached a predetermined density level of 100 Hounsfield units, CT 
acquisition was automatically started during an inspiratory breath 
hold. Images were reconstructed using EGG-gating to obtain 
optimal, motion free image quality. 
The scan data were reconstructed at various phases of the cardiac 
cycle using medium-to-smooth (826f) and sharp (846f) 
convolution kernel. Image reconstruction was retrospectively gated 
to the ECG. The position of the reconstructed window within the 
card'1ac cycle was ind'1v'1dually opt'1m'1sed to m'mim'1se mof10n 
artefacts. Datasets containing no or minimal motion artefacts were 
transferred to a remote workstation (Leonardo workstation, Siemens, 
Erlangen, Germany) for further evaluation. 
CT comr~ary ang~ography: ca~cu!ation of 
effective dose 
The effective radiation dose was calculated from the scan 
parameters using dedicated software (ImPACT CT Patient 
Dosimetry Calculator, version 0.99x), as described in the European 
Guidelines on Quality Criteria for Computed Tomography (Available at: 
http://WMV.drs.dklguidelines/cV quality/index. htm). 
cr da!a analysis 
Two experienced observers independently evaluated the CT data 
sets on both the original axial images and on multiplanar 
reformatted reconstructions for the presence of an occluded vessel. 
This Initial assessment was performed blinded to the anglographlc 
data. Subsequently, the observer was provided with the 
anglographlc Information, i.e. the occluded vessel in which PCI was 
performed, without having access to the angiographlc Images. After 
confirmation of the right vessel, the further CT analysis was 
performed without knowledge of the angiographic characteristics of 
the occluded vessel. In a few occasions, especially in case of heavy 
calcifications of the vessel, angiographic information on the start 
and end of the occlusion was provided to allow calculation of the 
occlusion length. To measure the length of the occlusion on CT we 
used a dedicated software program (Circulation®, Siemens, 
Germany), which allows creating a central lumen line through the 
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vessei. By rotating the vessel around this line the exact entry and 
exit point of the occlusio11 can be visualised, thus allowing us to 
measure the lertgth of the occlusion along the 3-dimensional vessel 
path without foreshortening. (Figure 3}. 
Figure 3. Measurement of the length of the oct:lusion by computed 
tomography coronary angiography. CT images showing an occlusion of 
the left anterior descending coronary artety (LAD). (a) Volume-rendered 
image showing the proximal part of the occlusion (arrow). (b) Using the 
Circu/atiorl' software the entire coronary tree can be ext/acted from the 
dataset. The start and end points for the vessel to be examined, in this 
example the LAD, are marked and a centreline through the middle of 
the vessel is displayed and labeled betlfeen these 2 points. (c) Maximal 
intensity projection showing the approximate length and composition, 
in this case non-calcified, of the occlusion. (d) After defining the 
centreline of the vessel, features of the occlusion such as length and 
composition can be evaluated. The markers Qla and Qlb set the 
boundary marker at the beginning and end of the occlusion, which in 
this case measures 14mm. The proximal part of the occlusion shows a 
small amount of calcium (arrowhead). 
Statistical analysis 
Assumptions for normality were checked by Kolmogorov-smimov test 
and by visual assessrnent cf Q-Q plots of res'1duals. Accord\ngly, log 
transformation was performed on tile variables with skewed distribution. 
ContinuollS variables are presented as mean ±lSD and differences were 
compared LlSing Student t test or Mann Whitney test categorical 
variables are presented as counts and percentages and differences were 
assessed by Fisher exact test or chi-square test, as appropriate. A tNO-
sided p value of less than 0.05 indicated statistical significance. 
The following variables were included in the multivariable analysis 
dataset: baseline characteristics (gender, age, diabetes mellitus, 
previous myocardial infarction, family history of coronary artery 
disease, smoking, hypertension, hypercholesterolaemia, previous 
PCI and previous coronary artery bypass surgery, vessel disease 
and target vessel), conventional angiographic characteristics (ostial 
location, stump morphology, presence of bridging collaterals, 
presence of side branch at the entry of the occluslon, degree of 
calcification and tortuosity [yes/noll-, and CTCA characteristics 
(ostial location, stump morphology, presence of side branch at the 
entry of the occlusion, calcification -at entry, -at exit, >50% CSA, 
length of the calcification, angulation as a continuous variable, 
tortuosity as a continuous variable and length of the occlusion as 
a continuous variable. Due to collinearity problems, some variables 
were removed from the modeL On the remainder of the variables we 
ran a backward selection procedure. Statistical analyses were 
performed with use of SAS V8.02. 
Results 
One hundred and thirty-nine (142 CTOsl cortsecutive patients were 
enrolled in this prospective registl)' of patients treated for a chronic 
total occlusion. 
The mean age was 60.7±10.8 years, most of the patients beirtg 
male {87.3%) (Table 1). For the majority of the patients (95.1%) 
this was the flrst attempt to open the CTO. Most of the occlusions 
were de novo lesions and the most frequently treated coro:1ary 
artery was tile left anterior descending (Table 2). Overall success 
rate was 62.7%. 
CTO characteristics by cmwentionai coronary 
angiography and CTCA 
By conventional coronal)' angiography, the mean vessel diameter 
was larger in successful procedures (2.9±0.4 vs 2.1±0.7, P=(l.02l 
as compared to procedural failures. Overall the length of the 
occlusion was 16.6±12.8 mm and there was no d'1fference in 
successful vs. unsuccessful cases (16.0±12.7 and 18,0±13.4, 
p=0.5). The presence of a side branch at tile entry was more 
frequently seen In failed cases (84.9 vs. 69.7%, p=0.03), 
Conversely, the presence of bridging col laterals was more frequently 
Table 1. Baseline characteristics, n .. 139. 
Age. yrs (mean+lSD) 
Male(%) 
Diabetes mellitus (%) 
Hypertension(%) 
Family history of CHD (%) 
Cllrrent smoking(%) 
Hypercholesterolaemia (%) 
Previous ACS ("'o) 
Previol!S PCI (%) 
Previous CABG (%) 
Vessel disease(%) 
One vessel disease 
Two vessel disease 
Three vessel disease 
Attempts to reopen the CTO {%) 
R& 
Second 
60.7±10.8 
87.3 
13.4 
40.1 
33.8 
23.9 
50.0 
40.8 
2M 
7.7 
51.4 
31.7 
16.9 
95.1 
4.9 
SO: stlndard deviation; CHD: cardiovascular heart disease; ACS: acute 
coronal)' syndrome; PCI: percutaneous coronary intervention; CABG: 
coronary artery bypass gr.lft 
CT Coron;3ry imgiograf;hy 
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Conventional angiography characteristics 
Type of era ("/o) 
De novo 94.4 92..5 95.5 0.6 
Target vessel ("/o) 0.5 
left anterior descending 42.3 50.9 37.1 
Left circumflex 13.4 11.3 15.7 
Right coronary artery 42.3 35.9 46.1 
Occluded length (mean±lSD) 15,6±12.8 18.CH-13.4 16.(H.12.7 0.5 
Ostial location (YfN) (Ofo) 17.8 20.8 15.7 0.4 
Stump morphology (%) 0.8 
Central 28.2 28.3 28.1 
Eccentric 26.1 24.5 34.8 
Bwm 37.3 41.5 34.8 
Side b1<1nch at entry (Y/N) ('!o) 75.4 84.9 69.7 0.03 
Bridging collate1<1ls (Y/N) ("!•) 53.5 43.4 59.5 0.04 
Collate1<1l1illing (Rentrop Classification [%]) 0.45 
0/1 21.5 22.7 13.5 
2 31.0 30.1 31.5 
42.3 37.7 44.9 
Angiogl<lphic calcification ('!o) 0.05 
Noncjmild 40.1 39.6 40.4 
Mode1<1te 32.4 22.6 38.5 
Severe 19.7 28.3 14.6 
Tortuosity (>45), ("'o) 45.8 43.4 47.2 0.58 
" 
Occlusion ends in bifurcation (YfN) 23.2 17.0 27.0 0.18 
E. 
Computed tomography angiographic characteristics 
Occluded length (mean±lSO) 27 .1±19.4 30.7+20.7 24.9+18.3 0.1 
• Ostial location (Y /N) (%) 14.8 15.0 14.6 0.9 ~
u Stump morphology ("/o) 0.28 
120 Central 16.4 17.0 15.7 
Eccentric 22.1 15.1 25.8 
Blunt 61.4 67.9 56.2 
Side b1<1nch at entry (Y/N) 42.3 43.4 41.6 0.8 
Collate1<1l filling (Rentrop Classification [%]) 
0/1 
2 
100 100 100 1 
Number of spots of calcium (%) 0.69 
No 27.5 22.6 30.3 
One spot 43.0 45.2 40.4 
Two spot 19.0 18.9 19.1 
Three or more 105 11.3 10.1 
Calcium at the entry ("/o) 52.1 58.5 41.6 0.04 
Calcium at the exit (%) 35.9 39.6 33.7 0.6 
Calcium >50% CSA (Y/N) (%) 43.0 54.7 35.9 0.03 
Calcium score of the occluded segment 
Volume (mml) 123.6±323.8 142.5±224.4 112.0±373.7 0.7 
Equivalent mass (g) 25.()±81.0 24.5±33.4 25.4±100.1 0.9 
Score (Agatston) 139JJ±411.5 142.6±258.1 136.9±484.9 0.9 
Tortuosity (%) o.s 
No 8.5 11.3 6.7 
One bend 43.3 41.5 43.8 
Two bends 31.2 26.4 33.7 
Three or more bends 12.8 15 11.2 
Angulation{%) 0.04 
No 65.2 53.8 72.1 
One bend 29.7 40.4 23.3 
Two bends 1.4 2.3 
Three or more bends 3.6 5.7 2.3 
CTO, chronic total occlusion; CSA, cross-sectional area. 
seen in successful cases (59.5 vs. 43.4%, p;::;0.04). Severe 
calcification, as defined qualitatively, was more prevalent in failed 
cases (28.3 vs. 14.6%, P""0.05). (Table 2) 
By CTCA, the occlusion length was widely dispersed, mean 
27.1±19.4 mm (range 2.6 to 93.4 mm) and longer as compared 
with CA. Although the occlusion length did not differ in successful 
as compared to failed cases (24.9±18.3 and 30.7±20.7, po:::Cl.l), 
the frequency of patients with an occlusion length >15 mm was 
significantly different, i.e. 632% in those w'rth procedural success 
vs. 82.7% in those with procedural failure (po;Q,02). 
CTOs witllout calcification were present in 27.5% of the treated 
lesions. The presence of severe calcification, defined as calcium that 
occupies more than 50% of the vessel cross-sectiortal area, was more 
prevalent in failures (54.7%} as compared to patients with a 
successful PCI procedure (35.9%} (p,0.03). The length of the 
calcified segments was longer in failed as compared to success cases 
(8.5±8.4 vs. 5.5±6.6 mm, P"'0.027). Whert calcifications were 
presertt irt the CTO, it was especially located at the erttry side of the 
occlusion. Interestingly, calcification at the entry of the occlusion was 
present in 58.5% of the failures as compared to 41.6% of the 
successful cases (P--0.04), while tile frequency of calcium at the exit 
was not different between the two patient groups. The absence of 
artgulation in the occlusion was also a predictor of favourable 
outcome: procedural success was 72.1% In CTOs withm:t anguration 
as compared to 53.8% in artgutated CTOs (p~.04) (Table 2). 
Of rtote, the calcificatiort patterns are affected by age but similar 
between genders (data not shown). Patients with severe 
calcification (>50% CSA) were older thart their courtterparts 
(63.9±9.0 vs. 58.3±11.4, p:::0.002). Pat'1ents w'1th longer 
calcification segments (cut-off set on >4.3mm - median of the 
length of calcified segments irt this population} were also older 
(63.4±9.7 vs. 55.8±11.2, po;Q.005). Patients with calcification at 
the erttry of the occlusion segment were 61.4±10.2 vs. 55.4±10.6 
year old, p:::O.OOO?, and also patients with calcification at the exit 
were older 62.6±9.5 vs. 55.9±10.7 year old, p-<0.0001. 
lrt Table 3 a comparison between CCA and CTCA for the detection 
of calcium in the occlusion is showrt. The angiographic estimation 
Table 3. Comparison between CT calcium score and angiographic 
calcification score. 
crc:A:c3kiiini" ---AiigtOgrijilift- Mta~±so· ·::.Min--· MaX'' 
$COr;ing ... : .scoring,. .. " 
Volume (mml) None or mild 69,7±103.1 1.9 462 
Moderate 207.7±546,0 3.3 2712.5 
""'" 
122.9±123.5 7.5 578 
p value 0.3 
Equivalent 
mass (g) None or mild 12.6±16,6 60.16 
Moderate 39.5:!:138,1 726.95 
Severe 31.7±402 1.64 179.5 
p value 0.4 
Agatston score None or mild 70.3±97.5 0.8 371.2 
Moderate 263.1±707 .7 1.1 3515.8 
""'" 
111.2:1:63.9 8.5 223.4 
p value 0.2 
CTCA: compLlte!:l tomography coronal)' angiography; SO: standard deviation: 
Min: minimum; Max: maximum 
CTTO Registry 1121 
of the presence and severity of coronary calcification differed from 
the quantitative CT calcium score indices (i.e. volumetric score, 
equivalent mass or Agatston calcium score). 
In the multivariable a11alysis the only variable that remained 
a sig11lflcant predictor of procedural success, was the abse11ce 
of severe calcification, i.e., calcium occupying >50% of the 
vessel CSA, as defined by CTCA {Table 4 and Figure 4). 
Table 4. Angiographic and tomographic predictors of success: 
multivariate analysis. 
·-::~:.::.~~~_-:-_::·.:coet5aent :·:::o1c :~::~s%:.as:.·::::p~vawe 
Previous PO -1.6 0.2 0.034 1.Z15 0.08 
Side bra11ch at the 
ently (A11gio) -1.9 0.15 0.02 1.184 0,07 
Tortu-osity (CTCA) -0,01 0.99 0.969 1.002 0.09 
calcification >50% 
CSA (CTCA) -1.8 0.17 0,036 0.747 0.02 
PCI: percLJtaneous coronary intervention; CTCA: computed tomography 
coronaiY angiog~<~phy; CSA: cross sectional area 
Figure 4. Assessment of calcification by computed tomography 
coronary angiography. Failed percutaneous coronary intervention in a 
patient with a chronic total occlusion of the left anterior descending 
coronary artery (lAD). (a) The angiographic borders of the occlusion 
are marked by arrows. (b) Final angiographic image showing 
persistent occlusion of the LAD. Insets show the wiring through the 
occlusion (inset 1) that appears to be in the false lumen as illustrated 
by the presence of contrast extravasation (arrows) once the wire is 
removed. (c) The IIOiume-rendered CT image clearly shows hea'l'j 
calcifications within the occluded segment (arrowheads). (d) Curved 
multiplanar reconstruction again highlighting the large calcifications 
(arrowheads) within the occlusion. 01, first diagonal branch. Sl, 
septrll branch. 
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Procedure related characteristics and effective 
radiation dose (Table 5) 
OVerall, the mean amount of contrast used was 455.4±202 ml and 
was not different between the patient treatment groups. The 
fluoroscopic time was higher in the failed cases as compared to the 
successful cases, 72.5 versus 53.1 minutes respectively, p...---{).007. 
The mean effective radiation dose of the PCI procedure was 
39.3±30.1 mSv. Dverail, the mean effective radiation dose of the 
preprocedural CT scan was 22.4 mSv: 19.2±6.5 mSv for the 
contrast-enhanced scan, 3.2±1.7 mSv for the calcium scoring 
scan. The mean effective radiation dose per scanner type was: 
14.4±5.7 mSv for 16-slice CTCA (n=34 patients}, 20.1±1.6 mSv for 
54-slice CTCA (n=42 patients) and 21.8±6.5 mSv for dual-source 
CTCA (n.:£3 patients). 
Table 5. Procedure related characteristics and radiation parameters, 
n .. 142 
Number of stents in 
the target vessel 1.8±1.4 
Average target vessel 
stent length (mm) 23.2;t5.2 
Average target vessel 
stent diameter (mm) 3.0±0.5 
Biplane use ('lo) 70.8 
Contlast used (ml) 455.4±201.9 
Procedure time (min) 132.2:t57.3 
Auoroscopic time (min) 60.3±40.1 
Dose area product PCI 
(cGy•cm~ 16171.5±11539.0 
Effective dose PO (mSv) 39.26±30.1 
Cllcium scoring ctdi 
Clllcium scoring dlp 
Eff~ve dose calcium 
scoring (mSv) 
CT ctdi 
CT dlp 
Effective dose CT (mSv) 
10.5±5.1 
159.5±80.3 
3.2±1.7 
62.9±18.6 
938.0±316.5 
19.2±6.5 
0.7±0.9 2.9:1.3 <0.001 
19.9:6.1 24.4±4.6 0.002 
3.3±0.6 3.1±0.7 
'·" 76.6 68.8 0.4 
457.8±214.7 4S4.2±195.8 Cl.93 
143.9±60.3 125.3±54.7 CI.06 
72.5±41.9 53.1±37.5 (1,007 
17598±13755 15240±9814 03 
42.5±36.5 37.1±25.1 0.34 
10.1±5.8 10.7±4.8 0.6 
153.9±88.1 162.7±76.2 0.6 
3.1±1.8 3.3±1.6 0.5 
64.1±20.7 62.4±17.4 0.6 
9n.7:t:335.9 917.6±305.3 0.3 
20±7.1 18.8±6.2 03 
CT: computed tomogT<lphy; ctdi: computed tomogT<lphy dose index; dlp: 
dose length index; mSv: millicsicvert 
Discussion 
In this registry of 139 patients we evaluated the possible mle of 
CTCA when attempting PCI of CTOs. We found that the distribution 
rather than the amount of calcium impacts on the procedural 
outcome of this particular group of patients, Not unexpectedly, 
CTCA was more accurate than CCA for defining the morphological 
features of CTOs. In particular, we found that the assessment of 
calcification by CTCA ms more predictive of success than CCA in 
the multivariate model. It is diffrcult to prove the added value of 
a preprocedural CT scan in terms of procedural outcome. However, 
it is fair to say that a better understanding of the anatomical features 
of an occluded vessel can modify our intentional treatment 
strategy11• Dedicated CTO wires and new treatment strategies have 
been developed recently and appear to be useful in selected 
cases;2. However, these new tools need to be used judiciously, and 
in our view, in the right anatomical context. A promising new 
strategy to treat CTOs, is the retrograde approach which has been 
introduced as an alternative route for recanalisation of otherwise 
difficult or impossible lesions and is gaining acceptance among 
interventlonalists due to its high success rate13• A possible 
explanation Is the fact that calcium is more prevalent at the entry of 
the occlusion, so a higher chance to cross/break the distal cap and 
make progress retrograde would encourage the operator to 
continue until success is achieved (Figures 5a and 5b). Our data 
corroborate what intuitively was written in the consensus document 
from the EuroCTO club14: "the distal fibrous cap is often less 
resistant than the proximal cap". Another anatomical factor that 
favours the retrograde approach is the presence of side branch at 
the entry side of the occlusion that in our series was related to failed 
cases (Figures 5a and 5b). 
The location of calcification is not only a strong determinant for 
crossing the lesion with the guidewire, but also influences the 
balloon selection. In severely calcified lesions small diameter 
balloons, i.e. 1.0, 1.1 and 1.25 mm, with a lubricious coating and 
acceptable shaft pushabllity are usually required14• 
Calcification of the coronary arteries has been related to age in 
several publicationsl5,lo. In our study, CTOs with longer and more 
severe calcified patterns were present in older patie11ts. Also, the 
mean age of patle11ts with calcifications at the entry and exit sides of 
the occlusion was significa11tly higher. 
Figure Sa. Retrograde approach. (a) Angiographic image, showing 
proximal occlusion (arrowhead) of the right coronary artery (RCA). 
(b) Angiographic image of the left coronary artery, showing a large 
septal branch (arrowheads). (c) Corri.!Sponding CT image of the RCA 
showing 2 consecutive non-calcified occlusions of the vessel. 
(d) Corresponding CT image of the left coronary artery, also showing 
the large septal branch. 
Figure Sb. Retrograde apprwch. &me patient ::;sin Sa. Illustration of 
the percutaneous retrograde technique. (a) 3-dimensional CT 
angiographic view, showing he occlusion of the RCA (arrow) and the 
large septal branch (arrowhead}. (b) Wiring of the septal branch 
(arrowhead). (c) The wire is introduced through the guiding catheter 
that is engaged in the left coronary artery (arrow) and was successfully 
advanced through the septal branch and finally retrograde through the 
RCA ending into the ascending aorta (arrowheads}. (d) Balloon 
inflation over the wire that has been positioned retrograde in the RCA. 
(e) Final angiographic result after wbsequent antegrade balloon 
dilatations and stenting of the vessel. 
Undoubtedly, this is a high-risk subset of patierJts in different 
aspects and the decision to choose a percutaneous interver~tion 
should envisage maximal chances for success at minimal patient 
risk. The amount of contrast used and the radiation dose a patient 
receives are '1mportant variables that have an impact on patient 
safety. The contrast lood during a CTO recanalisation attempt is 
higher as compared to non-CTO procedures17•18• In this study, the 
average amount of contrast used was455.4 mi. In addition, a PCI of 
a CTO is often characterised by a long procedural time and a high 
radiation dose, Usually during the procedure one view is 
maintained, or two orthogonal views in case of biplane use, which 
leads to an irJtense exposition of the same skin areas10 ar1d body 
segments14• The average radiation dose of a PCI procedure irl this 
study was 39.26 mSv. This is 8 times higher than the dose received 
during a conventional coronary angiogram 19• In addition, patients 
received a mean radiation dose during the preprocedural cardiac 
CT scan of 22.4 mSv. 
Clinical implications 
In experienced centres, the success rate of a percutaneous CTO 
recar~alisation attempt is on average 70%8.14• Knowing beforehand irJ 
which patients the chances of success are reasonably high appears 
to be worthwhile, as it has been showrl that a failed recanalisatiorJ is 
associated with a worse outcome and a higher rate of major cardiac 
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ever~ts20• The current study shows that CTCA is more precise than 
CCA for assessir1g the anatomical features of a CTO. At the cost of 
a significantadditiona: amour~! of contrast ar~d radiation, it would not 
be reasonable to propose a cardiac CT scan before each PCI attempt 
of a CTO. Instead, a cardiac CT scan seems most useful in patients 
irl whom the ar~giographic features look unfavourable, or in patients 
in whom a second PCI attempt is contemplated. The decisiorJ 
whether or not to perform a contrast-enhanced scar! after the 
calc'1um scor'mg scan depends or1 the information or1e wants to 
obtain: if the question is to have an idea of the amount of calcium in 
the occluded segment, a calcium scoring scan might be sufficient 
considerirJg the fact that most of the radiation exposure derives from 
the contrast-enhanced scan. Pursuing a "complete scan", includir~g 
the administration of contrast, might be preferred ir1 case of 
a suspected long occlusion, where one aims to obtain informatiorl or1 
the 3-dimensional course of the occlusion, including the distributiorJ 
of calcium. In addition, the contrast and radiatiorJ exposure of the 
patient should become less of an issue in the near future: new 
scanning protocols are dramatically reducing the radiation dose of 
a contrast-enharJced scan to less than 3 mSv21 and scheduling the 
cardiac CT scan at least a few days before the PCI would not 
increase the risk of contrast nephropaU1y. 
The radiation from a PCI is considerable, but necessary to do the 
procedure. Good arguments are needed before embarkir~g on 
a percutaneous recanallsation attempt and this decisiorJ process ir1 
general should incorporate the symptomatic status of the patier~t. 
documentation of myocardial ischaemia and, if possible, data with 
regard to the pre-procedural chances of success. The latter 
argumer1t would be ir1 favour of performing a cardiac CT scan ir1 
selected cases: patier~ts in whom the CT characteristics of a CTO 
are urlfavourable for PCI might be considered for an alternative 
therapeutic modality, i.e. medical treatment or bypass surgery. 
limitations ol the study 
Despite the fact that we failed to provide accurate data for occlusiorJ 
duration, which is an important marker of procedure failure5, we 
performed a detailed and selective quantification of the calcium 
present irl the occluded segmer1t, for which occlusiorJ duration is 
a surrogate marker as shown irJ a pathological study where 
fibrocalcific plaque increased with CTO age (p=:0.008)~. 
Although all the CTCA scans were discussed between the operator 
and someor1e trairJed in irrterpretir~g CTCA priorto the inteNentional 
procedure, there was r1o formal documerJtation of the changes in 
approach for treating the CTO in light of the CTCA findings. Thus, it 
was difficult to measure to what extent this knowledge concerning 
the CTO characteristics by CTCA impacts on the success rate. In 
order words, a severely calcified and long lesion might have 
discouraged the operator from a longer attempt 
In case of severe calcifications of the vessel, we relied on 
angiographic data to determirJe the length of the occlusion by CTCA. 
Although a limitation in this study, the repercussion in clinical practice 
would be minor, as the arJgiographic data are an esser~tial component 
of the therapeutic decision process for a given patient As mentior~ed 
in the discussion above, we would or~ly recommend a cardiac CT 
scan in selected cases to complement the angiographic information. 
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Conclusion 
Evaluation of CTOs by means of CTCA offers a better description of 
its anatomiC<l! features as compared to conventional angiography 
and predicts procedural success in patients referred for PCI. More 
specifically, the presence of severe calcification, i.e. calcium 
occupying >50% of the vessel CSA, as determined by CTCA is an 
independent predictor of procedural failure. The radiation exposure 
and amount of contrast used during a PCI attempt is considerable. 
The judicious use of a preprccedural cardiac CT scan makes sense 
and might modify the approach in case PCI is attempted or could 
drive the physician's preference to an alternative therapeutic 
modality, i.e. medica! treatment or bypass surgery. 
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PART 3 
INTERVENTIONS IN HIGH RISK PATIENTS 

CHAPTER 13 
PACLITAXEL-ELUTING STENTS FOR THE 
TREATMENT OF COMPLEX CORONARY 
LESIONS: IMMEDIATE AND 12-MONTH 
RESULTS 
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Paclitaxel·eluting stents for the treatment of complex 
coronary lesions: immediate and 12·month results 
lmad Sheiban, Gian Paolo Ballari, Claudio Moretti, Walter Grosso Marra, 
Emanuele Meliga, Pierluigi Omede, Filippo Sciuto and Gian Paolo Trevi 
Objective One of the drug-eluting stents that have been 
introduced into clinical practice is the paclitaxelweluting 
stent (PES). Several randomised, controlled clinical trials 
have already been conducted to evaluate the safety and 
efficacy of this stent, but data regarding clinical practice are 
still Jacking. The aim of this study was to evaluate the safety 
and efficacy of PESs in a 'real-world' population. 
Methods Two hundred and seventy-three patients with a 
high cardiovascular risk profile and complex coronary 
lesions were treated with PESs. Each patient was 
categorised using the following parameters: cardiovascular 
risk factors, clinical history, clinical presentation, 
angiographic pattern, and procedural characteristics. 
Primary endpoints were major adverse cardiac events 
(cardiovascular death, coronary artery bypass grafting, 
myocardial infarction, stroke, target vessel 
revascularisation, target lesion revascularisation, and 
remote revascularisation). 
Results A low rate of intraprocedural and periprocedural 
complications was observed. During the clinical follow-up 
period (mean 10.5 ± 4.2 months), 78% of patients were 
event-free. Twenty--six patients (9.80Jc) underwent target 
Introduction 
Coronary restenosis after successful percutaneous coron-
ary intervention (PCI) has ever been the major problem 
limiting the efficacy of this technique [1]. Several strat-
egies have been attempted to face restenosis [2-14], the 
latest of which was the use of drug-eluting stents [15-20]. 
One of these devices introduced into clinical practice is 
the paclitaxel-eluting stem (PES) (TAXUS Express2, 
Boston Scientific Corp., :\atick, Massachusetts, USA) 
[21-25]. At present. several randomised, contro!led 
clinical trials have been conducted co evaluate the safety 
and efficacy of this stcnt, albeit complex patients with 
complex lesions were often excluded, enrolling prefer-
ably patients with single and de novo lesions. The 
TAXUS IV trial [Z6,Z7], for example, enrolled 1314 
patients with single de novo lesions who were random~ 
ised to treatment with a slow-release PES versus a bare-
metal stent. Also the TAXL'S VI trial [28] (including 448 
patients with complex, long coronary lesions randomised 
to treatment with a moderate-release PES versus a bare-
metal stem) enrolled patients with de novo target lesions 
vessel revascularisation, but only 11 of them (4.2%) had 
target lesion revascularisation. Seven patients (2.70Jc) had 
myocardial infarction, and cardiac death occurred in 
two patients (0.76%). Only one case (0.37%) of subacute 
stent thrombosis and one case of late stent thrombosis 
were observed. 
Conclusions The present study demonstrates that the use 
of PESs is safe and effective also in patients with a high 
cardiovascular risk profile and complex coronary lesions. 
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located within a single native coronary vessel with a 
reference vessel diameter between 2.5 and 3.5 mm. In 
both these trials, patients with previous drug-eluting 
stent implantation, recent or acute myocardial infarction 
Cvll), low left ventricular ejection fraction, left main or 
ostial disease, bifurcation lesions or totally occluded 
vessels, which are all conditions frequendy met by 
interventional cardiologistS in clinical practice, were 
excluded. 
The aim of the present study was to evaluate the safety 
and efficacy of PESs when implanted in 'real-world' 
patients, in a high cardiovascular risk population with 
complex coronary lesions. 
Methods 
Patient population and protocol 
From May 2003 to December 2004, a total of 273 con-
secutive patients with a high cardiovascular risk profile 
and complex coronary lesions undergoing coronary angio~ 
plasty and PES implantation were included in the study. 
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Teble1 Baseline clinical characteristics of the study population 
(n=273) 
Curdiov!lllcular risk factors 
Hypertension 
Diabotoo 
Hyporlipidnomio. 
Fnmily histOTy of CAD 
Active smokfrlg 
History of CAD 
Previous Ml 
Previous CABG 
Previous PCI 
Chronic ronaJ failuro 
Poriphornl o.rtoriopnthy 
79.5% 
34.8% 
70% 
17.9% 
41.8% 
59.3% 
35.9% 
22% 
35.5% 
6% 
17.2% 
CABG, coronary artory bypass gmft; CAD, coronary artory dlscnoo: Ml, myocnrdiaJ 
inflll'ction; PO, parcutanoous coronnry intoiVOntion. 
Patients with contraindications to double antiplatelet or 
anticoagulation therapy were excluded. Informed con~ 
sent was obtained in accordance with the Declaration 
of Helsinki. 
Baseline clinical and angiographic characteristics are 
shown in Tables 1, 2 and 3. The following baseline 
parameters were assessed in all patients: cardiovascular 
risk factors (age, sex. hypertension, diabetes, hyperlipi~ 
daemia, family histOry for coronary artery disease [CAD] 
and active cigarette smoking), presence of prior MI, 
previous coronary artery bypass graft (CABG) or PCI, 
presence of specific comorbidities such as chronic renal 
failure and peripheral vasculopathy, clinical presentation 
(ST~elevation MI [STE~l], non~ST -elevation Ml 
[NSTE\11], unstable angina, stable angina, ventricular 
arrhythmias, acute pulmonary oedema or instrumental 
signs of ischaemia) and angiographic pattern (eA"tcnsion 
of CAD and lesion location). 
Procedural characteristics included the following 
parameters: number of treated vessels (single or multi~ 
vessel treatment), number ofPESs per patient, treatment 
of bifurcation lesions with single or double stent, final 
kissing balloon, debulking procedures (directional or 
rotational athcrectomy), and usc of pressure wire or 
intravascular ultrasound~guided revascularisations. 
Pre-procedural and post-procedural electrocardiograms 
were performed, and cardiac enzymes were measured 
at baseline, after the procedure, and daily until closure of 
the enzymatic curve. 
Tobie 2 Indications for angiography and percutaneous coronaty 
intervention 
STEMI 
NSTEMI 
Unsmblo angina 
Smblo angina 
lnstrumontnl signs of indmomia 
g.5% 
21.6% 
42.5% 
125% 
13.9% 
NSTEMI, nM-sT -olovution myocardial inftuction; SlBAI, ST-ol011ation myocardial 
infnrction, 
Tol>lo 3 Angiographic and procedural data 
Singlo-vossol diseaso 
Mu!tive3SOI diooase 
Typo of treated lesion 
T otnl occlusion 
Ostiallooion 
Bifurco.tion losion 
ln'lrtont rostenosis 
Loft mnin dioonoo 
Venous gmft stenoois 
Adjunctive d011icns and modicationn 
Diroctionnl or rotntionnl nthoroctomy 
Prooouro wiro ovuJuation 
IVUS ovuluution 
Glycoprotein lib/Ilia inhibitom 
Singlo-vossol troatmont 
Multivooool trootmont 
IVUS, intravnscutur ultmsound. 
Study medications 
21.2% 
78.8% 
19.4% 
15% 
18.7% 
10.7% 
7.7% 
3% 
"% 
1.8% 
1.1% 
20.1% 
<3.2% 
56.8% 
Aspirin was administered to all patients before the pro-
cedure and indefinitely thereafter. A loading dose of 
300 mg of clopidogrel was recommended before cathe~ 
terisation followed by clopidogrel 75 mglday or ticlopi-
dinc 250 mg twice daily for at least 6 months after the 
procedure. Glycoprotein lib/lila inhibitor usc was at the 
operator's discretion. 
Follow-up 
Clinical follow~up was scheduled for all patients 
after 1 month and then every 3 months until the 
end of the observational period (clinical follow~up 
ended for all patients on 30 April 2005). We reported 
results at 3, 6 and 12months of follow-up (that we 
considered as mid-term results) and outcomes at the 
closure of the study. Angiographic control was per-
formed only if non-invasive suess tests or clinical 
presentation (recurrence of angina) were suggestive 
of ischaemia. 
Endpoints 
Primary endpoints were major adverse cardiac events 
(:MACEs), namely cardiovascular death, CABG, MI 
(either STEM! or NSTEMI), stroke, target vessel revas-
cularisation (TVR), target lesion revascularisation (TLR), 
and remote revascularisation. 
Statistical analysis 
Continuous variables are expressed as mean± SD, dis-
crete variables are reported as percentages. Univariate 
analysis was conducted to evaluate the presence of cor-
relations between single clinical, angiographic and pro-
cedural parameters and the recurrence of intrahospital 
adverse events or ~ACEs during the follow-up. Odds 
ratios (ORs), 95% confidence intervals (Cis) and Pvalues 
were calculated for subgroup comparison. MACE-free 
survival distributions were assessed according to the 
Kaplan-Meier method. 
Results 
Patient and lesion characteristics 
The baseline clinical and angiographic characteristics 
arc summarised in Tables 1, 2 and 3. Essential hyper-
tension was present in 79.5% of patients, diabetes in 
34.8%, hyperlipidaemia in 70%, family history of CAD 
in 17.9%, and active smoking in 41.8% (Table 1). 
Previous MI was present in 35.9% of patients, 22% 
had a previous CABG, and 35.5% had a previous 
PC I. 
Clinical indications for angiography and PCI were 
represented by unstable angina in 42.5% of patients, 
NSTEMI in 21.6%, stable angina in 12.5%, STEMI in 
9.5%, and instrumental signs of ischaemia in 13.9% 
(Table 2). At angiographic evaluation (Table 3), 78.8% 
of patients had multivessel disease, 19.4% had total 
occlusion lesions, 15% ostial lesions. 18.7% bifurcation 
lesions, and 10.7% in-stent restenosis. 
A total of 362 lesions were treated and 401 PESs were 
deployed (mean 1.47±0.64 scents per patient, range 
1-6), with a mean diameter of 3.1±0.3mm and a 
mean length of 17.04±5.69mm. Lesion distribution 
was the following: 7.7% in the left main coronary 
artery, 38.7% in the left anterior descending coro-
nary artery, 20.4% in the left circumflex coronary artery 
(CX), 26.3% in the right coronary artery, 3.9% in the 
ramus, and 3% in the venous graft; 56.8% of patients 
underwent multivesscl treatment. Directional or 
rotational atherectomy was used in 2.9% of patients; 
pressure wire and intravascular ultrasound were used 
in very few patients (pressure wire 1.8%, intravascular 
ultrasound 1.1%). A large proportion of lesions (76.3%) 
were type BZ/C. During the procedure, glycoprotein 
lib/Ilia inhibitors were administered to 20.1% of 
treated patients. 
Double antiplatelet therapy with acetylsalicylic acid 
(administered to all patients before the procedure and 
indefinitely thereafter) and clopidogrel 75 mg!day or 
ticlopidinc 250 mg twice daily was administered to all 
patients for at least 6 months after the procedure. In only 
two cases (0.76%), the clopidogrcl or ticlopidine therapy 
was continued up to 12 months. 
Table 5 Clinical events at follow-up 
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Table 4 lntraprocedural and peri procedural complications 
PI'OC<Idurnl sllCCess 
PI'OC<Idurnl or in·hoopital dwth" 
Post·procodurnl myoerudiul iMfwction° 
Acute or subacute in·atont thrombosis 
Stroke" 
EmorgoMcy coronruy artOI)' bypass graft 
100% 
0.4% 
4% 
0.4% 
0.4% 
0% 
• Roforrod to tho snmo plltiorrt. docoosod for a stroke 8 days oftor tho procedure. 
0 Defined :man incrooso in cardiac onzymos of nt loastthreo times tho bruwJ vnluos. 
lntraprocedural and periprocedural complications 
Table 4 shows intraprocedural and in-hospital adverse 
events. Procedural success (defined as residual stenosis 
<20% after stent deployment) was obtained in all 
patients. No cases of intraprocedural death occurred; 
in-hospital death occurred in one patient (0.4%), an 
84-year-old female patient, with a histOry of CAD, 
previous MI and PCI, who underwent PCI for a 
:-.;sTEM!. Two critical lesions in the middle segment 
of the left anterior descending coronary artery were 
successfully treated (the first one with a PES and the 
second one with a bare~metal stent), but the patient died 
from stroke 8 days after the procedure. 
Post-procedural MI (defined as an increase in the cardiac 
enzyme creatine kinase~MB of at least three times the 
basal value) occurred in 11 patients (4%); no incidents of 
acute in-scent thrombosis or emergency CABG occurred; 
the subacute in-scent thrombosis rate was 0.4% (one 
patient) (Table 4). This event occurred in a 77-year-
old female patient, with a high cardiovascular risk profile, 
who underwent PC! and multiple PES implantation fora 
NSTEMI (two PESs in the left anterior descending 
coronary artery and one PES in the CX). Four days after 
the procedure, she had angina associated with electro~ 
cardiographic modifications. An angiographic evaluation 
was performed and revealed in-stent thrombosis of the 
PES deployed in the CX (probably due to stent under-
expansion), which was successfully treated with multiple 
dilatations with high-pressure balloons. 
Follow-up events 
Clinical follow~up results are shown in Table 5. Since the 
overall study patients were treated at different sub-
sequent times (from May 2003 to December 2004) and 
3 montl\s (n=264) 6months(n,218) 12months (n""103) Ovoroll (n"" 264) 
Evont-froo 95.1% 89% 79,6% 78% 
Myocnrdial infarcti<ln 0.76% 0.2% 0.97% "% 
CABG 0.34% 0.92% 1.0% 1>% 
1VR 2.3% 5% 9.7% 9.8% 
TlR 0.76% 2.3% 6.8% 4.2% 
RQmoto mv£1SCutariootion 1.1)% 4.1% ,.% 8.7% 
&roko 0% 0% 0.97% 0.38% 
Cl!rdi011ascular doath 0% 0% 1.9% 0,76% 
CABG, coronruy artol)' bypo.es gruft; TLR, tnrgot lesion rovnsculnriootion; TVR, tnrgot vcss.ol revnsculo.rit.l:l.tion. 
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clinical observation ended for all patients at the same 
time (on 30 April2005), the follow~up period varied from 
a minimum of 4 months to a maximum of more than 
20 months, with a mean clinical follow~up duration of 
10.5 ±4.2 months. During follow~up, clinical data were 
collected in 97% of the treated patients (n=264). 
At 3~month follow~up, 251 of the 264 patients (95.1 %) 
were evenr~free, twO patients (0.76%) had MI, one 
patient underwent eABG (0.34%), si:...: patients had 
TVR (2.3%), two patients had TLR (0.76%), and two 
patients had target vessel failure. Five patients (1.9%) 
underwent remote revascul::trisation for underestimated 
lesions at index procedure. l'\o stroke or death occurred 
during this period. 
At 6-month follow~up, complete for 218 patients, 89% 
were event~free. Two patients had MI (0.92%), two 
patients underwent eABG (0.92%), 11 patients had 
TVR (5%), five patients had TLR (2.3%), and nine 
patients (4.1%) had remote revascularisation for pro.. 
gression of CAD. l'\o stroke or death occurred. One !:ate 
in~stent thrombosis occurred in a 47~year~old male 
patient with multiple risk factors, previous MI and multi~ 
vessel disease who underwent Pel for unstable angina. 
He was treated with a single PES (3 x 16mm) in the 
proximal ex and only~balloon Pel at the distal segment 
of the same vessel. Mter discontinuation of double anti~ 
platelet therapy with ticlopidine (6 months after the 
procedure), he had an acute :\.11 with angiographic evi~ 
dence of in~stent thrombosis in the proximal ex. Repeat 
only~balloon Pel was performed successfully and he was 
put on double antiplatelet therapy with acetylsalicylic 
acid and clopidogrel for 1 year. No other events were 
observed in this patient. 
At 12~month fol\ow~up, complete for 103 patients, 79.6% 
were evem.free, one patient (0. 97%) had MI. one patient 
(0.97%) had stroke, two patients underwent eABG 
(1.9%), 10 patients had TVR (9.7%), seven of which were 
TLR (6.8%), and eight patients (7.8%) underwent remote 
revascularisation for progression of CAD. In this period. 
c::trdiac death occurred in twO patients (1.9%). 
During the whole clinical follow-up period (closed on 
April2005, mean follow-up 10.5 ±4.2 months), 78% of all 
treated patients were event~free; overall clinical event 
rates were the following: MI 2. 7% (seven patients), stroke 
0.38% (one patient), CABG 1.5% (four patients), TVR 
9.8% (26 patients), TLR 4.2% (11 patients). remote 
revascularisation 8.7% (23 patients). Death occurred in 
four patients (1.5%), two of which (0.76%) were cardiac 
deaths. 
Univariate analysis 
At univariate analysis (Fig. 1), the following character-
istics were statistically associated with a significant 
Flg.1 
Mnlo Vll. !omnia 
Dlobotle•vs.non-
dlnbatles 
Mlvs.olllor 
lndlcatlon5 
Un•tabloonglnn vs. 
othor Indications 
Multl-vs.olnglo-
va•ooldlsnnoo 
Multl-vo. •lnglo-
vooscltrootmont 
C/l32typo loolon vo. 
St/Atyp<>loslon 
GPIIb/lll•lnhlbllor 
~dmlnlstrntionVll. no 
odmlnlatr•tlon 
EF ::;35% vs. 
EF>35% 
Univariate analysis 
P=0.01 
--f----P=0.0004 
P=0.00065 
--+--- P=0.00062 
P=0.0082 
--!--- P=0.0124 
-+---P=o.orro 
P=0.0556 
Hybrid trootmont vs. 
onlyTAXUS 
troatmont -~P=0.46 
Odds ratio 
Univariate analysis: correlations between clinical, anamnestic, and 
angiographic characteristics and rocurronco of major adverso cardiac 
ovonts during follow-up. EF, ejection fraction; GP, glycoprotein; MI, 
myocardial infarction. 
increase in YfACE incidence: female gender (OR 0.43: 
95% Cl 0.22-0.86; P=0.014), diabetes (OR 2.73; 95% CI 
1.53-4.87;P::::: 0.0004), unstable angina (OR2.60; 95% CI 
1.47-4.60; P=0.00062), multivessel disease (OR 3.04: 
95% CI 1.29-7.39; P:::::0.0082), multivessel treatment 
(OR 2.09; 95% Cl 1.16-3.77; P=0.0124), type BZ/C 
lesions (OR 2.18; 95% ei 1.13-4.20; P:::::0.0179) and, 
surprisingly, use of glycoprotein lib/Ilia inhibitors 
(OR 3.58; 95% CI 1.82-7.08; P=0.0001). The latter 
might be ascribed to the more complex clinical and 
angiographic pattern of those patients who received 
glycoprotein lib/Ilia inhibitors during the index pro.. 
cedure, more commonly affected by diabetes and with 
multivesscl and diffuse disease. 
Event~free survival 
Event~free survival curves (Figs 2 and 3) show that 
the incidence of MACEs diminished after the first 
year following the index procedure. The majority 
of MACEs occurred within the first year of the 
procedure, and all TLRs occurred within 11 months, 
with a higher incidence between the third and eighth 
month. 
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Discussion 
As widely reported in the literature [16-Z3,25-Z8], the 
use of drug-eluting stents seems to be very effective in 
facing restcnosis after PC I. One of the drug-eluting stents 
introduced into clinical practice is the PES (TAXUS 
Fig, 3 
ExpressZ). At present, several randomised studies have 
demonstrated the safety and efficacy oftheTAXUS stent 
in preventing restenosis as compared to bare-metal stems 
[21,22,25,26,28], though these results have often been 
obtained in strictly selected populations that have not 
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included patients with complex clinical presentation and 
angiographic patterns. In a context of great expectations, 
but also of relative caution, the present study aims at 
evaluating the safety and efficacy ofPESs when used in 
clinical practice in an unselected 'real~world' population, 
including patients with a high cardiovascular risk profile 
and complex lesions. 
The population screened in this study included a large 
number of patients with multiple cardiovascular risk 
factors, patients with previous CABG and/or PCI, 
patients with multivessel disease and with type BZ/C 
lesions as well as a considerable proportion of diabetics 
(34.8% ). Despite the complexity of the treated popu~ 
l::ttion, our results are absolutely consistent with the data 
reported in previous randomised trials. The procedural 
success in all patients and the low rate of procedural and 
in~hospital complications confirm the safety of this 
device. The results obtained :in this study are in keeping 
with those reported in the TA.t'<CS IV tri::t! [27] (TVR 9.8 
vs. 7.1% in TAXUS IV;TLR4.2vs.4.4% in TAXUS IV). 
Moreover. since most of:\1ACEs were due to progression 
of coronarv atherosclerosis (remote revascularisation), 
these resuits should be considered very encouraging. 
Similar outcomes were also reported in the T AXCS VI 
trial [28]. 
As confirmed by a TAXUS IV trial subgroup study [29], 
univariate analysis pointed out that diabetic patients have 
a higher risk of YIACEs during follow~up if compared tO 
non-diabetic ones. In that series of patients, Hcrmiller 
eta!. [29] suggested the superiority ofPESs (TAXUS) for 
the treatment of diabetic patients as compared tO siroli-
mus-eluting stents, albeit this superiority was not con-
firmed in a recent randomised study [30]. Female gender 
as well as multivessel disease patients and complex lesion 
morphology (type BZ/C) have always been considered at 
higher risk for restenosis when treated by conventional 
stents. Also in the present study, a higher incidence of 
:MACEs was observed in these subgroups of patients, as 
previously reported by Lansky eta!. [31]. However, if 
compared to historical data on bare~metal stems, PESs in 
these patient subsets have significantly improved clinical 
outcome. 
With respect to drug-eluting stent use, the scientific 
community has often been concerned with the major 
risk of acute and subacute :in-stent thrombosis due to 
delaved in-s tent endothelialisation as a result of the drug 
antiProliferative effects. This is also the reason why 
double antiplatelet therapy is recommended for at least 
6 months after PES implantation. Despite the complexity 
of the patients treated, the in-stent thrombosis rate 
observed in this study was extremely low and similar 
to that reported in previous randomised trials. These 
results confirm the safety and efficacy of this device also 
:in an unselected and complex population, even if this 
issue warrants further evaluation in ad~hoc designed 
studies. 
Study limitations 
The major limitation of this investigation is that these 
findings are based on a single-centre observational study 
and the number of enrolled patients is relatively small tO 
generalise our results to all patients treated with PESs. 
However, our study population represents the so-called 
'real-world' patients who are daily treated regardless of 
inclusion or exclusion criteria. Despite a relative caution, 
such studies provide relevant safety and efficacy data on 
PESs when used in clinical practice, in high-risk patients 
with complex lesions who are usually excluded from 
randomiscd trials. 
Moreover, the present study is lacking an :mgiographic 
follow-up; in fact, only patients with clinical symptoms or 
instrumental signs of ischaemia underwent angiographic 
control. However, data deriving from previous random-
ised trials that scheduled an angiographic follow-up 
indicate that clinical outcomes are strictly related to 
the angiographic ones; therefore, it can be hypothesised 
that the low clinical event rate observed is likely to match 
with an equally low angiographic event rate. Conw 
sequently, it could be argued that the encouraging 
clinical outcome in this series of patients may correspond 
to an effective control of angiograph:ic restenosis. 
In conclusion, the present study demonstrates that PCI 
with PES implantation is safe and effective also in an 
unselected population with a high cardiovascular risk 
profile associated with complex coronary lesions. 
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SHORT- AND LONG-TERM OUTCOMES OF 
PERCUTANEOUS CORONARY INTERVENTIONS 
IN PATIENTS WITH SEVERE LEFT 
VENTRICULAR DYSFUNCTION 
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Short- and long-term outcomes of percutaneous coronary 
interventions in patients with severe left ventricular 
dysfunction 
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Abstract 
Aims: Poor lett ventricular function is considered a high risk condition for performing either percutaneous 
(PC I) or surgical revascularisation. The aim of this study was to evaluate immediate and long term results of 
PCiln patients with coro11ary artery disease (CAD} and severe left ventricular dysfunctioll (EF 5. 0.30). 
Methods and results: Seventy-eight consecutive patients with CAD and severe left ventricular dysfunct"ion 
(EF 5.30%) were selected. The majority of these patients (87%) had multivessel disease. Coronary 
allgioplasty procedure was mainly motivated by angi11a associated with clinical manifestation of heart 
failure (54%). Total 11umber of treated vessels was 181, and a total of 203 stents were Implanted 
(2.6 stentlpatient). Procedural success was achieved in 77 patie11ts (97.8%). The total procedural and ill-
hospital adverse eve11t rate was 7.8%. Mean follow-up period (FUJ was 25±6 months. Eve11t-free survival 
rate at the end of FU was 55%: repe<lt revascularlsatioll was performed in 21 patients (27.6%). Female 
ge11der, diabetes, new acute myocardial infarction and number of tre<lted vessels were indepe11de11t 
predictors for death and combined mayor adverse cardiac events (MACE) during the follow-up. 
Conclusion~ In symptomatic patients with CAD and severe left ventricular dysfunctio11, PCI can be 
performed with excellent procedural outcome and acceptable long-term morbidity a11d mortality. 
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Introduction 
Severe left ventricular dysfunction in patierrts with coronary artery 
disease is often, but not always, the consequence of an acute 
myocardial infarction or an ischaemic cardiomyopathy1• It is 
estimated that most patients with severe left ventricular dysfunction, 
undergo'mg heart tra11splantation, might have areas of hibemated 
myocardium and could benefit from myocardial revascularisation2. 
Even symptomatk paf:ents are often den·:ed appropriate 
interventional treatment due to fear of procedural failure and are 
maintained 011 heavy medical therapy, the fortu11ate few receiving 
cardiac transplantation. Such patients have very limited surviva! 
when treated medically'-4 and usually die of cardiac causes related 
to recurrent ischaemia or infarction, cardiac heart failure or 
ventricular arrhythmias. 
In patients with ischaemic dilated cardiomyopathy, myocar-dial 
revascularisation is highly indicated when myocardial viability is 
documented by non-·~nvas'1ve tests (dobutamine stress 
echocardiography, thallium 201 sci:ltigraphy, PEr). However, it 
must be also underl'rned that poor left ventr':cularfunctlon, per se, is 
considered a high risk condition for either percutaneous or surgical 
coronary revascularisation~. The clinical benefrt of percuta11eous 
coronary interve11tions (PCI) In such patients is not well established. 
The aim of the present study was to evaluate immediate and long-
term procedural and clinical outcome of PCI in patie11ts with 
obstructive coronary disease (mostly multivessel) and severe left 
ventricular dysfunction (EF <30%). 
Methods 
Study group 
Betveen January 2000 and December 2001, from the patients 
undergoing percutaneous coronary intervenf:ons ':n our centre 
after having performed myocardial viability studies, we selected 
78 consecutive patients with documented coronary artery disease, 
severe left ventricular dysfunction (EF.s30%) and evide11ce of 
viable myocardium. Indication for coronary angiography were made 
by the referring physician on the basis of chest pain and/or cardiac 
failure manifestations. Indications for PCI were made by the 
attending physician after having reviewed the coronary angiography 
and the results of myocardial viability studies. Myocardial viability 
was documented 'in all pat'rents by SPECT and/or by dobutam·me 
stress echocardiography. Left ventricular ejection fraction was 
assessed by transthoracic echocardiogram (using a planimetric 
method) and by left ventriculography at the time of diagnostic 
aflgiography. 
Caroliac catheterisation 
Diagnostic coronary angiography was performed in all patients to 
assess left ventricular fu11ction and the presence and exte11t of 
coronary artery disease. The left ventricular ejection fraction was 
estimated by a single-plane 35°RAO ventriculogram. PCI was 
performed ':n all paf1ents. Intention to treat was for complete 
revascularisation by PCI in all patients. Procedural and in-hospital 
evellls were mon·~ored '111 all. 
Long-term clinical follow-up 
Patients were followed with out-patie11t visits after one. three a11d 
every s':x momns or by phone \nteMews. At each v':s·:t, health status 
was assessed by a complete cardiac evaluation, including 
echocardiogram, when needed. An echocardiogram for the 
assessment of regional and global left ventricular function was 
performed routinely at discharge and at six months after PCI. Non-
fatal and fatal cardiac events were documented either by hospital 
charis or by coroner's reporis. Mean follow-up period was2&6 months 
(range: 22 to 39 months} and was completed in 92.3% 02!78 
patients). The following events were recorded during follow-up: 
1) cardiac and non-card'rac death, 2) recurrent symptoms, 
3) recurrent ischaemic events (myocardial infarction non-Q and 
Q-AMil. 4) congestive heart failure, 5) need for revascular':sat':on 
(re-PCI or CABG}. EF on transthoracic echocardiography was also 
evaluated. 
Statistical analysis 
Data are expressed as mean±SD or as percentage where 
appropriate. Multivariate analysis was performed using a Cox 
proportional hawrd model to assess pre-dictor clinical factors of long 
term outcome. A p value of less than 0.05 was considered 
sign':fical1l The follow':ng var'lables were entered in the mult'rvar\ate 
analysis: age, sex, coronary risk factors, extent of Coronary artery 
disease, lett ventr':cular funct':on, completef\ncomplete 
revascularisation, peri-procedural cardiac enzyme release previous 
myocardial infarction, previous CABG, previous PCI. 
Results 
Demographic and clinical characteristics of study patients are shown 
i11 Table 1. The majority of patie11ts 01 %) were males, mean age was 
64:!:7 years with 27 patients havi11g more than 65 and nine more 
than 75 years. Hypertension, diabetes, hypercholesteroiaemia, a 
h':story of smok':ng and a fam':ly history of coronary artery disease 
Table 1. Demographic and clinical characteristics. 
No. P<rtieJTts..78 
Ago 
$ex:: male/female 
Distribution of coronary risk factors: 
Hypercholesterol<lemia 
Hypertension 
Diabetes mellitus 
Cigarette smoking 
Family history 
Previous AMI 
Previous PCI 
Previous CAGB 
Only angina 
Angina associated with clinical manifestations of CHF 
Positive inducible ischaemia or myocardial viability 
Adjunctive medical therapy 
ACE inhibitors 
Beta Blockers 
Statins 
54±7 
55/23 
62"/o 
56"/o 
28"/o 
58% 
47% 
53"/o 
19"1o 
230fo 
37% 
54% 
,, 
100% 
58% 
58% 
were common, 36 patients (53%) had experienced a previous 
Q wave or non..Q myocardial infarction. Thirty-three patients (42%) 
had undergone a previous myocardial revascularlsation: 15 (19%) 
by PCI and 18 (23%) by coronary artery bypass surgery (CABGJ. All 
patients were on medical therapy with ACE-inhibitors. 58% were also 
receiving beta blockers and 68% of patients were on statins. Double 
anti-platelet therapy (/GA + clopidogrel orticlopidine) was continued 
for at least one month foilowing the procedure in a!l patients. 
Clinical indications for PCI procedure were mostly represented by 
angina and/or heart failure manifest:ltions: 29 patients had only angina 
and 42 patients had angiM associated with congestive heart failure 
manifest:ltion, in seven patients PCI procedure was performed on the 
basis of the worsening of left ventricular function associated with a 
positive non-invasive test for inducible ischaemia or myocardi<ll viability. 
left ventricular EF was 25±2% ranging from 23 to 28%. 
Angiographic characteristics are summarised in Table 2. Ten 
patients (13%) had single vessel disease and 68 (87%) had 
multivessel disease. All 18 patients with previous CABG had 
multivessel disease with at least one venous graft disease. 
Proceclura! and in-hospital outcomes 
All patients received lib/Ilia antagonists prior to procedure. In 
36 patients (47%) intra-aortic balloon contra-pulsation was used 
during the PCI procedure. Complete revascularisation by PCI was 
Table 2. Angiographic and procedural data. 
No. patients- 78 
-Single vessel disease 
- Multivessel disease 
No. Treated vessets..181 
LMCA 
Protected 
Unprotected 
LAD 
Diagonal 
LCX 
Marginal 
RCA 
PDA·PL 
SVG 
No. treated lesions 
No. stents implanted 
Multivessel PO 
Debulking prior stenting 
DCA 
ROTA 
GP IIb jiiia inhibitors 
Intra-aortic balloon contra-pulsation 
10 (12.8%} 
58 (87.2%) 
12 (7%) 
8 
4 
41 (23"/o) 
17 (9%) 
28 (15%) 
19 (10%) 
4(l (22%) 
15 (9%) 
8 (4%) 
243 3,1lesionsfpatient 
203 2.5 stent /patient 
1.1 stentjvessel 
58 87% 
3 3,9"/o 
2 2.5% 
78 10D"'o 
35 47% 
LMCA: left main coronary artery; lAD: left anterior descending artery; 
LCX: left cii'O.Imflex artery; RCk right coronary artery; PDA: posterior 
descending artery; f'L: postero-latel<ll br.~nch; SVG: saphenous vein gr.~ft 
DCA: directional coronary athcrcctomy; ROTA: rotation-abl.ltion 
atherect:omy 
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attempted '1n al', patients w'1th 181 vessels treated (2.3 vessel/ patient), 
23% of treated vessel were left anterior descending arteries, 8% 
were left main, 9% were diagonal branches, 17% were left 
circumflex arteries, 10% were marginal branches, 22% were right 
corona!)! arter'1es, 10% were poster'ior descending or postero-latera\ 
branches and 6% were saphenous vein grafts (Table 2). Multivessel 
PCI was performed in 88% of patients. Multiple stent implantation 
was used in 76% of patients. Oebulking before stent implantation 
by dlrectiona'. atherectomy was performed ·:n 4% ot pat'1ents. In two 
patients, rotationa: ablation atherectomy was needed because 
of heavily calcified lesions. A total of 203 stents were implanted 
(2.6 stent /patient, 1.1 stent/ vessel) . 
Technical procedural success was obtained in 98.7% of pat'1ents. 
Procedural death occurred in one patient (1.3%), non Q-AMI in 
three patients (3.9%). stroke in one patient (1.3%), emergency 
CABG was not needed in any case. One death occurred tvo weeks 
following the procedure for acute renal fa'llure. No other 
complication were observed. Thus total procedural and in-hospital 
major adverse cardiac events were 7.7% (fable 3). 
Table 3. Procedurnl and in-hospital outcome. 
No. patients-78 
Procedural success 77 (98.7%) 
Death (1.3%) 
Non Q-AMI (3.9%) 
Q-AMI 
Strolre {1.3"/o) 
Emergent CA8G 
In-Hospital death (1.3"/o) 
CA8G: coronary artery bypass grafting; AMI; acute myocardial infarction 
Clinical foHow-up 
During a mean follow up of 25±6 months 42 patients (55%) had 
event-free survivaL Nine patients (1 1.8%) died: seven (9.2%) 
cardiac, and two (2.6%} non-cardiac. Gard"1ac death was caused by 
left heart failure in three patients, ischaemic events in two patients 
and ventricular fibrillation in two patients. Sixteen patients (21 %) 
had recurrence of angina, while four patients (5.3%) had ne;v Ml 
(three non-Q, and one Q-AMIJ and five patients (6.6%) were 
hospitalised because of congestive heart failure. All 20 patients 
(26.3%) with recurrent angina or AMI required a repeat PC I. Thus, 
total major adverse cardiac events during the foil ow up were 44.7%, 
mainly represented by the need for repeat revasculaf1sation. In 
39 patients, left ventricular function assessed by echocardiography 
improved at six months from 25±2% to 39±5%, p< 0.001. In the 
remaining 37 patients, left ventricular ejection fraction was 
unchanged (basal conditions 26±4 vs 5-morrth follow-up 28±5, ns). 
Female gender, the presence of diabetes meilitus, previous CABG, 
new AMI, unchanged EF at six months following the procedure and 
the number of treated vessels were significantly predictors of death 
duri!lg follow-up.The same parameters were also s'1gn'rf1cant 
predictors for combined major adverse cardiac events during 
follow-up (Table 4). 
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Table 4. Predictor clinical fuctors of long-tenn outcome 
(multivariate analysis). 
--::~:::_-:::RR: ·'·~cC "WtUe"'::~· 
Dooth 
Diabetes 1.06 (1.42·1.02) <0.01 
Female Gender 1.41 (2.82-1.16) <0.01 
Hypertension 1,35 (2.02-0.64) NS 
Hypercholestcrolaemia 1.54 {2.55-0.97) NS 
Cigarette smoking 131 (2.05-0.38) NS 
Family history 0.81 (1.97-0.22) NS 
Chronic stable angina 0.54 (1.95--0.43) NS 
Previous AMI 1.23 (1.89-0.76) NS 
New AMI 1.18 (1.55-1.10) <0.001 
Previous CABG 1.25 (1.92-1.01) <0.05 
Previous PCI 1.37 (1.98-0.45) NS 
Unchanged EF a 6 months 1.31 (154-1.02) <0.01 
No. of treate<l vessels 1.42 (2.12-1.45) <0.01 
Combined MACE 
Diabetes 1.57 (3.16-1.18) <0.001 
Female Gender 1.62 (2.78-1.16) <0.01 
Hypertension 0.9 (1.56-0.45) NS 
Hypercholesterolacmia 1.35 (2.55--0.98) NS 
Cigarette smoking 1.17 (2.11·0.78) NS 
Family history 0.93 (1.76-0.68) NS 
Previous AMI 1.35 (2.92-1.05) <0.05 
Previous CABG 1.34 (2.59-1.11) <0.05 
Previous PCI 1.12 (2.65-0.84) NS 
New AMI 1.48 (3.12-1.23) <0.001 
Unchanged Ef at 6 months 1,55 (2..43-1.12) <0.01 
No of treated vessels 1.56 (2.951.28) <0.01 
CABG:coronary arteTy bypass gr.rfting; AMI: aCIJte myocardial infarction; 
CHF: cardiac heart fuilure; Re-PCI: repeat perclltaneous coronary 
interventions; New AMI: acute myocardial infarction occurred during the 
procedure. in-hospital or foUow-up period. 
Discussion 
Immediate afld loflg-term prognosis of patients with ischaemic 
cardiomyopathy following myocardial revascularlsation (both 
mechanical or surgical) have been investigated in few studies, .afld 
among these the majority were undertakefl many years ago when 
technoiogical and medica! treatments were different from the ones 
available at the present time (Table 5)::..11• 
Technical advances in the field of interventloflal cardiology with the 
Introduction of coronary stents and potent antlplatelet therapies 
have resulted in a marked increase If! the complexity of procedures 
and expaflded indications, even in patients considered as high-risk, 
like those included in the present study. One of the striking findings 
of this study is the safety of PCI as well as the favourable loflg term 
outcome in patients with severe left ventricular dysfunction due to 
coronary artery disease. This is in contrast with the data recently 
reported by Keelan at al from the DYNAMIC Registry12 where there 
was an observed increased in-hospital MACE (including mortality) 
in patients with left ventricular ejection fraction < 40 undergoing 
PCI. This discrepancy might be due to several factors: the Registry 
included patients recruited in 10 different sites, GP lib/Ilia inhibitors 
were used in only 24% of patients and it was not mentioned if Intra-
aortic balloon contra-pulsation was used while in the present study 
Table 5. Long-tenn clinical follow-up (range: 22 to 39 months; 
mean•Z8±6 months). 
Clinical follow-up: range 18 til 34 months (mean 25 ±6 months) 
Number of patients 75 
Death 9 (11.8%) 
Cardiac 7 (9.2"/o) 
Non-cardiac 2 (2.6%) 
Recurrent symptoms 
Angina 
Non Q-AMI 
Q-AMI 
CHF 
Repeat revascularisation 
RE·PCI 
CABG 
Total MACE during follow-up 
Event-free survival 
Total survival 
28 
16 
3 
' 7 
21 
19 
2 
34 
42 
67 
(36.8%) 
(21%) 
(3.9%) 
(2,6%) 
(9.2"/o) 
(27.6%) 
(45%) 
(55%) 
(88.2%) 
CABG: coronary artery bypass grafting; AMI: acute myoCJrdial infarction; 
CHF: C<lrtHac heart failure; Re-PCI: repeat perctrtancous coronal)' 
intciYcntions 
llblllla iflhibitors were used in all patients and in almost half of 
patients intra-aortic balloon contra-pulsation was employed during 
the procedure. 
Medical treatment for patleflts with severe left ventricu~ar function 
and coronary artery disease is associated with poor prognosis. 
Luciani and colleagt.Jes reported 28%, five year survfval in 72 patients 
with an average EF of 21%4• However, medical treatment have also 
been markedly improved over the last decade. Although many 
questions remain in attempting to optimise the management for 
these patients, myocardial revascularisatlon seems to offer some 
advantages. 
The BAR I study showed a seven year survival after PTCA in patients 
with reduced left ventricular function {EF<50%) and two vessel 
disease of 78%:3. The same study provided evidence that there was 
no slgflificant differences in seven year survival in an Initial strategy 
of PTCA or CABG among f!On-diabetic patients with three-vesse! 
disease, and among all patients with two-vessel disease involving 
the proximal left anterior descendent artery. The authors suggested 
that PTCA may be offered to such patients as an initial 
revascularisation without compromising the seven year survival. 
Hasdai and colleagues, reported among 611 patients undergoing 
PCI a higher 10 year mortality in patients with left ventricular 
dysfunction {EF<40%) compared to those with normal systolic 
function {47% vs 20%; P<(),0001)14• 
In a recent study by Ll et aJl$, 74 patients with ejection fraction 
<40% underwent percutaneous coronary aflgloplasty, including 61 
with stent back-up. During long-term follow up {29±23 months), 
58 (87.9%) of 66 patients with clinical success were alive, including 
44 {68.6%) free from cardiac events. In the present study, total 
survival at 25±6 months was 88.2% (with an event-free survival 
55%), similar to that reported in the previous studies, despite 
a more severe left ventricular dysfunction (EF < 30%) than those 
reported in those studiesl:>-15. 
Recent reports suggest that approximately 50% of patients with 
ischaemic cardiomyopathy have viable myocardium, afld 25% of 
these have sufficient amounts of viable myocardium resulting In 
a functional improvement (increased left ventricular ejection fraction, 
increased exercise capacity} following myocardial revascularisationtt.-ls. 
Improved functional status and symptoms after revascularisation, 
evefl with limited preoperative assessmeflt of myocardial viability, 
has beefl reported by Christian et alt7. 
All patients iflcluded in the present study had documented viable 
myocardium, but Oflly 39 patients showed a sigflificant 
improvement of ejection fraction at six months following the 
procedure. Improvement In ieft ventricular function after PCI is an 
Important predictor of long-term outcome. Multivariate analysis 
showed that unchar.ged EF at follow-up was significantly associated 
with Increased cardiac death and MACE. Worsening of left 
ventricular function related to new myocardial damage, either by 
intraprocedural AMI or occurring during follow-up, were also 
significant predictors for death and MACE. Muitivessel PCI as well 
as diffuse disease are often associated with slight increases of 
cardiac enzymes, and this may be the cause of greater occurrence 
of cardiac events in diabetics and In patients with complex lesions 
and side-branch involvement The loss of even small amounts of 
viable myocardium In these patients adds a further myocardial 
damage and might negatively lnfluer.ce long-term clinical outcome 
as shown by multivariate analysis. 
Taking into account these considerations, long-term clinical 
outcome Is acceptable considering the natural history in this patient 
subset. Total survival at> 2 years is excellent, although only SO% 
may bene1lt from PCI procedures with event-free survival. The key 
for a favourable long-term clinical outcome seems to be the 
recovery in left ventricular function, but unfortunately this cannot 
always be predicted by myocardial viability tests. All patients 
included in the present study had positive test, but only 53% had 
improvement of EF. On the other hand, it has been reported that 
myocardial revascularisation might improve functional capacity in 
patients with left ventricular dysfunction and negative myocardial 
viability test:~.20. Incomplete revascularisatiofl was not associated 
'M'th unfavourable outcome. In this series, revasculan'satlon was 
limited to vessels supplying areas with documented viable 
myocardium, thereby suggesting that In most cases an incomplete 
revascularisation may benefit patients with left ventricular 
dysfuflctlon if PCI is performed on the vessel targeted by the viability 
study. Caution should be made ir. patients selectior.; those with 
diffuse and complex coronary lesions are at higher risk for 
procedural compllcatiofls, especially biomarker elevatiofls following 
procedure must be carefully evaluated. Complex procedures 
associated with biomarker elevations might even worsen iong-term 
clinical outcome in these patients. 
Another Important finding of this study is that lor.g-term mortality 
remains high, even after successful coronary intervention. We found 
an overall mortality of 11% at 24 month follow-up, compared to 6% 
in the study by Di Sciascio2:. However, patients In our study had 
more frequent diabetes (28% versus 14%), more prior CABG {23% 
versus 6%), and more multivessel coronary disease (87% versus 
54%}. The mortality of 11% at 24-month follow-up In our study 
compares favourably to the 15-25% mortality rate at two- to three-
year follow-up reported in the angioplasty era. 
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Study limitations 
This is a non-randomised, retrospective, observational study with 
the all the inherent limitations of such a trial. There is no control 
group, however, it is well documeflted that prognosis In this 
subgroup of patients (EF<0.30l is very poor, even over a short time 
period. Event-free survival of 55% after a time period of25±8 months 
could be considered poor, but the main component of major 
cardiac events during the follow up period was recurrence of angina 
and repeat revascularisatlon. It could be speculated that better 
results might be obtained with the use of drug-elutingstents. Finally, 
all patients included in this study were on treatmeflt with ACE-
iflhlbitors, and the majority were also treated with statins {68%) and 
beta blockers {58%}, and this might influence clinical outcome. 
In conclusion, PCI in patients with severe left ventricular dysfur.ction 
and documented viability can be performed with excellent procedurol 
and In-hospital outcome in those patients with severe ischaemlc left 
ventricular dysfunction and evidence of viable myocardium, 
Predictors for unfavourable long-term outcome are represented 
by female geflder, the presence of diabetes, extent of coronary 
disease, lack of recovery in left ventricular function and new episodes 
of myocardial infarction. In some of these patieflts, PCI and repeat 
procedures represent the only therapeutic option. In addition, 
in carefully selected subgroups of patients with severe left ventricular 
dys'tunction and coronary artery disease, PCI may be considered 
as an alternative or a "bridge" approach for cardiac transplantation. 
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Abstract 
The safety of drug-eluting stents (DES) in patients undergoing percutaneous coronary intervention has 
been questioned in several independent meta-analyses (i.e .. systematic reviews of primary research 
studies employing statistical methods to provide pooled estimates) published or presented at the end 
of 2006. Other reviews and meta-analyses have followed in the beginning of 2007, albeit with unclear 
or conflicting results. This article provides a succinct perspective and critical appraisal of recently published 
meta-analyses focusing on DES safety, summarising key features ar.d findings of each work, and 
recommending avenues for further research and practice. 
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Introduction 
The occurrence of several duplicate meta-analyses focusing on the 
same clinical topic, and reaching sometimes frankly disparate 
conclusions, is not a surprise for researchers with a specific 
interest in systematic reviews or meta-analyses, as well as 
evidence-based medicine.1 This issue has however gained much 
larger and clinical implications with the recent publication of 
a plethora of meta-analyses focusing on the lo11g-term safety 
of intracoronary drug-eluting stents (DES). Interestingly, two meta-
atlalyses presented at the 2006 World Congress of Cardiology-,2-3 
both suggesting a potential late hazard with DES, have been 
followed by as ma11y as other eight overlapping works published in 
peer-reviB~Ned journals in less than seven months .... n 
We hereby provide a succinct and critical appraisal of recently 
published meta-analyses focusl11g on DES safety, summarisi11g key 
features and findings of each work, and recommending avenues 
for further research. 
Clinical and research context 
Percuta11eous coronary intervention (PCI) is a mainstay in the 
management of patients with coronary disease. Sir1ce its 
beginning as a balloon-only intervention, PCI vvas revolutionised 
by the introduction of bare-metal stentsP Whiie addressing many 
of the drawbacks of balloon-only PCI (e.g., abrupt closure), 
standard ster1ts are fraught by a significant risk of late failure due to 
neoi11timal hyperplasia and e11suing reste11osis, especially in small 
vessels and lo11g-lesions.13 The most rece11t development of DES 
has enabled us to address the problem of neolntimal hyperplasia, 
without sacrifici11g the mechanical properties of the metallic 
platform. 
Despite several promising data limited to short term follow-up14 or 
low risk patients, 1~ since 2004 a number of reports were published 
suggesting a pote11tial for late adverse events with DES.1"":7 Thus, 
it was only a matter of time before investigators with expertise 
in systematic reviewing processes and meta-analytic pooling wou!d 
exploit the superior statistical power of these approaches to 
unmask the long-term Increase in the risk of thrombotic events 
with DES. 
Further contributions to this research topic have been recently 
provided by the consensus Academic Research Consortium (ARC) 
definitions of defir1ite, probable, or possible stent thrombosis.l8 
However, even in the ARC context there Is still a risk of underesti-
mating thrombotic events if adjudication is based only on angiography 
or pathology, and conversely, overestimating thrombosis rates 
if myocardial infarction and sudden cardiac death are considered 
as a proxy for ster1t thrombosis. 
While there is little debate that DES increase in a statistically 
significant fashion the risk of protocol-defined stent thrombosis 
after dual antiplatelet discontinuation, the most important question 
is whether this risk is magnified as much as to become clinically 
relevant. We leave such a topic open to the discussion and 
informed decision of the reader, as this was indeed the main focus 
of all the meta-analyses recently published on DES, whose fi11dings 
on the risk of stent thrombosis, as well as of other events, are 
summarised ir1 Table 1. 
Critical appraisal of available meta-analyses 
Keeping in mind the guidelines from the Cochrane Collaboration, 19 
the Quality of Reporting of Meta-analyses (QUOROM) statement,<o 
and the Oxman-Guyatt index,1 we recognised a number of 
limitations ir1 the available DES meta-analyses. Indeed, a pivotal 
distinction should be made between meta-analyses based only on 
published ancl/or aggregate data, and thus limited in their ability to 
correct for incomplete or inaccurate data, and meta-analyses using 
data gathered at the patient or lesion level. in which all data sets 
from individual studies are pooled into a single data set, enhancing 
coherence ar~d quality, and enabling sophisticated subgroup or 
multivariable analyses.21 Corwersely, the latter type of works is 
most often limited by a smalier number of studies, thus potentially 
Increasing the risk of small study (e.g., publication) bias. 
Appraisal of recent meta-analyses on DES thus showed, as is 
commonplace In meta-analytic practice, that individual patient 
data analyses-1·7•11 were often limited by incomplete study search 
and inclusion (thus increasing the risk of small study bias), despite 
bei11g more intemally valid than study level analyses,2·5-6 thanks to 
thorough event adjudication, data checking and time-to-event 
analysis. Another work, despite beir1g originally proposed as a 
meta-analysis, was recently published as a systematic review, 
including raw quantitative data, but failing to present 
conventio11ally pooled data.3 The reasons for refraining from meta-
analytic pooling in this case were not reported. 
In addition, most works limited their adjudication of stent 
thrombosis to the protocol definition, which often proves different 
from study to study, and usually underestimates the real 
occurrence of this event. Only two of the meta-a11alyses 
systematically employed the recently developed ARC definitions of 
stent thrombosis, thus providing more i11formative data on its 
occurrence.s,:o On the other hand, the ARC criteria now include as 
well thrombotic events occurring after repeated treatment for 
restenosis ("secondary stent thrombosis"). This may be 
appropriate if repeat Intervention is performed with balloons or 
stents. Conversely, including ever~ts that occur after a well known 
pro~thrombotic therapy such as brachytherapy may be 
misleading.8.1° 
Finally, only one of the works was published by investigators 
without any evident financial or fundir1g interest in DES,2 as 
recommended by the Cochrane Collaboration and others.t9.22 
Synthesis and recommendations 
First, we should remember that no clinical trial to date was 
adequately powered for the appraisal of stent thrombosis, and in 
no case was this event the primary end-point. Thus, all 
speculations have been based on secondary and/or post-hoc 
analyses. Nominally statistical significant findings (p <0.05) were 
indeed found in some. but not all analyses, raising the issue of 
alpha error (the risk of false positive statistical tests due to the 
performance of many comparisons and sub-analyses). Similarly, 
no study to date was adequately powered (i.e., with a sample size 
sufficiently large to minimise beta error [the risk false negative 
findings]) to be able to confirm or disprove, in a precise and 
accurate fashiorJ, whether DES are associated with an increased 
SafetyofDES 1149 
review 
Table 1. Maln features and appraisal of recently published meta·analyses on the safety of drug-eluting stents (DES) in comparison to bare-
metal stents (BMS). Despite the heterogeneous findings. most meta..analyses cautioned that DES are associated with an increased risk in 
protocol~efined stent thrombosis, and that sirolimus.-eluting stents (SES) seem to be associated with increased mortality in diabetic 
J)<ltients. Conversely, thrombosis as defined by the Academic Research Consortium aiteria {ARC), i.e., including secondary stentthrombosis, 
does not seem to be more common in DES than BMS. 
Stiidy',::"W'>> TrialS: PitieritS _Miijoi'JinCiiiigs:·: _Criticiitili)pr.iiSal ' 
Bavry et al 14 5,575 DES are associated with an increase Pros: extensive search; inclusion of most eligible trials; increased 
{2005)~ in late stent thrombosis after 6 months late thrombotic risk also supported by different median times 
(p..0.014), even more evident after to thrombosis (P <0.05 for SES, PES, as well as both combined) 
1 year, with events occuning only Cons; only aggregate data J)!Joled; no appraisal of study quality; 
in the DES group, with an effect larger no appraisal of stent thrombosis according to ARC definitions; 
in PES (p-0.025) than SES (p-0.33) non-significance of data on SES largely explained by low statistical 
power 
camenzind et 5,218 First·generation DES appear associated Pros: long·term foUow·up; systematic contact with primary data 
al {2007)l with an increased lisk in late stent sources {companies); comparison between data presented 
thrombosis or death/myocardial at conference proceedings, peer reviewed, and on file 
infarction Cons: not formally a systematic review nor a meta-analysis; 
incomplete search and study inclusion;~ limited data on providers 
of source data; only aggregate data pooled; no appraisal of stent 
thrombosis according to ARC definitions: con~pt that late loss 
and thrombosis risk are inversely associated is only theoretical and 
not evidence-based; ZS no confidence intervals or p values 
reported despite availability of quantitative data 
Ellis et at 4 3,445 PES are associated with increased risk Pros: individual patient data analysis; long-tenn follow-up 
(2007)1 of stent thrombosis >6 months (p-D.049) Cons: incomplete search and study inclusion;~ no appraisal of 
stent thrombosis according to ARC definitions; data limited to PES 
Holmes et at 4 1,748 SES are not significantly a$SOciated with Pros: individual patient data analysis; long-term follow-up 
(2006)4 increased risks of all cause death, cardiac Cons: incomplete search and study inclusion;• no appraisal 
death or stent thrombosis of stent thrombosis according to ARC definitions; no separate 
appraisal of outcomes in diabetics; data limited to SES 
Kastrati et al 14 4,958 SES are overall safe ;md more effective Pros; extensive search; inclusion of most eligible trials; individual 
(2007)ll than BMS in preventing TLR and MACE.- patient data analysis 
but there is slight but significant Cons: no appraisal of stent thrombosis according to ARC 
increase in stent thrombosis after the definitions; no separate appraisal of outcomes in diabetics; 
first year (p-0.02) data limited to SES 
Mauri etal 4,545 DES are not significantly associated with Pros: systematic re-adjudication of events according to ARC 
(2007)10 increased risks of definite, probable definitions; individual patient data analysis; long-tenn follow-up 
or possible stent thrombosis as defined Cons; incomplete search and study inclusion;~ 27% (9/33) of stent 
according to ARC thromboses rc-adjudicated according to ARC definitions in BMS 
group occurred indeed after brachytherapy 
Moreno et al 25 9,791 DES are a$SOciated with fewer myocardial Pros: extensive search; inclusion of most eligible trials 
(2007) 0 infurctions than BMS at 5·12 months Cons: mid·tenn follow-up only; only aggregate data pooled; no 
of follow-up ())={l.03) appraisal of study quality; among DES included also those eluting 
biolimus, everolimus, and tacrolimus; no adjustment for different 
duration of thienopyridine treatment 
Nordmann et 17 8,221 DES are associated with an increased risk Pros: extensive search; inclusion of most eligible trials; lack 
al (20D6)l in non-cardiac death after 2·3 years, an of confl.icts of interest 
effect largely driven by SES (p--0.014) Cons: only aggregate data pooled; no separate appraisal 
of outcomes in diabetics 
Spaulding et al 4 1,748 SES are a$SOciated with an increased risk Pros: individual patient data analysis; long-tenn follow-up; 
(2007)" of death in diabetics (p..Q.008), while separate analysis according to diabetic status; systematic 
rates of death in non·diabetics, and re-adjudication of events according to ARC definitions; 
of myocardial infarction and stent Cons; incomplete search and study inclusion;"' 33% (5/15) of stent 
thrombosis overall are similar in SES thromboses re-adjudicated according to ARC definitions in BMS 
and BMS group occurred indeed after brachytherapy; data limited to SES 
Stone et al 5,251 DES are associated with an increased risk Pros; individual patient data analysis: long-term follow-up; 
(2007)~ of stent thrombosis >1 year (p<0,05), Cons: incomplete search and study inclusion;• no appraisal 
while rates of death or myocardial of stent thrombosis according to ARC definitions; no separate 
infarction are similar in DES and BMS appraisal of outcomes in diabetics 
~this refers to search Mtegies or inclusion criteria inappropriately limiting the number of included studies (e.g., including only studies with follow·UP 
>3 yeJrs [thus excluding those with follow-up <3 years] but willing, nonetheless, to provide precise quantitative synthesis for mid-term events; 
MAC&-major adverse Clrdiovascular events; PES-pJclitaxel-eluting stents; TLR~tlrget lesion revasc:ularisation 
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risk of thrombosis. This fact is also a clear reminder that statistical 
sigrlifica11ce stemmi11g from u11derpowered trials may 11ot tra11slate 
i11to cli11ically sig11ifica11t fi11di11gs. 
Most meta-analyses cautio11ed that DES are associated with a11 
i11creased risk in protocoi.(Jeflned ste11t thrombosis, a11d that 
sirolimus-eluti11g stents {SESJ seem to be associated with i11creased 
mortality In diabetic patie11ts. Corwersely, ARC.(Jeflned thrombosis 
does 11ot seem to be more common i11 DES tha11 BMS. However, the 
ARC decision to include secondary stent thromboses {i.e., those 
occurring after repeat intervention, even brachytherapy), while 
correct accordl11g to the i11tentlo11-to-treat pri11ciple. remai11s ope11 
to discussion and can be misleading in a setting where the primary 
goal is to u11derstat1d the pathophysiological substrate of a potentfally 
ominous event such as very late stent thrombosis. 
Several practical actions can be recommended, and to this end we 
borrow recommendatio11s from other colleagues to indivldua!ise 
patient management, including indications to percutaneous 
revascularisation vs surgery or medical therapy only, as well 
as indications toward a specific coronary device.23 
In addition, and focusing more on the evident discrepancies 
or redundar~cles in the current DES literature, we would like to 
stress that irl the future the following should be addressed: 
- A more thorough comparison of per-protocol and ARC-defined 
stent thrombosis events, which includes reasons for 
discrepancies: 
- A more thorough appraisal of the risks and benefits of DES 
{especially with SES} in diabetic vs 11on-diabetlc patients; 
- Strive for a unique, unanimous, collaborative, cumulative, 
prospectively planned and designed systematic review and 
individual patient data meta-aflalysis on DES similar to the or1e 
produced by the Antiplatelet Trialists' Collaboration.24 
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Abstract 
Ai~ Percutaneous coronary interventions (PCI) in high-risk cardiac patients are preferentially referred to 
specialised myocardial intervention centres (MIC). Included In this group are patients with a 
haemodynamlc collapse or high likelihood of haemodynamic collapse, either during balioon inflation or 
with acute vessel closure. The TandemHea~, a percutaneous transseptalleft ventricular assist (PTVA®J 
that can be introduced using standard catheterisationlaboratory techniques, offers Interesting perspectives 
to reduce procedural risks. 
Methods and results: Between September 2000 to July 2006, The TandemHeaft®, supported the 
circulation of 23 patients (age: range 46-74, mean 59) admitted to our centre for high risk, either 
emergency or elective, PC I. Successful implantation was achieved in 100% of patients. The mean time for 
implementation of circulatory support was 35 minutes (range 16-62). The index PCI was successful In all 
patients except tvo. A pump flow up to 4Umin was achieved with significant reduction of left ventricular 
filling pressures, pulmonary capillary wedge pressure and with significant increase of systemic arterial 
pressures. Duration of support ranged from 1-222 hours (mean 31±49,8 hours). Five patients died with the 
TandemHeartll' in place, four of whom were in Irreversible cardiogenic shock at admission. Mild to 
moderate access site bleeding was seen in 27% of patients. One patient experienced a loge syndrome of 
the leg. Core temperature (Ct) decreased to <.36.5°C in six patients, profound hypothermia (Ct < 35°C) was 
observed in tva patients. There was no technical device failure. 
Conclusions: The Tandem Heart®- PTVA® provides effective, total left ventricular support in very high risk 
PCI settings. The rate of device related cardiac and vascular complications was acceptable. 
• Corresponding author: Opt. of lnterventional Cardiology, Thoraxcenter, Ba583a, E!asmus Medical Centre, Dr. Molewaterplein 40, 3015 GO 
Rotterdam, The Netherlands 
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Introduction 
With increasing operator experience, refinement in technology and 
adjunctive pharmacological treatment, percutaneous coronary 
intervention (PCI) is now considered the treatment of choice for 
many high-risk subgroups In which PCI was previously contra-
indicated. PCI may even be a valuab:e option for those patients 
where coronary bypass grafting (CABGJ is clinically contra-
indicated1-3. Many of these procedures are elective. 
In general the benefits of a specific (percutaneous) procedure 
should be weighed against the risks involved; taking into account 
alternative treatment strategies, the interventional and intensive 
care team experlence4 and taking in consideration the individual 
patient risK scores, that may aid the operator In selecting or avoiding 
adjunctive pharmacotherapy or specific devices""9. 
Patients in whom it is considered that PCI poses a significantly high 
risk include these with high likelihood of haemoc!ynamic collapse, 
either during balloon inflation or with acute vessel closure4. In 
genera!, these are the patients in whom a large amount of the viable 
myocardium is supplied directly or indirectly by the affected artery. 
The development of a percutaneous ventricular assist device [VAD) 
that could be easily and quick!y Inserted prophylactically or in case 
of an haemodynamic collapse proves invaluable in this setting. 
The TandemHeaft®, a percutaneous transseptGll left ventricular 
assist device (PTVAI1P) system {CardiacAssist Inc., Pittsburgh, PA, 
USA), has been demonstrated to effectively reverse cardiogenic 
shock after myocardial infarction11 and to play an important role for 
bridging to another definitive therapy12• This system allows for rapid 
implementation of circulatory support using standard interventional 
techniques in the catheterisation laboratory and is designed to 
deliver up to 4.51itres of blood flow per minute. In this report, we will 
report on a single centre six year clinical experience with the 
TandemHea~ In high risk PCI procedures. 
Methods 
Patients selection 
Since 2000, the Thoraxcenter, Erasmus University Medical Centre, 
Rotterdam, The Netherlands started a program evaluating 
percutaneous left ventricular assist devices (LVAD) during high risk 
PCI. Betvveen September 2000 to July 2006, twenty-three patients 
admitted to our centre for acute coronary syndromes (ACS)/ ST 
segment elevation myocardial infarction (STEM I) or for elective PC I, 
were treated with TandemHea~. 
In non-elective patients, the inCicatlon for TandemHeaft® support 
was based on already established haemodynamic instability before 
the index PCI procedure, de~ned as typically with low cardiac 
output (cardiac index < 2.2 Vmln/m2J, peripheral signs of tissue 
hypopetiusion (decreased urine output and/or cold extremities), 
systemic hypotension (systolic blood pressure < 100 mmHg) 
despite vasopressor therapy and in the preser.ce of appropriate left 
ventricular filling pressures (pulmonary capillary wedge pressure, 
PCWP 2:15 mmHg). In case of presence of an intra aortic balloon 
pump (IABP) haemodynamic measurements were done with the 
IABP paused for 60 seconds. 
In patients who underwent elective PCI, circulatory assist was 
indicated in procedures which had a presumed high risk of 
ischaemic/haemodynamic complications, based on the preser.ce of 
severely depressed lett ventricular (LV) function and planned 
treatment of ~ one complex lesions in vessels supplying a large 
amount of myocardium. CABG was not considered a treatment 
option in any of these patients. Major exclusion criteria were 
predominant right ventricular failure requiring right ventricular 
support, severe aortic insufficiency, severe sepsis and anoxic brain 
damage. 
System description 
The TandemHeaJi® PTVAI1P (Figure 1-2) incorporates arterial 
perfusion cannula configurations ranging from 9 to 17 Fr, an unique 
21 Fr venous transseptal cannula, and a centrifugal blood pump. 
Oxygenated blood from the patient's left atrium is supplied to the 
pump by the trans-septal cannula and than returned to the patient's 
systemic arterial circulation. The centrifugal pump contains a single 
moving part (rotor/impeller) that is suspended by a thin lubricating 
film of fluid to reduce heat and friction, thereby reducing the risk of 
thrombus formation. The pump connects to a microprocessor-
based controller that displays PTVA speed and flow. These 
parameters are controlled by adjustment of a single knob. The 
controller also provides automatic system monitoring and alarms 
indicating conditions that require action. The system is designed to 
deliver up to 4.5-5 litres (L) of blood flow per minute, depending on 
the size of the arterial cannulation and the filling conditions of the 
left atrium, while operating at a relatively low speed (7500 
revolutions per minute, RPM). 
Figure 1. Schematic of the system deployed. The Tandemhea~ 
removes oxygenated blood from the left atrium via a 21 Fr transseptal 
cannula that is advanced from the femoral vein trough the inter-aflial 
septum into the left aflium (A). The oxygenated blood is returned into 
the arterial vascular system via a 15 up to 17 Fr arterial cannula by 
means of a cenflifugal pump (B). The cenflifuga/ pump contains 
a single moving part (rotorlimpe/fer) that is suspended by magnetic 
force on a thin lubricating film of fluid to reduce heat and friction 
thereby reducing the risk of thrombus formation. ' 
Figure 2. Microprocessor-based controlfer used in this series (A) 
displaying PTVA speed and flow. These parameters are controlled by 
adjustment of a single knob. The controller includes extensive self-
diagnostic and alarm features to ensure patierrt support without the 
need for constant operator surve!l!ance. Panel (8) shows the recently 
infloduced Escort Confloller. This light (21 pound or 9.53 kg) weight 
controller can be mounted at the patient's bedside and includes an 
easy-load infusion system. The fatter allows the lubrication fluid 
infusion lfne to be installed in seconds. 
Insertion technique 
A standard transseptal puncture technique, using an Inoue 
guidewire, was used to gain access into the left atrium from the right 
femoral vein. Transseptal puncture was carried out by an 
experienced operator only. The inter-atrial septum was dilated with 
an 2-stage 14121 Fr dilator and the venous inflow cannula was 
inserted (proper positioning In the left atrium was checked by either 
angiography and/or transesophageal echocardlography). One 15 Fr 
or 17 Fr perfusion catheter (Bio-medicus cannula, Medtronic, 
Minneapolis, MN, USA) was Inserted into the femoral artery and 
advanced to the common iliac artery. An ileac angiography was 
performed before the placement of the perfusion catheter to 
delineate the arterial anatomy and size and to disclose eventual 
luminal obstructions. In three patients a dual femoral approach with 
Y connection was used for arterial access. Both arterial and vertous 
canrtula were fixed to the skin with multiple sutures in order to 
secure the'1r positiort. The pump was placed on the upper leg of the 
patient. After checking the central venous pressure, priming and 
cautious de-airing of the entire system, the arterial and venous 
cannulas sets were connected to the pump by a heparin-coated 
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tygon tubing (up to 30 em length) and the pump was activated to Its 
maximum rotation speed. Output pump flow was measured by an 
external electromagnetic flow meter (HT 311, transonic). 
Device weaning and removal 
A predefined wean\ng protocol was initiated at the moment 
vasoactive drugs were reduced to a stable minimal level (dobutamine 
up to 4 ~gtkg/min., norepinephrine up to 0.1 4 ~gtkg/min.) provided 
stable haemocfynamic parameters (mixed venous or central venous 
saturation > 65%). A stepwise reduction of pump assist was 
performed, by reducing pump speed from 7500 to 3500 RPM (steps 
of 500-1,000 mUmin), adapted to the medical condition of each 
patiertt individually. The final removal decision was based on medical 
judgement A weanirtg period up to six months was respected for 
most patients. The pump was not stopped until immediately before 
removaL No specific instructions on access site closure were issued. 
Concomitant treatment 
The Index coronary intervention was performed after TandemHeaft® 
implantation and functioning. Arterial access was obtairted via the 
contra-lateral femoral artery and the interventional strategy was left 
to the operator, according to standard techniques. Standard 
Intensive care was provided to each patient. Patient sedat'1on and 
intubation was considered for clinical and/or comfort reasons. 
A balloon tipped pulmonary artery (PAl catheter was placed via the 
contra lateral femoral vein for haemodynamic monltor'1ng purposes 
If clinically indicated. cardiac output determinations were made 
using standard thermodilution techniques. 
During the index procedure, a constant flow (10 mllhl of heparinised 
infusate is maintained providing a localised concentration of 
heparin In the irtterior of the pump in order to obtain localised anti-
coagulation thereby minimising systemic heparlnisation, the risk of 
bleeding and thrombus formation. Additional boluses of heparin 
were administered peripherally to maintain the activated 
coagulation time to approximately 200 seconds during routine 
support (400 seconds durirtg insertion) or an activated partial 
thromboplastin time of between 65 and 80 seconds. 
Predefined safety endpoints and time periods 
The following predefined clinical events related to the LISe cf tile 
TandemHeaft® were assessed in each patient: any minor or majorTIMI 
bleeding9, laceration of the insertion vesselilimb ischaemia, device 
rejated tllromboembolic events. infective complications, residual atrial 
septum defect after device removal, device malfunctiort or failure. 
The Insertion time was de1lned as the time from providing of the 
Brockenbrough needle to the 'full' heparinlsation following connection 
of the femoral cannula to the pump. The duration of support was 
defined as the time from 'full' heparinisation at time of connection to 
the pump till t~e removal of the femoral cannula. 
Statistical analysis 
Variables with normal distribution were analysed using parametric 
tests while variables with a nort-normal distribution were analysed 
with non-parametric tests. Continuous variables are expressed as 
mean ±SD or median ±SO and differences are compared using 
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Student t test or Mann Whitney test Categorical variables are 
expressed as counts and percentages. Differences were assessed 
by Fisher exact test or chi-square test, as appropriate. All analyses 
were performed using SPSS version 12 statistical software (SPSS 
Inc., Chicago, IL, USA). A two-tailed p value< 0.05 was considered 
significant for hypothesis testing. 
Results 
Baseline characteristics 
Baseline clinical and procedural characteristics are listed in Table 1. 
Mean age was 59 ± 9.4 years, 19 patients (83%) were men. The 
eject1'on fraction was <30% in 16 pab'ents (70%). Fifu::en patients 
(65%) suffered a three vessel disease, six of whom with left main 
involvement. The indications for TandemHearJ:® support were 
elective/high risk PCIIn 15 patients and non-elective (emergency) 
In eight patients with ACS and acute heart failure. Eight pat~ents 
experienced an evolving(< 36 hours) myocardial Infarction, five of 
which were complicated by acute heart falluretcardiogenic shock 
(CS). Eight patients needed Intubation and mechanical ventilation 
as part of their medical treatment and 11 were on inotropic support 
at the start of the implant procedure. Standard EuroScore In our 
pab'ents ranged between 2 and 14 (mean 6.5) providing a surgical 
risk of mortality between 1.5% and 46.6% (mean: 11.3±11.6%). 
Very high risk patients (EuroScore > 9) were nine:3• 
Haemodynamic effects 
The TandemHeart® showed good performance, achieving flow rates 
up to 4.0 Umin. Mean systemic arterial pressure was 74.8±18 mmHg 
at baseline and 85.6±19 mmHgafter pump functioning (p"' 0.023). 
Table 1. Baseline characteristics; n (%) 
Age (mean±SD) 
"" 
Previous MI 
Previous CABG 
Clinical presentation 
CAD extension {23 pts) 
EF 
Indication for PTVA 
Intubation 
Inotropic support 
EuroScore (mean±SD) 
M 
F 
STEMI&CS 
STEM! 
NSTEMI 
UA 
Angina/dyspnea 
Scheduled PO 
lVO 
2VO 
3VO 
3VD + lM 
<20% 
20·30% 
30-50% 
>50% 
elective 
emergency 
HRP (=-6) 
VHRP {:>9) 
59±9.4 
19 (82.6) 
4 (17.4) 
11 (47.8) 
4 (17.4) 
5 (21.7) 
3 (13) 
1 {4.3) 
5 {21.7) 
8 {3.4.7) 
1 (4.3) 
3 (13) 
5 {21.7) 
9 {39.1) 
6 (26) 
11 {47.8) 
5 {21.7) 
3 {13) 
4 {17.4) 
15 (65.2) 
8 (34.7) 
8 {34.7) 
11 (47.8) 
6.5±3.4 
3 (13) 
9 (39.1) 
Pulmonary wedge pressure was 16.8±5.6 mmHg at baseline and 
13.6±6 after pump functioning (p, 0.002). The pulse pressure was 
reduced on support from 39.7±17.7 to 31.5±17 (p<0.001) 
(Table 2). In two patients the Initial period after implantation of the 
TandemHeaft® was characterised by a complete non- pulsatile 
arterial blood pressure (pulse pressure < 7 mmHg). In one patient 
with the recovery of the heart function < 24 hours after 
implantation, Increasing pulse pressures became evident. 
Modulation of pulsatllity with low amplitude to the non-pulsatile 
blood flow produced by the PTVA could be achieved by varying 
pump flow. One patient did not show recovery of pulsatile blood flow 
and he died with the TandemHeaft® in situ. 
Table 2. Hemodynamic effects of PTVA. 
. ·-- ·<"~·· "-· "_"]3asilfilei "_~J~JYA' 
MSBP (mean±SD) 
Pulse P (mean±SD) 
PCWP {mean±SD) 
74.8±18 
39.7±17.7 
16.8±5.6 
85.6±19 
31.5±17 
13.6±6 
0,023 
0,001 
0,002 
A pulmonary artery catheter was inserted in 20 out of 23 patients. The 
hemodynamic measurements reported were immediately before Tandem 
Hea~ insertion and at the end of the PCI procedure (before the patient 
was tr.lnsferred to the cardiac intensive care department) 
Procedural and clinical outcomes 
Procedural and clinical outcomes are summarised in Table 3. 
lndex-PCI procedural success was achieved in 42 lesions (96%). 
A total of 441esions were treated {one up to four lesions per patient), 
all including stent implantation (mean stent per patient rate: 2.3). 
The mean time for insertion of the TandemHeaft® was 34±12 
minutes {range 16-62), the procedural success was 100%. The 
circulatory assist period ranged from 1h to 222h, mean 31±49.8h 
One patient with a severe femoral artery stenosis needed PTA a11d 
stentlng of the Iliac artery vessel prior to ca11nulab'on. 
Seventeen patients were successfully weaned from the 
TandemHeaft®. In-hospital death occurred In six patients. In total 
five patients died with the device in situ, four of which were 
considered in irreversible CS at admission. Another patient admitted 
for CS was initially stabilised after 222 hours 011 TandemHeaft® 
Table 3. 
PCl Results; n {%) 
PCI success rate 
Number of treated lesions 
Stent per patient 
PTVA Insertion success rate 
PTVA Insertion Time (mean±SD) 
Assist period, hours (rangejmean:tSD) 
Death In hospital 
with PTVA in place 
at 6 months FU 
at 12 months FU 
at 2 years 
at 5 years 
* 4/5 patients suffered cardiogenic shock 
96"/o 
44 
2,3 
100"/o 
34±12 
1·222/31±49.8 
6 {26) 
5* {22) 
9 (39) 
10 (43) 
11 {47) 
11 (47) 
support. However, this patient developed abrupt circulatory failure 
after removal of the pump and died a few hours later. No further 
invasive treatment was possible due to the abrupt worsening of his 
clinical condition. During the follow-up period, three patients were 
lost and one patient died due to progressive heart failure <30 days. 
An uneventful six months follow-up was observed In 13 patients. 
Complications 
Potential compllcat'ions related with the LlS0 of Tandem Heart® are 
summarised in Table 4. In this series of patients, no procedural 
complications during device insertion were noted and no cardiac 
tamponade, thromboembolic events nor device failure occurred. In 
two elective cases (8.7%) the weaning needed to be postponed due 
to the occurrence of profound hypothermia (core temperature 
32.7 oc ar1d 34.2 °C} and the r1eed for active re-warming. Mir~or to 
mild access site bleedlr~g complicatior'!s occurred in 26% of 
TabLe 4. Potential complications of PTVA; n(%) 
Puncture of aortic root coronary sinus, posterior free waU 0 (0) 
TandemHeart pVAD system failure 0 (O) 
Thromboembolism 0 (0) 
Neurologic dysfunction 0 (0) 
Hemolysis o (0) 
cardiac tamponade 0 (0) 
Deep venous thrombosis 0 (O) 
Arrhythmias o (0) 
Systemic hypothermia (35-36.5) 4 (17.4) 
Profound hypotermia (<35) 2 (8.7) 
Bleeding 6 (26) 
cannulation site infection 
cannula dislogment 
Distal leg ischaemia 
Total no. of events 
TabLe 5. Exclusion criteria for this study were: 
0 
1 (4.3) 
13 
- Participation in another trial with an investigational drug/ device 
during the last 60 days 
- Concomitant disease that interferes with the prognosis, 
- Contra indications to standard drugs for coronal)' intervention and 
coronal)' heart disease. 
- Coagulopathy-chronic anticoagulant therapy j uncontrolled active 
bleeding. 
- CNS damage resulting in fixed dilated pupils not related to 
pharmacologies, 
- Severe aortic/mitral valve stenosis, significant aortic valve 
insufficiency. 
- Rupture of the ventricular wall 
- Right heart failure, define<! as the need of a right ventricular 
assist device. 
- Severe peripheral vascular disease (e.g, aorta-iliac occlusive disease). 
- Stroke of haemorrhagic or unknown origin 
- Non-haemorrhagic stroke, that took place within the past 30 days 
- A transient ischaemic atl:<1ck, that took place within the past 30 days, 
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patients (n-=6), rtone required specific treatment. Lower limb 
ischaemia complicated by a loge syndrome occurred in one patient 
with pre-existing severe periphernl vascular disease. This patient 
needed a fasciotomy. Dislocation of the venous cannula occurred In 
one patient and required pump removaL 
Most pumps were surgically removed in the operation theatre 
(no:::l2, 52%). A closure device (Prostar) failed to close completely 
the puncture site in two out of three attempts. A local compression 
device (Femostop, Rad't) was used successfully in these patiertts as 
well as in three others without any complication. 
Discussion 
PCI in high-risk coronary patie11ts with (potential) haemodynamic 
compromise Is challenging and may be considered a special 
dimension of MICl4 • Active circulatory support using VAD 
constitutes a valuable safeguard to reduce potential fatal 
i11tervention-related complicatiotls in this setting and is nowadays 
considered part of the current therapeutic armamentarium. 
IABP 'ts curre11tly the most widespread mechanical device used to 
support and to improve corortary perfusion in patients with acute 
heart failure. IABP implantation is easy and its use is safe and 
associated with a low inclder1ce of ser'tous complications. IABP may 
provide a lot of diastolic augmentation of coronary flow in patients in 
shock, however only limited forward output augmentation (up to 
about 0.5 Umln). This level of support has been shown to be 
scarcely able to Improve clinical outcomes ir1 the setting of complete 
hemodynamic collapsels. 
Active circulatory support using VAD combines the be11eflcial effects 
of the myocardial unloading and an increase in tissue perfusion 
pressure. Theoretically, this technique should also allow very early 
decompression ("unloading") of the left ventricle in massive 
myocardial infarction, thus enhancing the chances of recovel)' of 
the jeopardised ischemic non-infarcted areas16• In animal models, 
LV unloading prior to revascularisatior'l of the infarcted artery led to 
significant myocardial salvage in comparison to the implementation 
of unloading after reperiusion 17• A trial testing this concept, 
including one patient reported In this series, was stopped early due 
to poor recruitment. However, the concept could nicely be 
illustrated by echo contrast Imaging i11 one of our patients 
(Figure 3). Our data confirmed that TandemHeaft® support was 
associated with significant decreases In left ver~tricular filling 
pressures, mean systortc blood pressure and arterial pressures. The 
blood flow, up to 4.5 Umin, provided by the device may be 
sufficient to both optimally unload the LV and to prevent and even 
reverse organ dysfunction in cardiogenic shock patientsll·18• 
Patient selection Is the single most crucial factor in determining a 
successful outcome in patients who receive tempornry mechanical 
circulatory support Rapid diagnosis ar1d treatment are essential but 
are often based on limited information. The patient's history and 
overali clinical setting should be considered in the decision process to 
initiate circulatory support A pulmonary-catheter was used in the 
majority of the patients as adequate left ventricular filling conditions 
are essential for proper functioning of (preload to) the device. 
Haemodynamic data, including mixed (or central) venous oxygen 
saturation, may help to guide the overall patient select'ton, the 
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Figure 3. Echocardiographic contrast perfusion images in a patient on Tandemheart(r) circulatory support. PJnel A: low circulatory support (high 
wall tension, poor myocardial perfusion, contrast remains in the ventricle cavity). Panel 8: Full circulatory support with effective unloading of the 
left ventricle (low wall tension, good myocardial perfusion). 
management ar~d poter~ttal weaning decisions. lr~ our series fwe 
patier~ts died while on TandemHeafi:® support, four were ir~ profound 
CS at the time of treatment initiation. Patients beyond the 'irreversible 
edge' of CS prove bad candidates for this technique in this and other 
series11• Of interest, only three out of the successfully weaned patients 
(no:ol7l deceased during the FU period, suggesting this device may 
have a tangible impact on the long-term survival as well. 
The TandemHeafi:® can be used prophylactically and in bal1-out 
situations. In experienced hands cardiovascular support can be 
implemented in less thar~ 35 minutes. The most important 
drawback of the technique may be the difficulty of cannula 
insertion. Substantial atherosclerotic changes in the iliac artery and 
the consequent peripheral vascular disease are most common in 
the group of coronary patients who most benefit from the effects of 
the pump. In this series, a total number of 13 device-related in-
hospital adverse events rate were observed, 0.6 events per patient 
Many of them were access site complications. One patient 
developed a loge syndrome requesting a fasciotomy, but no other 
iatrogenic arterial insufficiency was noticed. Mild to moderate groin 
bleeding was encountered in six out of 23 patients (27%}, none 
needing a specific treatment. Most pumps were surgically rem-oved 
in the operation theatre in order to allow optimal local haemostasis 
and proper inspection of the cannulation site. A local compression 
or closure device may provide a valuable alternative given a clean 
puncture technique. Access site complications may be minimised 
by prior iliac angiography and by implementing an ultrasound 
guided puncture technique ofthe (common} femoral artery13• When 
necessary, the use of distal perfusion and antegrade cannulation of 
the superficial femoral artery may obviate peripheral vascular 
complications as well. 
As opposed to other modalities of percutaneous cardiopulmonary 
support (CPS} used in this indlcationl9.2°, the TandemHeafi:® 
system keeps the f)<ltlent's lungs as its own ventilator and may be 
used to support patients for a longer period of time without major 
haematological or pulmonary complications (up to 10 days in our 
series}. No thrombi formation was noticed either during the support 
or after the removal of the device and no thromboembolic event 
occurred. Evidence of clinical relevant haemolysis, which was a 
particular concern, was looked for but absent in our series (datl not 
shown}. Also this observation is in line with the Leipzig series11• 
Systemic hypothermia (<36,5QC} was observed in 25% of patients 
(n=6) but the temperature decreased below 35°C only in two cases. 
Contact of the system circuit with room temperature may have 
contributed to a cooling effect on the blood flowing through the 
pump. Other factors that may have contributed to heat loss are the 
use of general ar~aesthetlc agents and neuromuscular blockers 
leading to vasodilatation and the loss of muscular tonus. Correcting 
measures may be straightforwardly introduced to avoid or rapidly 
detect this complication in the future. 
Conclusion 
Our results create optimism for more widespread introduction of the 
TandemHeafi:® in the MIC setting. The concept of closed chest lett 
heart bypass, with lett atrial to femoral artery bypass, constitutes a 
relatively safe and reliable safeguard in high risk PCI and acute heart 
failure. TandemHeafi:® PTLA® can be rapidly and percutaneously 
implanted in the catheterisation suite using standard interventional 
techniques in both a prophylactic or emergency settings. The 
TandemHeafi:® provides more haemodynamic support than the IABP 
and is effective in stabilising haemodynamics. Access site 
complications remain the Achilles' heel of this technique. 
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Acute effects of alcohol septal ablation on systolic 
and diastolic left ventricular function in patients with 
hypertrophic obstructive cardiomyopathy 
P Steendijk,1 E Meliga,2·3 M Valgimigli,2 F J Ten Cate,2 P W Serruys2 
ABSTRACT 
Objective: Hypertrophic obstructNe cardiomyopathy 
IHOCM) often leads to heart failure. severe symptoms 
and death. Percutaneous transluminal septal myocardial 
ablation (PTSMA) by alcohol injection efficiently reduces 
left ventricular (LV) outflow tract pressure gradient and 
improves symptoms. We determined acute changes in 
haemodynamics and systolic and diastolic LV function 
after PTSMA. 
Methods: In 17 consecutive pat'1ents whh symptomatic 
HOCM referred for PTSMA, the target vessel was 
determined by myocardial contrast transthoracic echo-
cardiography. Ail over-the-wire balloon was inflated in the 
target vessel and multiple 0.5-ml alcohol injections were 
petformed. LV systolic and diastolic function was 
assessed by online pressure-volume loops obtained by 
conductance catheter at baseline and acutely after the 
procedure. 
Results: In all patients except two, a single septal branch 
was treated using a total of 2.0 (0.5) ml ethanol per 
patient The rest and post·extrasystolic gradient were 
significantly decreased after PTSMA (79 (38) to 14(10) 
mm Hg and 130 (50) to 34 (33) mm Hg, respectively, 
both p<O.OOl ). Ejection fraction decreased (78% (9%) to 
07% (13%), p<0.001). Cardiac output, heart rate and 
stroke work were unchanged, but systolic and diastolic 
volume increased. End-systolic and end--diastolic pressure 
signiticandy decreased (100 (27) to 129 (20) mm Hg, 
p<0.001 and 25 (0) to 21 (7) mm Hg, p = 0.049, 
respectively). Significant rightward shift (p<0.001) and 
decreased slope IP = 0.041) of the end·systolic pressure-
volume relation '1ndicated reducW contractility, whereas 
diastolic stiffness, -dP/dtMIN• and tau were significantly 
improved after the procedure. 
Conclusions: PTSMA acutely reduced systolic function 
but prompdy improved diastolic function with maintained 
cardiac output and stroke work. Improved diastolic 
function and increased end-diastolic volume compensated 
for the systolic loss and resulted in maintained 
haemodynamics. 
Hypertrophic obstructive cardiomyopathy 
(HOCM) is a genetic cardiac disease which is 
characterised by interventricular septum hyper-
trophy, a narrowed left ventric-ilbr outflow tract 
{LVOT), mitral regurgitation and mitral valve 
systolic anterior motion (SAM) resulting in 
LVOT obstruction.' Patients with HOCM are at 
high risk of dying or developing severe symptoms, 
and LVOT obstruction has been shown to be an 
independent predictor of development of heart 
fuilure symptoms and death.1 ' In patients who 
remain symptomatic despite optimal medical 
therapy, surgical removal of a small amount of 
muscle from the basal interventricular septum has 
been shown to be an effective therapy.' Recently, 
percutaneous trJ.nSluminal septal myocardial abla-
tion (PTSMA) was introduced as an attractive 
alternative procedure.:-10 PTSMA induces myocar-
di:ll infarction by selective injection of alcohol into 
one or more sept.1l branches of the left anterior 
descending coronary artery aiming at contractile 
dysfunction and thinning of the septum to reduce 
the LVOT pressure gradient. 11 Significant and 
sustained decreases in LV outflow tract pressure 
gradients have been reported in sever.:U studies after 
PTSMA at long-term follow·up,' 7 ' 2 .:Uthough a 
recent study indicated less favourable effects in 
young patients with big..~ basellne resting gradi· 
ents.1 ~ The role of PTSMA in reducing mitral 
regurgitation and SAM is still uncertain.' The aim 
of this study was to establish the acute changes in 
systolic and diastolic left ventricular function after 
PTSMA in order to better understand the complex 
series of events that follow the procedure and that 
result in a new haemodynamic status. 
METHOOS 
Patient population 
The study population consisted of 17 consecutive 
patients with symptomatic HOCM despite opti-
mal medic.:U treatment who were referred for 
PTSMA at the Thoraxcenter. The HOCM diag-
nosis was based on typical clinical, echocardio-
graphic and angiocardiographic findings. The 
inclusion criteria were New York Heart 
Association (NYHA) classi.Scation class II-rv, 
associated with any sign of obstructive LVOT: 
resting systolic gradient greater than 50 mm Hg or 
septal thickness greater than 15 mm, or a less than 
7-mm LVOT diameter or SA.'v'i of anterior m.itr.:U 
leaflet. The study group included two patients 
with confirmed familial HOCM and four patients 
in whom HOCM was presumably related to 
previous hypertension. fn the remaining patients 
the origin was unknown. The study was approved 
by the internal review board of the Erasmus 
Medical Centre and all patients provided informed 
consent before participation. 
PTSMA procedure 
A 6F transfemoral temporary pacemaker was 
positioned in the right ventricle. &seline haemo-
dynamic data, including L VOT gradient at rest and 
at provocation with the Valsalva manoeuvre, were 
measured via two retrograde 6F catheters intro--
duced percutaneously via the femoral artery and 
168 
placed one in the left ventricle and one in the ascending aorta. 
lntr<~procedural myo=dial contrast transthoracic echocardio-
graphy (TIE) was performed to determine the target vessel. 
The vessel was then selectively probed with a 0.014-inch guide 
wire through a 6F percutaneous coronary angioplasty guiding 
catheter. A 9·mm long, oversized over·the-wire balloon (1.5-
2.5 mm) was introduced and inflated and the distal vessel bed 
was contrasted. Alter verification of the correct balloon position 
and inflation, 1-2 ml of the echo contrast agent (Lcvovist, 
concentration 350 mglml, Schcring or Sonovuc, Bracco) were 
injected through the balloon catheter lumen under continuous 
1TE imaging. Once dye reflux into the left anterior descending 
(IJ\.D) coronary artCI)' was excluded and if probatory vessel 
closure by the inflated balloon had resulted in significant LVOT 
gradient reduction, multiple O.S·ml alcohol injections were 
performed. Each injection was performed slowly, over a period 
of 30 seconds. Special care was taken to avoid leakage of alcohol 
into the lAD and its major branches. The balloon remained 
inflated for 10 minutes after the alcohol administration to 
enhance tissue contact and to exclude alcohol reflux into the 
IJ\.D. Finally, all the hacmodynamic measurements (sec below) 
were repeated. The pacemaker lead was left in situ for at least 
48 hours and the patient had a telemetric recording during the 
whole hospitalisation period. 
Haemodynamics and LV function 
Left ventricular (LV) function before, during and after the 
PTSMA procedure was assessed by online LV pressure·volume 
signals obtained by a 7F combined pressure-conductance 
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Figure 1 S"1ngle-beat estimation of the end-systo~c pressure-volume 
relation (ESPVR) and end-diastolic pressure--volume relation (EDPVR). 
dP/dtMAX• maximal rate of LV pressure increase; ESV, end-systolic 
volume; LV, left ventricular; PMAX< isovolumic peak pressure. 
catheter (CD Lcycom, Zoetermeer, The Netherlands) intra· 
duced retrogradely into the LV and placed along the LV long 
axis. The catheter was connected to a Cardiac Function Lab 
(CFL-512, CD Lcycom) for display and acquisition of pressure· 
volume loops. The conductance catheter was calibrated by 
matching the baseline conductance-derived volume signals with 
end-diastolic and end·systolic volumes obtained by echocardio-
graphy before the procedure. Data analysis was performed 
offline by custom-made software. Haemodynamics and LV 
function were quantified by cardiac output and stroke volume, 
end-diastolic and end·systolic volume, LV ejection fraction, end· 
systolic and end-diastolic pressure, maximal and minimal rate of 
LV pressure change (dP/dtw.x, -dP/dt1,;.JN). The time constant 
of relaxation (tau) was determined using phase-plot analysis. 
Stroke work was calculated as the area of the pressure·volume 
ioop. The end-systolic pressure·volume relation (ESPVR) was 
estimated using a single-beat method adopted £rom Takeuchi et 
a!" as illustrated in figure 1. The ESPVR was characterised by its 
slope EES (end-systolic elastance) and its position as defined by 
the volume intercept at 150 mm Hg (ESV150, see fig 1). The end· 
diastolic stiffness constant Km was determined by fitting an 
exponential curve, P "'Aexp(Kro.V), to the diastolic trajectory 
of the pressure·volume loop, and we also determined end· 
diastolic stiffness, Em, as the linear slope of the diastolic 
trajectory (P"'- B+ Ew.V). 
Statistical analysis 
Continuous variables are shoiNll as mean (SD) and were 
compared using Student t tests. Categorical variables are 
presented as counts and percentage and compared with the 
Fisher's exact test. Differences were considered significant if the 
p value was <0.05. All statistical tests were two tailed. 
Statistical analyses were performed by SPSS (version 12.0.1). 
RESULTS 
Baseline patient characteristics 
Baseline clinical and haemodynamic characteristics are pre· 
sented in tables 1 and 2. Mean age at the time of the procedure 
was 62 (13) years. Angina occurred in six patients (35%), 
syncope in three (18%) and dyspnoea w;;,s present in eight 
(47%). All patients were symptomatic despite optimal medical 
treatment wit.~ j3.-blockers (53%), calcium channel antagonists 
(59%) and diuretics (35%): eight patients {47%) were in £\T\fHA 
class III and nine (53%) were in NYHA class II. In this series, no 
patients were in NYHA class N. The mean gradient at rest was 
Table 1 Baseline patient {n"' 17) characteristics 
Ago, years {moan (SO)) 62113) 
Malo 11 {64%) 
Fomalo 6(36%) 
Symptoms 
Angina 6 {35%) 
Syncope 3 {18%) 
OyspMOI! 8 {47%) 
Modicu~ons 
f)-blockers 9 {53%) 
Calcium dmnnol antngonists 10 {59%) 
Oiurotics 6 {35%) 
NYHA functional class 
II g (53%) 
Ill 8 (47%) 
w 0 (0%) 
Acute effects ofPTSMA on LV function in patients with HOCM 1169 
Table 2 Baseline (Pre) and post-procedural (Post) haemodynamic measurements (n = 17) 
~. ,,., p Vnluo 
Grodiont (mm Hg) 79(38) 14 (16) <0.001 
Post-cxtrosystolic grodiont (mm Hg) 130 (50) 34 (33) <0.001 
HR (bo~ts/min) 69(12) 67 (11) 0.326 
IN(ml) 86(28) at 1381 0.794 
CO (Vmin) 6(2.3) 5.3 (2.5 0.409 
W(l.mm Hg) 10.7 (3.7) 9.2 (4.4) 0.135 
ESV(ml) 33(14) 44 (19) 0.004 
EDV(ml) 110 (30) 119 (35) 0,073 
EF (%1 78(9) 67 (13) <0.001 
ESP (mm Hg) 166(27) 1~ (25) <0.001 
EDP (mm Hg) 25(5) 21 {7) 0.049 
LVPrw: (mm Hg) 187 (32) 147 (24) <0.001 
LVPMIN (mm Hg) 8.1 (3.3) 7.2 (3.7) 0.322 
dP/dtMAX (mm Hg!s) 1549 (289) 1438{244) 0.069 
-dP/d~IN (mm Hg/s) 1611 (248) 1310 (333) 0.001 
T!IU (ms) 111 (61) 57 (15) 0.011 
PMAX (mm Hg) 268 (40) 230 {36) 0.011 
E,s {mm Hg/rnJ) 1.93{1,16) 1.38(0.62) 0.041 
ESV1 ~0 (ml) 36(15) sa 1221 <0.001 
E,o (mm Hg!ml) 0,32{0.24) 0.19{0,09) 0.014 
Kcoll/ml) 0.025 (0.021) 0.021{0.019) 0.275 
CO, c:~rd~c output dP/dtw.x, mwcirool rotc of LV prossolll incnmsc; dP/d~1,._ mwcirool rotc of LV prossuro dodine; E,c. diostolic 
stiffness; Ers. and-systolic o~nce (slopo of ESPVR); EDP, ond-dbstolic prossuro; EDV, and-diastolic volumo: EF, ejection 
!mction; ESP, ond-systolic PlllSSUill; ESV, end-systolic volumo; ESV1,o. irrtcrcopt of ESPVR; HR, honrt rate; K.:Do di~stolic stiffness 
constnnt; Lifl>r.t~N< minlrool LV prossuro; Lifl>rr.AK. ponk loft wntricular (LV) systolic prossuro; PMPJO isovolumic pook prossuro; SV, 
stroko volumo; '!»!, mroko Wllr\:; tau, relaxation limo con:;t:nnt 
79 (38) mm Hg, the mean post-extrasystolic gradient w.:ts 130 
{50) mm Hg .md the me.:tn septal thickness was 21.7 (0.5) mm. 
Procedural results 
An average of 2.0 (0,5) m1 of ethanol was injected per patient. In 
.:til p.:ttients except two, only one septal branch was tte.:tted. In 
eight patients the first septal branch was tre.:tted, in six patients 
the second, in one the third. In two patients both the first and 
the second sept.:J branches were treated because of incomplete 
gradient relief .:tfter the treatment of the first one. No death or 
sustained ventricular arrhythmias occurred. Eight patients 
developed right bundle branch block, which was persistent 
in four. No patient required permanent pacemaker implanta-
tion after the procedure. Acute haemodynam.ic findings are 
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Figure 2 Acllte effect of percutaneous transluminal septal myocardial 
ablation: left ventricular (LV] outflow tract gradient before (Pre) and after 
(Post) procedure. 
summarised in figure 2 and table 2. The me.:m rest and post-
extrasystolic gradient were both significantly decre.:tsed after the 
procedure (79 (38) to 14 {16) mm Hg .md 130 (50) to 34 {33) 
m.m Hg, respectively, both with p value <0.001). The CO, HR, 
SV and SWwere unchanged. The ESV increased from33 (14) to 
44 (19) ml (p = 0.004); the EDV tended to increase from 110 (30) 
to 119 {36) ml (p = 0.07) and the ejection Ernction significantly 
decreased from 78% (9%) to 67% (13%) (p<0.001). Both ESP 
and EDP significantly decreased from 166 (27) to 129 (26) mm 
Hg (p<0.001) and from 25 (6) to 21 (7) mm Hg, respectively. 
LVPrEAK decreased from 187 (32) to 147 (24) (p<0.001). LV 
dP/dt""-"'X tended to decrease from 1549 (289) to 1438 (244) mm 
Hgls {p=c0.069) and -dP/dt,wN significantly decreased from 
1611 (248) to 1310 (333) mm..t-fg!s (p = 0.001). Both tau .md Ew 
were reduced from 111 (61) to 67 (15) ms (p = 0.011) md from 
0.32 (0.24) to 0.19 (0.09) mm Hg!ml {p = 0.014), respectively. 
The ESPVR showed a decreased slope (EES from 1.93 (1.16) to 
1.38 (0.62} mm Hg!ml, p = 0.041) md a shift to the right 
(ESV150 from 36 (15) to 58 (22) ml, p<0.001). Figure 3 shows a 
typical example of pressure-volume loops before and after 
PTSMA. 
DISCUSSION 
HOCM was first described in the late 1950s." "'A morpholo-
gical difference is made between subaortic obstruction and the 
more rare mid-ventricular obstruction. Symptoms and disease 
manifestations in patients with HOCM include dyspnoea, 
angina, palpitations, syncope, heart failure and sudden cardiac 
death. Obstruction of LVOT, diastolic dysfunction, cardiac 
iscbaem.i.J. and rhythm disturbances are t.~e main problems and 
underlying mechanisms in patients with HOCM.' '" 
Symptomatic patients not only have impaired quality of life 
but also seem to have an adverse prognosis; the occurrence of 
atrial fibrillation, ventricular tachycardia17 and myocardial 
ischaemia'" are all prognostically unfavourable fuctors. 
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Figure 3 Typical example of pressure-volume loops before (Pre) and 
after (Post) perclltlneous transluminal septal myocardial ablation. LV, left 
ventricular. 
Symptomatic HOCM patients are usually treated first with 
negatively inotropic substances, especially 13-blockers, calcium 
ant<.lgonists like verapantil, or disopyramide.10 These drugs may 
favourably modify LV diastolic function through their mti-
ischaemic actions although the effect on symptoms and LVOT 
obstruction is often Jimjted and present only in a select group of 
patients. Moreover, verapamil may prolong tau and increase 
filling pressures in some patients. A recent study indicated that 
disopyrarnide combined with )3-blockers may provide ameliora-
tion o£ symptoms without proarrhythmic effects.''' 
Atrioventricular sequentiJ.l pacing has been applied10 and was 
reported to reduce the outflow tract grJdient up to 30%, to limit 
cavity obliteration and reduce systolic pressures probably by 
inducing dyssynchronous apical contraction/' which was 
leading to a decrease in symptoms in patients without affecting 
septal thickness." Surgical myectomy has been the therapeutic 
option of choice for decades since the late 1950s,' 20 and patients 
tend to have improved markers of diastolic LV function and a 
favourable prognosis. Recently, PTSMA has been shown to be 
an attractive alternative to surgical myectomy. The induction of 
a limited "therapeutic'' infarction as a result of ethanol 
injectiod4 within the hypertrophied septal myocardium leads 
to !OCJ.lised thinning and region.;,! contractile dysfunction, 
which expands the left ventricular outflow tract, eliminates or 
reduces the mitral valve SNvl and thus reduces LVOT gradient 
and the resulting symptoms."'-'" 
Previous echocardiographic and magnetic resonance imaging 
studies have shown that LVOT gradient reduction is associated 
with a decreJsed afterload and an increased cardiac output,~" 
resulting in a higher diastolic pressure in the aorta along with a 
lower diastolic pressure in the LV. These c...i.anges enhJ.nce 
coronary flow and myocardial perfusion by increasing coronary 
6.lling pressure, leading to reduced subendocardial ischaemia and 
improved LV relaxation.'"~~' Moreover, the gradual regression of 
hypertrophy and the changes in LV geometry may explain the 
further long-term improvement in diastolic function;'l-'"' Most 
of these changes are .;,ssumed to achieve their maximum effect 
generally weeks or months after the procedure, but what 
happens immediately after the procedure is still poorly under-
stood. In the present study we used invasive conductance 
catheter-derived pressure-volume loops to assess the ncute 
effects of PTSMA on general haemodymmics, and systolic 
and diastolic LV function. This methodology has been validated 
extensively"" and has the unique advantage of providing 
continuous, online haemodynamics and relatively load-
independent indexes of systolic and dinstolic LV function. 
The results indicate that, despite the acute gradient reduc-
tion, general haemodynamics reflected by CO and S'W were not 
gre::J.tly affected. However, systolic function w.;,s acutely 
reduced: this was evidenced by .;, reduced ejection fraction 
resulting from increased EDV with maintained 5\f . 
Consistently, dP/dt.'MX decreased, although this effect just 
failed to reach statistical significance {p"" 0.069). Since these 
traditional indexes may be .:~ffected by the greatly altered 
loading conditions we also assessed systolic LV function by the 
ESPVR, a relatively load-i..'1dependent relation: the significant 
reduction in slope and the rightward shift of the ESPVR both 
clearly indicated a reduction in intrinsic systolic function. 
Conversely, diastolic LV function showed an acute improve-
ment: EDP decreased significantly despite the increase in EDV, 
and tau also improved significantly. In line with these finding, 
the EDPVR showed a decreased slope indicating improved 
diastolic compliance. The improved diastolic function and 
increased EDV (Frank-Starling effect) presumably compensated 
for the systolic loss and resulted in maintained stroke volume. 
The reduced systolic function most likely reflects the iatrogenic 
loss of functional cardiac muscle induced by the alcohol 
injection. The amount of the loss is related both to the site 
and t.~e size of the infarct area, which in turn depends on the 
quantity of eth.;,nol delivered and on the number of septal 
branc...i.es treated. In our series all patients, except two, had a 
single septal branch treated and the infarct .;,rea was similar in 
all patients (22.4 {6.9) nun~, evaluated by echocardiography). 
The acute improvement in diastolic function is in line with 
previously reported long-term effects. However, whereas long-
term improvements may be mainly due to regression of 
myocardial hypertrophy, the current findings suggest an 
improvement in intrinsic myocardial function: we speculate 
that relief of subendocardial ischaell'ia m.;,y pJrtly explain this 
acute effect. In Jddition, relaxation is known to be affected by 
systolic load via changes in intracellular calcium transients."' 
Potentially, acute systolic load reduction may also have improved 
relaxation via this pathway. Interestingly, -dP/dtMIK was 
reduced, suggesting a worsening of the isovolumic rebxation. 
This, however, can be explained because -dP/dtML'< reflects the 
very early part of diastole, this "active" relaxation phase is largely 
dependent on systolic properties that, in this acute setting, are 
iatrogenically depressed.""' 
Limitations 
Ideally, ESPVR and EDPVR are derived from multiple beats at 
altered loading conditions. In most pressure-volume loop studies 
a gradual reduction in preload is induced by b.;,lloon occlusion of 
the inferior ven.;, cava. In the present study group we were 
hesitant to npply this intervention because these patients with 
diastolic dysfunction and ncar cavity obliteration nt end-systole 
have very little reserve capacity and preload reduction was 
anticipated to result in large pressure drops and unstable 
ha=odynamics. Therefore we applied single-beat methodolo-
gies to derive ESPVR and EDPVR. These approaches were 
previously used and generally found to be reasonable estimates 
of multi-beat pressure-volume relations.'"" 40 
In conclusion, our mechanistic Endings describe the complex 
haemodynamic effects acutely induced by PTSMA and help to 
explain how treatment may result in immediate symptom relief 
well before remodelling of the LV cavity takes place. PTS,\1A 
acutely reduced systolic function but promptly improved 
diastolic function with maintained general haemodynamics. 
Acute effects ofPTSMAon LV function in patients with HOCM 1171 
Most previous studies indicated that 3-6 months after the 
procedure, both systolic and diastolic perform:mce indexes are 
improved; this difference is probably the result of the influence 
the tissue loss has on the systolic function in the acute phase 
while the compensatory and remodelling processes have not yet 
started. More geneml.ly, the present data could be relevant for 
operative risk assessment, post-procedural patient management 
and future optimisation of the procedure in high-risk heart 
failure patients. Our findings suggest that PTSMA am be safely 
applied in patients with severe heart failure symptoms. 
Compoting intl.H'tlstl: Nona. 
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CHAPTER 18 
EFFECTS OF PERCUTANEOUS 
TRANSLUMINAL SEPTAL MYOCARDIAL 
ABLATION FOR OBSTRUCTIVE 
HYPERTROPHIC CARDIOMYOPATHY 
ON SYSTOLIC AND DIASTOLIC LEFT 
VENTRICULAR FUNCTION ASSESSED BY 
PRESSURE-VOLUME LOOPS 
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Effects of Percutaneous Transluminal Septal Myocardial Ablation 
for Obstructive Hypertrophic Cardiomyopathy on Systolic and 
Diastolic Left Ventricular Function Assessed by Pressure-Volume 
Loops 
Emanuele Meliga, MD"'. Paul Steendijk, PhDb, Marco Valgimigli, MD. PhD', 
Folkert J. Ten Cate, MD, PhD', and Patrick W. Serruys, MD, PhD"* 
The aim of the present study was to determine the long-term effects of percutaneous 
transluminal septal myocardial ablation (PTS:MA) on systolic and diastolic left ventricular 
(LV) functions in patients with obstructive hypertrophic cardiomyopathy (HC). Ten con~ 
secutive patients with symptomatic HC despite optimal medical treatment were referred 
for PTSMA at our center. LV systolic and diastolic functions were assessed by online LV 
pressure-volume loops obtained by conductance catheter at baseline and at 6 months after 
the procedure. At follow~up, the mean gradients at rest and after extrasystole were 
significantly decreased compared with baseline (88 ± 29 to 21 ± 11 mm Hg and 130 ± 50 
to 35 ± 22 mm Hg, respectively, p <0.01 for the 2 comparisons). End~systolic and 
end-diastolic pressures significantly decreased (p <0.01), whereas end~systolic and end~ 
diastolic LV volumes significantly increased (p <0.01 for the 2 comparisons). Cardiac 
output and stroke volume were unchanged, as were ejection fraction (p :::: 0.25) and 
maximum dP/dt (p = 0.13). The slope of the end-systolic pressure-volume relation was not 
decreased, indicating a preserved contractility. The relaxation constant time, end-diastolic 
stiffness, projected volume of the end-diastolic pressure-volume relation at 30 m.m Hg, and 
diastolic stiffness constant showed a significant improvement of active and passive myo-
cardial diastolic properties. In conclusion, PTSMA is an effective method in the treatment 
of symptomatic patients with HC. At 6-month follow-up, the LV-aortic gradient was 
decreased and active and passive LV diastolic properties were increased. Myocardial 
contractility was not decreased and general hemodynamics was maintained. © 2008 
Elsevier Inc All rights reserved. (Am J Cardiol2008;101:1179-1184) 
Long~tenn clinical observations of patients treated with 
percutaneous transluminal septal myocardial ablation 
(PTSMA) have shown significant and sustained decreases in 
left ventricular (LV) outflow tract pressure gradients and 
improvement of symptoms.1.2 but thus far. complete infor-
mation about the long~term changes in systolic and diastolic 
LV functions after PTSMA are lacking. The aim of this 
study was to assess the long-term hemodynamic effects of 
PTSMA in a single center's population with obstructive 
hypertrophic cardiomyopathy (HC) by LV pressure-volume 
conductance catheter (pressure-volume loops). 
treatment who were referred for PTSMA at our center. The 
HC diagnosis was based on typical clinical, echocardio-
gr:aphic, and angiocardiographic findings. Inclusion criteria 
were New York Heart .A..ssociation functional classes IT to 
IV, LV outflow tract gradient >50 rnm Hg at rest or> 100 
mm Hg at provocation (after extrasystole, isoproterenol. or 
Valsalva maneuver), septal thiclaless > 15 rnrn, LV outflow 
tract diameter <7 rnrn, and systolic anterior motion of the 
anterior mitral leaflet Patients with concomitant cardiac 
abnormalities suitable for surgery were excluded. The insti-
tutional review committee of the Erasmus Medical Centre 
approved the study protocol and all patients provided in~ 
fanned consent before participation. Methods 
The study population consisted of 10 consecutive patients 
with symptomatic obstructive HC despite optimal medical 
"Dep:lrtment of InterVentional Cardiology, ThO!':IXcenter, Erasmu.~ 
Medical Center, Rotterdam. and Poepmment of Card.iology, Lei den Gni-
versity Medical Center, Leiden. The Netherlands~ and 9Jep:utment of 
Inter;entional Card.iology, S, Giov:mni Battista Hospit:ll.. Gniversity of 
Turin, Turin. Italy. Manuscript reeeived October 12. 2007: revised manu-
script received and accepted December 9, 2007. 
~corresponding author: Tel: 31-10-463-5260~ fax: 31-1{).436-9154. 
E-mail addre$$.' p.w.j.c.serruy:;@erasmusmc.nl fY,W, Serruy:;). 
Briefly, 2 catheters were placed in the left ventricle and 
the ascending aorta to record baseline hemodynamic data 
(see below). including LV outflow tract gradient at rest and 
at provocation with the Valsalva maneuver. Intraprocedural 
myocardial contrast transthoracic echocardiography was 
performed to detennine the target vessel. A 9-Illlll-long, 
oversized. over~the-wirc balloon (1.5 to 2.5 mm) was intro-
duced and inflated in the target vessel and 1 to 2 ml of 
echocardiographic contrast agent (levovist. concentration 
350 mglml. Shering or Sonovue. Bracco. Italy) was injected 
through the balloon catheter lumen under continuous echo-
cardiographic imaging. Once dye reflux into the left anterior 
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descendant artery was excluded and probatory vessel clo-
sure by the inflated balloon resulted in significant LV out-
flow tract gradient decrease, multiple 0.5-ml alcohol injec-
tions were perfonned (ethanol1.97:!::: 0.51 mlperpatienton 
average). Each injection was perfonned over a period of 30 
seconds. In all except 2 patients, only I septal branch was 
treated (first septal branch, 6 patients; second septal branch, 
2 patients; first and second septal branches. 2 patients). The 
balloon remained inflated for 10 minutes after alcohol ad-
ministration to exclude alcohol reflux into the left anterior 
descendant artery. All hemodynamic measurements were 
repeated. A 6F transfemoral temporary pacemaker was po--
sitioned in the right ventricle and left in situ for ~48 hours. 
Procedures were considered successful when postprocc· 
dural pressure gradient at rest was <16 mm Hg or when the 
percent pressure gradient decrease after the procedure was 
>50%.3.4 
LV dynamic data were recorded before. during. and after 
the PTSMA procedure by online LV pressure-volume sig-
nals obtained by a 7F combined pressure-conductance cath· 
eter (CD Ley com, Zoetenneer. The Netherlands) introduced 
into the left ventricle through the femoral artery. The cath· 
eter was connected to a Cardiac Function Lab (CFL-512. 
CD Leycom) for display and acquisition of pressure-vol-
ume loops. A Swan-Ganz catheter was placed in the pul-
monary artery through the femoral vein. Parallel conduc-
tance and cardiac output were determined by multiple 
injections of hypersaline solution and thennodilution to 
calibrate the volume signals of the conductance catheter.s·6 
Postextrasystolic gradient was determined by induction of 
extrasystoles from a pacemaker wire. Data analysis was 
perfonned offline by custom-made software. 
Hemodynamics and LV function were quantified by car-
diac output and stroke volume. end-diastolic and end-sys· 
tolic volumes. LV ejection fraction. end-systolic and end-
diastolic pressures, and maximal and minimal rates of LV 
pressure change (dP/dt). The isovolumic relaxation period 
(defined as the period between the time point of minimal 
dP/dt and the time point where dP/dt reached 10% of min-
imal dP/dt) was analyzed using phase-plot analysis and the 
time constant of relaxation was then determined. The end-
systolic pressure-volume relation (ESPVR) was estimated 
using the method adopted by Takeuchi et al7 and the change 
in contractility was determined by the change of the slope of 
the ESPVR line and its position, as defined by the projected 
volume value of the relation at 200 mm Hg (Figure 1). The 
end-diastolic pressure-volume relation (EDPVR) was esti-
mated using the method adopted by Klotz et al.8 The change 
in diastolic distensibility was calculated by the left to right-
ward shift of the EDPVR at the :fixed pressure level of 30 
mm Hg. The end-diastolic stiffness constant was deter-
mined by fitting a exponential curve. P (pressure) = A 
(paramete value) X exp(end·diastolic stiffness constant X 
volume). to the diastolic trajectory of the pressure-volume 
loop (Figure 2). and we determined end-diastolic stiffness as 
the end-diastolic pressure/end-diastolic volume ratio.9 
All patients were monitored in the coronary care unit for 
~48 hours. After discharge. patients were suggested to 
continue medical treatment with a cardioselective ~blocker 
or with a low dose of verapamil. After 6 months, all patients 
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Figure 1. Single-beat estimation of ESPVR using the method adopted by 
Takeuchi et aJ.l (A) Point series representing isovolumic contrnction and 
rel:oot.tion phru;cs ure selected and plotted on the pressure curve. E.~1irrutted 
theoretical maximal pre~sure reached in the left ventricle during an iso-
volurnic beat {Pm:J.X) is estirn:1ted by fitting a fifth-order curve to the point 
series. (B) ESPVR slope is represented by the «Juation of the line drown 
from Pmax to the left upper comer of the pressure-volwne loop of a real 
ejecting beat FL" = 6-month follow-up: LVP = LV pre.>sure: Pre= 
baseline: V we = volume intercept at 200 rom Hg. 
underwent invasive follow-up by LV pressure-volume con-
ductance catheter. 
Continuous variables are presented as mean :!::: SD and 
were compared using Student's unpaired and paired t tests. 
when appropriate. Categorical variables are presented as 
counts and percentages and were compared with Fisher's 
exact test Correlations between variables were tested by 
Pearson analysis. Differences were considered significant if 
the p value was <0.05. All statistical testS were 2~tailed. 
Data processing and statistical analyses were perfonned 
with SPSS 12.0.1 (SPSS, Inc .. Chicago.lllinois). 
Results 
Baseline and 6-month follow-up clinical characteristics and 
hemodynamic measurements are presented in Table 1. 
:Mean age at the time of the procedure was 61 :!::: 11 years. 
Angina was the principal manifestation in 3 patients (30% ), 
syncope in 2 (20%). and dyspnea in 5 (50%). Despite 
optimal medical treatment. 4 patients (40%) were in New 
York Heart Association class Ill and 6 (60%) were in New 
York Heart Association class IT. Mean gradient at rest was 
Chronic effects ofPTSMA on LV function in patients with HOCM \177 
A 
~------------------,---
) 
,,, ----------"'"""--------
,.,~~,f){> <i>ll,1',-?/?,.,'>,JJ,o., 
Volomo1rnn 
B 
.. ~--------------------
• 
• 
~;'!) 
! • ! :N-1: 
" 10--
'" '" "' 
-I ... / 
Figure 2. Single-beat estimation of EDPVR and end-di:!l.1o!ic constant 
(KilDl- (A) EDPVR i~ e:;cimated u.~ing the method adopted by Klotz et al.' 
EDP = a*EDV"',B represent~ the cqulltion of the e;.timated exponential 
curve. Alpha (a) and beta (/3), obtained by a sequence of calculations from 
a single set of pressure and volume values, represent coefficient$ of the 
estinlllted curve. (B) K130 detemllnation by exponential fitting. For more 
details, see Methods, V30 = volume intercept at 30 mm Hg. Other abbre-
viation.~ as in Figure 1. 
88 ± 29 mm Hg and mean postextrasystolic gradient was 
130 :::: 50 mm Hg. 
Heart rate at time of data acquisition was similar in at 
baseline and at 6-month follow-up. Mean gradients at rest 
and after extrasystole were significantly decreased at fol-
low-up. Stroke volume, cardiac output. and ejection fraction 
did not differ significantly. End-systolic and end-diastolic 
volumes increased and end-systolic. end-diastolic, and LV 
peak pressures significantly decreased after the procedure. 
LV maximal and minimal dP/dt values were not signifi-
cantly changed. Slope of the ESPVR line remained approx-
imately constant and relaxation time constant and end-dia-
stolic and end-diastolic stiffness constants were decreased. 
Projected volumes ofESPVR at 200 mm Hg and EDPVR at 
30 mm Hg were significantly increased. Figure 3 shows a 
typical example of pressure-volume loops before the pro-
cedure and at 6-month follow-up. 
Discussion 
Results of the present study indicated that. at 6-month fol-
low-up. (1) LV outflow tract gradient remained low at rest 
and at provocation, (2) general hemodynamics and intrinsic 
myocardial systolic properties were not affected. and (3) 
diastolic function was significantly improved. 
Short- and mid-term results of PTSMA are excellent for 
the decrease of LV outflow tract gradient obstruction. Pre-
vious studies have reported that at 3 months, mean pressure 
gradients at rest and at provocation (postextrasystolic gra-
dient) were significantly decreased. 10 showing a persistent 
75% to 80% decrease of LV outflow tract gradient com-
pared with baseline. Consistent with these data. in our study 
at 6 months. mean LV outflow tract gradient was 21 :±:: 11 
mm Hg. which is an 86% decrease compared with baseline. 
whereas postextrasystolic gradient was persistently de-
creased by 73% (from 130 :±:: 50 to 35 :±:: 22 mm Hg). 
suggesting the efficacy of this nonsurgical approach over 
time. Moreover, LV outflow tract gradient measured by 
echocardiography and simultaneous ventricular/aortic pres-
sure sampling showed a stable improvement and a limited 
recurrence of LV outflow tract obstruction in studies with 
even longer follow-up.11 
General hemodynamics and systolic function have been 
reported to deteriorate soon after the procedure. but at mid-
term follow-up (3 months). several noninvasive studies 
have reported ejection fraction and cardiac index not to be 
significantly decreased.1Z·13 The acute changes most likely 
re"fl.ect iatrogenic loss of functional cardiac muscle induced 
by alcohol injection. The amount of the loss is related to the 
site and size of the infarct area. which in turn depends on the 
quantity of alcohol delivered and on the precision of the 
alcohol delivery in the target region. Use of an echocardio-
graphic contrast-guided approach to identify the target ves-
sel and probe the correct vessel closure before the alcohol 
injections (see Methods) is of crucial importance to avoid 
large LV infarctions and subsequent risks of hemodynamic 
impainnent and arrhythmias. 
In our series. general hemodynamics represented by car-
diac output and stroke volume was not affected at 6-month 
follow-up. Increase of end~systolic volume was accompa~ 
Died by a similar increase of end-diastolic volume that. 
thanks to the Frank-Starling effect most likely compensated 
for the systolic loss and resulted in maintained stroke vol-
ume. Systolic function. represented by ejection fraction and 
maximal dP/dt. did not show a significant decrease. Because 
these systolic indexes are known to be affected by different 
loading conditions, the intrinsic systolic properties of the 
left ventricle were also assessed by ESPVR, a relatively 
load-independent index of contractility.14 In our series. 
there was no significant change in ESPVR slope. thus indi-
cating a preserved intrinsic systolic function. The rightward 
shift of the ESPVR generally representing a worsening of 
systolic properties, in these patients had a limited signifi-
cance because it was partially dependent on the modifica-
tions of LV hemodynamics occurring after the procedure 
(decrease of mitral regurgitation, increase of end-systolic 
volume, and concomitant increase of end-diastolic volume). 
The LV outflow tract gradient decrease is associated with 
a decreased afterload and an increased cardiac outputlS-17 
resulting in a higher diastolic pressure in the aorta. a lower 
diastolic pressure in the left ventricle. and a higher coronary 
filling pressure. The increased myocardial perfusion. grad-
ual regression of hypertrophy. and subsequent changes in 
LV geometry18,19 are considered the main causes of the 
long-term improvement of diastolic function. 
In our series. LV diastolic function showed significant 
changes: end-diastolic pressure decreased significantly de-
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Table 1 
Baseline patient clmrnctl:fistics :md hemodynamic mem;urements at \xt~linc :md FU 
Patient No. Aso Symptom :Medic:Jtions NYHA Gradient PES Gradient HR sv co ESV 
(yrs)/S~ Class (mmHg) (mmHg} (be:~.t.Jmin) (ml) (Limin) (ml) 
4SIF D C,Di m Ba.'\dine 103 176 60 99 6 37 
FU 16 21 60 l!O 6.6 31 
50/F D c rr Bnscline 81 112 49 96 4.7 
" FU 22 40 60 88 5.3 58 
50/F D B.C rr B=line 77 164 76 106 8.1 46 
FU 
" 
53 82 109 8.9 47 
4 53/M D B.C rr Ba.'>eline 57 59 60 107 6.4 52 
FU 9 ll 65 101 6.6 68 
54/M D B, Di m B=line 145 199 75 130 9.3 30 
FU 41 68 5S 128 7.3 43 
66/M s B.C rr Bnscline 89 144 70 102 7.2 24 
FU 31 5S 64 98 6.2 45 
7 68/M A B.C rr Ba.'\dine 59 68 57 ll3 65 
" FU 10 13 59 81 5.3 50 
70/M A B,Di m B:JScline 75 117 83 115 9.3 38 
FU ll 78 liS 9.2 49 
71/M A B.Di m Ba.'ieline 124 179 67 78 5.2 35 
FU 30 49 74 103 7.7 33 
10 77/F s B.C rr Ba.'\eline 68 84 85 109 31 
FU 19 23 56 97 55 59 
Mean= SD 61 :':: II B:JScline 88 :':: 29 130 :'::50 68 :':: 11 105 :':: 14 72 = 1.7 35 = 8 
FU 21 =II 35:::: 22 66 = 9 103 = 14 6.9 = 1.5 45::!:11 
p viluc <0.01 <0.01 0.52 0.79 056 <0.01 
A = :mgin:l: B = {3 blockers: C = ~cium :mtlgonists: CO = cnrdinc output: D = dyspne:~.; Di = diuretics: dP/dt,._, = maximal rntc of LV pres>ure 
inCI'e:l."l!; dP/dt,.. = mnxim;U rnte of LV pressure decrease: EDP = end-diastolic pressure: EDV = end-dinstolic volume:~ = dia.o;to\ic stiffness: Ees = 
slope of ESPVR: EF = ejection frnction: ESP = end-systolic pre.o.surc: ESV = end-systolic volume: FU = 6-month follow-up: HR = hemt mte; Keo = 
diastolic ~'tiffness constant: LVPPHAK = peak LV systolic pressure: NYHA = New York Hear Associntion; PES "' postcxtr:J.systolic: SV = stroke volume; 
PVIocps 
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Figure 3. Typi~ example of pressure-volume (PV) loops before the 
procedure (gray line) :md at 6-montb foUow-up (black line). Abbreviations 
m; in Figure l. 
spite the increase in end-diastolic volume and end-diastolic 
and end-diastolic stiffness constants decreased significantly. 
In line with these findings, EDPVR showed a decreased 
slope and projected volume of EDPVR at 30 mm Hg sig-
nificantly increased, indicating improved diastolic compli-
ance and distensibility. Previous echocardiographic studies 
evaluating active myocardial relaxation found that active 
myocardial relaxation properties were abnormally altered in 
patients with HC but normalized after PTS:MA. at 1- and 
2-year follow-ups.20.ZI In line with these results. our study 
showed that active relaxation properties of the myocardium 
" '" "' '" 
Figure 4. Ch:mges of dP/dt over time during the isovolurnic relaxation 
period before PTSMA (dashed line) and at 6-montb follow-up (darted ll.ne) 
represent n typicnl example of dP/dt biplmsic pattern. 
improved after the procedure. as confirmed by the signifi· 
cant decrease of the relaxation time constant More inter-
estingly, analyzing selectively the isovolumic relaxation 
phase, we noticed that changes due to the procedure were 
quantitative (decrease of relaxation time constant and min-
imal dP/dt) and qualitative. At baseline, the isovolumic 
relaxation cunre showed an interesting biphasic trend. with 
an early and steep slowdown phase followed by a significant 
increase in dP/dt and a second slowdown phase. This pecu-
liar trend. markedly evident in 8 of 10 patients. disappeared 
after the procedure (Figure 4). The mechanisms responsible 
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Table 1 
Continued 
EDV EF ESP EDP LVP- dP/dt:,.,. dP/dt,.;" T'" £, v~ E., v. Koo 
(ml) (%) (mm Hg} (mm Hg) (mm Hg} (mm Hg!s) (mmHg!s) (ms) (mmHg!ml) (ml) (mmHg/ml) (ml) (1/ml) 
138 71 186 24 195 1199 1601 92 1.97 51 0.174 140 0.019 
140 78 181 19 185 1495 1355 76 1.84 67 0.136 164 0.013 
124 77 170 20 190 1150 1320 96 0.82 42 0.160 l3l 0.019 
147 60 [[5 [[ 152 1092 1663 60 0.84 90 O.D75 170 O.oJ5 
[50 70 166 18 185 1975 1838 76 1.77 66 0.120 !56 0.021 
!56 80 124 19 149 1576 1710 52 1.45 132 0.122 165 0.020 
160 67 123 15 165 1404 1475 104 1.21 71 0,094 164 0,015 
169 60 121 [[ !50 1434 1169 72 1.01 108 0.066 178 0.012 
!59 79 207 24 212 1704 1630 108 2.25 34 0.152 162 0.014 
169 79 [[3 20 [50 1630 1306 56 2.04 liS 0.118 l7l 0.014 
125 81 168 17 183 1751 1660 84 2.30 43 0.136 129 O.QJ8 
144 68 141 14 166 1516 1490 36 2.14 100 0.097 166 0.012 
140 77 142 17 168 1691 1613 80 1.65 60 0.121 145 0,017 
141 64 112 12 144 142& 1312 44 1.43 96 0.085 170 0.011 
[53 75 !50 25 179 2199 1696 72 !S3 68 0.161 172 0.016 
168 69 139 29 133 2172 1568 40 1.38 98 0.175 l7l 0.019 
112 69 !93 34 207 1463 1559 108 0.88 47 0.304 122 0.024 
136 76 112 9 130 1393 1352 56 0.92 106 0.070 167 0.021 
140 77 142 28 180 1722 1364 96 1.80 65 0100 144 0,018 
!57 62 ll3 15 160 1546 1568 72 1.41 105 0.096 162 0,012 
140± 16 75 ±4 164±26 22 ± 6 186 ± 15 1625 ± 328 1575 ± 155 92 ± 13 1.61 ± 052 55± 12 0.17 ± 0.6 146 ± 16 0,018 ± 0,002 
152± 13 70 ± 8 127 ±21 16 ± 6 152 ± 16 1528 ± 270 1449::: 177 56± 13 1.45 ± 0.47 101 = 16 0.1 ::: 0.04 168 ± 4 0.014 ± 0.003 
<0.01 0,25 <0.01 <0.01 <0.01 0.13 0.24 
for these alterations of the active relaxation phase in this 
setting are not clear. Previous studies have described a 
similar biphasic curve in patients with aortic stenosis::Z and 
during the isovolumic contraction phase, attributing the 
cause of this pattern to the asynchrony of some LV seg-
ments during this phase.23 Other reports have demonstrated 
that increased coronary vascular resistance,24 increased wall 
stress, and myocyte disarray::s may lead to diastolic LV 
asynchrony and delayed relaxation. Moreover. it has been 
reported that. although myocardial systolic torsion is greater 
in patients affected by HC than without HC, the uncoiling of 
the myocardium occurred abnonnally and was shown to be 
significantly delayed and depressed. 26-28 We speculate that 
this biphasic pattern of relaxation may be the expression of 
the ovennentioned anatomic and hemodynamic alterations. 
The reinstating of nonnal hemodynamic conditions and 
gradual regression of LV hypertrophy after PTSMA may 
therefore explain the drastic "nonnalizati.on" of the isovolu-
mic relaxation curve pattern. 
Ideally, ESPVR and EDPVR are derived from multiple 
beats at altered loading conditions, usually by balloon oc-
clusion of the inferior vena cava. In the present study group 
we were hesitant to apply this intervention because patients 
with HOCM have very little reserve capacity and preload 
decrease was anticipated to result in large pressure de-
creases and unstable hemodynamics. Therefore we applied 
single-beat methods to derive ESPVR and EDPVR. 
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THE CASE 
A 48~year~old man presented in December 2005 
after a syncopal episode whilst exercising in the 
gym. This was the first time he had experienced 
syncope and he had no relevant medical history. 
Holtermonitoringwas performed and the patient 
was diagnosed with paroxysmal atrial flutter. 
He was previously very fit, cycled 30 min daily, and 
e:'(ercised regularly at the gym. He did not smoke 
ordrinkalcohoLAfter hls collapse, the patient had 
progressive chest pains on maximum exertion and 
felt increasingly lethargic. The patient had five 
siblings, one of whom had an undiagnosed heart 
murmur that was never clinically evaluated. 
On physical examination, the patient's pulse 
was regular (70 beats per min [bpm]) and he was 
normotensive (blood pressure 120/75mmHg). 
His heart sounds were normal, but there was a 
grade 3 systolic ejection crescendo-decrescendo 
murmur, best heard between the apex and left 
sternal border, that radiated to the suprasternal 
notch, but not to the carotid arteries or neck. This 
murmur increased to grade 4 with the Valsalva 
maneuver and with isometric exercise (hand~ 
grip), but diminished when the patient squatted 
down. Electrocardiography revealed sinus rhythm 
(75bpm) with poor R~wave progression, early 
repolarization in precordial leads Vl and V2, and 
tall R~waves in limb lead II and precordial leads 
V2 and V3. On an exercise bicycle test, the patient 
achieved a maximum workload of 140W and 
showed a good hemodynamic response (heart 
rate 176bpm; blood pressure 213/97mmHg). 
He had mild anginal symptoms at maximum 
exertion, but there were no ischemic changes on 
electrocardiography. Transthoracic echocardio~ 
graphy (TTE) revealed a hypertrophied inter~ 
ventricular septum, with a maximum end 
diastolic thickness of 17mm (anterobasal) and 
a basal left ventricular outflow tract gradient 
(LVOTG) of 95mmHg (flow velocity 4.9mls). 
There was a 3+ systolic anterior motion (Sfu.\1) 
of the mitral valve (see Supplementary Movie 
online), resulting in an eccentric jet of mild (1+) 
mitral regurgitation into a dilated left atrium 
184 
(diameter48mm). On the parasternallong-a.-..:is 
plane, the point of aortal septal attachment was 
15 mm below the aortic root There was notice-
able diastolic dysfunction-the mitral valve E 
to A -wave ratio was 1.1 (diastolic dysfunction 
is defined in our institution as an E to A wave 
ratio of0.75-1.5). Left ventricular (LV) diameter 
and systolic function were both nonnal. A diag-
nosis of severe hypertrophic obstructive cardio-
myopathy (HOCM) was made on the basis of 
echocardiography results and the patient was 
started on metoprolol (75 mg twice daily). Over 
the next 18 months, despite medical treatment, 
the patient's palpitations persisted and dyspnea 
worsened He was diagnosed with NYHA class 
II-III heart failure 18 months after presentation 
and was referred for percutaneous transluminal 
septal myocardial ablation (PTSMA). 
As preparation for PTSMA., the patient under-
went coronary angiography, which showed no 
clinically important coronary artery disease. The 
right coronary artery was dominant, and from 
the left anterior descending artery there were 
two large first septal vessels (Figure lA). The LV 
ejection fraction (LVEF) was 70% with aLVOTG 
of 78 mmHg (Figure 2A). A cardiac MR1 scan 
confirmed local septal hypertrophy with SA..\1, 
a normal myocardial mass (l43g), and a good 
LVEF (77.4%). Delayed, contrast-enhanced MRl 
using gadolinium diethyl-triaminepentaacetic 
acid (0.2mmo1Jkg: intravenously) showed no 
fibrotic areas (Figure 3A). At 23 months after 
initial presentation, the patient chose to undergo 
PTSMA. He was mildly sedated and his left coro-
nary system was cannulated withaJudkinsleft4, 
6-French catheter inserted into the right femoral 
artery through a 6-French sheath. Intravenous 
heparin (70 IV !kg) was administered to keep the 
activated clotting: time at more than 300s. As a 
precaution, a temporary pacing w:ire was placed 
in the right ventricle via a 6-Frcnch sheath in the 
right femoral vein and left in situ for 48h after 
septal coil ablation. The first two septal branches 
were crossed using Hi-Torque Whisper® (Abbott 
Vascular, Santa Clara, CA) 0.4mm guidewires. 
Contrast TIE-performed by sequentiallyinflat-
ing a 2X8mm over-the-w:ire coronary dilatation 
catheter (Voyager®; Abbott Vascular) proximally 
at 810.6kPa (8atm) and injecting ultrasound con-
trast media through the lumen-showed opacifi-
cation of the septal bulge area, indicating that the 
first two septal perforators were involved.1 These 
vessels were coil embolized using a designated 
microcatheter (E:"<cclsio:r® SL-10; Boston Scientific, 
www.nature.tomjcllnlcalproetlcc/CDrdlo 
Rgure 1 The patient's coronary angiograms. {A) Angiogram taken before coil 
implantation. (B) Angiogram taken after coil implantation. White arrows show 
coils in 1st and 200 septal vessels. 
Rgure 2 Hemodynamic assessment of left ventricular outflow tract gradient 
{A) Assessment before coil implantation. (B) Assessment after coil implantation. 
The continuous pressure recordings during ectopic heart beats show a decrease 
{from 78mmHg to 35mmHg) immediately after septal coil occlusion. 
Fremond, CA) to push forward a self~coiling 
w:ire40mminlength with the 0.4mm guidewire, 
which fonned a coil with a diameter of 2 mm 
when the microcatheter was withdrawn. A total 
of four coils were used, two in each of the septal 
perforators (Figure lB). The entire procedure 
took 75min to complete, with the first septal per-
forator treated after 42 min and the second vessel 
after 64 min. 
Online LV pressure-volume measurements 
were performed following retrograde introduction 
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Figure 3 Gadolinium-enhanced MR! scans. (A) Scan taken before coil 
implantation. (B) Scan taken 48h after coil implantation, demonstrating that 
infarction was confined to the basal anteroseptum (mass 8.1 g; volume 7.7mQ. 
White arrow shows the infarcted basal septal vessel. 
Table 1 HemodynarnicmeasurementsatbaSellneand after percutaneous 
trarislumlnaJ Septal coil embolization. 
Hemodynamic measurement Beton> ... , Pvalue 
HR(bpm) 75.1%0.33 74,7±0.44 0.08 
SW(LxmmHg) 9.9±0.39 9.S:t0.27 0.002 
SV(mQ 99.3±1.11 93.7±3.3 0.001 
CO(IImln) 7.46±0.75 7.01±0.25 <0.001 
EF(%) 75.h0.97 69.9±1.48 <0.001 
ESV(ml) 32.8±1.61 40.2±1.71 <0.001 
EDV(ml) 132.2±1.78 134'.t2.54 0.09 
ESP(mmHg) 117.1±3.14 119±2.95 0.31 
EDP(mmHg) 22.1±1 18.3±1.5 <0.001 
dP/dtw.x (mmHg/s) 1455±36 1472±40 0.37 
-dP/dtMIN (mmHg/s) -1541±32 •1826±152 0.001 
Tau (mls) 78.8±3.17 79.7±2.72 o•1 
EES (mmHg/mQ 1.44:1;0.05 1.42±0.03 026 
EEO (mmHg/mQ 0.19±0.003 0.16±0.01 <0.001 
V30EOPVR 138.2±2.1 144±3.42 0.001 
Abbrovlr.ltlons: bpm, beats per min; CO, cardiac output; dP/~ mtlldmum rate of lV prcssur(l 
change: dP/~IN• minimum rate of LVprossuro change; EDP, end diastolic pressuro; EDPVR. &nd 
diastolic pressuro--volumo roi:!Uonshlp; EDV. end diBstollc volui'M: fro, diastolic stiffness; Ee,. 
ond systolic elastanee (slope: of el'ld systolic prossure-:volumo roi:!Uonshlp) el'llluated by single-
beat estlmatlon 113; Ef, ojection fmctlon: ESP. end systolic pressure: ESV. end systolic volume: HR, 
heo.rt mto: LV,IG!tventrlcular; Sl, strokevolumo;SN, stroke work; Tau, roliD:atlon time constant; 
V30eoPVR• Intercept of EDPVR atSOmmHg (EDPVR assoosod by single beat estimatlon 15j. 
of a 7~French combined pressure-conductance 
catheter (CD Leycom, Zoetermeer, The Nether~ 
lands) from the contralateral groin to the LV long 
axis. The catheter was connected to the CFL-512 
cardiac function laboratory (CD Leycom) for 
acquisition and display of pressure-volume 
" 
rmu 
loops. Data analysis was perlormed offline by 
custom~made software. Hemodynamics and LV 
function were assessed by the indexes defined 
in Table 1. Immediately following septal occlu-
sion, there was a decrease in the continuous 
LVOTG pressure recordings (from 78 mmHg to 
35mmHg) during ectopic heart beats (Figure2B). 
No gradient across the LV outflow tract was 
recorded during normal R-R intervals. The acute 
hemodynamic findings observed using pres-
sure-volume loops are summarized in Figure 4 
and in Table 1. Peak levels of cardiac enzymes-
creatine kinase-MB (36.6!lg!l) and troponin T 
( 0.43!lg/l)-indicated limited infarction. Cardiac 
lv1R.I performed48h after PTSMA demonstrated 
diminished regional wall thickening in the basal 
septum and eradication of the SAM. Delayed, 
contrast-enhanced lv1R.I (Figure 3B) with gado-
linium revealed recovery of LV function (LVEF 
75.4%) and that the infarct was confined to the 
basal anteroseptum (mass 8.1 g; volume 7.7ml).2 
Following routine observation in the coronary 
care unit for 48 h, the patient had an unremark-
able hospital stay and was discharged 4 days after 
PTSMA on mctoprolol 75 mg twice daily. At a 
clinic visit 1 month after hospital discharge, the 
patient was asymptomatic and TTE revealed no 
clinically significant LVOTG; metoprolol was, 
therefore, discontinued. 
DISCUSSION OF DIAGNOSIS 
HOCM is an autosomal dominant condition 
affecting 1 in 500 adults worldwide.3 The increase 
in LVOTG seen in patients with HOCM is caused 
by marked myocardial hypertrophy, particularly 
of the LV septum, and the associated abnormal 
SAM of the anterior mitral leaflet As the obstruc-
tion worsens, cardiac output decreases causing 
fatigue, syncope, dyspnea, angina, arrhythmias, 
and sudden death. 4 Many of these symptoms 
were observed in this patient, who first presented 
with paroxysmal atrial flutter, syncope, and exer-
tional angina. Crucial to the patient's diagnosis 
of HOCM were echocardiographlc findings in 
accordance with criteria specified in the ACC 
and European Society of Cardiology guidelines, 5 
including a maximum wall thickness of 15mm 
or more. HOCM is considered severe if flow velo-
city is 4m/s or more with a LVOTG of 50mmHg 
ormore.5 
DIFFERENTIAL DIAGNOSIS 
The most likely differential diagnosis for the 
patient's presentation is aortic stenosis, which can 
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occur at or above the aortic valve. Other possible 
diagnoses include a globally hypertrophic heart-
sometimes seen in athletes and hypertensive 
patients-or an infiltrative disease, such as 
amyloidosis. The fact that this patient had asym-
metric septal thickening and no subvalvular 
disease permitted the diagnosis ofHOCM. 
TREATMENT AND MANAGEMENT 
Negative inotropes, such as ~-blockers and 
calcium antagonists, are usually used as first-
line treatment of HOCM. In drug-refractory 
cases, PTS:MA. (usually with alcohol) and surgi-
cal myectomy are alternative therapies.5 Alcohol 
septal ablation is associated with relatively low 
mortality (1-4%), but unpredictable diffusion 
of alcohol within the myocardial capillary bed 
can cause high-grade atrioventricular block (in 
5-30% of patients).6 Furthermore, initial stun-
ning of the myocardium can only transiently 
improve the LVOTG, and ultimate resolution 
can require several months of septal remodeling. 7 
Surgical myectomy offers immediate and perma-
nent abolition of the LVOTG and the opportunity 
to perform simultaneous mitral valve repair. This 
procedure does, however, require general anesthe-
sia, carries a mortality of 1-4%, and is associated 
with a risk of requiring permanent pacemaker 
implantation, albeit a low one (1 %).5•8 The chal-
lenge, therefore, is to find alternative methods for 
PTS:MA. that can effectively control the infarct size 
while improving the outflow gradient9•10 
Arterial coil emboli7..ation has been success-
fully used to manage acute bleeds, arterial 
aneurysms and patent ductus arteriosus.l1 In 
addition, Durand et aL have shown promising 
results with this technique in 20 drug-refractory 
patients with HOCM.12 An average of 3.6 
(± 1.9) coils were used in each patient, and at 
6 months TTE showed that the mean LVOTG 
had decreased significantly from 80 ± 25 mmHg 
to 39±28mmHg (P=O.OOl).B No ventricu-
lar arrhythmias or permanent atrioventricular 
blockage were observed. The LVOTG reduction 
is caused by gradual changes in LV geometry 
over several weeks or months, which result in an 
increased cardiac output and a decreased after-
load that, together with a reduced LV diastolic 
pressure, improve diastolic function.14 General 
hemodynamics immediately after PTS:MA. arc, 
however, poorly understood. In this case, the 
patient's stroke volume, cardiac output and 
stroke work were significantly reduced immedi-
ately after PTS:MA.. An increase in end systolic 
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Figure 4 Pressure-volume loops acquired before (black line) and after (red line) 
coil implantation. The slope of the end systolic pressure-volume relationship 
(ESPVR) is represented by the equation of the line that includes the end systolic 
elastance point (superimposable with the end systolic volume [ESVJ) and the 
esftmated theoretical maximum pressure point (P max). The change 'tn contract'tr!ty 
was determined by the change of the slope of the ESPVR line and its posltion. 
The relationship showed a rightward shift and a slight decrease in slope of the 
ESPVR, indicating a trend towards reducing the intrinsic systolic function. 
The end diastolic pressure-volume relationship (EDPVR) was estimated using an 
exponential curve (end diastolic pressure=o.xend diastolic volume [EDVh Alpha 
(a.) and beta$) are obtained by a sequence of calculations from a single set of 
pressure and volume values, representing the coefficients of the estimated curve. 
Diastolic left ventricular function showed an acute improvement of the isovolumic 
relaxation phase (increased minimum rate of left ventricular pressure change) and 
an improved diastolic compliance (lower end diastolic pressure and decreased a.). 
volume and the reduction in stroke volume led 
to a decrease in LVEF and a subsequent acute 
decline in systolic function. The ma.'iimum 
rate of LV pressure change (dP/dtMAX) did 
not, however, decline (P= 0.37). As the above 
traditional indices can be affected by changes 
in loading conditions, we also assessed systolic 
LV function by examining the end systolic pres· 
sure-volume relationship. This relatively load-
independent relationship showed a rightward 
shift and a slight decrease in slope after the pro-
cedure (Figure 4), indicating a trend towards 
reduced intrinsic systolic function (P=0.369). 
Conversely, diastolic LV function showed an 
acute improvement in the minimum rate of LV 
pressure change (dP/dtMIN). This finding sug-
gests a faster isovolumic relaxation phase in the 
patient after PTSMA, leading to significantly 
reduced end diastolic pressure (EDP) and dia-
stolic stiffuess (Jlw; calculated asEDP dmded by 
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end diastolic volume), thus indicating improved 
diastolic compliance. In line with these findings, 
the end diastolic pressure-volume relationship 
(EDPVR) showed a decreased slope as con~ 
firmed by the increase in V30EDPVR· V30EDPVR 
is extrapolated from theEDPVR equation, which 
was obtained according to the single~beat estima~ 
tion method developed by Klotz et aL 15 In our 
patient, diastolic function was evaluated using 
several indices, including the minimum rate of 
LV pressure change, the relaxation time con~ 
stant, ~0, EDPVR, and V30EDPVR· The passive 
properties of the left ventricle acutely improved 
immediately after PTSMA-Ew decreased and 
V30EDPVR increased. These findings are related to 
the reduction ofEDP. In both cases-the increase 
in V30EDPVR and the decrease in Em-a decrease 
in EDP led to results that can be interpreted as an 
improvement in diastolic function. 
CONCLUSIONS 
This Case Study illustrates the immediate changes 
in general hemodynamics, and in systolic and 
diastolic properties, following septal coil emboli~ 
zation in a patient with drug~ refractory H OC.\1. 
The acute negative effects of this therapy on 
pressure-volume hemodynamics are probably 
due to the important influence that tissue loss 
has on systolic function in a phase where the 
compensatory processes have not begun. At 48 h 
after the procedure, cardiac MRl demonstrated 
recovery of systolic LVEF in this patient 
Supplementary information in the form of a 
movie is available on the Nature Clinical Practice 
Cardiovascular Medicine website. 
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Adipose-Derived Cells 
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He:ut failure is by far the most common cause of hospital:ization in Western countries. with onerous eco-
nomic consequences. Cell therapy holds great promise for use in tis~-ue regeneration and is increasingly used 
in an effort to improve outcomes in cardiac disease. Recently it has been shown that adipose tissue, in 
addition to committed ad.ipogenic, endothelial progenitor cells and pluripotent vascular progenitor cells. also 
contains multipotent cell types (adipose-derived stem cells., ADSCs) that, in cell culture conditions. have 
shown to have :m impressive developmcntll plasticity including the ability to undergo multilinea.ge differen~ 
tiation :md self-renewal. ADSCs express multiple CD marker :mtigens similar to those observed on MSCs 
and are also capable of secreting a large number of angiogenesis-related cytok.ines. including vascular endo-
thelial growth factor, granulocyte/macrophage colony stimulating factor, stromal.-dcrivcd factor-la, and he-
patocyte growth factor. Adipose tissue can be harvested in large quantities with minimal morbidity in several 
regions of the body and, on average, 100 m1 of human adipose tissue yields about 1 x !Qfi stem cells. Studies 
conducted in porcine AMI models have shown a significant LV functional improvement with no report of 
any potentially fatal arrhythmias. The A.POLLO trial. a prospective, double blind, randomized, placebo-
controlled trial currently in the recruiting phase. is a 'ii.rst-in-man~ study that explores the safety and feasibil-
ity of ADSC transplantation in patients with acute MI. 
Key words: Cardiac regeneration; Adipose-derived stem cells; Heart failure; Acute myocardial infarction 
INTRODUCTIO!'l 
Primary PCI, thanks to enormous improvements in 
materials and devices, is nowadays considered the gold 
standard for the treatment of AMI and leads to excellent 
safety and efficacy results. Nevertheless, revasculariza-
tion therapies, though able to restore perfusion and con-
tractile function of postinfarct stunned or hibernated 
myocardium. have no effect on necrotic tissue. 
Postinfarction myocardial necrosis and subsequent 
formation of fibrotic scar that replaces viable myocar" 
dium leads to depressed systolic function. reduced dia" 
stolic compliance. left ventricular remodeling. and ulti" 
mately to congestive heart failure progression. by far the 
most common cause of hospitalization in Western coun~ 
tries. with onerous economic consequences. 
The potential of cell transplantation to repair dam~ 
aged myocardium and to grow new viable tissue is at-
tractive. and has been widely studied in both experimen-
tal and clinical conditions using various cell types 
(8-10,24.35.42). 
The characteristics of the ideal cell still remain to be 
defined. but it appears clear that among the cells effi-
cient in the treatment of heart disease. cells that are au-
tologous, nonembryonic. do not require culturing to ob-
tain a therapeutic dose, and can be administered during 
the same procedure may be logistically easier to use. 
Mesenchymal stem cells, referred also to as marrow 
stromal cells (MSCs), have shown to have some of the 
above-mentioned ideal properties~ MSCs in fact are 
multipotent adult stem cells that can expand in culture 
and are able to differentiate into multiple mesenchymal 
cell phenotypes, including bone. cartilage, and fat. In 
addition. MSCs are capable of nomnesenchymal pheno" 
typic differentiation into neurons, skeletal muscle pro-
genitor cells. vascular endothelial cells, and cardiomyo-
cytes (14.20,22.31 ,405355). 
So far. these cells have been harvested from bone 
Address correspondence to Prof. P. W. Serruys, M.D., Ph.D., Director of the Intcrventional Cardiology Dep:utment. Thoraxccntcr, Erasmus MC, 
Eramus University, Dr Molewaterplcin 40, 3015 GD. Rotterdam. The Netheri:mds. Tel: 0031104635260; E-mail: p.w.j.e.serruys@crasmusmc.nl 
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marrow, a tissue source that presents multiple limita-
tions. including: a) donor site morbidity limits the 
amount of marrow that can be obtained (generally 
40-50 ml) (3.18): b) MSCs represent <0.01% of all nu-
cleated bone marrow cells in healthy volunteers (approx-
imately 1 in 25.000 to 1 in 100,000) (4.5): and c) re-
quires extended time in culture to obtain therapeutic cell 
doses by ex vivo cell expansion. rendering treatment in 
the acute phase of myocardial infarction impractical. 
Recently it has been shown that adipose tissue. in 
addition to committed ad.ipogenic, endothelial progeni-
tor cells and pluripotent vascular progenitor cells. con-
tains multipotent cells. similar to MSCs (58,59). This 
finding has generated major interest because, in contrast 
to bone marrow. large quantities of adipose tissue can 
be easily and safely harvested with minimal morbidity. 
making it an appealing source for cell therapy. 
CELL CHARACTERISTICS 
Adipose tissue has a notable plasticity during life. Al-
though cellular hypertrophy can partially enable in-
creases in volume. large variations are usually associ-
ated with an increase in adipocyte count (cellular 
hyperplasia) accompanied by a conconritant expansion 
and remodeling of the :microvasculature supplying these 
cells (1). 
The hyperplastic process of the adipose tissue was 
formerly thought to be mediated by a population of uni-
potent progenitor cells called preadipocytes. These cells 
have been demonstrated to have potential beyond that of 
the adipocytic lineage, with an impressive develop-
mental plasticity (23.58), including the ability to un-
dergo multilineage differentiation and self-renewal (49, 
54,57.59) (Fig. 1). These cells. present within the stro-
mal vascular fraction of adipose tissue. are generally re-
ferred to as adipose-derived stem cells (ADSCs).ADSCs 
are a cell population with properties that are very simi-
lar. though not identical. to those of marrow-derived 
MSCs (7,38.39.52). 
These cells have extensive proliferative capacity and 
are able to undergo differentiation along both mesenchy-
mal lineages (adipogenesis. chondrogenesis.. osteogenesis) 
(11.14.20.2231.40.53.55) and nonmesenchymallineages 
(endothelial, smooth muscle and neurogenic), confirm-
ing the transdifferentiation ability of ADSCs (40.41). 
In culture, these cells have a surface phenotype rather 
similar to the MSC phenotype (fable 1): both cell types 
express CD117 (stem cell factor receptor), CD105, 
STROL and CD166 (multilineage differentiation mark-
ers) (6.19.26.43). CD90. CD54 OCAM-1). CD44 and 
CD29 (~1-integrin) (13.14). whereas both cell types do 
not express the endothelial markers CD3L CD34, and 
the hematopoietic marker CD45 (7.19). 
However, MSCs and ADSCs have a number of rela-
tively slight distinctions, the most interesting of which 
is the reciprocal expression pattern of the very-late·acti-
vation antigen 4 or VLA-4 (CD49d!CD29) and its cog-
nate receptor vascular cell-adhesion molecule 1 or 
VCAM-1 (CD106). ADSCs express VLA-4 but not 
VCAM-1 in the majority of donors, while MSCs usually 
express VCAM-1 and not VLA-4 (7). 
The consequences of these properties are not clear 
yet. but this observation is fascinating because both 
these molecules play an important role in the homing 
and mobilization process of hematopoietic stem cell 
from bone marrow (44.48). 
MSCs and ADSCs are also known to secrete a large 
number of angiogenesis-related cytokines (37). ADSCs 
in standard cultures secrete high levels of hepatocyte 
growth factor (HGF), vascular endothelial growth factor 
(VEGF). placental growth factor (PlGF). transforming 
growth factor-~ (TGF-~). fibroblast growth factor 
(FGF), granulocyte/macrophage colony stimulating fac-
tor (GM-CSF), monocyte chemotactic protein-1 (MCP-
1), and stromal-derived factor-la (SDF-1a), suggesting 
an important role of ADSCs in neovascularization 
(36.37). 
Clonally derived, multipotent cells from adipose tis-
sue display an immunoprivileged behavior (39). Less 
than 1% of ADSCs express the cell surface MHC class-
L while class-Jl is almost absent (25), being therefore 
poorly recognized by T lymphocytes. Moreover, ADSCs 
have the ability to suppress lymphocyte reaction in a 
dose- and time-dependent fashion: such immunosup-
pression probably occurs via the production of IL-4, IL-
10, and TGF-~. responsible for the inhibition of lympho-
cyte proliferation (34). 
These characteristics, together with the easy avail-
ability and the small amount of tissue needed for their 
isolation. suggest that ADSCs might even have potential 
as immunoprivileged universal donor cells with the pro~ 
spective possibility to be used also for allogenic trans-
plantation. 
Large quantities of subcutaneous adipose tissue can 
be safely harvested using liposuction in several regions 
of the body. A typical harvest out of 100-200 ml of 
human adipose tissue contains about 5 x 107 nucleated 
cells. After enzymatic digestion. filtration, and centrifu-
gation processes, the nonbuoyant stromal cells part from 
the buoyant adipocytes (29.32.33). The nonbuoyant frac-
tion can yield in excess of I x 106 stem cells (from 100 
cc of fat tissue), about 45-fold more than a typical har-
vest of bone marrow aspiration (of 40 ml), which nor-
mally contains 2.5 x 104 MSCs in a mature adult (3.30). 
The ADSC-containing fraction can be cultured with dif-
ferent media (e.g., DMEM-F12: EGM~2-MV, a-11EM. 
etc.) and supplemented with different growth factors 
(e.g., VEGF. insulin-like growth factor. basic FGF, etc.) 
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Figure 1. Multiple mechanisms of cell regeneration enacted by ADSCs. 
to stimulate expansion and differentiation into dedicated 
lineages. Due to the great concentration of ADSCs nor-
mally present in an adipose tissue harvest. it is also pos-
sible to obtain therapeutic cell doses in as little as 1 after 
liposuction, without further expansion in culrure (32.33). 
therefore avoiding cell alterations often associated with 
culturing. 
Table 1. Cell Surface Characteristics of Adipose-Derived 
Stem Cells and Mesenchymal Stem Cells 
Cell Surface Marker 
CD29 
CD44 
CD54 
CD90 
CD!05 
CDI66 
STR0-1 
CD31 
CD34 
CD45 
CD49D 
CD106 
ADSCs 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
MSCs 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
DIFFERENTIATION CAPABILITIES OF ADSCs 
ADSCs, similarly to MSCs. have the ability to un-
dergo differentiation along both mesenchymal (fat. 
bone, cartilage) and nonmesenchymallineages (endothe-
lial cells, smooth muscle) (13,15,20,22,44,45), demon-
strating that adipose tissue contains pluripotent cells. 
Furthermore. concerning muscle differentiation, evi~ 
dence shows that ADSCs have the capability to differen~ 
tiate into contractile cells with either striated muscle 
cells or cardiomyocyte features (12.21.27.50.56). 
In Vitro Studies of ADSC Differentiation 
After isolation and expansion of processed lipoaspir~ 
ate (PLA) clones. PLA cells expressed multiple CD 
marker antigens similar to those observed on MSCs. as 
observed by Zuk et aL in 2002 (58). During in vitro 
culture with various supplementation, PLA clones dif~ 
ferentiated into different mesodermal lineages (exam~ 
ined lineages were: osteogenic, chondrogenic. adipo-
genic), while some clones exhibited differentiation 
potential into all of these lineages. These trilineage 
clones were designated as ADSCs. confirming therefore 
the presence of a stem cell population within adipose 
tissue. In addition to mesodermal lineages. PLA cells 
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and clones showed the capability to differentiate into pu~ 
tative neurogenic cells. exhibiting morphology and a 
protein pattern consistent with the neuronal phenotype. 
In 2005. PlanatwBenard et al. (32) obtained extraordi-
nary results by plating fresh ADSCs in a semisolid cul-
ture. After 3 weeks of culture, ADSCs morphologically 
developed into ventriclewlike. atrial-like, and pacemaker-
like cells, displaying tight intercellular connections (evi~ 
denced by Cx-43) and spontaneous as well as triggered 
action potentials with beating. Moreover. these differen-
tiated cells expressed the cardiac~specific transcription 
factors Nkx2.5, GATA-4. and MEF-2C. the structural 
cardiac proteins ~~myosin heavy chain (MHC). myosin 
light chain~2 ventricular (MLC~2v). myosin light chain-
2 atrial (MLC-2a) as well as the atrial natriuretic peptide 
(A:.W). whereas the skeletal marker MyoD and smooth 
muscle actin were not expressed. Consistent with these 
results, after 3 weeks of exposure of ADSCs with a per~ 
meable cell membrane to rat cardiomyocyte extracts, the 
ADSCs expressed cardiomyocyte markers including sar-
comeric alpha~actin, desmin, and cardiac troponin I. as 
well as the gap junction protein connexin-43 (Cx-43) 
and started to beat spontaneously, as observed by Gaus-
tad eta!. in 2004 (17). 
In Vivo Studies of ADSC Differentiation 
Several groups have so far reported data about the 
safety and efficacy of ADSCs to regenerate damaged 
myocardium in both small (rats) and large animals 
(pigs). Strem and colleagues (46) in 2005 used intraven-
tricular injections to deliver freshly isolated ADSCs 
from Rosa 26 mice (expressing the ~-galactosidase 
transgene) into syngeneic recipient mice. following 
myocardial cryoinjury. ~-Galactosidase-positive cells 
were found in treated mice together with the expression 
of :MHC, Nkx2.5. and troponin I at 14 days posttrans-
plantation. suggesting that ADSCs have the ability to 
engraft injured myocardium and express specific cardia-
myocyte markers in vivo. 
In another study conducted by the same group, syn-
geneic freshly isolated ADSCs were injected into the LV 
chamber of 10 female Lewis rats after 60-min occlusion 
of the LAD, resulting in significant increases of 5.1% 
and 7.7% delta in LVEF at 4 and 12 weeks (Fig. 2). 
respectively. compared with control rats (saline treated, 
n = 10). This study also demonstrated significant improve-
ments in both d.P/dt,.,. and dP/dt,;, in the ADSC-treated 
rats compared to controls (Table 2) (47). Moreover. in 
accordance with the previous study. cell engraftment 
was demonstrated 7 days after transplantation (Fig. 3). 
Delivery of ADSCs by intracoronary infusion into 
pigs 2 days after an acute J\1I through a LAD balloon 
occlusion resulted in a 3% absolute increase in L VEF 
while the untreated pigs showed a 9% decline at 6-
month follow-up (p < 0.01) (51). Likewise, intracoro~ 
nary infusion of either ADSCs or MSCs in an acute J\1I 
pig model resulted in an 11.4% improvement of absolute 
L VEF after 4 weeks, compared to only 2% improvement 
in the nontreated group (p < 0.003) (50). 
Freshly isolated ADSCs given immediately after re-
perfusion in a porcine A:.\1! model resulted in a 8% 
L VEF increase compared to controls at 8-week follow-
up (p = 0.023) (2). 
Interestingly, concordant with the functional im· 
provement, wall thiclmess and capillary density were 
both significantly increased in the border infarct areas 
of the treated group. compared to the control group (28). 
In a study recently published by Miyahara and col-
leagues (29). ADSCs were transplanted directly onto in-
farcted murine hearts as a monolayered cell sheet. After 
transplantation. the engrafted sheet gradually grew to 
form a thick stratum that included newly formed vessels, 
undifferentiated cells. and cardiomyocytes. Autologous 
transplantation of ADSC sheets resulted in a decreased 
L VEDP, improved maximum and minimum d.P/dt, in-
creased diastolic wall thiclmess. increased left ventricu-
lar fractional shortening, and decreased diastolic wall 
stress. compared to dermal fibroblast sheets taken as a 
control. 
Human Studies of ADSC Differentiation 
ADSCs have been used successfully in a variety of 
indications in humans, including bone reconstruction. 
the treatment of Crohn's disease fistulas (15.16). os-
teogenesis imperfecta (21). and for breast augmentation 
and reconstruction after partial mastectomy (56). The 
APOLLO trial. currently recruiting patients. is the "first-
in-man" study that explores the safety and feasibility of 
ADSC transplantation in patients with acute Iv11. The 
APOLLO trial is a prospective, double blind. random-
ized, placebo-controlled. sequential dose escalation 
study that will enroll up to 48 patients (4 cohorts of 12 
patients each) with acute J\1I at the Thoraxcenter, Eras-
mus MC, Rotterdam. 
Eligible patients are enrolled following primary PCI 
and undergo liposuction and isolation of the adipose-
derived regenerative cells fraction (ADRCs) using the 
CelutionTM system (Fig. 4). ADRCs are then injected 
within 24 h from the primary PCI into the culprit coro-
nary artery. 
Main safety end points include: major adverse car· 
diac or cerebral event (MACCE) rates. serious adverse 
events (SAEs)/adverse events (AEs) rates and a compos-
ite clinical end point of death. J\1I, stroke. and rehospi-
talization for heart failure. Main feasibility end points 
are: absolute L VEF and changes in L VEF from baseline 
to 6 months, J\1I size, regional wall thickness and thick-
ening in all segments. LV end systolic volume (LV-
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Figure 2. L VEF evaluated by echocardiography at 4 and 12 weeks showed a significant improve-
ment in the group treated with ACSCs (ADC) compared to the control group (Control). 
ESV), LV end diastolic volume (LV-EDV), and change 
in perfusion defect after revascularization to 6 months 
as measured by contrast enhanced MRl, echocardiogra-
phy, and scintigraphy. 
Patients will be followed for 36 months and will un-
dergo imaging studies (2D/3D echocardiography, LV 
angiography, MRl, SPECT), functional evaluation (left 
ventricular pressure-volume relationship), clinical eval-
uations, and laboratory testing at 6. 12, and 18 months. 
SIDE EFFECTS, ADVERSE EVENTS 
AND POTENTIAL HURDLES 
The main issue related to transplanted cells is their 
potential arrhythmogenicity. Previous reports conducted 
using skeletal myoblasts showed an increased rate of ar-
rhythmic events in the treated groups that raised impor-
tant interrogatives on the safety of this treatment and 
that led often to prophylactic AICD implantation (27). 
Although limited safety data are available to date, in 
vivo preliminary animal studies conducted using ADSCs 
have not reported an increase in any potentially fatal 
Table 2. dP/dt Evaluated at 12 Weeks by :Millar Pressure Tip 
Catheter Is Significantly Higher in the Group Treated With 
ADSCs Compared to the Control Group (Saline Treated) 
Saline Treated 
tdP/dt 2837.61 (30Ll9) 
-dP/dt -2716.49 (331.83) 
ADC Treated 
5494.46 (550.76) 
--6323.28 (544.61) 
Values are mmHg/s with SE in parentheses. 
p-Value 
0.015 
0.003 
arrhythmias. For instance. loop recorder monitoring in 
pigs treated with ADRCs (12) did not show an increase 
in fatal arrhythmic events or sustained arrh)'thmias (e.g., 
bradycardia lower than 45/min or tachycardia above 
165/min) in the treated animals. Programmed right ven-
tricular stimulation did not show an increase in suscepti-
bility for arrhythmias by ADRC treatment. On the con-
trary, cycle length was significantly longer in theADRC 
group at the beginning of an induced arrhythmia. sug-
gesting rather a reduction in the overall inducibility of 
malignant arrhythmias than an increase in susceptibility. 
In addition, there have been no reports on arrhythmias 
in patients who underwent intrarnyocardial injections of 
ADRCs using the NOGA delivery system in patients 
with chronic myocardial ishemia in the PRECISE trial. 
Issues associated with tissue harvest in patients with 
a recent AMI under high doses of anticoagulants. GP 
lib-Ilia inhibitors, and aspirin are a potential concern. 
owing to the highly developed vascularization of adi-
pose tissue and the consequent bleeding risk However, 
only a relatively small amount of tissue is required to 
obtain an effective cell dose, and hemostasis at the site 
of liposuction can easily be achieved by local pressure. 
CONCLUSIONS 
Human adipose tissue is an interesting source of 
multipotent stem cells that have the ability to differenti-
ate into several mesenchymal and nonmesenchymallin-
eages (including vascular and cardiomyocytes lineages). 
demonstrate stem cell-like extensive self-renewal, and 
secrete several factors with angiogenic and antiapoptotic 
effects. Moreover, ADSCs/ADRCs. unlike bone mar-
198 
Figure 3. Histologic samples taken at day 7 posttransplantation in the A\11 broder region of ADC-treated rats showing ADSC 
engraftmcnt Left: green channel on. Right: green channel o-ff. Red= anti-GFP immunostaining, blue= DAPI. 
row-derived MSCs. can be easily and safely obtained in 
large numbers. without the necessity to culture and ex-
pand them to obtain a therapeutic dose. 
ADRCs have already been used in humans in differ-
ent clinical settings with excellent results and few side 
effects. Preclinical studies conducted in animal AJv11 
models showed that ADSCs have the capability to dif-
ferentiate into cardiac muscle cells as well as to excrete 
different growth factors with important pro-angiogenic 
effects that led to a significant improvement of ejection 
fraction and wall thickness. 
The APOLLO trial, a "first-in-men" study conducted 
with ADSCs in AMI patients. will provide fundamental 
Figure 4. The CelutionTM svstero. Reproduced with oennission 
data about the safety and efficacy of these cells in hu-
mans, providing an essential insight on what could be 
their role in the treatment of cardiovascular disease. 
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Abstract 
Heart failure is a major health problem and myocardial infarctiorl (Mil is, at the preser1t time, the mair1 
cause. Cell therapy hold great promise for use in tissue regeneration and is increasingly used ir1 an effort 
to improve outcomes in cardiac disease. Recently it has been shown that adipose tissue, in addition to 
committed adlpogenic, endothelial progenitor cells ar1d pluripoterlt vascular progenitor cells, contains also 
multipotent cell types (adipose derived stem cells, ADSCs) that, in cell culture conditions, have extensive 
proliferative capacity and are able to differentiate into several lineages, meser1chymal or not. 
ADSCs, similarly to MSCs, express the CD105, STROl, CD166, CD1l7,CD90, CD54, CD44and CD29 sur-
face markers. Moreover, ADSCs are also capable of secreting a large number of growth factors, ir1cluding 
vascular endothelial growth Factor, GranulocyteJMacrophage Colony Stimulating Factor, Stromai Derived 
Factor-lalpha and Hepatocyte Growing Factor. 
Adipose tissue can be harvested in large amour1ts with minimal morbidity and, owing to the large concentra-
tiorl of stem cells contained ir1 a typical harvest, therapeutic doses of ADSCs can easily be isolated in as little 
as an hour after liposuction, obviating the need for culture. Several studies cor1ducted in porcine AMI mod· 
els have shovvn a significant LV functionat improvement, with no report of ar1y potentially fatal arrhythmias. 
The APOLLO trial, a prospective, double blind, randomised, placebo controlled, sequential dose-escalation 
study conducted at the Thoraxcenter, Erasmus MC, will be the 'First-irl-Man' study that will explore the 
safety ar1d feasibility of ADSC transplantation in patients with acute MI. 
• Corresponding author: Thcraxcenter. Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands. 
E-mail: p.w.j.c.serruys®erasmusmc.nl 
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Introduction 
Despite recent developments in the treatment of corol'!ary artery 
disease and the introduction of new devices and effective post PCI 
therapies, the loss of cardiac tissue and the resulting impairment 
of left ventricular fur~ction after myocardial infarction (Mil remains 
a main cause of he<Jrt failure, defining the need to find an effective 
treatment to ameliorate this major health problem and its econom-
ic consequences. The potential of cell transpla11tation to repair darn-
aged myocardium is attractive and has been widely studied in both 
experimerrtal and clinical conditions using various cell typesl·<\ The 
quest for the ideal cell is still ongoing, as the attributes of the ideal 
cell a11d working mechanism of cell regeneration still remain to be 
defi11ed. Nonetheless, there appears to be a consensus that, among 
the cells effective in the treatment of heart disease, cells that are 
autologous, non-embryonic, do not require culturing to obtairo a 
therapeutic dose, and can be administered during the same proce-
dure, may be logistically easier to use and thus may have wider 
application in catheterisation laboratories. 
The most extensively studied and characterised cells, that have 
been shown to have some of the above mentioned ideal properties, 
are mesenchymal stem cells (MSCs). MSCs are muH:ipotent. adult 
stem cells, that can expand in cell culture and are able to differen-
tiate into multiple cell phenotypes including bone, cartilage, neu-
ronal and skeletal muscle progenitor cells, but also into vascular 
endothelial cells and cardiomyocytes7·13• 
Many previous cell therapy trials in patients with AMI, have been 
using mononucleated bone marrow derived cells (8MCsl1417, that 
consist of a heterogeneous cell population. A small fraction 
of these unfractioned BMCs are MSCs. Results of these trials 
showed an improvement of regional wall motion, global ejection 
fraction and, in some cases, a reduction of infarct size in the 
treated group14·10• Selected MSCs were evaluated by Chen and 
colleagues in 200418 in 34 patients demonstrating a significant 
improvement of regional wall motion, glob<il ejection fraction, 
reduction of infarct size, but also reduction of left ventricular end 
diastolic volume {LVEDV) in the treated group, confirming the 
encouraging results obtained from previous preliminary animal 
studies1~21, So far, these cells have been harvested from bone 
marrow, however, limitations of this cell source are: 1) the number 
of MSCs in bone marrow is rather low; MSCs in fact represent 
<O.Dl% of all nucleated bone marrow cells in healthy volunteers 
(approximately 1 in 25,000 to 1 in 100,000)22.zJ; 2) donor site mor-
bidity limits the amount of marrow that can be obtained (generally 
limited to no more than 40 ml)24.25 and consequently 3) the long 
time required to obtain therapelllic cell doses by ex vivo cell expan-
sion renders treatment in the acute phase of myocardial infarction 
impractical. 
Recently It has been shown that adipose tissue, In addition to 
committed adipogenic, endothelial progenitor celis and pluripo-
tent vascular progenitor cells, contains also multipotent cell 
types26.27. This finding has generated major interest because, 
in contrast to bone marrow, adipose tissue can be easily and safe· 
ly harvested in large quantities and with minimal morbidity regard-
less of the condition of the patient, making it an appealing source 
for cell therapy. 
Cell characteristics 
Adipose tissue, differently from most tissues, has a remarkable 
plasticity during life. Although Increases in volume can be partially 
obtained by increasing the amount of lipids stored in the already 
existing adipocytes (cellular hypertrophy), large increases In volume 
are usually associated with an increase in adipocyte count (cellular 
hyperplasia) accompanied by a concomitant expans'1on and remod-
elling of the microvasculature supplying these cells28. 
The hyperplastic process of the adipose tissue and supporting vas-
cular bed is mediated by a cell population present within the stro-
mal vascular fraction of adipose tissue generally referred to as adi-
pose derived stem cells (ADSCsl. These cells, prev'1ously supposed 
to be mono-potent adipocyte progenitor cells, called pre-adipocytes, 
have actually been demonstrated to have an impressive develop-
mental plasticitf7.29 including the ability to undergo multi-lineage 
differentiation and self-renewai26.3().3Z (Figure 1). 
Figure 1. ADSCs actions end effects; ADSCs have an impressive 
developmental plasticity including the ability to undergo multi-line-
age differentiation, to act by paracr!ne effects and to display an 
immuno-privileged behaviour. 
ADSCs are a cell population with properties that are very similar, 
though not identical, to those of marrow derived MSCs=. These 
cells have extensive proliferative capacity and are able to differenti-
ate in cell culture conditions into osteogenic, chondrogenic, myo-
genic llneages7•13,37 and, more recently, into a 11eurogenic phel1o-
type9,38. 
In culture, these cells express surface markers that are sim'1larto 
those expressed by MSCs (Table 1): both cell types express CD lOS, 
STROl and CD166 (multi-lineage differentiation markersJ394<, 
CD117 (stem cell factor receptor), CD90, CD54 (ICAM-1), CD44 
and CD29 (beta-1 integrin)l3A:l·44, whereas both cell types do not 
express the endothelial markers CD31, CD34 and the haematopo'r-
etic marker CD45~.39 (Figure 2). 
Recent studies showed that freshly isolated human ADSCs from 
subcutaneous adipose tissue tested positive for the aforementioned 
Adipose derived stem cells 
Table 1. Cetl surface characteristics of adipose derived stem cells 
and mesenchymal stem cells. 
ceu;;suifaCe iliifkef: ~-~:--ADSCS_:--.-
CD29 
CD44 
CD54 
C090 
CD105 
CD166 
STR0-1 
CD31 
CD34 
CD45 
CD49D 
CD106 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Figure 2. Representative sample of freshly isolated ADRCs. CD45+, 
CD34bright and CD3lbright cells correspond to approximately 38.6, 
56.5 and 6./rJ, of total cells. Cells were analysed using FACSDiva 
software (Picture from Cytori Therapeutics). 
markers of haematopoietic and endothelial lineage. Flow cytometric 
characterisation of human ADSCs In culture revealed that the per-
certtage of cells positive for CD34 expression decreased markediy 
after 1 week of culture45 suggestirtg that the adhesion of ADSCs to 
plastic leads to a selection similar to that seen with MSCs, increas-
ing the proportion of a unique population of cells with immature 
characteristicsffi. 
One of the most interesting differences In surface makers between 
MSCs and ADSCs is a reciprocal expressiort pattern of the very-late-
activatiort arttigen 4 or VLA-4 (CD49d/CD29} and its cognate recep-
tor vascular cell· adhesion molecule 1 or VCAM-1 (CD106}. AOSCs 
express VLA-4 but rtot VCAM·l in the majority of donors, while 
MSCs usually express CD106, a component of VCAM-1, and rtot 
VL.A-435. 
The cortsequertces of these properties are not clear yet and rteeds 
further investigation, but this observation is fascinating since both 
these molecules play an important role irt haematopoietlc stem cell 
homing and mobilisatiort from the borte marrow47•48• 
MSCs but also ADSCs are knowrt to secrete a large number of 
angiogenesis-related cytokirtes45. In ADSCs in startdard cultures, 
high levels of Hepatocyte Growth Factor (HGF}, vascular 
Endothelial Growth Factor CVEGF}, Placental Growth Factor (PGF), 
Trartsforming Growth Factor-~ (TGF-~). Fibroblast Growth Factor 
{FGF}, Granulocyte/Macrophage Colony Stimulating Factor (GM-
CSF), Monocyte Chemotactic Protein-1 (MCP-1} artd Stromal 
Derived Factor-1alpha (SDF-lul were observed, suggesting an 
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active role of ADSCs in neovascularisatiort45A9• ADSCs and MSCs 
both possess the capability to suppress lymphocyte reaction irt a 
dose-depertdent and time dependent fashion; such immunosup-
pression probably occurs via the production of cytokines (including 
IL-4, IL-10, and TGF-M responsible for the inhibition of lymphocyte 
proliferation50•51• 
Clortally-derived, multipotertt cells from adipose tissue display 
furtllermore an immuno-privlleged behaviour33. Less thart 1% of 
ADSCs irt f<lct express the cell surface MHC ciass-1 whereas class- II 
is almost absent52. Therefore ADSC are poorly recognised by T-lym-
phocytes, as suggested by the absence of irtfiltration by myeloid CD3 
positive cells. Whertlnjected into immuno-competentX-Iinked muscu-
lar dystrophy (mdxl mouse muscles, ADSCs were seen to differentiate 
into functional muscle cells, integrated by fusing with host cells and 
were rtot rejected up to 6 months after transplantation33. This, togeth-
er with the easy availability and the small amount of tissue needed 
for their isolation, suggests !.'lat. ADSCs might even have potential 
as Immune-privileged universal donor cells with the capacity to be 
used not only for autologous but also for allogeneic t.-ansplantation. 
HatVest and expansion 
Subcutaneous adipose tissue can be safely and quickly harvested in 
large quantities in several regions of the body, using converttiortal 
liposuction. A typical harvest out of 100-200 ml of human adipose 
tissue would yield about 50xl06 rtucleated ce!ls. During a 
regular liposuction procedure, it is not uncommon for plastic sur-
geons to remove irt excess of 2,000 ml of fat. The samples are then 
enzymatically digested, filtered and centrifuged to separate the 
non-buoyant stromal cells from the buoyant adipocyte;f6.5:1.54. 
The non-buoyant fraction can yield in excess of 1x1Q6 stem cells 
(from 100 cc of fat tissue}, about 45 fold more than a typical harvest 
of bone marrow aspiration (of 40 ml} which typically conlairts 
2.5xl0'- MSCs in a mature aduitz"·S&. If necessary, the ADSC contairt-
irtg fraction can be cultured with different media (e.g. DMEM-F12: 
EGM-2-MV, a.-MEM etc.} and supplemented with differertt percent· 
ages of serum artd growth factors (e.g. VEGF, lrtsulin Like Growth 
Factor, bF Growth Factor etc.) to stimulate differentiation into dedi-
cated lineages and expansion. (Figure 3) Owirtg to the great concen· 
I 
I Al!io!C-':. 
_, __ _ 
Figure 3. ADRCs form cords in an in vitro tubule formation assay. 
ADRCs cultured for 1 week form cords in EGM-2. Immunofluorescence 
was used to detect CD31 (red) and von Willibrand factor (vWF, green). 
Cell nuclei were detected by DAPI (blue). Adult dermal fibroblasts 
were used as a control (bottom row). 
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tration of ADSCs normally present in the adipose tissue harvest. it is 
also possible to instantaneously obtain therapeutic eel! doses, with 
no need for further expansion in culture%. In contrast to BM-derived 
MSCs, therapeLrtic doses of ADSCs can easily be isolated in as little 
as an hour after liposuction45•46. This not only obviates the need for 
culture, bl.rt also avo"1ds cell alteraf1ons associated with cultur"1ng. 
Differentiation capabilities of ADSCs 
Numerous studies have demonstrated that ADSCs, similarly to 
MSCs, have the capability to undergo differe11tiation Into several cell 
types along both mesenchymal (fat, bone, cartilage muscle, nerve) 
and non-mesenchymal lineages (blood vessel)7•13.38,57, demonstmt-
ing that adipose tissue actually cont.ai11s pluripotent cells. 
111 particular, as fur as muscle differe11tiation is concerned, evidence 
showed that ADSCs have the ability to differentiate into contractile 
cells w"llh both str"1ated muscle cells or cardlornyocytes featurW,S..%2. 
In vitro studies of ADSC differentiation 
After two weeks of culture in RPM I medium, 20% to30% of ADSCs 
increased in size, changed shape a11d began to beat spontaneous-
ly when observed under a phase contrast microscope by three 
weeks, as observed by Rangappa et al i11 200357• Likewise, after 
three weeks of exposure to rat cardiomyocytes conditioned DMEM 
medium, ADSCs expressed cardiomyocyte markers including sar-
comeric alpha-actin, desmin, and cardiac troponin I, as well as the 
gap junction prote"1n Connex"m-43 (Cx-43) and started to beat spon-
taneously, as observed by Gaustad et al in 200458. 
In 2005, Planat-Benard et al 53 obtained similar results by plating 
fresh ADSCs in a semi-solid culture. After three weeks of culture, 
ADSCs morphologically developed into ve11tricle-like, atrial-like and 
pacemaker-like cells, displaying tight inter..cellular connections (evi-
denced by Cx-43) and spontaneous, as well as triggered actio11 
potentials with beating. Moreover, these differentiated cells 
expressed the cardiac-specific transcription factors Nkx2.5, GATA-4, 
and MEF-2C, the structural cardiac proteins I)-myosin heavy chai11 
(MHC), myos"1n light chaln-2 ventr"1cular (MLC-2v), myosin light 
chain-2 atrial (MLC-2al as well as the atrial natriuretic peptide 
(ANPJ, whereas the skeietal marker MyoD and smooth muscle actin 
were not expressed. 
In vivo studies of ADSC differentiation 
Several groups have so far reported data about the safety a11d effi-
cacy of ADSCs to regenerate damaged myocardium 111 both small 
(rats) and large animals (pigs). 
Delivery of ADSCs by intracoro11ary infusion to pigs two days after an 
acute Ml through a LAD balloon occluslo11 (Watanabe et al, 2004) 
resulted in a 3% absolute increase in LVEF while the untreated pigs 
showed a 9% decline at 6-month FU (P<0.01)59. Likewise, intra-
coronary i11fusion of either ADSCs or MSCs in an acute Ml pig model 
(Vallna et al, 2004) resulted in a 11.4% improveme11t of absolute 
LVEF after 4 weeks, compared to only 2% Improvement i11 the non-
treated group (P<0.003)00• 
Strem and colleagues61 in 2005 used intraventricular i11jections 
to deliver freshly isolated allogeneic ADSCs from Rosa 26 mice 
(expressing the beta-galactosidase transgene) into syngeneic recip-
Basic knowledge 
ient mice, following myocardial cryoinjury. Beta-galactosidase posi-
tive cells were found in treated mice together with the expression 
of MHC, Nkx2.5 and with troponin I at 14 days post transplantation, 
suggesting that ADSCs have the ability to e11graft injured myocardi-
um and express specific cardiomyocyte markers in vivo. 
Freshly Isolated ADSCs given immediately after repeliusion in a 
porcine AMI model (Ait et al) resulted in a 8% LVEF increase com-
pared to controls at 8-week FU (p=0.023)62. 
Interestingly, concordant with the functional ·Improvement, wall 
thickness and capillary density were both significantly increased 
in the border infarct areas of the treated group, compared to the 
control group53. 
In a study recently published by Miyahara and colleagues54, ADSCs 
were transplanted directly o11to infurcted murine hearts as a mono-
layered cell sheet. After transpla11tation, the engrafted sheet gradu-
ally grew to form a thick stratum that included newly formed ves-
sels, undifferentiated cells and cardiomyocytes. Autologous trans-
plal"ltation of ADSC sheets, resulted in a decreased LVEDP, 
improved maximum a11d min"1mum dP/dt, increased diastoflc wall 
thickness, increased left ventricular fractio11al shortening and 
decreased diastolic wall stress, as compared to dermal fibroblast 
sheets taken as a control. 
Human studies of ADSC differentiation 
ADSCs have bee11 used successfully in a variety of indications 
in humans, including the treatment of Croh11's disease f:stulas64·65 , 
osteogenesis imperfectaGG and for breast augmentation and recon-
struction after partial mastectomy67• So far, ADSCs have not been 
used to treat patients w"1th Ml or "1schaemic heart disease. The 
APOLLO trial will be the 'First-in-Man' study that will explore 
the safety a11d feasibility of ADSC transplant.atlol"l in patients with 
acute MI. This study is a prospective, double blind, randomised, 
placebo-controlled, sequential dose-escalation, study that will enrol 
up to 48 patients with acute Ml at the Thoraxcenter, Erasmus MC, 
Rotterdam. 
Eligible patients will be emolled following primary PCI and will 
undergo liposuction and isolation of the adipose derived regenera-
tive cells fraction (ADRCsl using the CelutionrM system (Figure 4). 
ADRCs will then be injected w"1thln 24 hours from the primary PCI 
into the culprit coronary artery. 
Main safety endpoints will include: major adverse cardiac or cere-
bral event (MACCEl rates, serious adverse events (SAEsl/adverse 
events (AEsl rates and a composite clinical endpoint of death, Ml, 
Figure 4. The Celution"" system, a fully automated device for the iso-
lation of adipose derived and adipose regenerative stem cells. 
Adipose derived s'tom cells 
stroke and re-hospitalisation for heart failure. Main feasibility end-
points are: absolute LVEF and changes in LVEF from baseline to six 
months; Ml size; regional wall thickness and thickening in all seg-
ments; LV- end systolic volume {LV-ESV); LV- end diastolic volume 
{LV-EOV); and change in pe!fusion defect after revascularisation to 
six months as measured by contrast enhanced MRI, echocardlog-
raphy and scintigraphy. 
Patients will be followed for 36 months and will undergo imaging 
studies {20!30 echocardiography, LV angiography, MRI, SPECD, 
functional evaluation {left Ventricular Pressure-Volume 
Relationship), clinical evaluations and laboratory testing at six, 12 
and 18 months, 
Side effects~ adverse events and potential 
hurdles 
One of the biggest issues related to cell therapy is the potential 
arrhythmogenicity of the transplanted cells. Previous reports con-
ducted using BMCs and skeletal myoblasts showed an increased 
incidence of arrhythmic events in the treated groups that often led 
to AICD implantation68. 
Though limited safety data are available to date, in vivo preliminary 
animal studies have not reported an increase In any potentially fatal 
arrhythmias. 
Loop recorder monitoring in pigs treated with ADRCsW did not 
show an Increase in arrhythmic events throughout the eight week 
follow-up period {one death in the control and ADRC group within 
the tirst week after Mil. No sustained arrhythmias (e.g. bradycardia 
lower than 45/min or tachycardia above 165/min) were recorded 
in surviving animals. Moreover, at the end of the study period, pro-
grammed right ventricular stimulation failed to show an increase 
in susceptibility for arrhythmias by ADRC treatment On the con-
trary, a signiticantly longer cycle length could be seen in the ADRC 
group at the beginning of an induced arrhythmia. This tinding 
implies rather a reduction in the overall inducibility of malignant 
arrhythmias than an increase in susceptibility. 
Issues associated with tissue harvest in patients with a recent AMI 
under high doses of anticoagulants, GP lib-Ilia inhibitors and 
Aspirin are a potential concGrn, owing to the highly deveiopGd vas-
cularisation of adipose tissue and the consequGnt bleeding risk. 
HowevGr, only a relatively small amount of tissue is required to 
obtain an effective cell dose, and haemostasis at the site of liposuc-
tion can easily be achieved by local pressure. 
Conclusions 
Human adipose tissue is a uniquG source of multi-potent stem cells 
that have the ability to differentiate into vascular and cardiomy-
ocy'"..es lineages, secrete several factors with angiogenic and anti-
apoptotic effects and demonstrate stem cell-like extensive self-
renewal. Moreover, ADSCs!AORCs, unlike bone marrow-derived 
MSCs, can be Gasily and safely obtained In large numbers, without 
the necessity to culture. 
AORCs have been already used in humans in different clinical set-
tings with excellent results and few side effects, Preclinical studies 
conducted in animal AMI models showed encouraging results and 
displayed their in vivo capability to differentiate into cardiac muscle 
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cells as well as to excrete different growth factors with important 
pro-angiogenic effects that led to a significant improvement of ejec-
tion fraction and wall thickness. 
The results of the APOLLO trial will provide an understanding of the 
roal safety and efficacy of ti1ese cells in AMI patients, giving new 
insights on their possible future role in the treatment of cardiovas-
cular disease. 
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Abstract 
Reperfusiort artd medical therapies are able to restore blood flow and to improve symptoms, functional 
class and '1n some cases '1ncrease survival. Cell therapy may be a poterttiaUy attractive approach to restore 
myocardial contractile pelformance after an infarctiort injury. 
In the presence of fibrotic post·infarction scar with no detectable myocardial viability, direct myocyte 
precursors, i.e. myoblasts, are one of the first and still most encouraging cell types used in ceil-based 
therapy, being cortsidered as a poterttial s.ource of new muscle fibres. 
D'~rect '1ntramyocardial myoblast injection durirtg opert-chest surgery or as a stand-alone percutarteous 
procedure has been shown to be feasible and safe in several animal and human clirtical studies. 
The presertt review explores the current clinical experience with autologous skeletal myoblasts transplan~ 
tatiort in patients with post-irtfarction heart failure. 
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Introduction 
Heart failure is rapidly becoming a major worldwide epidemic and, 
in western countries, is by fur the most common cause of hospitali-
sation. The increasing prevalence of heart failure directly relates to 
increasing age1, a significant reduction In sudden cardiac death due 
to rapid revascularisation, the use of internal cardio-defibrlllators 
(IC0s}2 and improved long-term survival of patients with acute 
myocardial infarction (AMI}. 
Myocardiai necrosis, and the subsequent formation of fibrotic scar 
which replaces viable myocardium, leads to depressed systolic 
function, reduced diastolic compliance, left ventricular remodelling, 
aneurysm formation and ultimately to the progression of congestive 
heart failure. 
Revascularisation therapies have been able to restore perfusion and 
contractile function to post-infarct stunned or hibernated myocardi-
um. Chronic medical therapies are further able to improve symptoms, 
functional class and, in some cases, increase survival, however these 
medical interventions are not capable of replacing or repairing dam-
aged myocardial tissue. The potential to repair and grow new tiss-ue 
within the necrotic scar as a result of cell transplantation has thus 
drawn widespread attention, resulting in several dinical studies shar-
ing the common purpose of regenerating or repairing myocardium by 
the delivery of new contractile or pluripotent cells3":0• 
One of the first and still most encouraging cell types used in cell-
based therapy are autologous skeletal muscle stem cells (a!so 
referred to as myoblastsl. Skeletal myoblasts are mononuclear 
progenitor cells usually residing in a quiescent state between the 
basal membranes of skeletal muscle fibres. Following muscle Injury, 
recruited non-contractile myoblasts proliferate and differentiate into 
functional (contractile) skeletal myocytes, ultimately fusing into 
multinucleated myotubes. When transplanted intra-miocardially, 
myoblasts have been shown to differentiate into myotubes1l·l3 and 
contract synchronously with host cardiomyocytes, even in the 
absence of gap junctions. 
The literature suggests that skeletal myotubes, in fact, are not capa-
ble of expressing the trans-membrane protein connexin 43 (Figure 1), 
a necessary element in achieving mechanical and electrical cou-
pling with myocardial tissue, and thus do not couple with resident 
cardiomyocytes14·15. 
Nonetheless, myoblasts have been shown to actively contribute to 
systolic contraction. It was hypothesised that stretching signals and 
direct ionic trans-membrane currentsl2,l6 may enhance the con-
tractile function wrthin the area of fibrous post-infarction scar tissue 
with a lasting positive effect on global systolic functiont?.ts. In addi-
tion to the aforementio11ed mechanical effects, myoblasts may 
improve cardiac function also by paracrine mechanisms. These 
cells are capable of secreting vascular endothelial growing factor 
CVEGF} and Insulin growth factor I (IGF-11 in concentrations which 
can mobilise reside11t quiescent cardiac cells and promote angio-
genesis19·20. Moreover, myoblast engraftment is associated with a 
marked attenuation of matrix metalloproteinase-2 and -9 up-regula-
tion. This, together with VEGF and IGF-1 release, may protect peri-
infarction tissues against fibrotic remodelling2l. 
Cell therapies can be delivered via intracoronary injection, percuta-
neously by direct injection in the ventricular wall or with an open 
Figure 1. Formalin fixed paraffin embedded rat heart stained with 
Connexin 43 using LSAB-DAB. Note membrane staining pattern. 
chest approach. While some cell types including bone marrow-
derived and blood-derived endothelial progenitor cells22 are capable 
of extravasating and migrating to ischaemic areas, skeletal 
myoblasts are not, making intracoronary delivery infeasible and 
even potentially harmful due to potential obstruction ofthe microcir-
culation and possible embolic micro-infarctions. In contrast, direct 
myoblast Injection during open-heart surgery or as a stand alone 
percutaneous procedure has been shown to allow unrestricted cell 
uptake from the circulation without embolic risk in several animal 
and human clinical studiesB.z:>.25, 
Cell transplantation during open heart surgery 
The initial clinical experience with myoblast transplantation was 
achieved using trans-epicardial delivery during open-chest CABG 
surgery on patients with severely reduced LVEF2&J1. This approach 
showed certain advantages, including easy access to the target area 
and delivery of a sufficient amount of cells per injection. Results 
from this early experience were encouraging, After the f1rst case 
report on autologous skeletal myoblast transplantation was pub· 
lished in Lancet In 2001 by P. Menasch0, two phase-1 studies on 
the safety and efficacy of combined myoblast transplantation and 
CABG were started in Europe - Paris and Poznan - In 2002 and 
2003, respectively24-26. Both studies showed the procedure to be 
safe and effective, providing a significant improvement in regional 
wall motion (by TIEl and global LVEF, as well as an increase in 
viability by positron emission tomography (PETJ and a significant 
Improvement in symptoms. These encouraging results were 
confirmed in the same year by Herreros and colleagues27 in a pop-
ulation of twelve patients with previous Ml and manifest ischaemic 
coronary artery disease. At 3 months, both regional and globalLY 
function were increased (LV improved from 35.5±2.3% at baseline 
to 53.5±5% at 3 mortths), with viability of the treated cardiac tissue 
in the area of prior infarct area demonstrating improvement by PET. 
No cardiac arrhythmias were detected during the follow-up period. 
Long-term follow-up results from a multicentre, dose-escalating 
safety study of myoblast transplantation during CABG (24 patients) 
or LVAD Implantation (6 patients) was also published In 2005 by Dib 
and colleagues31. Magnetic resonance imaging (MRll scans, as well 
as echocardiographic and PET evaluations, showed increased via-
billty of the grafted scar and an improvement in the mean LVEF from 
28% to 35% and 36%, after 1 and 2~year follow up, respectively. 
Further, histological analyses of hearts from patients undergoing 
LVAD treatment and subsequent heart transplantation, demonstrat-
ed survival and engraftment of skeletal myoblasts within the infarct-
ed areas of the myocardium. 
At the 2006 AHA meeting, Menache and colleagues presented the 
six month follow-up of the MAGIC trial, a multi-centre, randomised, 
placebo-controlled trial designed to assess the safety and efficacy of 
two doses of myoblasts (high dose: 8xlQG cells and low dose: 4xlQG 
celis) injected concomitantly with CABG. The original study design 
called for 300 patients, however the trial was suspended following 
an interim analysis of the first 120 patients, as the study was not 
expected to meet Its primary efficacy endpoint (regional and global 
wall motion improvement at six months by echo analysis). It is note-
worthy, however, that evidence of positive remodelling presented in 
the 8x1QG cell group, as LVEDV, LVESV and LVEF improved signifi-
cantly vs. control as measured by MUGA. Further, both the inci-
dence of MACE and ventricular arrhythmias did not significantly dif-
fer between the treated and the control group, suggesting that the 
procedure Is safe artd not associated with an increased risk of 
arrhythmic events or sudden death. Though data deriving from the 
aforementioned trials are encouraging, many eligible patients who 
could poterttially benefit from myoblast transplantation are not can-
didates for epicardial surgical delivery due to their clinical condition 
and the risks associated with surgery and general anaesthesia. 
Moreover, proper Interpretation of the clinical outcomes obtained in 
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these cell therapy studies is difficult because of the confounding 
and beneficial effect of the concomitant revascularisation proce-
dure. Thus, a minimally invasive, catheter-based delivery approach 
Is highly desirable. A percutaneous approach with cell injection as 
a stand alone procedure allows for targeting areas Inaccessible by 
surgery (e.g. septum), treating high-risk patients and performing 
repeat injections with minimal risk. More importantly from a scien-
tific perspective, percutaneous cell transplantation allows for the 
evaluation of intra myocardial myoblast implantation without con-
founding factors. 
Endo-ventricular approach 
Myoblasts delivery via endo-verttricular catheters allow direct cell 
injection into the targeted area of the injured lett ventricular wall. 
Catheter-based trans-endocardial injectlorl is performed using a 
needle catheter advanced across the aortic valve and positioned 
perpendicularly against the ventricular wail under fluoroscopic guid-
ance or, in some cases, using an electromechanical mapping of the 
endocardial surface (NOGAl which is capable of defining viable and 
scarred myocardium (Figure 2)B.32.J3, In 2003 the Rotterdam groups 
employed this technique to inject autologous myoblast suspensions 
into the area of post-infarction injury of five patiertts. This early 
experience, the first to document the feasibility of this particular 
approach, showed a significant increase in LV ejection fraction 
(LVEF) and regional wall motiort at three months follow-up by 
angiography, as well as a trend towards increased LVEF as observed 
by angiography and nuclear scan at the six month follow-up. 
··•-··· RAO lir1ear 
AP linear 
Figure 2. Unipolar (left) and linear (right) NOGA maps acquired during cell delivery procedure. The myocardial scar is scaled red indicating an 
area with a< 6 mV voltage and a < 2% shortening. Black dots indicate the trans-endocardial injection sites. 
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A sub-study cor~ducted to evaluate the efficacy of myoblast trar~s­
pl<mtatiorl on regional and global LV functional by dobutamine 
stress echocard'1ography with dobutamlne infusion and tissue 
doppler imaging CTDI), likewise showed an improvement in the tar-
get wall systolic velocity and global LV function during low dose 
dobutamine infusion, indicating an improvement in the contractile 
reserve34. More impressively, these haemodynamlc Improvements 
were shown to persist one year after percutaneous myoblasts trans-
plantation: pressure"volume loop analysis confirmed both systolic 
and the diastolic functional recovery (Figure 3)35• 
In 2004, Jnce and colleagues published the results of a case con-
trol study irl which myoblasts were injected in six post-AMI patients 
with severe chronic LV dysfunction. At 12 month follow up, LVEF of 
tre<Jted patients rose from 24±7% at baseline to 32:10% with a slg" 
nificant Improvement of NYHA functional class, while in matched 
control patients LVEF decreased from 25±5% to 21±4% (p value 
<0,05) and NYHA functional class remained ur~changed23 . Similar 
results, though not as significantly pronounced, were observed 
by Serruys et al36 in the first multlcerltre study (n=-15) designed 
to assess the safety and feasibility of trans--endocardial myoblast 
injections. At 12 months follow-up, both regional wall motion scores 
and NYHA functional class were significantly improved while LVEF 
increased from 34±10% to 37±10% (p:;:0.26). 
The safety and efficacy of skeletal myoblast transplantation using 
the Myocath® delivery system (Bioheart, Inc., Sunrise, FL, USA) 
is currently under investigation in tvo multlcentre clinical trials 
ongoing in Europe (SEISMIC, phase II trial) and the US 
(MYOHEART, phase I trial). The SEISMIC trial will emol46 patients, 
randomised 2:1 to the MyoceJITM treatment arm (n:::30) versus opti-
mised medical therapy controls (n=16). All patients will be analysed 
for six months. Recruitment for the MYOHEART study, a non-ran-
demised trial, was recently completed. All patients will be analysed 
for 12 months, with the expected study completion date being 
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November 2007. In e<Jch of the aforementioned studies, interim 
analysis data evaluated for DSMB review suggest positive trends 
towards improvement in treated patients especially respective to 
patient quality of life, though at this time these are statistically non-
significant observations. 
Although shown to be fe<Jsible and safe, cell delivery by percuta-
neous based injection requires further optimisation. It is challenging 
to consistently achieve full and stable apposition with the ventricu-
lar wall with most end a-ventricular catheter systems currently avail-
able as injection pressures can push back the needle tip from 
the myocardium, potentially allowing a back flush of cells from the 
puncture site to occur. In addition, following deployment, needle 
positioning against the endocardial surface does not synchronously 
follow the natural he<Jrt movement, which makes injection into thin 
post-Infarction scars or in the border zone of the infarct difficult 
In order to minimise these technical issues and to make the procedure 
easier, safer and more effective, a new generation of transendocardlal 
delivery systems are being designed. The most prominent change 
consists of a different needle tip design: the traditional end hole 
needle has been replaced by a closed tip needle with side-port holes 
(e.g. MyocathTM, Bioheart Inc.) In order to spread the cell injected over 
a larger t:Jrget area, rather than relying solely on perpendicularly deliv-
ery to a single spot (Figure 4). This rele<Jse pattern could diminish the 
risk of perforation and improve catheter stability with more reliable wall 
apposition by decre<Jslng Injection pressures and back flush, 
Trans-venous approach 
Catheter based cell infusion through cornnar; veins is a relatively 
novel approach. 
The injection catheter, residing within a coronar; vein and moving 
together with the heart wall, provides stability to the deliver; system 
and allows an accurate and effective cell delivery, while minimising 
the possibility of cell loss and wall perforation . 
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Figure 3. Steady-state pressure-volume loops (A), end-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure-volume relation-
ship (EDPVRJ (8), for each patient. LV: left ventricular. 
Figure 4. Old Myocathr~>< catheter with a single end hole needle (left} 
and the new Myocath1M delivery system with side port holes (right). 
So far, the most compelling results using the trans-venous injection 
delivery in humans have been achieved by Slminlak and co-
workers24·25 in the POZNAN trial~5 , a phase one clinical trial 
designed to assess safety a11d feasibility of autologous myoblast 
transplantation performed by the TransA.ccess® catheter, a compos-
ite catheter system combining a phased array IVUS and a pre-
shaped extendable 24 gauge nitinol needle. 
The TransAccess system is placed In the target coronary vein 
{Figure 5), the intravascular orientation is performed using the cor-
responding artery, pericardium, and ventricular myocardium as 
landmarks with IVUS imaging {Figure 6). After verification of the 
proper TransAccess catheter position, the nitinol needle is extend-
ed Into the myocardium and the injection catheter (Microlume™) 
is advanced through the needle deep into the myocardial scar area, 
to allow myoblast suspension injection. 
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Agure 6. TransAcce~ system orientation by IVUS imaging. The nee-
dle is oriented taking the corresponding artery, the pericardium, and 
the ventricular myocardium as landmarks. 
The use of the a11terior Interventricular vein and the middle cardiac 
vein, parallel to the posterior descending coro11ary artery, both were 
shown to be feasible. Two to four intramyocardial injectio11s were per-
fmmed in each patient delivering up to 100 million cells in 0.6-2.5 ml 
of saline solution. The procedure was reported to be technically suc-
cessful In 11ine out of 10 patie11ts and did not cause a11y peri proce-
dural adverse event. At six months follow-up, NYHA class improved 
Figure 5. Trans--coronary-venous myoblast transplantation using anterior interventricular vein (A,S,C) nnd middle cardiac vein (D,E,F). A,C: coro-
nary angiography; 8,0: coronary venography, C,F: Trans Acce~ catheter system positioned within vein- arrow indicates tip of the microcatheter 
during cell injection. 
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'mall paf1ents and LVEF, assessed by echocardiography, s'lgnificant-
ly increased by three to eight percentage points in six out of nine 
patients, confirming both the safety and feasibility of trans-venous 
intramyocardial myoblast injections by the TransAccess® system. 
Safety issues 
While ex vivo experiments suggest the possibility of cell fusion and 
the formation of a synchronous beating network in a co-culture of 
myoblasts and card'lomyocytesOJ.38, several stud'1es have shown 
skeletal myotubes to be Incapable of expressing connexln 43 (gap 
junction protein) and physically coupling with host cardiomyocytes, 
and from beating in synchrony with the rest of the heart12.39M. 
In the absence of this electromechan'1cal coupling, the arrhythmD-
genic mechanlsms remain unclear. Myoblasts have been shown to 
generate burst of <Jction potenti<Jis, which may induce ventricular 
extrasystoles and tachycardias through electr~rtonic interactlorJs41• 
Moreover, an arrhythmogenic role could be related to the injection 
procedure Itself, including myocardial puncture, lnflammatol)' 
response to injured transplanted myoblasts (paracrine effect) and 
immune reactions41• M<Jjor ventricular arrhythmias were observed 
in the major'1ty of humans studies conducted thus far, irrespective 
of the delivel)' route or cell dose8.25.2G,28.31. 
In the first clinical series published by Menasche at af2&, four 
patients who underwent autologous skeletal myoblast transplanta· 
tlons dur'1ng CABG exper'1enced sustained episodes of ventricular 
tachycardia [VT). Similarly, the possible arrhythmogenic effect has 
also been observed in studies using an end~rventrlcui<Jr catheter 
approach. In the study conducted by Smits et al~2• one patient 
experienced sustained VT at six weeks and subsequently received 
subsequently an lCD, while more seriously, two sudden deaths 
occurred. These events prompted DSMB consultation <Jnd the rec-
ommendation for all subsequent f)<ltients to receive prophyi<Jctic 
lCD implantation. Interim results from the MAGIC trial presented at 
the AHA 2006 scientific session, however, suggested no statistical· 
ly significant difference between the treatment and placebo groups 
in terms of ventricular arrhythmias. The interim analysis of the SEIS· 
MIC study suggests similar results. It should be emphasised that 
f)<ltients enrolled In these initial studies did not receive prophylactic 
antiarrhythmic therapy even though the target population of 
advanced ischaemic chronic heart failure easily develops ventricu-
lar arrhythmic events through the natural progression of the dis-
ease. Statistical analysis indicates that the risk of arrhythmic events 
is largely restricted to the first 30 days following the procedure, and 
recent clinical data suggest that prophylactic lCD implantation and 
use of Class Ill anti·arrhythmic medication may largely control risk 
of arrhythmias Immediately following cell Implantation. 
Amiodarone was administered prophylactically to all patients in the 
POZNAN trial, and VT episodes occurred only in a single patlent 
who was not compliant with amiodarone use during the first few 
weeks following the procedure25. In fact, It could be suggested that 
myoblast related VT may be circumvented by concomitant ami~r 
darone therapy, thereby obviating an AICD implantation. 
In sum, though several clinical trials in a small number of patients 
initially suggested a potential risk of ventricular arrhythmia following 
myoblast transplantation, it remains difficult to ascertain whether 
skeletal myoblasts are indeed arrhythmogenic as well as to unveil 
the underlying mechanism. Because the majority of episodes of 
ventricular arrhythmias occurred early after transplantation, it is 
plausible that their occurrence may be related to the procedure 
itself (due to the intra myocardial puncture or lnflammatol)' reaction) 
rather than to the lack of gap junctions betweer. the graft and host 
myocardium, which would result in later term arrhythmic events. 
Conclusions 
Although cell therapy for human cardiac regeneration is still an 
experimental field and only taking its f1rst steps in clinical practice, 
a considerable number of preclinical animal studies and phase I 
human studies have been completed over the past years. These tri· 
a is have shown that autologous myoblast transplantation, both dur· 
ing cardiac surgel)' and by percutaneous injection, is feasible, safe 
and appears to hold significant promise. However, the cell delivel)' 
still needs to be improved and the occurrence of arrhythmic com. 
plications needs to be observed carefully, with prophylactic 
attempts made :0 minimise their occurrence during the initial days 
fo:lowing transplantation. Several large phase 1/11 clinical studies <Jre 
currently under way in both Europe and the USA (e.g. SEISMIC and 
MYOHEART II) in order to assess the real potential arrhythmogenic 
effect as well as the efficacy of myoblast transplantation in chronic 
post-infarction myocardial lnjul)'. The final results from these trials 
will be available within the next year and will provide useful insight 
as to the possible future role of autologous myoblast therapy in the 
treatment of chronic heart failure. 
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Cell therapy may be a potentialty attractive approach to restore myocardial contrac-
tile performance after an infarction injury. Mu!tipotent stem cells are currently being 
studied as a possible cell source for myocardial repair within the first few days after 
the infarction onset in non-revascularizable areas of the left ventricle having viable 
myocardium. In the presence of fibrotic post-infarction scar with no detectable myo-
cardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a 
potential source of new muscle "fibres. We review the current clinical experience with 
transplantation of the autologous skeletal myoblasts in patients with post-infarction 
heart failure, focusing on percutaneous cell transplantations performed as a sole 
procedure. 
Introduction 
Despite the recent developments in the treatment of 
coronary artery disease, congestive heart failure caused 
by myocardial infarction still remains a major health 
problem, affecting millions of patients worldwide with 
massive negative economic consequences. Myocardial 
necrosis and subsequent formation of fibrotic scar that 
replaces viable myocardium may lead to depressed systo-
lic function, left ventricular (LV) remodelling, aneurysm 
formation, and ultimately to congestive heart failure. 
In the last few decades, improved treatments and an 
ageing population has lead to longer post-myocardial 
infarction survival resulting in increased prevalence 
of post-ischaemic heart failure. 1 Consequently, the treat-
ment of heart failure has gained widespread attention. 
The possibility of repairing and growing new 
myocardium within the necrotic tissue as a result of 
cell transplantation has been widely studied in both 
experimental and clinical conditions.2•7 
Among the variety of cells studied, autologous skeletal 
myoblasts are one of the most encouraging cell sources 
*Corresponding author. Tel: +48 60221n02; fax: +48 6129nSOO. 
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for cardiac repair. Skeletal myoblasts, or satellite cells, 
are progenitor cells usually residing in a quiescent 
state under the basal membrane of skeletal muscle 
fibres, until recnJited to proliferate and differentiate 
into mature skeletal myocytes in response to injuries 
(Figure 1). They are of their autologous origin, the 
ability to be amplified in vitro, and have high proliferative 
potential resistance to ischaemia and preclinical efficacy.8 
These characteristics have led clinical investigators to 
evaluate the effect of transplanted autologous myoblasts 
in patients with post·infarction heart failure. Myoblasts 
differentiate into myotubes and maintain muscle proper-
ties when transplanted into an infarct area.9"11 
Electromechanical properties of myocardial and skel-
eta{ muscle tissues differ significantly. Cardiac cells act 
together synchronously due to the presence of spedal 
cell·to-cell junctions containing N-cadherin and connexin 
4312•13 (Figure 2). The latter is a transmembrane protein 
playing an important role in mechanical and electrical 
coupling within cardiac tissue.14 The lack of gap junction 
protein expression like connexin 43 on skeletal myotubes 
prevents them from being physically coupled with host 
cardiomyocytes, suggesting that these cells do not beat 
in synchrony with the rest of the heart. 10•1S·16 
224 
Cardiomyocyte Skeletal muscle 
• Single nudei (central) 
• Gap junction (+) 
.. Cx43 expression(+) 
t?? 
• Multinucleated (peripheral) 
• Gap junction (-) 
• Cx43 expression (-) 
• Myoblast (satellite cell) 
Myotube 
• Multinucleated 
• Gap junction (-) • 
• Cx43 express;on (·) ,._lolllllllllllllll 
FU$lon and differentiation 
Figure 1 Myobl.asts are usuaUy in a quiescent state under the basal membrane of skeletal muscle fibres. After being gathered and expanded, myoblasts 
are transplantated into an infarct area where they differentiate into myotubes and maintain muscle properties. It is stm unclear whether myoblasts can 
transdlfferentiate into cardlomyocytes. 
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Figure 2 Cell to cell junction. C<ldherin (A) has an important structural role linking the cytoplasmatlc plaque on the inner :;lde and coupling with other 
catherlns on the extracellular side. Connexon 43 (B) !s composed of ill: subunits and forms channels between cardiac cells in order to create an electrical 
coupling. 
However, it has been shown that the lack of junctions 
between grafted cells and host tissue does not preclude 
improvement in LV contractile functionY It has been 
suggested that transplanted cells can contract synchro-
nously even in the absence of connections between 
cells, probably by stretching or by direct transmembrane 
channetling of electric currents. 10•18 The direct contri-
bution of these engrafted cells in improving systolic func-
tion was noticed in several studies that indicated a 
positive effect of skeletal myoblasts on myocardial con· 
tractility lasting over time and correlating with the 
number of implanted cells.19•20 Although certain ex vivo 
data suggest that skeletal myoblasts may acquire few 
characteristics of cardiomyocytes or may fuse with 
them forming chimeric cells, 21 it has been assumed that 
the grafted cells do not transdifferentiate, instead 
retaining the morphological and electrophysiological 
properties of skeletal muscle.9•17 
The capability of myoblasts to improve cardiac func· 
tion cannot be explained only in terms of electromecha· 
nical integration or direct contribution. Other 
mechanisms were found to play an important role. One 
hypothesis proposes that the engrafted celts could affect 
post-infarction remodelling by limiting the expansion of 
the post-infarction scar.22- 24 A second possible mechan-
ism is the paracrine effect that myoblasts exert on sur-
rounding myocardial cells. This hypothesis is derived 
from the observation that these cells are able to 
release pleiotrophic factors such as vascular endothelial 
growth factor and insulin growth factor 1 that could 
mobilize resident quiescent cardiac cells and promote 
angiogenesis. 25- 27 These factors in association with a 
marked attenuation of matrix metalloproteinase-2 
and -9 up-regulation may work as antifibrotic agents 
protecting peri-infarction tissues. 28 
Since skeletal myobtasts do not extravasate and may 
cause microembotizations after intracoronary delivery, 
their potential application in myocardial regeneration 
requires direct cell injection into the area of damaged 
myocardium. Transepicardial cell injection during open-
chest surgery and several catheter-based methods have 
been proposed and studied in clinical trials.8•29- 33 
(Figures 3 and 4). 
Initial clinical experience: open-chest 
myoblast transplantation 
The first report on autologous skeletal myoblast trans· 
plantation during open-chest cardiac surgery was pub-
lished in the Lancet in 2001 by Menasche et al. 34 After 
that case report, two smau phase-one clinical trials 
were started in Paris and Poznan. 8•35 In both trials, 10 
patients with severely reduced LVEF undergoing CABG 
received transepicardial myoblast injection. Five 
months after the procedure, a significant improvement 
in symptoms by one NYHA class, an increase of regional 
watt motion, an increase of global LV ejection fraction 
{LVEF) as well as an increase in tracer activity on positron 
emission tomography (PET) were observed, suggesting a 
Ftgure 3 Myoblast-delivering approaches. 
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new onset of metabolic activity in the previously non-
viable scar area. However, 4 years after combined myo-
blast transplantation and CABG, in almost one-third of 
the Poznan series the end-diastolic LV diameter was 
increased (unpublished own observation) generating 
doubts about the previously reported capability of trans-
planted cells to reduce ventricular dilation.23•24 In two 
other similar phase-one studies published by Herreros 
et al.30 and Chachques et a/.,32 a total of 21 patients 
received myoblast injection during CABG. Consistent 
with prior studies, improvements of regional watt 
motion and global LYEF were noted, suggesting safety 
and feasibitity of the method. 
In a recent multicentre dose-escalating safety trial 
conducted in the USA, published by Dib et at.,36•37 11 
patients underwent myoblast transplantation during 
open-chest surgery. The echocardiographic evaluation 
as welt as PET and magnetic resonance imaging (MRI) 
scans showed an increased viability of grafted scar, 
whereas the mean EF improved from 11..7 to 35.9%. 
In 2004, Menasche et at. started the MAGIC trial, a mul-
ticentre, prospective, randomized, double-blind, 
placebo-controtled trial designed to evaluate the 
effects of skeletal myoblast transplantation in the 
context of severe ischaemic heart failure in a population 
of 300 selected patients. The study was prematurely dis-
continued in February 2006 after 120 patients were 
enrolled (97 treated) because of the high incidence of 
ventricular arrhythmias. The assessment of the risk/ 
benefit ratio is currently under way and the trial could 
be resumed after the approval of the Data Monitoring 
Committee. 
Cell transplantation during cardiac surgery has certain 
advantages including easy access to the target area and 
possible delivery of large numbers of cells per unit. 
However, direct transepicardial approach may cause 
additional risk to the patient during surgery, since candi· 
dates for cell transplantation often have a history of mul· 
tiple infarctions and LV dysfunction, and clinical 
symptoms of severe heart failure. Moreover, the 
interpretation of clinical outcomes obtained from trials 
evaluating myoblast injection during CABG is not possible 
because the effects of the two procedures performed at 
the same time cannot be easily distinguished and ascer· 
tained. However, in light of these limitations and of the 
trend towards less-invasive, diagnostic, and therapeutic 
procedures, percutaneous approaches with celt injection 
as a sole procedure are under investigation. 
Percutaneous myoblast transplantation: 
cell injection as a sole procedure 
Catheter-based transendocardial or transcoronary vein 
injections, performed as a sole therapy, may allow the 
evaluation of effect of myoblasts without confounders. 
It may also enable repeated celt injections in patients 
with severe myocardial injuries, since excessive number 
of transplanted celts in a single injection may result in 
only a smatl percentage of grafted cells survived. Jn 
fact, despite more than 10 years of work in this field, 
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FigurE' 4 Different trans-endocardial and trans-coronary-venaus cell del!very systems use{j in recent trials. 
the delivering technique has stilt to be improved; about 
90% of successfuUy delivered cells teak back out of 
the injection site or die within the first week.38 Direct 
ceU injection in the ventricular watt can be achieved 
both by a transendocardial29 or a transcoronary vein 
approach. 33•39 
Catheter-based transendocardial injection is per-
formed using a needle catheter directed perpendicularly 
to the inner surface of the target area using an electro-
mechanical mapping of the endocardial surface.40"42 
Although this technique has been demonstrated to be 
feasible, cell delivery by direct injection may be difficult: 
endoventricu\ar catheter systems currently available 
have limited stability so that a back-flush of cells from 
the puncture site is to be expected. In addition, the 
needle positioned against the endocardial surface does 
not follow the heart movements making the injection in 
thinned post-infarction scars or in the border zone of 
the infarct very chaUenging. 
Catheter-based cell infusion through coronary veins is a 
relatively new approach recently used in a pilot trial by 
Siminiak et al.43 and it consists of a catheter-based endo-
vascular system incorporating an IVUS source and an 
extendable needle (TransAccess, Trans Vascular, Menlo 
Park, CA, USA). The TransAccess catheter is a monorail, 
composite catheter system combining both a phased 
array IYUS and a pre-shaped adjustable nitinol needle. 
After placing the TransAccess system in the target coron-
ary vein through the coronary sinus, the needle is 
oriented using IVUS images of the corresponding artery, 
the pericardium, and the ventricular myocardium as 
landmarks (Figure 5). The nitinol needle is extended 
into the myocardium and a micro-infusion catheter 
(Jntralume, TransYascular Inc.) is then advanced 
through the needle while simultaneously injecting of 
the therapeutic agent. In contrast to the transendocar-
dial approach, where cells are injected perpendicularly, 
the TransAccess system delivers cells parallel to the 
ventricular walL 
Figure S lVUS image of the Trans.Access system in a coronary vein. The 
needle is oriented using fVUS imaging taking the corresponding artery, the 
pericardium, and the ventricular myocardium as landmarks. 
Clinical trials evaluating percutaneous myoblast trans-
plantation performed as a sole procedure in patients with 
post-infarction heart failure studied both endoventricu-
tar and transcoronary-venous catheter systems. 
In 2003, the Rotterdam group29 injected autologous 
myoblast suspensions into the area of post-infarction 
injury of five patients using an endoventricular catheter 
under electromagnetic guidance (Figure 6). Although 
the small sample size evidently precludes any conclusions 
about efficacy, this early experience has primarily docu-
mented the feasibility of this approach. An increase of 
LVEF and regional wall motion was observed at 3-month 
follow-up by angiography, though nuclear radiography 
and MR! failed to confirm this improvement. At 6 
months, a trend towards increased LVEF was observed 
by both angiography and nuclear scan. A sub-study con-
ducted to evaluate short- and !on~;-term results of 
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Figure 6 Unipolar voltage (left) and linear local shortening (right) NOGA maps. The myocardial scar is scaled red indicating an area wfth a <6 mV 
voltage and a <2% shortening, Black dots indicate the transendocard1al1njection sites. 
myoblast transplantation on regional and global LV func~ 
tional by two-dimensional echocardiography with dobu~ 
tamine infusion and tissue Doppler imaging (TDI) 
showed an improvement of target wall systolic velodty 
and of global LV function during low-dose dobutamine 
infusion, indicating an improvement of contractile 
reserve.44 (Figure 7). 
In a recent study published by the same group, 10 to 15 
injections of autologous myoblasts using Myostar'" 
{Cordis, Warren, NJ, USA) were given using an 
endoventricular approach. At 6-month follow-up, an 
increased EF and cardiac output, a reduction of 'systolic 
volume, and a trend towards improved stroke work 
were observed. These haemodynamic improvements 
were confirmed by pressure-volume loops analysis 1 
year after percutaneous myoblast transplantation.45 
(Figure 8). 
Another recently published study describes the results 
of transventricular injections using the fluoroscopy-
guided MyoCath™ catheter {Bioheart, Weston, FL, USA) 
or the NOGA™ -guided catheter system (Biosense-
Webster, Waterloo, Belgium). The study failed to show 
improvement in the EF but wall motion score index 
improved both at rest and under low-dose dobutamine.46 
A third catheter-based study, the POZNAN trial, was 
recently published by Siminiak et alY This study was 
performed as a phase-one clinical trial to assess the 
safety and feasibility of both the TransAccess® catheter 
system and the percutaneous autologous myoblast trans-
plantation performed as a sole therapy. Two to four intra-
myocardial injections delivered up to 100 million cells in 
0.6-2.5 ml of saline solution to each patient. The trial 
confirmed the feasibility of intramyocardial injections 
using the TransAccess® system with an extremely 
predse advancement of the micro-lumen catheter in 
the remote target area up to 4 em deep within the 
injured myocardium. The procedure was reported to be 
technically successful in all but one patient and did not 
cause any periprocedural adverse event. 
The use of both the anterior interventricular vein and 
the middle cardiac vein, parallel to the posterior des-
cending coronary artery, were shown to be feasible. In 
addition, compared with the anterior interventricular 
venous approach, in the POZNAN trial, a middle vein 
approach to advance the TransAccess® system succeeded 
in getting closer to the apical segments of the left 
ventricle. 33 The tack of procedural success in one 
patient, related to the inability to appropriately position 
the guiding catheter across the venous valve at the 
bifurcation of the great cardiac vein, suggests the need 
for a new and refined guiding catheter. 
At 6-month follow-up, NYHA class improved in all 
patients and EF, assessed by echocardiography, signifi-
cantly increased by 3 to 8 percentage points in six out 
of nine patients.12•14 
Again, efficacy data, although considered promising, 
have to be interpreted cautiously because of the small 
size of the sample. These results, however, confirm pre-
vious laboratory findings in which autologous myoblasts 
delivered through the coronary sinus route significantly 
improved regional wall motion and global LV function. 47 
Safety issues related to myoblast 
transplantation 
!t may be speculated that the inability of skeletal myo-
blasts to transdifferentiate to cardiomyocytes and to 
fonn junctions with neighbouring cells may be a substrate 
for ventricular re-entry arrhythmia. Current experimen· 
tal and clinical data indeed suggest a possibility of 
increased risk of arrhythmogenidty. In the first clinical 
series published by Menasche et al.,8 four patients who 
underwent autologous skeletal myoblast transplantations 
during CABG received an implanted automatic internal 
cardioverter-defibrillators (A!CD) due to sustained epi-
sodes of ventricular tachycardia (Vf). In the Poznan 
CABG phase-one experience,35 episodes of sustained 
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Figure 7 A significant increase of peak systolic velocity measured byTDI is shown at baseline (upper part) and at 1-year follow-up (lower part) both at 
rest (A and C) and after a low-dose dobutamine stress echocardiography (8 and D). 
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Figure 8 PV loops at baseline, 6 months and 12 months after myoblast transplantation. A s1gn!flcant lncr<:asc in stroke volume, contractility 
(represented by ESPVR increased slope and leftward shift} and of diastolic stiffness (represented by upward shift and steeper EDPVR) is shown both 
at 6 and 12 months. 
ventricular tachycardia {VT) were observed in first two 
patients during early post-operative period, but prophy-
lactic amiodarone administration in the other patients 
prevented VT episodes so that no anti-arrhythmic treat-
ment was continued later then 6 weeks during follow-up. 
In the MAGIC trial, designed by Menasche et al., all the 97 
treated patients received an AICD after cell transplan-
tation: the trial was susoended in Februarv 2006 after 
120 patients were enrolled and the assessment of the 
risk/benefit ratio is currently under way. 
The possible arrhythmogenic effect has been also 
noticed in trials using an endoventricular catheter-based 
approach. In the study conducted by Smits et al.,46 one 
patient received an AICD 6 weeks after the myoblast 
injection and more seriously, two sudden deaths 
occurred. tri~2erin2 the study steerin2 committee to 
consult the independent data safety monitoring board. 
The trial was temporarily suspended and resumed after 
having implemented the safety measures. Observations 
from percutaneous series in the POZNAN trial43 indicate 
successful prevention of cell transplantation-related ven· 
tricutar arrhythmias by prophylactic amiodarone adminis· 
tration, suggesting that AICD implantations are not 
necessarily needed in all patients who undergo myoblast 
transplantations. 48 
ln the absence of electromechanical coupling, the 
arrhythmogenic mechanisms remain unclear. One poss-
ible explanation is that myoblasts, having the ability to 
generate burst of action potentials, may induce ventricu-
lar extrasystoles through electrotonic interactions.49 
Moreover, an arrhythmogenic role could be related to 
the procedure in itself, including myocardial puncture, 
inflammatory response to transplanted cells and 
immune reactions49 rather than to possible problems 
with electromechanical coupling between newly devel-
oped myocytes and cardiomyocytes. 
At the current stage, with only a small number of 
patients having undergone autologous skeletal myoblast 
transplantations, it is difficult to predict whether skeletal 
myoblasts are really arrhythmogenic, especially because 
patients with ischaemic LV dysfunction easily develop 
ventricular arrhythmia. Nevertheless, future studies on 
cell transplantation in patients with post-infarction 
heart failure will have to focus on potential arrhythmo-
genic effect. Similarly, large phase-two/three clinical 
trials are needed to assess the efficacy of myoblast trans-
plantation in chronic post-infarction myocardial injury. 
Conflict of interest: none declared. 
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~=Intervention 
Rationale and interim analysis data from the SEISMIC study 
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Deportment, S. Giovanni Battista HospitaL University of Tun'n, Italy; 3. Bioheort Inc., Sunn'se, FL, USA 
R. Spencer 1s Jn employee or 810htWi Inc. TN: SEISMIC mvcslif:.Jiors ;md study Sites JppcJr 1n me JppendiX. 
Tile study wJs sponsored by Ro!Jwrt Inc. The' omcr Juthors /JJve no con!IJC! of mtcrcst to dec/Jre. 
Introduction 
Cardiovascular disease continues to be a major health epidemic 
throughout the world and is the leading cause of mo~bidlty and mor-
tality in the Western world, with its prevalence constantly increasing 
in developing courttries. At present coronary artery disease, includ-
ing post-Infarction chronic heart failure, accounts for over 7 milliort 
deaths per year {over 2 milliort in Europe alone), and this number 
is expected to rtearly double in the next 20 yearsl2. 
These facts clearly illustrate the need for improvemertt in the revas-
cularisatlon and medical therapies currently available, as well as for 
the development of novel therapies capable of preventing or revers-
ing negative remodelling and even regenerating failing myocardium. 
In the last 10 years, repair of cardiac muscle by stem cells in 
patients with post-ischaemic chronic heart failure has beert tested 
in several preclinical and phase 1-11 clirtical studies utilising different 
cell types artd means of delivery3-10• 
Although almost all of these studies achieved promising results both 
in terms of safety and efficacy, few direct clinical side-by-side com-
parisons have been performed, and thus the quest for the Ideal cell 
type is still ongoing. Several preclinical studies have recerttiY been 
performed to compare the beneficial effects of different cell ty;Jes 
for cellular cardiomyoplasty (Table 1). According to these preclini-
cal studies, in the sub-acute or chrortic Ml settirtg, skeletal myoblast 
transplantation may be more effective !hart transplantation of bone 
marrow monortuclear cells, dermai fibroblasts, cardiac fibroblasts 
or adult cardiomyocytes11•14• 
These results may be related to the superior degree to which 
myoblas1s exhibit resistance to ischaemia as compared with cardicr 
cytes. Further, myoblasts appear to have a noticeable impact 
on cardiac systolic furtdion as compared with the passive effec1s 
of fibroblasts and other cell types ort cardiac compliance15• To date, 
the feasib'tlity of myoblasts for the treatment of CHF has been cort-
firmed irt several clinical trials irt which autologous skeletal 
myoblasts were implanted either durirtg open-chest surgeryl&-L9 
or via percutaneous deiivery8.9.20 as a stand alone procedure 
{Table 2). These encouraging results have led to the design of new 
myoblast transplantation protocols, which are currently under irtves-
tigatiort irt ongoing clinical studies and which we hope will impart a 
clearer understanding of their applicability in future clinical practice. 
The SEISMIC study: rationale and description 
Rationale 
Previous data derived from pre-clirtical studies demonstrated that 
the implarttatiort of autologous skeletal myobiasts may lead to 
replacemertt of non-functionirtg myocardial scar with functional 
contractile tissue and consistent improvement In global LVEF, 
regional wall motion and viability. Results from phase I-ll cHnical tri-
als suggest skeletal myoblast implantation at the time of CABG may 
lead to similar effects, as do recent studies using percutarteous 
delivery as a stand-alone procedure. For these reasons autologous 
skeletal myoblast (MyoCeiJ1'>1) implarttatiort using the MyoCath® 
~Corresponding author: Thoraxcenter, Erasmus University Medical Center. Rotterdam, PO Box 2040, 3000CA Rotterdam, The Netherlands. 
E-mail: p. w.j.c.serruys@erasmusmc.nl 
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Clinical status and controversies 
Table 1. Preclinical studies comparing skeletal myoblasts (SKMyo) with other cell types implantation. 
st·uoy--- -~ speaes" ceu tY'iie"'" 
Hutcheson et a[11 Rabbit SKMyo vs. FB SKMyo superior to FB. SKMB improve both systolic 
and diastolic function. FB only improves diastolic 
Horackova et aP~ 
"" 
SKMyo vs. tardiac FB vs. cardioMyo Myotube formation in SKMyo treated animals, 
SKMyo superior to cardioMyo and cardiac FB regarding 
remodelling; functional improvement in SKMyo 
treated animals 
Agbulut et al14 
'" 
SKMyo vs. AC133+ Myotubes in SKMyo treated group, 
No difference regarding LV function 
Ott et atn 
'" 
SKMyo vs.SMMCs SKMyo superior to BMMCs regarding LV function 
FB -fibroblasts; cardioMyo~ cardiomyocites; BMMCs~ bone marrow mononudeated cells; LV"' left ventricle 
Table 2. Comparison of clinical studies using myobtasts for post~ infarction chronic heart failure. 
Stiidf ''ei:Lrt)iiii'' ·-·Patie-ritS" 'LVEF' , "ROiite'Of\1-.ilii/e'iii- . ResULts-
treated (n) 
Menasche et at17 SKMyo 10 24:1:4% transepicardial j global LVEF 
Herreros et al111 SKMyo 11 36±8% transepicard\al j global LVEF, j regional wall motion 
and j viability 
Siminiak et al"9 SKMyo 10 25-40"/o transepicardial j global LVEF, j regional wall motion 
Chachques ct al10 SKMyo 20 28±3"!. transepicardial j global LVEF, 1 regional wall motion 
and j viability 
Smits et al9 SKMyo 36±11"/o transendocardial- NOGA guided i global LVEF, i regional wall motion 
Siminiak et alij SKMyo 30-49"!. tlans-<:oronaTY-venous j global LVEF 
w Smits et al20 SKMyo 15 34±10"/o transendocardial- NOGA guided i regional wall motion, NYHA class improvement 
SKMyo ~skeletal myoblasts; NOGA"' non-fluoroscopic electromechanical mapping; LVEF- left ventricle ejection fraction; NYHA ~ New York Heart a m 
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234 endoventricular catheter delivery system is being evaluated ir. tllis 
ra11domised, controlled study to explore the feasibility lh8Se cells 
may provide In adding a r.ew dimer~siorJ to the ir~terventional mat1-
agemer~t of posHnfurct deterioration of cardiac function in patients 
Wth cor~gest'ive heartfaUure. 
MyoCe!l™ 
MyoCell™ is a proprietary technology of Bioheart Incorporated 
(Sunrise, FL, USA) and is composed of autologous skeletal 
myoblasts expa11ded ex vivo from an individual patient's skeletal 
striated muscle biopsy. Autologous skeletal myoblasts are isolated 
and subsequently expanded from approximately 10 grams of a 
skeletal muscle biopsy via a proprietary cell culturing process. 
Harvest is by trypsinisation, cell collection, and repeated washing 
with a commercially available transport medium to ensure removal 
of a11y residual serum from culturing. Following final re-suspension 
in transport medium, release testing is conducted and MyoCell™ 
is packaged and labelled for return shipment to the patient's treat-
ing physicial1 for intra myocardial implantation. MyoCeiJTM has bef!n 
previously delivered endovascularly via specifically designed percu-
taneous catheter delivery systems {MyoGath®, MyoStar® and 
TransAccess®). 111 the SEISMIC study, MyoCellrM is injected into the 
regio11 of akinetic myocardial scar resulting from prior infarction. 
Multiple injections, each containing 0.5 mL of cell suspension 
(25 x 106 cellslml) and spaced approximately lcm apart, are per-
formed to deliver MyoCeiJTM to the target region. The inte11ded dose 
of MyoCell™ for each patient is between 150 and 800 x 106 cells. 
The maximum 11umber of injections for each impla11tation proce-
dure is 32 and the maximum number of ce!ls injected is 800 x 106. 
MyoCath0 
The Bioheart MyoCath® catheter (Figure l) is a 115 em long, 8 Fr 
needle i11jection catheter with a deflectable tip and extendable 25 G 
stai11less steel needle. A deflection knob and needle advancemer~t 
control trigger are used (Figure 2) to manoeuvre the tip, advance 
the needle and control the needle depth. 
During the procedure, a small i11cision is made in the patient's groin 
to provide arterial access i11 customary fashion. The catheter is 
adva11ced through an arterial femoral sheath retrograde across the 
aortic valve and into the left ventricular cavity. The injectio11 tip of the 
MyoCath® is then positioned to the desired l11jection site of the left 
ventricle (via fluoroscopic guidance). The needle is advanced to a 
pre-set length by depressing the 11eedle adva11ce/retraction control, 
causi11g the needle to penetrate the target tissue to the pre-set 
depth. The attached syringe is then depressed to deliver the thera-
peutic dose {0.5 mUper injection) to the injection site. After 
injection, the 11eedle is retracted, the tip is repositioned, and anoth-
er injection is made. Subsequent injections, approximately 1 em 
apart, are made to all desired areas affected by prior infarct to com-
plete the cellular cardicmyoplasty procedure. 
The Bioheart MyoCath® delivery system has been used in more 
tha11 50 patients a11d three clinical studies worldwide without note 
of any serious adverse cii11ical events during the implantation 
procedure. 
Tlw $£/SMIC study 
······························································~················· 
Study design 
The SEISMIC Trial {Safety artd Effects of lmplartted [Autologous] 
Skeletal Myoblasts [MyoCelln-1] usirtg art lrtjectiort Catheter) is a 
phase II, opert-label, rartdomised, multicerttre study desigrted 
to assess the safety artd cardiovascular effects of myogertic muscle 
stem cells, as delivered by the MyoCath®, in congestive heart failure 
patients post myocardial infarction(s). Forty-six patients were target-
ed for enrolment at 12 study centres throughout Europe, with two-
thirds of the patients randomised to the MyoCeJITM treatme11t arm, 
a11d the other third ra11domlsed to the control arm (and receivi11g 
standard medical thera;Jy o11lyl. 
Here we report the DSMB interim a11alysis of the first 25 ran-
demised patients. 
Enrolment was completed in the beginning of 2007. Per protocol, 
ail eligible patients experienced a Q-wave myocardial Infarction 
at least 90 days prior to the surgical muscle biopsy resulti11g In 
a large area of akinesia (as confirmed by angiography and echocar-
diography) and residual glob<ll left ventricular ejection fraction 
at screeni11g of:::. 20% and~ 45% (as assessed by MUGA scan). 
Functional class was NYHA II or Ill without requlreme11t, or it1dica-
tiort for revascularisation (ruled out by a11giography or dobutamine 
stress scintigraphy). Optimal medical therapy was to have beert ini-
tiated at least 2 months prior to study erttry, and all patie11ts enrolled 
must have been fitted with an lCD (single-lead) at least 6 months 
prior to enrolme11t in the protocol. All randomised patients were 
Figure 1. Cell delivery and distribution (green) performed using the 
new tip-closed with side holes Myocath (on the left) and the old tip 
with single end-hole catheter (on the right). 
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initiated on anti-arrhythmic therapy (amiodarot1e) at screening, 
for at least o11e month pre- and post- procedure; both groups were 
followed for 6 months and evaluations were done at baseline, 
1 month, 3 months and 6 mortths by office visits as well as by lab-
oratory and instrument tests (ECG, echocardiography, dynamic 
ECG-Holter and MUGA scan at 6-month FU). 
The primary safety endpoint of the study is the observed number of 
serious adverse events (SAE) in the treatment arm vs. control arm 
at 3 and 6 mortths, while the primary efficacy endpoint is observed 
improveme11t in LVEF (as measured by MUGA) at 3 and 6 months 
vs. baseline for both the treatmerttar~d control arms. Additional sec-
ondary endpoints include improvement in 6-mir~ute walk time, 
NYHA classification, QOL score (Minrtesota), global and regional 
contractility, wall thickness, coronary perfusion and changes in 
overall infarct size at 3 and 6 months vs. baseline. SAEs were 
defi11ed by the study protocol as any adverse event deemed fatal, 
life-threatening, requiring unexpected hospitalisation or resulting 
in permanent impairment, as well as any events which the investi-
gator deemed Jeopardising toward the patient. 
Preliminary safety data 
Safety data was available in December 2006 on 25 of the 46 ran-
demised patients (16 treated with Myocelln-1, 9 controls), with 
a minimum follow-up period of 30-days for all patients evaluated. 
At baseline, treated patients on average experienced their last 
Ml 9.3±5 years prior to screerting (range 2-21), while control patients 
on average were 7.1±4 years removed from their last Ml (range 2-16). 
Ten treated patients had documented prior history of Vf (63%) while 
6 control patients had experiertced prior VT (67%). In the treatment 
arm, mean LVEF was 30.0%±10.4%, with 8 patients (50%) NYHA 
Class Ill, whiie control arm patients entered with a mean LVEF of 
32.8%±11.1 %, with 3 patients (33%) NYHA Class Ill. On average, 
treated patients provided 7.9±4 grams of muscle tissue and were 
injected with 598±110x1QG cells over 24±41njectiot1s. Ail patiertts 
were treated with cells:::. 50% positive for CD56 staining. 
Twelve rton-hierarchical serious adverse events (Table 3) occurred 
i11 the treatmertt group in 6 of 16 patients: 1 death (due to multi 
organ failure), 6 vr with appropriate lCD firing (5 deemed possibly 
related to cell therapy and all resolved), 1 case of worsening heart 
failure (patient recovered), 1 case of pericarditis (patiertt recov-
Deflection knob lnserUon depth gauge 
-j Working length r- I Needle depth control 0 
lh,======FJI=={):I:'2~~~~~~~~~~~J~/ Injection port ) 
Figure 2. The MyocathTM hand piece. 
Needle advancement 
control _ 
c, 
Sheath port 
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Table 3. Description of arrhythmic Serious Adverse Events (SAE) 
occurred in the treabnent arm. 
SAE -oays·arter ·"-outCome ·Retat~o·nsliip ·h 
procedure 
VT+ICD firing 5 Recoveretl Probable to Myocell 
VT+ICD firing !! Recovered Probable to Myocell 
VT+ICD firing !2 Recovered Probable to Myocell 
VT+ICD firing 25 Recovered Probable to Myocell 
VT+ICD firing 8 Recovered Probable to Myocell 
VT+ICD firing Prior to cell Recovered Not related with Myocell 
implantation 
NSVT Self resolving Plausible to Myocell 
VT ~ventricular tachycardia; ICD~ implantable cardiovcrter defibrilla-
tor; NSVT ~ non-sustained ventricular tachycardia 
ered), 1 NSVT (self-resolving}, 1 post-biopsy haematoma (resolved) 
and 1 report of herpes zoster (resolved). In the control arm, n.vo 
non-hierarchical serious adverse events occurred in 2 of 9 J)<ltients: 
l non sustained VT and 1 diverticulitis, both which resolved. 
Regarding the treated J)<ltients, VTs episodes with lCD firing 
occurred in 4 patients (2 patients with 2 events and 2 J)<ltient with 
1 event each). Or~e patient had two seP<Jrate episodes at day 5 and 
11 post transplantation and, after a period of clinical recovery, pro-
gressively declined and died of multiple organ failure approximate-
ly 30 days after the index procedure. The other multi-firing lCD 
pal'lert exper'1enced 2 sep(lrate f1r'1ngs at 12 and 25 days post trans-
plantation, with complete recovery thereafter and no further reports 
of VT. The other 2 patients experiencing 1 event each both fully 
recovered, with no other VTs episodes were observed. One patient 
experienced appropriate lCD shock 8 days post implant, while the 
other patient experienced appropriate lCD shock prior to the c-ell 
implar~tation procedure. Ail arrhythmic events occurred within the 
first mor~th following the transplantation procedure. 
Of note, 3 of the 4 treated patients experiencing 6 VT events were 
confirmed non-compliant with prophylactic amiodarone use per 
protocol, and all 4 of these patients had documented prior history 
of VT with lCD firing prior to entering the study. 
Preliminary efficacy data 
Though the limited amount of data currently available does not 
allow for meaningful insight into the efficacy of the MyoCell therapy, 
prelimir~ary trends appear encouraging. 
Six-minute walk distance data available for 3 treatment group P<Jtlents 
and 4 control group patients demonstrate six mir~ute walk distance 
improved, on average, 97±51.4 meters as compared to an average 
decline of20±147.1 meters experienced by the control group paf1er1ts. 
NYHA Class data available for 8 treatment group J)<ltients and 
6 control group patients revealed that 37.5% of the treatment group 
patients improved by at least one NYHA Class at 3 months follow-
ing treatment as compared to 0% of the control group patients. 
50% of the treatment group patients improved by at least one 
NYHA Class at 6 months following treatment as compared to 25% 
percent of the control group patients who improved. 
None of the treatment group patients experienced a decline in 
NYHA Class at either 3 or 6 months following treatment 
LVEF as assessed by MUGA also showed a trend in improvement 
for the treatment group, with treated patients Improving from 
30.0 %±10.4% at baseline to 31.7%:!:21.8% at 6 months while 
control patients declined from 32.8%±11.1% to 31.7%±8.3% over 
the same time. 
50% of treated pa~ents exper'1enced an improvement 'm LVEF while 
57% of the control J)<ltients exhibited a reduction in LVEF. 
Conclusions 
Management of heart failure J)<ltlents with advanced cardiomyopa-
thy is a daunting task- patients often present with multiple medical 
conditions, a history of arrhythmia and littie available In terms of 
al~ernative treatments to standard medical therapy. Novel therapies 
are needed to provide improved treatment options, and cell therapy 
is a promising start to this endeavour. Though complete efficacy 
data are not yet available ar,d safety data are not yet fully adjudiC<Jt-
ed, these preliminary results suggest that myoblast therapy for CHF 
is largely safe and effective. Arrhythmic events are largely manage-
able with close observation and prophylactic use of ICDs and amio-
darone therapy; when arrhythmic SAEs do occur, they typically 
appear during the first month following implantation and C<Jn large-
ly be mitigated with appropriate mediC<Jl management. Patients 
receiving myoblast-based cell therapy also tend to show improve-
ment in quality of life and mechaniC<JI function over time, as evi-
denced in prior (completed) clinical studies and In the initial trends 
reported above. We look forward to receiving the 1'1nal data ·m order 
to reach more definitive conclusions. 
Appendix 
The following Investigators and institutions P<Jrtlcipated in the SEIS-
MIC study: P.W. Serruys, Erasmus MC, Rotterdam, The Netherlands; 
J. Bartunek, OLV Zlekenhuis, Aalst. Belgium; V. Legrand, CHU de 
Liege Sart-1ilman, Liege, Belgium; W. Van Mleghem, ZOL Campus, 
St.Jan, Genk, Belgulm: C. Nienaber, University Hospital Restock, 
Germany; J. Schafer, Hamburg University Cardiovascular Center, 
Hamburg, Germany; C. Hehrlein, University of Freiburg, Germany; 
J. Waltenberger, University Hospital, Maastricht, The Netherlands; 
C. Macaya, lnstltL:to Cardiovascular, Hospital Clinlco San Carlos, 
Madrid, Spai:A Gershllck, University of Leicester, Glenfield Hospillll, 
Leicester, United Kingdom; N. Peters, St Mary's Hospital and 
Imperial College, London, United Kingdom; T. Siminlak, Poznan 
University School of Medical Sciences, Poland; P. Smits, MCRZ, 
Rotterdam, The Netherlands. 
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Introduction 
Cardiac failure secondary to ischaemic heart disease is a leading 
cause of morbidity and mort<Jlity1• Infarction leads to cell loss by 
oxidative stress and reperfuslon injury. Chronic ischaemia and 
myocyte loss produces progressive expansion of the infarct area, 
fibrous replacement of the myocardium and predisposes to dilation 
of the left ventricle2, a majorfactor in survival3. Progenitor/stem cell 
therapy has potential fOr promoting strJctural and functional repair 
of the myocardium, 
Progenitor/stem cells may stimulate either angiogenesis4·5 by the 
release of growth factors and anti-apoptotlc factors {including Akt, 
VEGF and FGF}, and/or vasodilation (by VEGF} with an increase in 
iN OS bioavailabillty that may help maintain cell viability and encour-
age blood flow. More controversially, progenitor/stem cells from the 
bone marrow, circulating blood or embryonically-derived, may lead 
to myocardial cell regeneration6•7• However to date, improvements 
in cardiac function and structure have been modesf'9• 
Current delivery techniques Include 2-D angiographically guided 
endocardial injection and catheter based intracoronary release. 
However, these techniques have general limitations that include 
imprecise on-table Identification of the best areas to target, poor 
abrlity In targeting a specific area, and mediocre identification of the 
treated area at follow-up. In addition, lntracoronary release has spe-
cific drawbacks such as Induction of Ischaemia, or the 'shedding' of 
cells into the general circulation. Two particular clinical settings that 
appear particularly appropriate for progenitor/stem cell therapy are 
those of recent anterior myocardial infarction that results in reduced 
LV function and of chronic, ischaemic, dilated cardiomyopathy. 
The development and integration of electromechanical mapping 
technology, NOGAm> XP (Biologics Delivery Systems™, Cordis 
Corporation, Diamond Bar, CA, USA) with the development of a mag-
netically navigable injection catheter, the MyoStarTM injection catheter 
(Biologics Delivery Systems™), could transform cell delivery. 
This article will review the principles of magnetic navigation with 
the forthcoming technology; consider how localisation, delivery and 
follow-up might potentially be improved compared with current 
techniques; discuss the relevance to two of the clinical settings that 
might derive the most benefit; and mention the possibilities of 
improved percutaneous revascularlsation that might be used 
to optimise the local milieu for progenitor/stem cell survival. The 
purpose of this article is to suggest and speculate upon how this 
technology might allow integration of the real-time visualisation 
~Corresponding author: Amsterdam Department of lnterventionaf Gardiofog;, OLVG, le Oosterparkstraat 279, 1090 HM, Amsterdam, The Netherlands. 
E-mail; markspatterson@doctors.netuk 
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of target tissue with site directed deliverability in order to reduce 
procedure times and irradiation, and to simultaneously improve 
efficacy and follow-up. 
Magnetic navigation system 
The magnetic navigation system (Niobe®, Stereotaxis, StLouis, 
MO, USA) consists of t.No adjustable permanent magnets on either 
side of the fluoroscopy table (see Figure 1). 
In essence the system does three things. Firstly, the system oper-
ates using a 3-D reconstruction that is either produced from angie-
graphic images (as in the case of coronary arteries) or, alternative-
ly, an imported 3-D reconstruction from an external system e.g. 
NOGN~ XP. Seco11dly, the spatial orientation and :ocation of this 
reconstructloll Is matched to the real-life patient's internal cardi.ac 
anatomy; i.e. coronary artery or cardiac chamber. Thirdly, the model 
gives the real-time, on-line vectors to direct an extemal mag11etic 
field to orie11tate a magnet 011 an l11travascular device to match the 
direction required for navigation through the 3-0 reconstruction. 
The result is the ability to use 3-0 information in real-time in patient 
therapy. 
Figure 1. Magnetic navigation system is shown with the magnets in 
position on either side of the patient. 
The magnetic navigation system has been described in detail pre-
vlously'0·ll. Briefly, the interacting magnetic field produces a 
15 em uniform magnetic field of 0.08 Tesla that can be increased 
to 0.1 Tesla. Computer controlled movements of the magnets 
allow redirection of this externally applied magnetic field vector in 
360° in all planes. For cardiac chambers a 3-D volume rendered 
reconstruction is imported and aligned for navigation. For coro-
nary artery use, the 2-D locations of points on X-ray images are 
known in relation to the Image intensifier, angiography system and 
table and this allows production of a 3-D reconstruction from 
2 views separated by at least 30°. The result is real-time, on-table 
localisation of the reconstruction within the chest of a patient dur-
ing a procedure to allow direction of therapy. Adjustment of the 
magnetic vectors from the model synchronised to the X-ray 
system adjusts tip-magnet direction in the patient to produce 
deflection of the wire. This gives reproducibly precise steering of 
the tip of the intravascular device and this steering Is independent 
of the factors that can restrict convef!tio11al procedures such as 
poor transmission of manipulation. 
New technology for progenitor/stem 
cell delivery 
Previous methods for ef!docardial stem cell delivery had several 
drawbacks in identification, cell delivery and therapy. Identification 
of the sites for injections was poor and depended on strategies such 
as marking acetate sheets overlaid on the X-ray screen, delivery was 
time-consuming with poor targeting, and follow-up was hampered 
by imprecise knowledge of where the injectio11s had been and 
therefore depended on generalised LV measurements rather then 
the region of interest. 
The magnetic navigation system can Integrate other 3-D volume 
rendered information such as MSCT, MRI or the NOGA® XP 
mapping system, see Figure 2, to give precise steering/direction 
of injections. 
Infarct localisation is possible by current techniques such as MSCT, 
which is capable of identifying infarcted areas of myocardium:z, 
and integration can provide a 3-D volume rendered map of the 
damaged myocardium. However this information is not reai-time 
and was of limited use In treating the patient on the table. 
New technology is under current development The NOGA® XP 
mapping system gives information on the functloflal and electrical 
properties of the myocardium simultaneously with real-time, p~ecise 
localisatlol1 by producing a map of the left ventricle (see Figure 2J. 
This may allow differentiation between the extent of the infarct and 
peri-infarct regions as well as giving valuable information for follow-
up. This, together with the MyoStarrM injection catheter to allow 
magnetically enabled cell delivery (see Figure 3) may not only allow 
areas to be identified by electrical and mechanical mapping meas-
urements but also deliver injections of cell therapy. 
Potentially, this could give several major advantages. Firstly, 
integration of real-time electromechanical mapping would give a 
real-time, on-table 3-D LV map for exact localis.:~tion. Secondly, 
electromechanical mapping may discriminate between viable and 
non-viable infarcted areas e.g. lde11tifying electrically active but 
non-contractile areas such as stunned myocardium. Therefore 
this combination of detection methods could enable new strate-
Figure 2. Graphic showing reconstruction of LV mapping. 
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Figure 3. MYOSTAR™ injection catheter to have electromechanical guidance provided by the NOGA110 XP. 
gies that tailor delivery of cell therapy to particular areas. Thirdly, 
a magnetically navigable injectlo11 catheter could precisely direct 
cell itljection and simultaneously integrate spatial and electrical 
informatiotl. Fourthly, an electromecha11ical map could aid follow-
up both to ldetltify the region on the map that was previously treat-
ed, a11d also to give qua11tifiable illformation for specific locations 
on the map. Definable delivery of stem ceils would allow Investi-
gation of specific locations or patterns of cell delivery. As dlfierent 
parts of an i11farcted area may have discordartt electrical and 
mechanical properties, with intact electrical but poor mechanical 
activity, this may ailow Identification of sturtned myocardium in 
penumbral regions that might derive particular benefit from stem 
cell irtjection. Additionally, current estimates of the resolution of 
the new system suggest that this could localise positions to within 
1 mm that would represent a major improvemertt An idea of the 
type of the i11formatlon that may be available with this system for 
diagnosis and follow-up is seen in Figure 4. 
limitations of current celt delivery techniques 
The strategy of ertdocardial injection has suffered from a number of 
limitations. The current technique of LVa11giography gives mediocre 
localisation as the erttire LV volume is seen o11ly in 2-D pictures from 
different views. This technique gives little idea of the location of the 
watershed or penumbral area that might cortl<lin stunned rather 
then necrotic cells. l11jection sites, and particularly areas that might 
be particularly susceptible to improvement with cell therapy, are 
poorly identifiable In real-time, and are difficult to access with 
current equipme11t. 
lntracoronary injection has been the other widely used technique 
and has Its own limitations. Release of cells depertds on 
haematogenous spread, and this may be poor in areas that are 
poorly revascularised or are still occluded, therefore reduci11g 
the effectiveness in these areas. This inhomogeneous delivery may 
preve11t delivery to salvageable areas that have competitive flow 
Figure 4. NOGA"" electrical (UNIV, at top) and mechanical (LLS, at 
bottom) maps from a human patient in the stem cell treatment group. 
The maps on the left are those performed at the time of injection and 
maps at right are those at four month follow-up. An area of viability, 
showing normal electrical activity, can be noted on the upper right map. 
The maps on the right show improvement in both electrical and 
mechanical function. LLS ""' linear local shortening: UNIV""' unipolar 
voltage. 
from a neighbouring territory that Is, however, insufficient for 
long-term survival. As i11tracoronary i11jection often uses occlusion of 
the proximal vessel this results in further ischaemic i11sult witr, 
further, possibly Irreversible. damage and cell loss and reducer: 
perfusion pressure leading to collapse of pinched microvasculatur\·. 
Additionally, loss of cells t'lat do pass through the microvasculature 
into the general circulatlo11, also known as 'shedding', may lead 
to the drawback of these progenitor cells reaching areas where con-
ditions favourable for angiogenesis are present but cli11icaily 
unwa11ted, e.g. 11eoplastic neovascularisa~ion or ischaemic areas 
such as retinopathy. 
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Implications for the clinical situation 
of cell delivery 
Twa particular situations may be particularly appropriate for treat-
ment of ceil therapy; these are recent anterior infarction with signif-
icant LV impairment and non-revascularisable chronic lschaem ic 
C<lrdiomyopathy. While these situations have some simllar'1ty such 
as extensive cell loss and unattractiveness for cardlothoracic sur-
gery, there are specific reasons why precisely directed endocardi-al 
injection may hold particular .advantages. These have advantages 
over and above the general .advantages of improved diagnosis with 
two modalities, precise site-directed delivery and follow-up dis-
cussed above. 
The purpose of using cell therapy In the treatment of recent acute 
Ml is to prevent maladaptation or remodelling and so preseiVe LV 
contractile function and thus exercise tolerance. This group may be 
the most effective group to treat with cell therapy in order to max-
imise myocardial cell salvage. As discussed above, endocardial 
i11jection may be advantageous over intracoronary delivery as it 
delivers cells to areas that have a restricted or absent blood supply. 
This direct delivery via the endocardium overcomes the problem of 
tissue swelling related to ischaemlc damage that may cause pinch-
ing of the microvasculature to reduce haematogenous delivery to 
peripheral sections of the infarct territory, i.e. to the pe11umbral 
areas that may be particularly suitable for salvage. In addition, 
endocardial injection decreases shedding of cells into the circula-
tion s'1nce cells are ·mjected within the t'1ssue thus placing decreased 
11umbers of cells into the bloodstream. 
In the treatment of chronic heart failure there h.as already been tis--
sue loss and often, this is combined with severe lschaemlc coro-
nary disease. Cell therapy aims to reverse the chronic changes by 
improving the vascular bed and salvaging as much myocardium as 
possible. This situation would particularly benefit from addition of 
new myocardial cells, although the ability to produce new myocytes 
remains controversial. Precise delivery to electrically and mechan-
ie<illy definable areas could allow uniform coverage or other distri-
butions to target specific areas. In addition the risk of perforatio-n 
of a thin myocardium may be minimised by use of electrical signals 
via the adjustable and retractable needle providing exact depth 
control together with monitoring of the ECG for reverse potentials.. 
Revascularisation 
A further option enabled by the magnetic navigation system is tlie 
ability to treat complex coronary disease. fts the predominant cause 
of LV dysfunction is ischaemic heart disease, the partial or complete 
recovery of the native coronary circulation may encourage both 
recovery of native myocytes and prov'de a milieu for better uptake 
and differentiation of stem cells. 
The ability of the system to support PCI has been demonstrated in 
a number of scenarios from simple to complex lesions13 and evl~ 
dence suggests that this system may be particularly advantageous 
in more difficult anatomy14 and is capable of successfully treating 
CT0s15• The integration of MSCT data (see Figure 5) allows 
the m'iss'mg segment of the vessel to be judged {see Figure 6) and 
the superimposiTion of this data by co-registration gives an Indica-
tion of the pathway. 
Delivery techniques and self imaging 
Figure 5. The panel on the left shows the rcw dl!tli from angiography 
and the panel on the right shows the reconstructed MSCT. 
Figure 6. The panel on the left shows the co-registered points applied 
to the MSCT image that was imported into Navigant and the panel on 
the right shows the computer reconstructed pathway that is derived 
trom CT and projected onto the reconstruction in Navigant. 
Conclusion 
Magnetic navigation may aid the peliormance of cardiac stem cell 
transplantation by allowing Integration of spatially localised, 3-D vol~ 
ume rendered information with real~time tissue visualisation in mul-
flple modallt'1es to give s'1te directed deliverability to reduce proce-
dure times and Irradiation, and improve efficacy simultaneously. 
The development of the NOGA® XP system and the magnetically 
navigable MyoStar™ Injection C<ltheter may lead to improved detec-
tion of non-functional myocardium, better delivery and more pre-
cise follow-up. 
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Abstract 
Aims: Haemoglobin based oxygen carriers (H BOCsl are considered in the treatment of patients with acute coronary 
syndromes (ACS) undergoing percutaneous coronary i11tervention (PCI}. In light of their pote11ti<ll vasopressor and 
colloidal properties, their effect on coronary ph).siology, safety and tolerability 11eeds to be establlshed. 
Metllods and resultS: In this phase II pilot trial, 45 patients were randomly assigned, (1:1:1) to double blind 
treatment with a 30 minute intravenous (IV) infusion of either 15 or 30 g of HBOC..20l, compared to an 
equivalent volume of no11-oxygen carrier colloid control. Systemic, pulmonary, and coronary haemodynamics 
were studied during this i11fusio11 period. IV HBOC-201 administration produced an increase in systolic blood 
pressure (SBP), pulmonary capillary wedge pressure and calculated systemic vascular resistance (SVRl a11d a 
concomitant decrease in cardiac output (COl: there was a decrease in mixed venous saturation (SV02l 
following IV HBOC..20L The left ventricular stroke work index (LVSWI) was llotaltered by HBOC..201 treatment 
Of note, no coronary vasoconstriction was observed, nor were there significant changes in resting average peak 
velocity (APV), coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. The 
percentage of patiellts wit.'l adverse events did not differ between tl1e HBOC..201 treated a11d control groups 
(76% vs. 63%, respectively, P""0.49). Seven serious adverse events (SAE) occurred ill six patients ill the 
treatment group and two in mo patiellls in the control group. Only one SAE (hypertension) was judged HBOC-
201 related. Patiellts in both the HBOC..201 and control group had a similar incidellce of increased liver alanine 
transaminase (31% vs 31%, respectively, NS); 10% of the patients in the HBOC-201 group had increases 
greater than three times the upper limit of llormal. Differelltial increases were noticed i11 some inflammatory 
markers (IL-6, CRP) 1&24 hours after infusion betveen tne HBOC..201 arms alld the control group. 
Canclusion: No compromise in tl1e coro11ary blood flow or LVSWI was observed despite HBOC-20l's known 
vasoactive effects. Olle SAE was adjudicated as "drug relatedH and fully resolved. The clinical relevallce of 
the differential rise in certain biochemical markers alld the adverse effects of plasma haemoglobin in the 
context of ACS 11eeds further investigation. 
• Corresponding author: Thoraxcenter, Ba583a, Erasmus Medical Centre, S Gravendijkwaf 230, 3015 CE Rotterdam, The Netherlands 
E-mail: p.w.j.c.scrruys@erasmusmc.nf 
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Introduction 
Prompt reperfusion o~ ischaemic myocardium is the major focus of 
acu~e treatment of patients with ST-segment elevation myocardial 
infarction (STEM I). With (primary) PCI emerging as the new gold 
standard of ACS reperfusion therapy, new questions are arising 
about the best pharmaco-'1nvas'1ve strategy to l1m'1t the amount of 
myoCJrdial damage occurring during the ischae:nia and early 
reperfusion per:ods. BeCJuse of their ability to deliver oxygen, 
HBOCs have been considered for use ir~ tr.e tre2tment of ACS. 
HBOC-201 is a cell-free polymerised bovine-haemoglobin solution in a 
balanced salt soiLrtion. HBOC-201 may act as a direct tissue oxygen 
dor.or and ar. "oxygen bridge" betweer. RBCs and tissuesl.2, 
facilitating oxygen transport from erythrocytes through plasma to the 
endotheli~.:m and organs and eventl.lally to post-stenotic areas where 
plasma oxygen transport can improve tissue oxygenation.3 HBOC-201 
can be stored at room temperature for a period of up to three years. In 
a dog myocardial ischaemia-repetfusion model, infLJSion of HBOC-201 
prior to coronary artery occlusion reduced myocardtal infarct size.4•5 
The current study is the f1rst. attempt at irrtrc:dudng HBOC-201 ·m 
the treatment of ACS and addresses safety issues ir. the controlled 
setting of elective PCI. 
Methods 
Stmly design 
The COR-0001 trial was a randomised 3-arm (1:1:1), doub:e-blind, 
placebo-controlled, dose-finding pilot (phase Ill study designed to 
investigate the safety and tolerability of IV HBOC-201 versus ;an 
equivalent amount of artificial colloid In patients with stable angina 
and non-ST-segment elevation (NSTEJ ACS schedu!ed for elective 
PCL 
The study hcd one corrtrol arm and two act'ive tre<Jtment arms w'1lh 
HBOG-201 delfvered at different doses. In one arm 230 ml HBOC-201, 
equivalent to 30 g bovine Hemoglobirl (Hbl was infused over 
30 minl.rtes. lr. the second arm 115 ml of HBOG-201 was infused over 
15 min Liles. at the same infusion speed of the first arm; thus delivering 
15 g of Hb, sequentially followed by a 115 ml infusion of Voluven-
FreseniLJS (a colloidal volume expander chosen for its molecular weight, 
similar to that of the study drug). The corrtrol arm consisted of 230 ml 
Voluven-Fresenius infused over 30 minliles. Randomisation was 
stratified by clinical site, using permuted blocks of six patients.6 Patients 
were allocated to a treatment by a central allocation telephone seri1ce. 
Patients, investigators and the members of the Data Safety 
Monitoring Board (DSMBJ were blinded to the treatment allocation 
during the study period. For blinding purposes in the catheterisation 
laboratory a double dummy technique was used (see online-only 
Data Supplement for details). The study was performed under 
Medical Ethics Committee approval and in accordance with the 
Declaration of Helsinki. 
Patient popu~ation 
The patients were enrolled in five centres in The Netherlands, 
Germany and Belgium selected for their expertise in cardiac 
physiology studies (Appendix 1, online---only Data Supplement). 
Patients were eligible for the study if they had ei:her unstable angina 
or NSTE ACS and had a severe stenosis in at least one coronary 
artery eligible for PCI. All patients had to provide written informed 
consent. Major exclusion criteria were: significant haemodynamic 
compromise requiring Inotropic or vasopressor support, significantly 
altered left ventricular funct'1on (eject'1on fraction <35%), severe 
hypertension (>1801110 mmHg) not adequately controlled by 
antihypertensive therapy at time of study enby, renal impairment 
(serum creatinine >1.6 mgldll or contra-indiCJtions to the use of 
adenosine and/or standard drugs for coronary intervention and 
coronary artery disease. The patient weight at inclusion was limited 
to a maximum of 110 kg. 
Study procedures 
Tl;e catheterisation laboratory procedure was divided into three 
consecutive phases: the baseline, the study drug 'mfusion !Jeriod 
(230 ml solution/30 minutes) and the index PCI procedure. 
Haemodynamic monitoring and control angiography were 
performed at baseline and at three consecutive +jn'.e points (10', 
20', 301 during the study drug infusion period. PCl, including 
adjunctive therapies, were performed according to sta:~dard 
institutional practices. No standard medications used in the 
management of patients with ischaemic heart disease were 
withheld by the study protocol, stopping rules on study drug 
infusion were predefined (online-only Data Supplement}. 
Safety endpoints and assessments 
The primary endpoint of the study was the in-hospital safety 
assessment ir.cluding systemic and coronary haemodynamks, 
thrombotic events, ur~toward drug interaction effects, allergic 
reactions, drug-dye interactions, met-haemoglobin formation, 
serious adverse events, as well as biochemical markers of 
inflammation, myocardial necrosis, rena: and hepatic function. The 
extent of deviation of blood values beyond ~he limits of normal was 
graded by the DSMB/CEC members. Calculated measurements of 
eGFR (estimated glomerular filtration rate) by the Cockroft-Gault 
equation were used for estimating and reporting renal dysfunction.? 
Additional analysis included a 30-day clinical follow-up, de<Jth (all-
cause mortality), recurre11t myocardial infarction, recurrent 
myocardial ischaemia and serious adverse events. 
Patient symptoms and adverse ever1ts were evaluated by the study 
investigators using a graded severity index.8 An independent Data 
Safety Monitoring Board/ Clinical Event Committee (DSMBICEC) 
reviewed aggregate safety data (including blood values} to identify 
potential patient safety issues. Safety monitoring and adjudication of 
cli11'1cal events w'1th respect to their clirlical relevance was performed 
by this committee. The data as classified by the DSMB/CEC was 
used in the final safety analysis unless otherwise specified. 
A doppler steerable guidewire (036 mm [0.014 \n.J 'in diameter) 
(Fiowire, Volcano Corporation, Rancho Cordova, CA, USA) was 
positioned in a reference coronary artery without any significant 
stenosis and was coupled to a real-time spectrum analyser and 
video CJssette recorder. Coronary flow velocity and coronary flow 
reserve measurements were performed at baseli11e and after the 
study drug infusion period i11 the first 30 consecutive study patients. 
H80C1flfusiol'l cfuting PC/ 
To assess coronary flow reserve (the ratio of peak hyperaemic 
velocity to average peak velocity at base line), maximal hyperaemia 
was ir~duced with peripheral IV infusion of adenoslne (140 ).lg/kglmin).9 
Each measureme11t was duplicated to check for consiste11cy. 
Coronary blood flow was calculated as follows: (the average peak 
velocity ~ 2) x the cross-sectional area of the coronary artery, 
calculated as 1tX (diameter of the artery.;. 2)2, which assumed a 
time-averaged parabolic velocity profile and a cylindrical coronary 
artery.w Coronary vascular resistance (in mmHg/ml/mln) was 
calculated for the reference vessels as the mean arterial pressure 
divided by the coronary blood flow. The coronary vascular 
resistance index was calculated as the average peak velocity (APV) 
hyperaemic divided by the me<Jn arterial pressure at rest 
Quantitative coronary angiographic assessments of the vessel segment 
comprising the flow wire as well as the coronary diameter at the tip of 
the Doppler wire, (betNee11 two side branches), were performed by an 
independent core laboratory (Cardialysis, Rotterdam, The 
Netherlands) with the use of edge-detection techniques.:1 
Systemic haemodynamic me<Jsurements included arterial blood 
pressure, recorded from a 7 Fr guiding catheter in the ascending 
aorta; pulmonary-artery and capillary wedge pressure (measured 
from the distal port of a 7 Fr Swan-Ganz catheter) and right atrial 
pressure (measured from the proximal port of the Swan-Ganz 
catheter). The heart rate and cardiac output, determir~ed by 
thermodilution, were also recorded. Standard haemody11amlc 
formulas were used to calculate systemic and pulmonary vascular 
resistance and their indexes. 
Statistical analysis 
Continuous baseline characteristics were analysed with one way 
analysis of variance and categorical variables with the Fisher's Exact 
test. For individual variables, values during and after administration 
of the study drug were compared with base-line values by a mixed 
model analysis of variance on change from pre-infusio11 with the 
factors of time, treatment and time by treatment Interaction. The 
different groups were compared by an analysis of covariance with 
tre<Jtment as a factor and the pre-infusion value as a covariate. 
Multiple comparisons between the treatment groups were 
performed with the Bonferroni correction. Differences were 
considered significant when P values were iess than 0.05. All 
statistical analyses were performed with SAS version 8. 
cardialysis (Rotterdam, The Netherlands) was the core laboratory 
for angiographic and ECG analysts and the data management and 
coordinating centre. All listed authors (see appendix 1, online-only 
Data Supplement) participated in the study design, enrolment of 
patients, and/or data interpretation. 
Results 
Study population 
A total of 47 patients were enrolled betwee11 December 2003 and 
March 2005. During this period, in November 2004, the Steering 
Committee temporarily suspended patient enrolment 011 the 
recommendation of the DSMB to permit a detailed analysis of a SAE 
described below. This SAE was adjudicated by the committee and 
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individual review to be procedure and not drug related. The study 
was allowed to resume in January 2005. At this occasion the DSMB 
raised it's concern about the critical elevations in SBP following IV 
HBOC-201 encountered in some patients and a protocol 
amendment instructing SBP management was issued. Of the 47 
patients randomised, o11e patient withdrew consent before any 
study drug infusion and one patient did not receive any study 
medication; both patients were excluded from analysis. The 
remaining 45 patle11ts concluded the planned 30-day follow-up. 
Analysis was by ir~tention to treat, including one patient in whom the 
30 g dose was inadvertently infused inste<Jd of the 15 g dose. 
As shown in Tabie 1, treatment groups were equally matched with 
respect to age, weight, anginal status and the overall cardiovascular 
risk profile at screening. There were five diabetic patients in the 
HBOC-201 group and no11e in the control group. 
Table 1. Baseline characteristics of the study population. 
.. ""Ciiiitiiil~·- "'is:gHBOC:2_0(_-·3o·g·H_BOt-201 
": -" .,. .. (n,..16L m~.-<1\111171 ,;" __ (n•12L. 
Age., years 60.5 ±7.5 56.8 :1:10.3 52..8±6.5 
M•~ 11 (69) 12 (71) 10 (83) 
Weight 80.2:1:12.4 84.1:1:12.4 81.3±13.4 
Stable angina 3 (19) 4 (24) 6 (50) 
Unstable angina 
Tobl 13 (81) 13 (76) 6 (50) 
Class IB 3 (19) 3 (18) 0 
Class IIB 8 (SO) 8 {47) 6 (50) 
ctassms 2 (13) 2 (12) 0 
PrevioU5 non-Q-w<we MI 3 (19) 2 (17) 
Previous PO 3 (19) 1 (6) 2 (17) 
Diabetes Melitus 0 3 (18) 2 (17) 
Hypercholesterolaemia 6 (38) 4 (24) 9 (75) 
Cigarette smoker 4 (25) 4 (24) 
Hypertension 10 (63) 9 (53) 8 (67) 
Diastolic blood pressme 
(mmHg) 75.3:1:13.4 77.6:1:11.2 72.3:1:12.2 
Systolic blood pressure 
(mmHg) 131.0:1:20.5 141.7:1:18.4 139:1:18.0 
Data is represented as numbers with percentages or as mean values with 
standard deviations. 
Systemic hemodynamic effects 
The most important haemodynamic effects of an IV infusion of 
HBOC-201 are summarised in Table 2. In both active tre<Jtment 
groups, there were significant increases in systemic arterial blood 
pressure (systolic, diastolic, or mean pressure) in cor~junction with a 
significant reduction in cardiac index at 30 minutes after HBOC-
201 infuslor~. The calculated systemic vascular resistance (SVR) 
{and pulmonary vascular resistance, PVRJ was significantly 
Increased in these patients. A dose relationship could not be 
established for these phenomena {Figure 1a·b-c·dl. Critical 
elevations In SBP following IV HBOC..201 administration, for the 
purpose of this study defined as a SBP >180 mmHg, was seen in 
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Figure 1.1 Relative change with respect to baseline values in systemic mean blood pressure (a), cardiac output (b), systemic VJscular resistance 
(c) and central venous (right atrial) pressure (d). Effect of contlol or IV HBOC 15 g and 30 g on MBP (al), SVR (bl), CO (cl) and CVD (dl). 
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Figure 1.2 Relative change with respect to baseline values in pulmonary mean blood pressure (a), cardiac output (b), systemic vascular resistance 
(c) and pulmonary cardiac wedge pressure (d). Effect of control or IV HBOC 15 g and 30 g on PAP mean (1.2a), PVR (1.2b), CO (1.2c) and PCWP 
(1.2d). Measurements were made at baseline (pre-infusion) and at three different time-points during a 30 minute infusion period: 10', 20' and 
so·~nd of infusion. Values are shown as means ±SD for all patients. 
HBOC infusion during ?CI 
0 '~'''0' ,,,, 
9129 {31 %) of the patients. Critical blood pressure elevations were 
reduced following the protocol amendment that instructed the use 
of appropriate antihyperte11sive treatme11t (IV llltroglycerin) when 
necessary; 7120 {35%) patients before the ame11dment versus 2!9 
(22%) patients post amendment. One patient was unresponsive to 
IV nitroglycerin and required nifedipine in order to control blood 
pressure. However, despite the reduction in absolute number of 
pa!:ients experiencing a clinically significant hypertensive episode, 
there was no difference be Ween the amounts of nitroglycerin {NTG) 
used before and after the DSMB amendment i11structing the use of 
NO donors to correct systolic blood pressure (a detailed description 
is provided in the online-only data supplement). At Wo hours post 
infusion (data not shown), arty statistical differertce irt MAP 
remairted bebNeen the active treatment groups artd the control 
group. A sigrtificartt decrease in heart rate was seen only in the 
HBOC-20115ggroup. 
In all three groups the pulmonary capillary wedge pressure (PCWP) 
increased fo!lowing infusion at 30 minutes; the irtcrement was 
signiflcan~y greater in both HBOC-201 groups compared to control, 
(Table 2, Figure 1.2--d), never reaching the predefined critical level 
of 20 mmHg. There were no significant changes in calculated left 
ventricular stroke work index. 
A significant decrease in mixed venous saturation (SV02l was 
noticed followirtg IV HBOC-201 {baseline: 77.4%±7.7%, 
30 minutes: 70.7%±8.3%, p:::0.002l: in severt patiertts below the 
level of 65 %. However, the irtdex of systemic oxyge11 consumptiort 
(\102), assuming an arterial oxygen saturation (Sa02) of 97% in ali 
patients, did not change from baseline {calculation, see online-only 
data supplement). 
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Coronary haemodynamic effects 
The effects of IV HBOC-201 on the diameter of coronary arteries 
(reference vessel) and on flow velocity before and after IV adenosine 
administration are shown in Table 3. Intravenous administration of 
HBOC-201 caused no significant changes in the restirtg APV, 
coronar;-artery diameter or coronar; vascular resistance. The 
coronary biood flow velocity reserve tended to increJse and this 
90 
80 
70 
Mixed venous Oxygen Saturation (MVOS) 
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..... [)ose15 
~•- Dose30 
60L-~~~--~=-~~=-~~=----Prc-ln1uslon 10 min. 20 min. 30 min. 
Figure 2. Relative change SV02 with respect to baseline values. 
Measurements were made at biJseline (pre-infusion) and at three 
different time-points during a 30 minute infusion period: 10', 20' and 
30'~nd of infusion. Values are shown as meanS:tStandard error. 
Table 2. Systemic and pulmonary haemodynamic variables at baseline and at the end of the study drug infusion period. 
15 9 HBOC-201 30-9 HBOC.:201- COi'lti'ol' 
:. -.{n•.17)_ "_{n•11}. {n•16) _ 
var~abtt:: :·: SiSetiiie __ :- .fosOrifuS!Oid.Vitiie:(t) :·_::BaSeline- :.'I'OSflrifuSfoil:.t_Vatiie (+) .:~·.aaseuiit: -.-~St:lnhisiOri-_~Vawt:ti·} 
Systolic Blood Pressure {mmHg) 145±24 153±30~ 0.34 140±15 158±2.6* 0.006 125:1:25 123±20 0,4g 
Mean Arterial Pressure (mmHg) 100±12 111±15* 0.02 97±11 112±16* <{l.001 90±13 90±13 0.95 
Pulmonary Arterial Pressure (mmHg) 
'""" 
24±7 2g±7 0.002 23±7 30±8 0.003 21±5 24±5 0.13 
Diastole 1">5 16±7 0.006 12>5 15±4 <0.001 1!±3 12>4 0.30 
Mean 17±5 
"" 
0.001 17±5 2!±5 <0.001 14±3 
"" 
0.06 
Pulmonary-capillary wet:lge pressure 
(mmHg) 
'" 
14>4. <0.001 10±3 15±3 <0.001 9>3 1!±3 o.og 
Heart rate (beats/min) 69±8** 60±8 0.001 57±9 57±12 0.46 60±8 59±7 0.36 
cardiac index (Litresjmin/m2) 2.87±0.49 2.51±0.56~ 0.008 2.66±0.36 2.45±0.55~ 0.16 2.64±0.44 2.94±0.59 0,002 
Systemic-vascular resistance index 
{dyn.sec.cm-5) 133g±270 1820±52r <0.001 1409±236 1799±370* <0.001 128g±369 1177±3g5 0.02 
Left Ventricular Stroke Work Index 
(g.mjm~) 51±11 54±11 0.52 55±5 59±20 0.29 4g±11 57±13 0.07 
Data is repre-.:ented as numbers and percentage-.: or mean V<~lue-.: with stlndard del'iJtions 
n: Number of patients per indicated group 
(+}: P values calculated with the mixed linear analysis of variance model 
~: Different from control {P<0.05). calculated with analysis of coV<~riance with bascline V<~lue as cOV<Iriate 
u: Different from control and HBOC-20130 g (P<O.OS), Calculated with one-way analysis of variance 
Avcr.~ge for baseline/post infusion is derived from matched data 
In the high dose treatment group, data were available for 11 out of 12 patients 
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Table 3. Coronalj' haemodynamics at b<~Setine and at the end of the study drug infusion period. 
~=·:·.-.-:::.-:::.-:::::::.~==~==-·=====:·::::~:~::-:·:::::::::::=~=·-:.=:-~:::::~-~~l:fa:oc;.20llii;-zor::::::~.=-=- ~-:::=contiOt:.(n;1tL::::.,:::=~-~ 
-----~--······~_-Vina6ff'~_'=~·::·:::~::::::::::~,~--~:··---~---~--~'"~~-----~----~:::aasetiiii:~-J·D$tlii1iiiiOiC61Wf(+f_:·.B3Stlflit.;::tostiiifUSiiiit~JYiliit~(t)-;::~ 
Diastolic Systolic Velocity Ratio -at rest 1.78±1.03 1.50±0.65* O.Q3 1.62±0.40 1.91±0.87 0.19 
Avetage Peak Velocity- hyperemic {em/sec) 45±18 57±25* O.Ql 36:1:16 341:14 0.59 
Avetage Peak Velocity- at rest (em/sec) 18±8 22±12 0.09 19±8 18±4 0.60 
Coronal)' Row Reserve 2.64±0.93 2.70±0.72 0.74 2.10±0.98 1.97±0.81 0.67 
"--'"--~----~--~----·--------- ---,----w---~.,~ ~-=_:::.:::_)IB'<IC.~20t:cn;;ts)~.:~:~:::::~~=:::·:=::::~::contrOC(ii;lor::::-_::::::--_:.:~~-
97±10 116±14 "'0.001 102±14 99±11 0.37 
28±13 33±20 0.26 28±13 25±15 o. 72. 
Mean Arterial Pressure- at rest (mmHg) 
Coronary Blood Flow- at rest (mljmin) 
Coronary Artery Diameter by QCA (mm) 2.72±0.68 2.63±0.77 0.35 2.53±0.50 2.35±0.49 0.43 
Coronary Vascular Resistance- at rest (mmHg/mVmin) 4.32±2.28 4.78±2.82 0.68 4.52±2.30 5.00±2.60 0.64 
··_-_'HIIO't;20l]ii-;;·19).::~_::: :·":COiitiOC(ia';;,:-iOf:::_:::=:::~~::·--
Coronary Vascular Resistance index 0.47±0.16 0.49±().21 0.36 0.35±0.14 0.35±0.14 0.99 
Data is represented as mean values with standard deviations followed by number of observations. ~: Different from control at (1'<0.05). Calculated with analysis 
of covariance with baseline value as covariate. (+) P value calculated with mixed linear analysis of variance model Mean±SO followed by number of observations. 
Coronal)' Vascular Resistance: -At b=line 6 missing values (4 missing reference diameter, 2 missing Mean Arterial Pressure/Average Peak Velocity); 
-At post infusion 7 missing values (5 missing reference di:Jmeter, 2 missing Mean Arterial Pressure/Average Peak Velocity); For mean arterial pressure. 
coronary blood flow and coronary artery di:Jmeter, only patients with an existing value for coronary vascular resistance are included. 
increase may be related to a significant augmentation in driving 
pressure. A detailed QCA analysis of the reference vessel did not 
show any angiographic coronary vasoconstriction brought about by 
the study drug (Table 1, online-only Data Supplement). Coronary 
flow studies were terminated early (n=31) after a futility analysis by 
the DSMB considering the presented data and the potential patient 
burden of this invasive procedure. 
Safety and tolerability 
This study was aimed at providing as much safety information as 
possible about the IV administration of HBOC-201 in acute 
cardiology and PC I. The mean [±SDJ amount of study drug solution 
Table 4. Reported adverse events (serious and non..serious) . 
infused in this study was: 238.1 (±34.2) ml for the 15 g H80C-
201group, 230.3 (±3.0) ml for the 30 g HBOC-201 group and 
247.9 (±67.2) ml for the Voluven only group. One patie11t 
accidentally received two unUs of Voluven. In none of the paf1ents 
did the study drug infusion have to be stopped for pre-defined 
safety reasons. 
Patients were followed up for 30 days post PC I. During this period, no 
additional SAE occurred. The number of patients who experienced at 
least one adverse event was higher in the active treatment groups 
(75.9% pooled), as compared to the control group (62.5%) (Table 4), 
the difference is not significant statistically (p-vaiue=0.49). In total, 
eighteen adverse events were considered to be study drug related, 
.. ~-~----"~-----~-~-~---"'~" .~ry«,,~,,-,"·~·-_-.. -·_--_~""."C:OiitrOl'"'":-·-";-~:f.S:'iliBD~·2'o'l'"~' :3·o~_g_:H_Bo'C::zo:C:POOletfHIKIC::tOl 
(1'1•16).' (n-17) _(n~12)__ _ _ " (n~29) · 
. --" -.-.. .. ' .. "_Ne._Np;_(%) Ne.Mp_("/o)' " __ :_N~Np.:(%).. Ne.Np:.(%). 
Adverse events Total 15,10 (53) 19,11 (65) .23,11 (92) 42,22 (76) 
Product-related 0 6,6 (35)* 12,8 (57)'* 18,14 (48)* 
Proce<lure-retated 5,5 (31) 2,2 (12) 6,5 (42) 8,7 (24) 
Serious adverse events Total 2,2 (13) 3,2 (12) 4,4 (33) 7,6 (21) 
Serious adverse events 
as coded by ICD-9 code 
Product-related 0 1,1 (6) 0 1,1 (3) 
Procedure-related 0 1,1 {6)q[ 1,1 (8) 2,2 (7) 
Abdominal pain 
Cardiac arrest 
Chest pain 
CifA 
GI haemorrhage (low) 
Haematemesis 
Hypertension[GOube1] 
Non-ST-segment elevation 
acute coronal)l syndrome 
Malaise & fatigue 
Nausea & vomiting 
0 
0 
1,1(6) 
0 
1,1 (6) 
0 
0 
1,1 {6) 
1.1 (6)q[ 
0 
1,1 (6)!jf 
1,1 (6)!jl 
0 
1,1 (5) 
0 
1,1 {3) 
1,1 (3)~ 
0 
1,1 {3)q[ 
0 1,1 (J)q[ 
1,1 (8) 1,1(3) 
0 1,1 (3) 
3,3 (25) 3,3 (10) 
1,1 (8) 1,1 (3) 
1,1 (8) 1,1 (3) 
n: number of p,;ticnts; Nc-numbcr of events; Np-11umber of patients that experienced Jn event;%: percentage of patients that experienced the event Qlk. 
Cerebra Vascular Accident GI: Gastro Intestinal; q[: the same patient ~: different from control (P-<0,05), Calculated with fishe(s Ex.:lct Test. 
Hypertension: tJble only includes hypertensive episodes reported by the investigator.; (table 4 bis: incidence of critical elevations of blood pressure 
adjudicated by CEC, online version only) 
one of which (a hypertensive episode) was serious. The difference in 
the number of events between the IV HBOC-201 treatment groups 
and the Voluven groups was mainly driven by the rise in liver (n~l 
and/or pancreas enzymes (n:=l) and the number of hypertensive 
episodes {n:=lO) (SBP>180mmHg). In addition, one HBOC-201-
treated patient experienced abdominal pain. 
One patient suffered a periprocedural electromechanical 
dissociation CEMDl, which followed a prolonged wedging of the 
guiding catheter during the PCI procedure. The patient required a 
prolonged resuscitation in the catheterisation laboratory. The 
clinical evolution was complicated by a watershed cerebral 
infarction and lower gastrointestinal bleeding. The patient 
experienced a full recovery. This incident was subject to detailed 
investigation by the DSMB supported by an independent 
neurologist while patient enrolment in the study was temporarily 
suspended. The EMD, reported as anSAE, was adjudicated to the 
procedure and not to the study drug; the neurological event 
reported as an SAE was putatively attributed to the period of 
hypotensior~ experienced during the prolonged cardiac 
resuscitation of this patier~t. The cardiac arrest and "watershed 
infarction" were counted as one event. 
No clinically significant changes were noted in haematological or 
chemical values following IV HBOC-201, except for the cardiac 
markers and liver transaminases. A significant rise in CK-MB levels 
>3 times ULN was documented in one patient, but this enzyme 
abnormality was not likely due to HBOC-201 treatment as the 
patient suffered procedure related serious complications and had a 
prolonged resuscitation period. 
Through hospital stay, patients in both the HBOC-201 and control 
group had a similar incidence of increased liver alanir~e 
transaminase (31% vs 31%, respectively, NS); 10% of the patients 
in the active HBOC-201 group had elevated aspartate 
aminotransferase (ASD or alanine aminotransferase (ALTI or lactate 
hydrogenase (LDH) enzymes {>3 times ULNJ compared with none 
in the control group (Table 5). No patients had an abnormal total 
bilirubin (>3.0 mgfdl and 2:100% increase) or Alkaline Phosphatase 
(>250 IU/L and 2: 100% increase) value, and no jaundice or hyper 
bilirubinaemia was reported, Two patients in the treatment group 
showed an increase in pancreatic enzymes {serum amylase >1.5 
ULNJ. No effect of the drug was observed on the renai function 
(Table 5). Overall, there was a slight increase in plasma 
methaemogiobin level following IV HBOC-201 (average value pre--
HBOC: 0.50% /6-8 hours post-HBOC: 0.75%, P:= 0.007 and post 
18-24 hours 0.90%, P<0.001) with two patients above the cut-off 
level of 1.0% {data not shown}. 
The IV HBOC administration was associated with a statistically 
signiflcant differential increase in inflammatory markers (IL-6, and 
CRP}, measured at 18-24 hours after HBOC infusion, between the 
treatment arms and the control group, without any clear dose 
response relationship (Figure 3}. 
Discussion 
We report on the first study in which HBOC-201 has been 
administered to patients with acute coronary syndromes 
undergoing PCI. 
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Figvre 3. Effect of control or IV HBOC 15 g and 30 g on s-ICAMl (:J), 
IL-6 (b) :Jnd CRP (c). A dose relationship could not be established for 
any of these markers in the active IV HBOC-201 arms. 
StJtistiC:JI ilnalysis is performed on log-scale. For presentation, the 
geometric mean±the SWndard-e"or is given on the original scale. 
*Significantly different from pre-infusion (?<0.05). Effect of time. 
#Significantly different from control at 18-24 hours (P<0.05). Effect 
of treatment. 
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Table 5. Laborato'Y testing on organ function (Liver/kidney) 
Peak AST > 3x ULN~ 
Peak ALT (SGPT) 1·3x ULN~# 
Peak ALT (SGPT) > 3x ULN* 
Peak ALP >ZX ULN* 
Increase in serum Creatinine (Cr) >O.Smg/dl 
Decrease in eGFR>25% from baseline 
tcr >O.Smg/dl or kGFR>25% 
.............. 
5 (33) 
1 (7) 
1 (7) 
iS'"9'HBOC:201'-
(n-17) 
N (%) 
2 (13) 
4 (25) 
2 (13) 
Clinical research 
1 (8) 
2 (17) 
1 (B) 
1 (B) 
3 (25) 
3 (25) 
~uLN: upper limit of normal; AST: asp<lrtate aminotr.msfcrase; ALT: alanine tr.mSJminase; ALP: alkaline phosphatase; eGFR: estimatcU glomerular filtration 
otc 
Cut-off levels for total bilirubin, serum alanine aminotr.msferasc and alkaline phosphat:lse levels were chosen according to the definition of drug·related 
hepatotoxicity.~ The mean change in ALT expressed as a ratio (24 hrs follow up/Baseline) was 0.71 (contro~ P..0-02) V'i 1.01 {HBOC·201, P-0.91), the mean 
change in ALP expressed as a mtio {24 hrs follow up/Baseline) was 1.07 (controL P-0.02) V'il.ll (HBOC·201, P-0.09). 
# Allll patients in this group had ele~~<~ted ALT ~~<~lues ;rt the baseline 
Several haemoglobin·baSed oxygen carriers are currently being 
studied in clinical trials for various indications. Most are derived 
from human or bovine blood and have been chemically modified, 
resulting in molecules that differ in size, molecular weight, 
oxygen affinity, viscosity. and oncotic activity. Every formulation 
should be considered a unique drug with its own physical 
characteristics, pattern of biological activity, and profile of 
adverse reactior~s. 
HBOC·2Dl is a cell free, endotox'm free, giL:taraldehyde cross·l'lnked 
bovine polyhaemoglobin in so:ution with an average molecular 
weight of 250 kDa (molecular weight ranging 130..500 kDal and a 
viscosity less than plasma 0.3 cer~tipoise at 37°C). Only trace 
amounts (2%) of ur~modified haemoglobirl and stabilised tetramer 
(molecular weight 65 kDa) are detected. HBOC-201 has an oxyger1 
dissociation curve that is right-shifted with a P50 of 40 mmHg, 
compared to 27 mmHg for native human haemoglobin. These 
features provide excellent oxygen·transport properties. 
The pathobiological effects of cell·free plasma haemoglobin are a 
concem.:2 Vascular homoeostasis is deper1der1t on the 
compartmentalisation or physical separation of haemoglobin from 
the endothelium.13 However, unlike single haemoglobin molecules, 
polymerised-HBOCs like HBOC-201, that are mostly ir1 the form of 
large soluble haemoglobin complexes (98% is~ 130 kOa), are not 
expected to readily cross the intercellular endothelial junctions of 
blood vessels to exacerbate vasoconstrictive effects. 
HBOC-201 is a colloid solution, and avoidance of circulatory 
overload is another important consideration. In our study 
population, a volume of up to 250 ml HBOC-201, equivalent to 30 g 
haemoglobin glutamer-250 bovine, was infused over a 30 m·lnute 
time period. lr1 none of the patients did the study drug infusion have 
to be discontinued for pre-defined safety reasons, such as an 
excessive increase in pulmonary wedge pressure. 
IV HBOC-201 in this study population resulted ir1 an increase in 
systolic blood pressure, a decrease in CO, and an increase in 
calculated SVR suggesting a vasoconstrictive effect. A critical 
elevation in SSP could be reversed by the intravenous 
administration of a nitric oxide donor, nitroglycerin, consistent with a 
putative role of nitric oxide scaver~ging in vasoregulation.l~l7 
The increase in SVR (afterload) in patients receiving HBOC-201 
most likely contributed to the differential increase in PCWP between 
the control and treatment groups. The increase in preload observed 
after HBOC-201 must be interpreted as a normal physiological 
compensatory reaction to an increase in afterload (or~ly observed in 
the HBOC-201 group} and to an increase in plasma volume 
expansion (induced in both groups). This increase in tilling pressure 
dDes not reflect an intrinsic myocardial depressing effect of the 
compound nor a detr'1mental effect on the myocard'1al systolic 
fur~ction, since the Left Ventricular stroke Work index (LVSWI) 
remained unchanged regardless of the treatment received. 
A decrease in mixed venous saturation was observed ir1 both 
treatment arms and in some patients saturation went below 65% 
(Mean Sl/02 at baseline 77.4, at 30 minutes 70.7, p-=0.002). The 
most plausible explanation for this phenomenon is a reduction in 
resting cardiac output associated with study drug infusion; 
consequently the arterio·venous 02 difference would have to 
increase by lowering the mixed venous saturation. The metabolic 
demand of patients lying at rest on the cath lab table was probably 
unchanged and hence not a factor contributing to the fall in Sv02. 
There is no indication that IV HBOC-201 affected global oxygen 
consumption. 
Our data clearly show that IV HBOC-201 had no effect 0r1 resting 
and hyperaemic coronary blood flow. This suggests that the 
autoregulatory mechanism of the coronary circulation was not 
adversely affected by the infusion of HBOC-201. In addition, there 
was no angiographic coror~ary vasoconstriction observed in the 
major epicardial vessel brought about by this drug. 
This safety and feasibll'tty study was designed to detect as many 
safety signals as possible; the DSMB was prospectively informed 
about the potential side effects of IV·haemoglobin solutior1s. The 
multitude of endpoints specifically scrutinised by either the 
ir~vestigators or the DSMB and CEC may have cor~tributed to the 
apparently large number of adverse events reported. 
Systemic removal of bioavailable nitric oxide has already been 
shown to cor~tribute to clinical morbidities, including severe 
oesophageal spasm and dysphagia. abdominal pain and 
thrombosis.17·19 The low incidence of these nitric oxide.related 
HBOC infusion during PCf 
clinical side effects in the present study, as compared to the 
literature, may be explained either by the lower dose of IV HBOC.. 
201 used, by a conco;nitant use of nitric oxide donors and/or by the 
unique properties of the investigational drug. 
A transient rise in concentrations of liver transaminases and/or 
pancreatic enzymes was seen in 10% of the patients following IV· 
HBOC..201. These patients were typically asymptomatic and without 
clinical sequelae during the 30 day follow-up. Since the liver Is the 
norma: Hb catabolic site, the absorption-distribution-metabolism 
and excretion {ADME) of HBOC-201 also involves the hepato-
pancreatic systems, possibly inducing an upregulation of enzyme 
activity in response to an incre<~sed metaboiic load. Elevations of 
trnnsaminases and lipase have been observed in previous animal 
studies and clinical trials with HBOC-201. These enzyme elevations 
are generally not associated with hepatic or pancre<~tic dysfunction. 
The potential clinical importance of the increases in liver 
transaminases should be the subject of further investigation. 
No adverse effect of the drug on renal function was observed. 
Nevertheless, given the recognised nitric oxide scavenging potential 
of the haemoglobin solutions, caution should be exercised when 
administering active HBOC-201 to patients with known renal 
dysfunction or in circumstances where the renal plasma flow is 
known to be reduced (i.e., NSAID use). 
Nitric oxide reacts with oxyhaemoglobin to rapidly form the 
oxidation product, nitrate (N03-), and methaemoglobin which is 
inactive.20 The compara~ively slow reduction of methaemoglobin 
back to the active form makes the formation of methaemoglobin of 
potential clinical importance. In this study, the plasma level of 
methaemoglobin increased slightly following IV HBOC-201, 
remaining within the physiological range in most of the patients. 
When the circulating methaemoglobin values in both treatment 
doses were pooled, a significant difference was found betvveen the 
;lre-infusion value versus the 18-24 hour value {ratio 1.76, 
P=0.003). This difference is not considered clinically significant. 
In our study, the circulatory leveis of hs-CRP, IL-6 and s-ICAM in the 
whole population remained in the broad range of variability 
observed in patients with ACS undergoing PCL2: The differential 
rise in circulatory levels of inflammatory markers following IV HBOC-
201 compared to the control treatment is in accordance with 
previous observations indicating pro-inflammatory properties of 
plasma haemoglobin and heme.22 Heme stimuiates the expression 
of the adhesion molecules ICAM-1 (intracellular adhesion molecule-ll, 
VCAM-1 (vascular cell adhesion molecule-1) and E·selectin on 
endothelial ceils in vitto.2324 The clinical significance and extent of 
our observations has to be established in further work. 
Study limitations: These results reasonably apply to medium- to low-
risk patients suffering CAD and C<Jnnot be extrapolated to patients 
with an evolving or recent transmural myoe<Jrdial necrosis or 
haemodynamic instability because such ~tients were excluded 
from this study. IV HBOC-201 might provoke more pronounced 
systemic haemodynamic effects in patients with other 
cardiovascular conditions or different baseline characteristics. The 
favourable profile of HBOC-201 in this trial warrants additional 
animal studies and clinical trials, including in particular, studies in 
higher risk ACS (STEM I) patient populations. The current trial did 
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not focus on myocardial oxygen consumption or tissue oxygenation 
during IV HBOC-201. Investigation of HBOC-201 oxygen transport 
properties and the potential for this therapeutic to preserve 
myocardial tissue oxygenation in humans is currently under way. 
In conclusion, despite its known vasopressor effect Intravenous 
administration of HBOC-201 does not interfere with the 
autoregulation of coro:lary blood flow both at rest and after maximal 
hyperaemia. The safety profile of HBOC-201 in this study refiects 
mar~y of the known side effects of haemoglobin based solutions. 
When clinically contextualised, the SAEs observed in the HBOC-
201-treated patients arose from other factors and, with the 
exception of increased blood pressure, were not considered 
product related. However, some adverse events (AEs) of cell-free 
plasma haemoglobin observed in this study remain a concern and 
need further investigation. This work provides a first step towards 
exploring a new pharmacological strategy that could broaden the 
temporal window for PC I, particularly in patients suffering a STEM I. 
While we recognise that this small population study did not include 
STEM I patients, investigated oniy two doses of HBOC-201 and was 
not aimed at demonstrating efficacy or beneficial effects of this 
oxygen carrier during ischemia, the results are encouraging enough 
to pursue additional studies to gather that information. 
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Abstract 
Aims: To test the hypothesis that lntracoronary infusion of pre--oxygenated HBOC-201 during brief, total 
coronary artery occlusion would prese!Ve left ventricular function. 
Methods: Immediately following a successful PCI, the target coronary artery was occluded without {"dry 
occlusion") -or with- infuslon of pre-oxygenated HBOC-201 distal to tile stentvla theguidewireshaft of an over-
the-wire balloon for up to three minutes at an infusion rate of 48 mVmin. A cross-over design was applied. Early 
signs of myocardial ischaemia were evaluated by left ventricular pressure-volume loops and intracoronary ECG. 
A 12-lead Holter ECG was activated before the PCI and deactivated four hours after the study period. Primary 
endpoints were change in left ventricutar relaxation indices and in the sum ofST segment deviations. 
Resul~ None of the measured parameters differed significantly from their respective baseline values during 
HBOC-201 infusion. By contrast, ejection fraction (EF), cardiac output (COl and minimal rate of LV pressure 
change (dP/dT MIN) decreased significantly and the end diastolic pressure (EDPl and time constant of 
relaxation Increased significantly during dry occlusions (P<0.05). The end diastolic pressure-volume 
relationsllip (EDPVR) at the fixed pressure level of 30 mmHg 0/Jr), an index of myocardial compliance, 
reflected greater myocardial stiffness during dry occlusions compared to occlusions with HBOC-201 infusion. 
Conclusions: lntracoronary infusion of oxygenated HBOC-201 is capable of preseNing left ventricular 
function, likely through maintenance of myocardial oxygenation. It is hypothesised, that in an acute setting, 
HBOC.20lcould seNe as an oxygen bridge to reperfusion by PCI extending the "golden" time period 
during which permanent myocardial damage is unlikely. 
~Corresponding author: Thoraxcenter, Ba-583, S Gravendi}kNa/24{), 3015RD, Rotterdam, The Netherlands 
E-mail: p.w.j.c.serruys@erasmusmc.ni 
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HBOC-201 infusion during f!lectNe PC! 
Introduction 
HBOC-201 is a cell-free, endotoxin-free, glutaraldehyde-
polymerised haemoglobin solution produced by chemical 
modifiC<Jtion of bovine haemoglobin. Initially developed as an 
alternative to red blood cells for anaemic surgiC<JI patients, HBOC. 
201 has the ability to restore tissue oxygenation In persistently 
ischaemic tissue. By facilitating oxygen diffusion and convective 
oxygen delivery, HBOC-201 may act as a direct oxygen donor and 
increase oxygen transfer between red blood cells and between 
RBCs a11d tissues1.2. These mechanisms could '1mprove tissue 
oxygenation3, especially in post-stenotic areas that free plasma, but 
not RBCs, is capable of reaching. HBOC-201 can be stored at room 
temperature for a pef1od of up to three years and does not require 
cross-matching. 
Because HBOCs can deliver oxygen, they have been considered as 
an adjunct treatment in ACS. Studies conducted in animal models 
demonstrated that both the prophylactic (before induction of 
ischaemia) and late (after ischaemia onset) HBOC Infusion are well 
tolerated and effective4-<l. 
The safety and tolerability of HBOC up to 230 ml in low to moderate 
risk cardiac patients scheduled for elective PCi has recently been 
investigated ir1 the COR-001 trial9• This study showed that 
intravenous HBOC-201 administratiorJ did not compromise 
autoregulation of coronary blood flow, despite the known 
vasoconstrictive properties of this drug, or myocardial function as 
assessed by the left ventricular stroke work. A transient increase in 
the mear1 arterial blood pressure (MAP) and systemk vascular 
resistance was observed, consistent with the purported nitric-oxide 
scavenging activity of the drug. 
The present study is a first step towards establ'lshing the efficacy 
and safety of oxygenated HBOC-201 in preserving myocardial 
function using PCI techniques to induce brief coronary artery 
occlus'1on in humans. Additional safety information regarding intra-
coronary delivery of oxygenated HBOC-201 has also been collected. 
Methods 
StlldY design 
The COR-0002 pilot trial is a slngle-cer~tre, phase II, placebo-
controlled, crossover, single-blind study conceived to test the 
hypothesis that HBOC-201 admir~lstration improves myocardial 
"oxygenation" and myocardial fur~ction during brief coronary 
occlusion. Enrolled subjects underwent coronary balloon occlusion, 
with and without oxygenated HBOC-2011ntracoronary infusion 01-
12 gfdl at 43 ml/mln up to 3 min). The study was approved by the 
Medical Ethics Committee of the Erasmus Medical Centre 
(Rotterdam, The Netherlands) and was performed ir1 accordance 
with the International Conference on Harmonisation of Good Clinical 
Practice (ICP/GCPJ guidelines. 
Patients 
Patient inclusion and exclus'ron cr'iter'1a are summarised in Table 1. 
In brief, patients were eligible for the study if they were admitted for 
either documented silent ischaemia, stable angina or unstable 
Figure 1. The COR-0002 trial was divided into three phases: 
a preparation period (pre-treatment ph:Jse), a treatment phase and 
a follow-up phase. The study period began after the lesion was 
wccesstully treated (PC/ and stenting). Continuous 12-lead HOLTER 
EGG was recorded from pre-PCI to four hours after the study period 
ended (follow-up). PC!: percutaneous coronary intervention. 
angina (Braunwald class 1-1118)1°. To optimise safety and size of the 
area at r'1sk, eligibility was further constrained to patients with a 
target lesion in the proximal part of the left anterior descending 
corona~ artery, In the absence of associated angiographically 
visible collateral vessels. Further, a successful index PCI, with focal 
stenting of the target lesion during the same cath lab session, was 
required prior to initiating the study period. 
The pre-PCI star~dard 12-lead ECG recording corresponds to the 
baseline for quantitative dynamic analysis of ST changes over time 
during the study period. Written informed consent was obtained 
from all patients before the initiation of any study-specific 
procedures, Including pre-treatment sedation. 
Study procedures 
Data collectiorJ points and study desigrJ are depicted in Figure l. All 
subjects were followed from study inclusion to hospital discharge. 
An Independent physician was appointed to monitor safety and 
welfare of the study subjects ar~d revieN the clinical events during 
the study period. 
Concnmitant treatment 
Standard medications used in the management of subjects with 
ischaemic heart disease were not withheld per study protocol with 
the exception of analges'rcs. Use of analges'1cs was restr'rcted as 
much as possible and were not administered immediately before 
study drug infusion. 
PRE-TREATMENT PHASE 
Laboratory testing, inciuding haematology (haemoglobin, 
haematocrit, platelets and INRJ and blood chemistry (creat'1nine. 
LDL, AST, ALT, amylase, troponin T, CK total and CK-mbl, was 
performed at pretreatment b<lseline (within 24 hours of the study 
per'1odl and e'1ghl hours post PCI. HBOC-201 was pre-oxygenated 
within 24 hours of the study period using a proprietary system 
designed and validated for this purpose (Figure 2). 
Continuous 12-lead Hailer monitoring. On arrival In the cath :ab, the 
patient was connected to a continuous 12-!ead Holter ECG 
recording device which was activated before the PCI and 
deactivated four hours after the study period. The Holter data were 
sent to an independent ECG core laboratory (Cardialysis, 
Rotterdam, The Netherlands) where ST segment changes over time 
Table 1. Key inclusion/exclusion criteria. 
IildiiSIOii critei:liL 
- Males or females between 18 and 80 years of age 
- Stable angina pectoris (Ccs- Class 1, 2, 3, 4) or unstable angina 
(Braunwald class I-m, B) or documented silent ischaemia. 
- Baseline ECG with stable sinliS rhythm and no signs of myocardial 
ischaemia, with no Q waves, bundle branch block or intra ventricular 
conduction disturbances. 
- Normal left ventricular wall motion with preservell (ejection fraction 
.'!55"/o) systolic global left ventricular function. 
- Non-occlusive stenosis, located in the proximal segments of the left 
anterior descending artery andjor circumflex artery or right coronary 
artery requiring PCI with coronary stenting. 
- Secondary inclusion criteria to be assessed after completion of 
stenting procedure. 
Kij_ e>:CtiiSiOn ·cntena 
- Non-ST segment elevation myocardial infarction (patients with any 
troponin T elevation within the last 5 days). 
- History or ECG evidence of prior myocardial infarction in the 
territory supplied by the vessel undergoing PCL intraventricular 
conduction defects/baseline ST-segment abnormalities on the 
surface ECG. 
- Moderate to severe aortic or mitral valve disease. 
- Angiographically visible collateral vessels to the target vesseL 
- Hypertension not adequately controlled by anti-hypertensive 
therapy at the time of study entry (> 140/100 mmHg). 
- Uncompensated congestive heart failure or signs of pulmonary 
oedema. 
- Significant haemodynamic compromise and/or cardiogenic shock 
requiring inotropic or pressor support. 
- Known history of COPO with FEVl> <1.0 L 
- Serum creatinine> 1.6 mgjdL 
SC!i:oiid<irY iixc:I.UsiOri-fo- be ·.asS'e'md iipOii--cOrilptetioii of COTOnaiy 
stenting _procedure 
Active myocardial ischaemia 
Coronary spasm 
TIM! in treated vessel< 3 
Any deterioration in subject's status between informed consent and 
randomisation, ie SSP> 180 mmHg, PCWP or LVEDP > 20 mmHg 
CCS: Canadian Cardiovascular Society Scale; Pcr: percumneous coronary 
intc~r.tion 
Figure 2. In vitto oxygenation system. In this closed circuit system, 
HBOC-201 is pumped across a liquid-gas exchange apparatus in 
which the gas side is supplied with a continuous stream of medical-
grade oxygen. The exiting oxygenated HBOC-201 is collected into pre-
sterilised bags at a concentration of 11-13 gldl. 
were analysed by an experienced, independent analyst who has no 
knowledge of the order of study treatments. ST-segment shift 
compared to baseline was analvsed in the lead that demonstrated 
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the most severe alterations as well as in all leads showing ST-
segment changes<! 1 mm (at 60 ms after the J-point}. 
Patient instrumentation. Vascular access was obtained using the 
femoral approach with a standard Seldinger technique. Usually, a 6 
or 7 Fr arterial sheath was selected. Prior to starting the PCI 
procedure, a conductance catheter was inserted ir~to the left 
ventricle by ar1 additional8 Fr arterial sheath (details concernir~g the 
haemodynamlc data acquisitior~ are provided below in "Left 
ventricular haemodynamics"). A Swan-Ganz catheter was placed in 
the pulmonary artery via the femoral vein for cardiac output 
determinations by thermal and hypertonic saline {NaCI 10%) 
dilutior~ methods. 
INDEX PC! PROCEDURE PHASE 
An index PCI procedure was performed according to standard 
institutional practices. All patients were pretreated with aspirin and 
clopidogrel (300 mg) 2-8 hours prior to the intervention. PCI 
procedural success was defined as successful stent deployment in 
the target lesion with a residual percent in-stent diameter stenosis of 
< 15% and TIMI 3 flow of the target vessel without the need for 
bypass surgery and in the absence of death. 
THE STUDY PHASE 
Upor1 successful completior~ of the index PCI procedure, a short 
over-the-wire (QTW) bailoon (Hellos 1.5, Goodman, Japan) was 
positioned ir~side the stent using a conventional 0.014 inch 
guidewire (Balance Middle Weight, Guidant, Indianapolis, IN, 
USA). The OTW balloon was used to temporarily re-occlude the 
ster~ted segment and to perform the study-specific, selective 
intracoronary infusion. Before any study drug infusion, an 
occlusion test was performed with contrast injectiort through the 
guidirtg catheter to confirm that complete occlusion could be 
achieved. A conventional 0.014-irtch guidewire {Balance Middie 
Weight, Guidant, Indianapolis, IN, USA) was inserted outside the 
OTW balloort, distal to the stent (in the "region of interest") to allow 
for continuous "online" intracoronary ECG mortitoring (Figure 3). 
Printouts of these ECG recordings were collected and ser~t to the 
independent ECG core laboratory (Cardiaiysis, Rotterdam, The 
Netherlands). 
Guidewire 
for ECG 
Figure 3. A short over-the-wire balloon was positioned inside the stonted 
segment using a long conventional 0.014 inch guidewire (Balance 
Middle Weight, Guidant, Indianapolis, IN, USA). EGG signs of 
myocardial ischaemia were assessed by an intracoronary lead positioned 
in the guidewire shaft of the over-the-wire balloon catheter and placed 
distal to the stent in the region of interest 071¥: over-the-wire. 
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HBOC-201 infusioh 
Study occlusion and fluid infusion: All subjects underwent two lntra-
stent balloon occlusions {balloon inflation pressure=0.5 atml. 
During one occlusion, a continuous intracoronary infusion of pre-
oxygenated HBOC-201, warmed to 37°C, was administered through 
the OTW lumen at a rate of 48 mllmin {maximum volume Infused is 
144 mil. HBOC-201 was warmed via an in-line clinical fluid warmer 
(Astotherm®pJus, Model AP220S, Futuremed America, Inc., 
Granada Hills, CA, USA) positioned immediately proximal to the 
intracoronary OTW hellos balloon catheter. HBOC-201 was 
contained within the sterile, high-pressure Infusion line wrapped 
around the heating coli of the clinical fluid warmer. The infusion rate 
of 48 ml per minute was selected, based on the efficacy of 
intracoronary oxygenated HBOC-201 '111 sw'111e subjected to 
simultaneous coronary occlusion. The infusion rate employed in 
this preclinical study was extrapolated to a corresponding rote in 
man after adjustment for differences in the average body weights of 
the animals and subjects of the COR-0002 trial. 
The control occlusion period was performed similarly, but without 
infusion {termed "dry occlusion"). Subjects were assigned to 
receive pre-oxygenated HBOC-201 during the first occlusion period 
and 11o-infusion during the second period or vice versa. Each 
occlusion and infusion period lasted for up to three minutes. Three 
patients received oxygenated HBOC-201 during the first coronary 
occlusion and two patients received a dry occlusion as the first 
experimental interventioll. Pre-determined criteria for premature 
interruption of the balloon occlusions were: 
- .:=: 100% increase of left ventricular end-diastolic pressure 
(LVEDPJ from baseline 
- Sustai11ed ve11trlcular arrhythmias (ventricular tachycardia or 
ventricular fibrillation) 
- lntolemble chest pain (angilla) 
- Significant hypertension (systemic blood pressure rise to 
> 180 mmHg) 
- Significant LV dysfunction {EF decrease to less than 35%) 
Once the balloon had been deflated and the infusion stopped, 
a "resting period" of 20 minutes followed for all recorded pam meters 
to return to baseline (In particular LVEDP). The treatment period 
concluded after the second deflation, once all parameters had 
returned to their baseline values. A control angiogmm was performed 
immediately after each balloon deflation to allow off-line quantitative 
coro11ary angiogrnphy (QCAJll of the region of interest 
Left ventricular haemodynamics 
Left ventricular haemodynamic data were recorded before, during 
and after the procedure by online left ve11tricular pressure-volume 
signals obtained by a 7 Fr combined pressure-conductance 
catheter (CD Leycom, Zoetermeer, The Netherlands) introduced 
into the left ventricle via the femoral artery. The catheter was 
connected to a Cardiac Function Lab (CFL-512, CD Leycom, 
Zoetermeer, The Netherlands) for display and acquisition of 
pressure-volume loops. Parallel conductance and cardiac output 
were determined by multiple injections of hypertonic saline solution 
and thermodilution, respectively, in order to calibrate the volume 
signals of the co11ductance catheter. Data analysis was perform-ed 
off-line by custom-made software. Cardiac functioll was quantified 
by cardiac output and stroke volume, stroke work, end-diastolic and 
end-systolic volume, LV ejection frnction, end systolic and end 
diastolic pressure, maximal and minimal rate of LV pressure change 
(dP/dtMAX and dP/dtMIN}. The lsovolumic relaxation period 
(defined as the period between the time point of dP/dtMIN and the 
time point where dP/dT reached 10% of the dP/dtMAX value) was 
analysed using phase-plot analysts and the time constant of 
relaxation (Tau) was then determined. The end diastolic pressure-
volume relationship {EOPVRJ was estimated using the method 
adopted by Klot: et at12. The change in diastolic distensibility was 
calculated by the relative left and rightward shifts of the EDPVR at 
the fixed pressure level of 30 mmHg {V30). Systemic 
haemodynamics were quantified by systolic, d'1astolic and mean 
systemic arterial pressure recorded every three minutes through the 
guiding catheter for the durntion of the study period to investigate 
any possible hypertensive effects of HBOC-201 infusion. 
Objectives 
The main objectives of this study (Table 2) were early signs of 
myocardial ischaemia during intrastent balloon Inflation defined as 
changes in left ventricular relaxation (Tau and dP/dT Ml"'l and changes 
in the sum of ST segment deviations {assessed by continuous 12-lead 
Holter ECG monitoring) compared to baseline. Secondary objectives 
included changes in the cardiac performance measured by LV 
pressure volume loop analys]s. clinical signs of myocardial ischemia 
and changes in coronary vascular tone measured by QCA. 
Because of the crossover study design, it is not possible to make a 
direct comparison between treat'Tlent modalities (HBOC-201 vs. 
dry occlusion). However, it was possible to assess treatment safety 
Table 2. Study endpoints. 
P.iiiniTiiifdPOfritF~ .. -. -~;=-"·:::::-:,·-- .. ···-~·::.:=:---~-~·~ 
The change in left ventricular relaxation indices (rd.axation time 
constant Tau (ms] and pressure-halftime [ms] as measured by left 
ventricle pressure-volume loop analysis) and the change in the sum of 
ST segment deviatiollS (as assessed by continuous 12-lead Holter ECG 
monitoring) compared to baseline. 
s«Oridali(eJl'GpOliitS~---·~:~:::-·":?_"=:,::::::-~-~o-•::::.','""-:::::-: 
- Left ventricular haemodynamics as assessed by Left ventricle 
pressure-volume loops. Parameters taken into account are: 
- heart rab: 
- Left ventricle end-systolic pressure and volume, 
- left ventricle end-diastolic pressure and volume, 
- maximal and negative dP/dt {mmHg/s), 
- left ventricle ejection fraction {%), 
- left ventricle stroke work {mmHg.ml). 
- The change of ST segment as recorded at intracoronary ECG 
measures during balloon inflation. 
- The local (V<Jsoconstrictive) effect of HBOC-20l(r) 011 coronary 
artery diameters as assessed with off-line quantitative coronary 
analysis based on angiograms performed before and immediately 
after study drug infusiollS. 
- Safety endpoints as measured by in-hospital occurrence of: 
-thrombotic events by: abrupt vessel closure (angiographic) 
-anaphylactic type of reactions by: clinical signs 
-life-threatening cardiac arrhythmias (sustained venbicular 
tachycardia, ventricular fibrillation, asystole, 2nd or 3rd degree 
atrial-ventricular block) as recorded by the 12-lead Holter ECG 
- any (serious) adverse events 
from the haemodynamic responses, intracoronary and Holter 12· 
lead ECG monitoring and QCA measurements during the treatment 
period. Holter 12-lead EGG monitoring corttinued for four hours 
after conclusion of the study period and a 12-lead ECG was 
recorded at discharge or four days post treatment, whichever was 
earlier. Blood chemistry {LDH, ALT, AST, amylase, CK, CK-MB, 
troponin n was collected 6-8 hours post-treatme11t for compariso11 
to pre-index PCI baseline values. Additional safety endpoints 
included the in-hospital occurrence of adverse events. 
Statistical analysis 
Variables with normal distribution were analysed using parametric 
tests while variables with a non-normal distribution were a11alysed 
with non-parametric tests. Continuous variables are expressed as 
mean±SD or median ± inter-quartile range (IQR) and differences 
were compared using Student t test or Mann Whitney test. 
categorical variables are expressed as counts and percentages, 
All values were normalised in order to account for baseline variability. 
Normalisation was done by dividing each response to treatment 
(HBOC-infusion or dry occlusion) by the respective baseline. This 
method of normalisation was selected because it was an appropriate 
strategy to minimise the variability associated with differences in 
baselines between subjects. Differences were assessed by T- test or 
chi-square test. All statistical tests were two-tailed. All analyses were 
performed using SPSS version 12 statistical software {SPSS Inc., 
Chicago, IL, USA). A P value <0.05wasconsidered significant. Due to 
the descriptive nature of this study, no sample estimation was utilised. 
Results 
Subject baseline characteristics are described in Table 3. Patients 
(n=5) of mean age of 54.4±14 years underwent stent implantation 
for proximal (n=5) and/or mid lAD lesion (n=ll and were enrolled 
in the present study. stent per patient ratio was 1.8±1.3. Diagnosis 
•.. 
'" :. r,., 
!"' '· 
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at admission was class II stable angina for ali five patients. 
Hypertension was present in two patients, hypercholesterolaemia in 
three and familiar risk factor in one patient. No patient was diabetic. 
The mean ejection fraction (EFJ was 66±10% and the mean 
EuroSCORE was 1.1±0.32%. Procedural and haemodynamic 
results are illustrated in Figures 4, 5 and 6. None of the measured 
haemodynamic parameters differed significa11tly from their 
respective baseli11e values during HBOC infusiol1. When data 
obtained during HBOC infusion and dry occlusion phases were 
compared, a statistical difference was shown for all systolic and 
diastolic performance indexes evaluated exceptdP/dTMAX. EF, CO 
and dP/dTMIN decreased significantly during dry occlusions from 
median values of0.98 (IQR 0.09), 1 (0.06) and 0.99 (0.08) to 0.78 
(0.22), 0.9 (0.16) and 0.85 (0.16), respectively. EDP and Tau 
'" •ro 
''EDP 
10DJ'jtM4;t 
• DJ'jtmln 
''" 
Figure 4. Box plot illusttating the changes in haemodynamics that 
occurred during HBOC infusion (H) and dry occlusion (0) compared to 
baseline values (8). Solid lines inside the boxes: median; box ends: IQR. 
stars and circles: outsiders. 
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Figure 5. Pressure-volume loops derived from the five patients at baseline, during HBOC-201 infusion and dry occlusion. An important rightward 
shift of the PV loop occurred in all patients except PT005 during dry occlusion. By contrast, HBOC-201 infusion increased ESV and EDV in only 
one patient (PT004). 
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Figure 5. Mean EDPVR and V30 at baseline, during HBOC-201 
infusion and dry occlusion. 
Table 3. Baseline characteristics. 
Age 54.41:14 
Me" 5 (100) 
Arterial hypertension (40J 
Hyperc:holesterolaemia (60) 
Current Smoking (OJ 
Diabetics (OJ 
Familiar risk factor (20) 
Previous AMI (O) 
Previous PCI (20) 
Previous CABG (0) 
Previous cerebrovascul<lr event (20) 
Stable angina (100) 
Class II (100) 
LVEF 66±10 
Lesion location 
proximal LAD 5 (100) 
mid LAO 1 (20) 
Stentjpatient 1.8±1.3 
EuroSCORE 1.1.±0.32 
AMI: acute myocardial infarction; PCI: percutmeoLJS coronary inte!Vcntion; 
CABG: coronary artery bypass g1<1ft; LVEF: left ventricu\i!r ejection fraction; 
LAD: left anterior descending. 
OatJ are number ("to) or meJn (±Standard deviation). 
increased siglllficantly during dry occlusions from median values 
of 1 (0.39) and 1 (0.16} to 1.5 (0.71) a!ld 1.21 (0.23), respective~y. 
The change in dP/dTMAX was not statistically significant (from 
1 (0.04) to 1 (0.28), p=0.7ll. Dur'mg dry occlusion, an '1mportant 
rightward shift of the PV loop occurred in all patients but PT005, 
while during HBOC infusio!l, ESVand EDV did not increase with the 
exceptioll of PT004. V30 decreased from 172 ml at baseline to 
164 ml and 156 ml during HBOC infusion alld dry occlusion, 
respectively (p=0.21). 
lntrastent occlusions peliormed with infusion of pre-oxygenated 
HBOC-210 all lasted the intended three minutes duration; 
specifically, criteria for premature interruption of the inflation were 
!lever met. However, mean duration for dry occlusions was 
2.13 ± 0.12 min and premature termination of the occlusion was 
necessary in all subjects. Table 4 identifies the reason(s) for 
terminating the dry occlusion in each ])<ltient. 
lntracoronary EGG data were available ill four out of five patients. 
Data from patient two (PT002l were considered not analysable Oy 
the independent core laboratory. ST segr;>.ent changes are shown 'm 
Figure 7. During HBOC infusion, ST segment showed no significallt 
changes from baseline while it was found to be slgllificantly elevated 
during the dry occlusion phase ill patients three, four and five. 
Of note, transthoracic ECG did not show any significant change both 
during the study phase and duri11g the occlusion period. 
Table 4. Reasons for premature interruption of dry occlusion 
ph= 
· rrematUte" · nme·--· Maln·reaso·n· · · 'MditiOn·arreason· 
(Y/N) (.;n) 
PTOOl y 2.15 LVEF-:35% multiple extrasystoles 
PT002 y 2.05 EDP:>20mmHg multiple extrasystoles 
PT003 y 2.45 LVEF-:35% 
PT004 y VT 
PT005 y 2.31 Chest pain multiple extrasystoles 
LVEF: left ventricular ejection fraction; EDP: end diastolic pressure; 
vr: ventricular tlchycardia 
QCA of the arterial segment distal to the stent (Table 5) did not show 
major differences in reference vessel diameter (RVO). minimal 
lumen d'1ameter (MLD) and d'1ameter stenos'1s (DS) duri11g infus'1on 
of HBOC compared to baseline values. 
From a safety point of view, mean systolic blood pressure (SBPJ 
increase durillg the HBOC infusion was 10.8±10.5 mmHg. SBP 
never reached the critical values defined prospectively for protocol-
specified pharmacological intervention with nitrates and/or nifedipine. 
There were no noteworthy findings in the clinical chemistry 
])<lrameters a!ld no serious adverse events in any patient through 
the 4-day fol!ow-up phase occurred. 
Discussion 
The main results of this study are: 1) lntracoronary i11fusion of 
oxygenated HBOC-201 maintained leit ventricular haemodynamic 
status during total proxima\ LAD occlusion~ 2) LV systol'ic and 
diastolic properties were not affected during HBOC-201 i!lfuslon 
while they significantly deteriorated during the dry occlusio!l; 
3) intracoronary ECG showed no significant ST segment changes 
during HBOC infusion; 4) QCA indicated no conduit coronary 
vasoconstriction by the study drug; 5) HBOC-201 did not cause any 
adverse event or significantly alter blood chemistry parameters 
through the follow-up per'1od. 
The COR-0002 study was designed to test the hypothesis that pre-
oxygenated HBOC-201 is capable of supporting myocardial 
metabolism a!ld preserving function during total coronary occlusio!l 
in humans. The experimental design selected is a sequential 
intrastent angioplasty balloon inflation model with intracoronary 
infusion of pre-oxygenated HBOC-201 compared to the same 
occlusion with no infusion. Parameters of systolic and diastolic 
function and ST segment changes were measured to determine 
whether intracoronary delivery of oxygenated HBOC-201 
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Figure 7. fnttacoronary (red fine) and surface (grey lines) lead changes in ST segments during the dry occlusion and HBOC-201 infusion 
interventions. During HBOC infusion, ST segment showed no significant chBnges from baseline while it was found to be significantly elevated 
during the dry occlusion phase in patients three, four and five. 
Table 5. Quantitative coronary angiography (QCA) analysis. 
RVIf(minL -:- ~MLD-_(iiliil) ::-_.:OM%): 
PT B 0 H B 0 
001 3.1 2.58 2..77 2.5 2.23 2..2.7 19 15 1B 
002 3.11 NA 3.23 2.44 NA 2..2.7 22 NA 30 
003 2..2.8 2..2.3 2..07 1.7 1.86 25 17 3 
004 2..2.2. 2..2.3 2..2.2. 1.94 1.97 1.84 13 12 17 
005 2..86 2..67 2..2.8 1.95 1.76 1.78 32 34 22 
PT: patient RVD: reference vessel diameter; MLD: minimal lumen diameter; OS: diameter stenosis; B: Baseline; D: occlusion phase; H: HBDC infusion. 
to myocardium at risk mitigates ischaemia. Local delivery of 
oxygenated autologous blood to the myocardium at risk through the 
central lumen of a dilated balloon catheter has previously proven 
to be safe, feasible and effective in patients In the setting of routine 
coronary artgioplasty13• A 0r1e minute coronary occlusion and 
simultaneous infusion of blood at 60 mllmirl reduced, but did not 
eliminate, arrhythmias artd angina associated with control 
occius:ons performed in the absence of infusion. Higher infusion 
rates tested only in vitro resulted in concernirtg levels of haemolysis 
and potassium release, events that are obviated with Infusion of 
HBOG-201. As in this prior study, we selected a comparable, low-
risk CAD patient population scheduled for elective PCI to assess the 
impact of irttracoronary pre-oxygenated HBOC-201. 
Percutaneous coronary angioplasty provides a unique opportunity 
to study the response of the human myocardium to brief periods of 
controlled ischaemia and reperfusion and the ootential impact of 
study drugs. The present study involved repeated intracoronary 
balloon inflations with an interver~ing period of normal perfusion 
following successful deployment of a stent in an isolated proximal 
LAD stenosis. Acute recruitment of collateral vessels and ischaemic 
preconditioning may be a major cor~foundlng factor during 
successive balloortlnflatlons in PTCA studies5,l4-LG, Previous studies 
have shwn that if the duration of the first balloon inflation is longer 
than a "threshold" of- 60 to 90 seconds, ir1dicators of myocardial 
ischaemia including chest pain severity, abnormalities of left 
ventricular regional wall motion artd ST-segment elevation are 
attenuated during subsequent balloon Inflations. These 
observations provide evidence of myocardial adaptation induced by 
the first period of ischaemia17·'9 • We anticipated this potential 
interference by using an alternating crossover clinical trial desigrl. 
Furthermore, patients with angiographically evident collateral 
vessels supolving the area of interest were excluded20. 
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The evaluation of early signs of myocardial ischaemia in this trial 
relied on continuous, invasJve recording of PV loops, a technique able 
to provide deta'iled, reliable data on ventricular and myocardial 
performance21 throughout the entire cardiac cycle. isovolumic 
relaxation was evaluated by the peak rate of pressure decline 
(dP/dTMIN) and by the ventricular relaxation time constant Tau (-r). 
During the dry occlusion phase, early after balloon inflation, 
dP/dTMIN sJgnfflcantly decreased while 1: significantly increased, 
both early indicators of myocardial ischaemia. During HBOC infusion, 
neither dP/dT nor Tau changed significantly from baseline values. 
suggesting HBOC substantially mollified the ischaemia otherwise 
induced by balloon inflation. Alterations of the isovolumic relaxation 
phase are the earliest and most sensitive signs of ischaemia-induced 
left ventricular dysfunction. Early asynchronous segment re-extension 
and regional non-uniformity also contribute to early onset and slower 
rate of ventricular pressure fall and might contribute to these diastolic 
dlsturbancW. Passive ventricular characteristics are well described 
by the end-diastolic pressure-volume relationship (EDPVR}. 
Myocardial ischaemia often results in elevated left ventricular end 
diastolic pressures and in changes of the slope and position of the 
entire EDPVRZJ-25. Such shifts, when they occur, retlect a volume-
independent increase in chamber stiffness. 
in this series of subjects, LVEDP did not significantly increase during 
HBOC infusion, but increased continually in all subjects during the 
dry occlusion. Consistent w~h these results, VJJJ decreased more 
evidently during dry occlusion than during HBOC infusion, 
indicating greater myocardial stiffness during dry occlusion. It is 
interesting to note that the slope of the EDPVR remained 
unchanged during coronary occlusion with HBOC infusion 
compared to the dry occlusion phase, suggesting worsening of 
diastolic properties predominantly due to a reduction of myocardial 
distensibility. The pathophysiological mechanisms of this shift are 
not completely understood but It is thought to be due to an 
increased level of Intracellular Ca++ during diastole26 and to 
impaired myosin-actin cross-bridge inactivation secondary to 
elevated ADP concentrations27·~. Ventricular irtteiclctions and 
pericardiai constraints may also contribute to these shifts. 
Akin to diastolic function, systolic furtctlons are Importantly intluenced 
by ischaemia. HBOC largely averted systolic dysfunction. Ejection 
fraction (EF) and stroke volume (SV}, major indexes of the ejection 
phase properties, did not show significant Vclriations from baseline 
during coronary occlusions with HBOC infusion while they were 
significarttly reduced during the dry occlusiort phase. These resufts 
were achievable despite the fact that the occlusions were performed 
in the proximal part of the LAD coronary artery which supplies a large 
"area at risk." Consistent with these results, dP/dTMAX• commoniy 
used as an lsovolumic phase index of cardiac contractility, did not 
vary significantly from baseline during HBOC Infusion suggesting 
preservation of systolic myocardial performance. It is also noteworthy. 
however, that the dP/dT MAX values did not differ from baseline even 
after the onset of ischaemic conditiorts during dry occlusions, 
notwlthstartdlrtg a wide IQR and outliers. It is likely that the shortness 
of the ischaemic period (criteria for premature interruption of the 
ischemic period were met in all subjects) and the load-dependence of 
dP/dT ... v mitil!ated the real effect of ischaemia on the mvocardium. 
Early electrical signs of ischaemia irt the area of interest were detected 
by using intracoronary ECG, a technique able to detect early signs of 
ischaemia with high sensitivity'O. In this series of patients, HBOC 
infusion did not cause any significant alteration of the ST segment 
The non-significant changes that occurred during the infusiort phase, 
moreover, were only negative alterations (ST depression), suggesting 
that the myocardial wall was efficiently and protected by the drug. On 
the corttrary, a sigrtitlcant ST elevation, a sign of transmural 
ischaemia, was detected in three out of four patients during dry 
occlusion phase. In PTOOl, the ST elevation did not reach significant 
levels most likely because the occlusion was Interrupted relatively 
early, due to severe EF impairment (EF<35%) and the presence of 
multiple extra-systoiic beats. In all patients, ST tended to remairt 
elevated even after the balloon deflation while no ST alterations 
occurred durirtg the resting periods following HBOC infusiort. 
In the COR-0001 clinical trial9 the major side effect of the study 
drug was an increase of systemic VcJSCuiar resistance, a mechanism 
not completely understood but possibly related to putative NO 
scavenging by HBOCs. Importantly, however, intravenously 
administered HBOC-201 had no effect on conduit or microvascular 
coronary tone in COR-0001 subjects. In the present study, QCA 
analysis demonstrated that the intracoronary irtfuslon of HBOC also 
failed to a iter conduit corortary artery tone, as indicated by a lack of 
effect on RVD, MLD and DS. The absence of coronary 
vasoconstriction, despite exposure to undiluted HBOC-201, further 
supports the potential utility of HBOC-201 in complicated patient 
subsets such as those with coronary artery disease. 
Limitations 
The present pilot study reports the results from a small series of five 
patients. Therefore, caution must be exercised In the interpretation 
of these data. 
Although oxygenated HBOC-201 substantially preserved LV function, 
ameliorated or prevented cardiac arrhytllmla and sharply reduced or 
elimirtated coronary angina, treatment with study drug irt this clinical 
trial was not fully optimised. In swine studies, intracoronary infusion 
of oxygenated HBOC-201 at 30 m!lmin preserved approximately 
80% of LV regional wall motion during coronary artery occlusion 
(unpublished datal. Lower infusion rates yield proportionately less 
protection against coronary occlusion artd higher Infusion rates 
achieved full preservation of regional wall motion in swine. 
Extrapolating the 30 ml/min infusion rate in pigs to the average 
patient weight in the current clinical trial yields an infusion rate of 
48 ml/min, the rate admirtistered to subjects in this trial. Hence, 
higher intracoronary infusion rates based on individual body weights 
or coronary tlows rnay have provided even greater LV protection 
against interruptions in coronary blood flow. 
In summary, intracoronary oxygenated HBOC-201 represertts a neN 
category of pharmacologic stlcltegies that may have utility in patients 
undergoing PCI. The results of this exploratory trial provide 
preliminary evidence that HBOC-201 can effectively preserve 
myocardial mechanical and electrical properties '1n the face of total 
coronary occlusion. This represents an important next step in the 
clinical development program forth is product as a treatment for acute 
mvocardlal ischaemic svndromes. Future studies will be reauired 
to determine if intracoronaty and/or intravenous oxygenated HBOC.. 
201 can enhance treatment efficacy in more complicated patient 
populations including STEMI and in cases where lesion access is 
difficult or when microvascular pathology contributes to low TIM I flow. 
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Taking into consideration the published literature to date, the use of drug-eluting stents (DES) 
in patients with unprotected left main (ULM) coronary artery disease appears overall beneficial 
in comparison with bare metal stents (BMS). In particular, the use of DES is associated with sig-
nificant reductions in target lesion revascularization, target vessel revascularization and MACE 
(major adverse cardiac events). In unspecified lesions, in-stent restenosis has been linked to the 
occurrence of acute coronary syndromes; but in the setting of left main restenosis, the risk of sud-
den cardiac death becomes a concern. Thus, the antiproliferative action of DES is of paramount 
importance in ULM lesions, and to date, DES should likely be recommended whenever percutane-
ous coronary interventions (PCI) for ULM is envisioned. Pooled analyses of registry data confirmed 
the early and mid-term safety and efficacy of DES implantation over BMS, under the premise that 
PCI is performed by experienced operators. Also, very-long-term follow-up of patients with ULM 
coronary artery disease treated with DES demonstrated a satisfactory rate in both single and 
composite outcomes. The progressive reduction of adverse events overtime suggests 
that DES are persistently effective. When PCI is performed electively, the event-free survival 
over a period of3 years is excellent. This is independent of lesion location, stenting technique or 
type of drug-eluting stent used. When PCI is performed emergently, the favourable long-term 
clinical outcomes are hampered by lower event-free survival at shorter term follow-up. 
It is interesting to note that in the in diabetic population with unprotected left main coronary 
artery disease the efficacy of DES is significantly influenced by the use of insulin. In fact, adverse 
outcomes comprising cardiac death, myocardial infarction, need of re-intervention and MACE 
was significantly increased in patients with insulin-dependent diabetes mellitus. The safety 
profile of drug-eluting stents appeared overall consistent with what has been reported in 
recent trials and registries focusing on selected patient/lesion subsets. The incidence of definite 
acute, sub-acute, late and very late stent thrombosis was low and not significantly related to 
cardiac death. 
Notwithstanding the encouraging results obtained with DES for the treatment of ULM 
coronary artery disease, current guidelines still recommend surgical revascularization as the 
primary procedure. In all major institutions, current standard approach to patients presenting 
with significant ULM coronary artery disease is to have them evaluated by both interventional 
cardiologists and cardiac surgeons and to reach the decision to opt for PCI or surgery by con-
sensus, on the basis of hemodynamic conditions, vessel I lesion characteristics, the presence of 
comorbidities and patient and/or referring physician preferences. 
The results ofthe recently published SYNTAX trial represent a milestone and certainly will be 
taken into consideration in the upcoming guidelines. Guidelines are dynamic and in constant 
flux and have to be updated according to new evidences coming from clinical experience. 
New-generation DES approved for clinical use, new technical strategies, new adjuvant thera-
pies performed in the cath-lab, and prolonged dual anti platelet treatment have significantly 
decreased the risk of adverse events (including late in-stent thrombosis), making PCI a safe and 
effective alternative to surgery in several high-risk subsets of patients. 
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In the context of chronic total occlusions both sirolimus-eluting stents and paclitaxel elut-
ing stents have now been reported to be correlated with improved long-term clinical and 
angiographic outcomes compared with their BMS counterparts. Several studies reported high 
procedural success rates (particularly evident using the retrograde approach), single digit rest-
enosis rates and no increase in stentthrombosis or late occlusion after DES implantation. Good 
clinical results were observed also in chronically occluded saphenous vein grafts. Though the 
benefit of DES in this lesion subset has not been formally evaluated (SVG lesions have been 
excluded from randomized trials), the available data coming from observational studies are 
encouraging. Remaining issues are the long-term safety and efficacy of DES in SVG lesions, 
considering that long-term events frequently result from the progression of other lesions in 
the vein. Regardless of the future progress in this field, we think that DES treatment currently 
is the best approach for SVG lesions. Despite extensive real-life use of DES in patients with 
multivessel disease, we cannot deny that sufficient data are still lacking. Rather than looking at 
the incidence of new revascularizations, which may be considered an acceptable"side effect" of 
any PO strategy compared with CABG, we need to demonstrate equivalency or superiority in 
terms of Ml and death evaluated no earlier than 5 years. 
Coronary artery disease aside, advances in cardiovascular interventional techniques have 
allowed percutaneous treatment of conditions that either previously required open operations 
or have not been amenable to treatment. 
Hypertrophic obstructive cardiomyopathy is a relatively common condition (prevalence of 
around 1 in 2000 persons) . The traditional method for the management of these patients has 
been the use of beta-blockers or calcium channel blockers, dual chamber pacing or surgical 
ventricular septal myectomy. Over the last decade, percutaneous approach to treatment of out-
flow tract gradient by ablating or creating a controlled infarction of the ventricular septum, has 
also been shown to be safe and effective. Percutaneous transluminal septal myocardial abla-
tion (PTSMA) as well as septal coil embolization acutely reduce systolic function and improve 
diastolic function, maintaining cardiac output and stroke work. At long-term follow-up, the 
effects on general haemodynamics improve; in fact, while the LV-aortic gradient remaines low 
and active and passive LV diastolic properties are stable, myocardial contractility and systolic 
funcion improve. The indications for performing PTSMA are still being defined. Up to date, this 
novel technique may be a particularly attractive alternative in the elderly or those who because 
of significant co-morbidities cannot undergo /are refused by surgeons. 
The enormous improvements in PCis Jed to excellent rates of survival after an acute 
myocardial infarction. This increase has lead to a concomitant increase in the prevalence of 
post-infarction heart failure (HF) with at least a third of patients manifesting HF symptoms 
within a year. Currently, this increase is attributed both to limited efficacy of pharmacological 
agents at reducing left ventricle remodelling and HF exacerbations, and to underutilization of 
these drugs in general practice. Finally, post-infarction HF patients are surviving longer, in part 
because of a wider use of implantable cardioverter defibrillators. With the awareness that both 
Summary and Conclusions 1277 
tissues and bone marrow (BM) contain undifferentiated immature 'stem' cells normally used to 
replenish body tissues throughout life, and that these cells can be harvested and delivered to 
sites of injury, a new therapeutic option has emerged: the transplantation of stem or progenitor 
cells for functional repair or even regeneration of vasculature, acutely injured and/or failing 
myocardium or previously irreversibly damaged heart- giving hope for cell-mediated preven-
tion, treatment and possibly even cure ofCVD. Trials performed to date have focused on the use 
of BM-MNCs, EPCs, MSCs and other cells throughout the continuum of cardiovascular disease, 
from advanced coronary atherosclerosis to end-stage HF, with the most patients treated follow-
ing AMI. Three recent meta-analyses suggest that BM-MNCs provide statistically significant yet 
small (in clinical terms) benefit when administered post-AMI. However, on close examination 
of individual studies, the outcomes are discrepant. Whether the discrepancies represent differ-
ences in disease context, patient population, cell type and dose or some other factors remains 
to be resolved.ln other words, 7 years after the initiation of the first study we still have as many 
(or more) questions as answers. 
Among the variety of cells studied, autologous skeletal myoblasts are one of the most 
encouraging cell sources for cardiac repair. They are of their autologous origin, the ability to 
be amplified in vitro, and have high proliferative potential resistance to ischaemia and pre-
clinical efficacy. These characteristics have led clinical investigators to evaluate the effect of 
transplanted autologous myoblasts in patients with post-infarction heart failure. Myoblasts 
differentiate into myotubes and maintain muscle properties when transplanted into an infarct 
area. The direct contribution 
of these eng rafted cells in improving systolic function was noticed in several studies that 
indicated a 
positive effect of skeletal myoblasts on myocardial contractility lasting over time and cor-
relating with the number of implanted cells. 
Recently it has been shown that adipose tissue, in addition to committed adipogenic, 
endothelial progenitor cells and pluripotent vascular porgenitor cells, contains multipotent 
cells, similar to MSCs. ADSC have extensive proliferative capacity, are able to undergo differ-
entiation along both mesenchymal lineages and non-mesenchymal lineages, are known to 
secrete a large number of angiogenesis-related cytochines and display and immunoprivileged 
behavior. 
This finding has generated major interest because, in contrast to bone marrow, large quanti-
ties of adipose tissue can be easily harvested with minimal morbidity, making it an appealing 
source for cell therapy. The APOLLO trial will provide important data about the safety and 
efficacy of these cells in humans, providing an essential insight on what could be their role in 
the treatment of cardiovascular disease. 
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In detotop heden gepubliceerde literatuur lijkt hetgebruikvan geneesmiddelafgevende stents 
(Drug Eluting Stents, DES} bij patienten met een aandoening van de linker hoofdcoronair over 
het algemeen gunstiger in vergelijking met normale meta len stents (Bare Metal Stent, BMS). 
Het gebruik van DES is met name geassocieerd met een significante afname van target laesie 
revascularisatie, target vaat revascularisatie en MACE (major adverse cardiac events: ernstige 
cardiale gebeurtenissen). In ongespecificeerde laesies wordt restenose van de stent in verband 
gebracht met het optreden van een acuut coronair syndroom; in de setting van linker hoofdres~ 
tenose is het risico op plotse hartdood echter zorgwekkend. De antiproliferatieve werking van 
DES is daarom van enorm belang bij ULM (unprotected left main coronary~ onbeschermde linker 
hoofdcoronair) laesies.Tot op heden moet DES waarschijnlijk worden aanbevolen wanneer per-
cutane corona ire interventies (PCl} voor ULM worden gepland. Gepoolde analyses van registra-
tiedata bevestigden de gunstiger korte- en middellange termijnveiligheid en -werkzaamheid 
van DES implantatie in vergelijking met BMS, mits de PCl door een ervaren chirurg uitgevoerd 
wordt. Tevens toonde de zeer langetermijn follow up van patienten met ULM coronarialijden 
die met DES waren behandeld bevredigende enkelvoudige en samengestelde resultaten. De 
progressieve afname van bijwerkingen in de loop van de tijd suggereert dat de effectiviteit van 
DES persisteert. Wanneer electieve PCl wordt verricht, is de incidentvrije overleving over een 
periode van 3 jaar uitstekend. Dit is onafhankelijk van laesielocatie, stentingtechniek of type 
geneesmiddelafgevende stent dat gebruikt wordt lndien in spoedgevallen PCl wordt verricht, 
worden de gunstige langetermijn klinische resultaten verstoord door een lagere incidentvrije 
overleving bij kortere termijn follow up. 
lnteressant hierbij is dat in de diabetespopulatie met onbeschermde linker hoofdcoro-
nairaandoening de effectiviteit van DES significant beYnvloed wordt door het gebruik van insu-
line. De negatieve uitkomsten zoals hartdood, myocardinfarct, noodzaak voor re-interventie 
en MACE waren zelfs significant verhoogd bij patienten met insulineafhankelijker diabetes 
mellitus. Het veiligheidsprofiel van geneesmiddelafgevende stents bleek over het algemeen 
overeen te komen met de rapportage in recentetrials en registraties van geselecteerde patient/ 
laesie subsets. De incidentie van duidelijke acute, subacute, late en zeer late stenttrombose was 
laag en niet significant gerelateerd aan hartdood. 
Ondanks de bemoedigende resultaten met DES voor de behandeling van ULM coronari-
alijden, wordt in de huidige richtlijnen operatieve revascularisatie nog steeds als primaire 
procedure geadviseerd. In aile grote instellingen is evaluatie door interventiecardiologen en 
hartchirurgen de huidige standaardbenadering van patienten met significant ULM coronari-
alijden, waarbij wordt getracht consensus te bereiken over ofwel PCl ofwel een operatie, op 
basis van de hemodynamische toestand, vaat/laesie eigenschappen, de aanwezigheid van 
co-morbiditeit en de voorkeur van de patient en/of arts. 
De resultaten van de recent gepubliceerde SYNTAX trial betekenen een mijlpaal en zullenzeker 
in overweging worden genomen in de nieuwe richtlijnen. Richtlijnen zijn dynamisch en constant 
in beweging en moeten volgens de nieuwste inzichten uit klinische ervaring worden bijgewerkt. 
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Nieuwe generatie DES die goedgekeurd zijn voor klinisch gebruik, nieuwe technische stra-
tegieen, nieuwe adjuvans therapieen in het cath-lab, en langdurige duale antiplaatjes behan-
deling hebben het risico op bijwerkingen (inclusief late stenttrombose) significant verlaagd, 
waarmee PCI een veilig en effectief alternatief is voor operatie in verscheidene hoogrisico 
subsetspati€nten. 
Sirolimus-afgevende stents en Paclitaxel-afgevende stents correleren beide in de context 
van chronische totale occlusies met verbeterde langetermijn klinische en angiografische 
resultaten vergeleken met hun BMS-tegenpolen. Verscheidene studies meldden hoge pro-
cedurele succescijfers {met name evident bij de retrograde benadering), zeer !age restenose-
cijfers en geen toename van stenttrombose of late ocdusie na DES implantatie. Er werden 
eveneens goede klinische resultaten waargenomen in chronisch geoccludeerde implantaten 
in de vena saphena. Hoewel het gunstige effect van DES in deze laesie subset niet formeel 
is geevalueerd (SVG laesies zijn van gerandomiseerde trials uitgesloten), zijn de beschikbare 
data uit observatiestudies bemoedigend. Resterende kwesties zijn de langetermijnveiligheid 
en -werkzaamheid van DES in SVG laesies, waarbij in overweging moet worden genomen 
dat langetermijn incidenten vaak het gevolg zijn van de progressie van andere laesies in de 
ader. Ongeacht de toekomstige vooruitgang op dit gebied, den ken wij dat DES behandeling 
op dit moment de beste benadering is voor SVG taesies. Ondanks het uitgebreide gebruik in 
de praktijk van DES bij patienten met multivaataandoeningen, vatt niet te ontkennen dat er 
nog onvoldoende gegevens beschikbaar zijn.ln plaats van ons te richten op de incidentie van 
nieuwe revascularisaties, die een acceptabele bijwerking genoemd kunnen worden van een 
PCI strategie in vergelijking met CABG, moeten we de gelijkwaardigheid of superioriteit wat 
betreft myocardinfarct en overlijden na 5 jaar aantonen. 
De vooruitgang in de cardiovasculaire interventionele technieken heeft het mogelijk 
gemaakt aandoeningen die eerder via open operaties werden behandeld of niet behandeld 
konden worden nu percutaan te behandelen. 
Hypertrofische obstructieve cardiomyopathie is een relatiefveet voorkomende aandoening 
(met een prevalentie van ongeveer 1 op de 2000 personen). De traditionele methode voor 
de behandeling van deze patienten was het gebruik van betablokkers of calciumkanaalblok-
kers, duale kamerpacing of operatieve ventriculaire septale myectomie. In het afgelopen 
decennium is gebleken dat ook een percutane benadering als behandeling van outflow tract 
gradient door ablatie of induceren van een gecontroleerd infarct van het ventriculaire septum 
veilig en effectief is. Percutane transluminale septum myocard ablatie (PTSMA) en septaal coil 
embolisatie verlagen acuut de systolische functie en verbeteren de diastolische functie, waarbij 
de cardiale output en stroke work blijven behouden. Bij langetermijn follow up verbeteren de 
effecten op de hemodynamica. Terwijl de LV aorta gradient laag blijft, en de actieve en passieve 
LV diastolische eigenschappen stabiel blijven, verbeteren de myocardiale contractiliteit en sys-
tolische functie. De indicaties voor het verrichten van PTSMA moeten nog worden vastgesteld. 
Deze nieuwe techniek kan in het bijzonder aantrekkelijk zijn voor ouderen of patienten met 
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significante co-morbiditeiten die geen operatie kunnen ondergaan of die door de chirurg 
worden geweigerd. 
De enormeverbeteringen van PCls hebben tot een uitstekende overleving na acuut myocard 
infarct geleid. Deze stijging heeft geleid tot een gelijktijdige stijging van de prevalentie van 
postinfarct hartfalen, waarbij tenminste eenderde van de patienten binnen een jaar sympto-
men van hartfalen (HF) vertonen. Deze stijging wordt nu toegeschreven aan zowel de beperkte 
effectiviteit van farmacologische middelen in het verlagen van de remodellering van de linker 
ventrikel en HF exacerbatie, en het ondergebruik van deze geneesmiddelen in de algemene 
praktijk. Tot slot overleven postinfarct HF patienten Ianger, deels vanwege een breder gebruik 
van implanteerbare cardioversie defibrillatoren. Met de kennis datzowel weefsels als beenmerg 
(BM) ongedifferentieerde onvolwassen 'stam'cellen bevatten die normaal gebruikt worden om 
tijdens het Ieven de lichaamsweefsels aan te vullen, en dat deze cell en geoogst en geplaatst 
kunnen worden in gebieden met letsel, is een nieuwe therapeutische optie ontstaan: de 
transplantatie van stam- of progenitorcellen voor hetfunctionele herstel ofzelfs de regeneratie 
van vasculatuur, acuut letsel aan en/of fa lend myocard of een eerder irreversibel beschadigd 
hart - hoopgevend voor celgemedieerde preventie, behandeling en mogelijk zelfs genezing 
van cardiovasculaire aandoeningen. De trials die tot op heden zijn verricht concentreerden zich 
op het gebruik van BM-MNC (beenmerg mononucleaire eel), EPC (endotheliale progenitorcel), 
MSC (multipotente stamcellen} en andere cellen in het continuUm van de cardiovasculaire 
ziekte, van gevorderde coronaire atherosclerose naar eindstadium HF, waarbij de meeste pati-
enten een acuut myocardinfarct hadden doorgemaakt. Drie recente meta-analyses suggereren 
dat BM-MNC statistisch significante doch gering (in klinische termen) gunstig effect hebben bij 
toediening na acuut myocardinfarct. Bij een nauwkeurig onderzoek van de individuele studies 
zijn de resultaten uiteenlopend. Of de discrepanties door verschil in ziektecontext, patientpo-
pulatie,celtype en dosis of anderefactoren worden verklaard moet nog worden uitgezocht. Met 
andere woorden, 7 jaar na de aanvang van de eerste studie hebben wij nog steeds evenveel (of 
meer} vragen dan antwoorden. 
Onder de diverse cellen die onderzocht zijn, zijn autologe skelet myoblasten een van de 
meest bemoedigende celbronnen voor cardiale reparatie. Zij zijn van autologe oorsprong, 
kunnen in vitro worden geamplificeerd, en hebben hoge proliferatieve potentiele weerstand 
tegen ischemie en preklinische effectiviteit. Deze eigenschappen hebben klinisch onderzoe-
kers ertoe gebracht het effect te onderzoeken van getransplanteerde autologe myoblasten 
in patienten met postinfarct hartfalen. Myoblasten differentieren in myotubuli en behouden 
spiereigenschappen wanneer zij getransplanteerd worden in een ge·infarcteerd gebied. De 
directe bijdrage van deze ge"implanteerde cellen wat betreft de verbetering van de systolische 
functie werd opgemerkt in verscheidene studies die een positief effect toonden van skelet-
myoblasten op myocardiale contractiliteit dat in de tijd aanhoudt en correleert met het aantal 
geTmplanteerde eel len. 
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Recent is aangetoond dat adipeus weefsel, naast de gecommitteerde adipogene endotheliale 
progenitorcellen en pluripotente vasculaire progenitorcellen, multipotente cellen bevat, gelijk 
aan MSCs. ADCS (Adipose Tissue Derived Cells) hebben uitgebreide proliferatieve capaciteit, zijn 
in staat te differentieren langs beide mesenchymale lijnen en non-mesenchymale lijnen, staan 
erom bekend een groot aantal angiogenese-gerelateerde cytokines uit te scheiden en tonen 
een immune privileged gedrag. 
Deze bevinding heeft grote belangstelling gewekt, omdat, in tegenstelling tot beenmerg, 
grote hoeveelheden adipeus weefsel eenvoudig kunnen worden geoogst met minimale 
morbiditeit, waarmee het een aantrekkelijke bron voor celtherapie wordt. De APOLLO trial 
Ievert belangrijke data over de veiligheid en effectiviteit van deze cellen bij de mens, en Ievert 
daarmee een wezenlijk inzicht van wat de rol kan zijn in de behandeling van cardiovasculaire 
aandoeningen. 
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